---
document_datetime: 2023-09-21 21:04:17
document_pages: 148
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-003820-ii-0117-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-003820-ii-0117-epar-assessment-report-variation_en.pdf
version: success
processing_time: 569.8563237
conversion_datetime: 2025-12-22 08:31:10.372789
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

24 March 2022 EMA/224169/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0117

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................7                       |
| 2.1. Introduction.........................................................................................................7 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................7           |
| 2.1.2. About the product............................................................................................10      |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ......10                                                                                                |
| 2.1.4. General comments on compliance with                                                                                  | GCP........................................................11                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11          |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................12                                             |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................12    |
| 2.3.1. Introduction....................................................................................................12   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................12      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................17         |                                                                                                         |
| 2.3.4. PK/PD modelling..............................................................................................18      |                                                                                                         |
| 2.3.5. Discussion on clinical                                                                                               | pharmacology...................................................................18                       |
| 2.3.6. Conclusions on clinical pharmacology.................................................................19              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................19    |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................19                     |
| 2.4.2. Main study(ies)                                                                                                      | ...............................................................................................19       |
| 2.4.3. Discussion on clinical efficacy............................................................................77        |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................80          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................81  |
| 2.5.1. Discussion on clinical safety ............................................................................           | 137                                                                                                     |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 140                                                                                                     |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 140 |
| 2.6. Risk management plan......................................................................................             | 140                                                                                                     |
| 2.7. Update of the Product information ......................................................................               | 142                                                                                                     |
| 2.7.1. User consultation...........................................................................................         | 142                                                                                                     |
| 2.7.2. Additional monitoring.....................................................................................           | 142                                                                                                     |
| 3. Benefit-Risk Balance............................................................................143                      |                                                                                                         |
| 3.1. Therapeutic Context .........................................................................................          | 143                                                                                                     |
| 3.1.1. Disease or condition.......................................................................................          | 143                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 143                                                                                                     |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 143             |
| 3.2. Favourable effects ............................................................................................        | 143                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 143                                                                                                     |
| 3.4. Unfavourable effects.........................................................................................          | 144                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 144                                                             |
| 3.6. Effects Table....................................................................................................      | 144                                                                                                     |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 146                                                                                                     |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 146                                                                                                     |

<div style=\"page-break-after: always\"></div>

3.7.2. Balance of benefits and risks  ...........................................................................  146

3.7.3. Additional considerations on the benefit-risk balance ......................................... 146

3.8. Conclusions .....................................................................................................  147

4. Recommendations ...............................................................................  147

5. EPAR changes  ......................................................................................  147

<div style=\"page-break-after: always\"></div>

## List of abbreviations

## Abbreviation

Definition

1L

First-line

AE

Adverse event(s)

AEOSI

Adverse events of special interest

APaT

All Participants as Treated

BICR

Blinded Independent Central Review

cHL

Classical Hodgkin lymphoma

CI

Confidence interval

CIN

Cervical intraepithelial neoplasia

CPS

Combined Positive Score

CR

Complete response

CRC

Colorectal cancer

dMMR

Mismatch repair deficient

DOR

Duration of response

ECOG PS

Eastern Cooperative Oncology Group Performance Status

ESMO

European Society for Medical Oncology

EU

European Union

US FDA

United States Food and Drug Administration

HNSCC

Head and neck squamous cell carcinoma

HR

Hazard ratio

IA1

Interim analysis 1

ITT

Intention-to-treat

mAb

Monoclonal antibody

MSI-H

Microsatellite instability-high

NCCN

National Comprehensive Cancer Network

NSCLC

Non-small cell lung cancer

ORR

Objective response rate

OS

Overall survival

PD

Progressive disease

PD-L1

Programmed cell death ligand 1

<div style=\"page-break-after: always\"></div>

## Abbreviation

## Definition

| PD-L2   | Programmed cell death ligand 2               |
|---------|----------------------------------------------|
| PFS     | Progression-free survival                    |
| PK      | Pharmacokinetic                              |
| PR      | Partial response                             |
| PRO     | Patient-reported outcomes                    |
| Q6W     | Every 6 weeks                                |
| RCC     | Renal cell carcinoma                         |
| RECIST  | Response Evaluation Criteria In Solid Tumors |
| RSD     | Reference safety data                        |
| SAE     | Serious adverse event                        |
| TNBC    | Triple-negative breast cancer                |
| US      | United States                                |
| USPI    | United States Package Insert                 |
| WBC     | White blood cell                             |
| WOCBP   | Women of childbearing potential              |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 12 October 2021 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include a new indication for Keytruda, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults; as a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 38.1 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0043/2018 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH received Scientific Advice from the CHMP on 28 June 2018 (EMEA/H/SA/2437/23/2018/II). The Scientific Advice pertained to clinical aspects of the dossier.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Armando Genazzani

Co-Rapporteur:

Jan Mueller-Berghaus

| Timetable                                                                            | Actual dates     |
|--------------------------------------------------------------------------------------|------------------|
| Submission date                                                                      | 12 October 2021  |
| Start of procedure                                                                   | 30 October 2021  |
| CHMP Rapporteur's preliminary assessment report circulated on                        | 22 December 2021 |
| PRAC Rapporteur's preliminary assessment report circulated on                        | 30 December 2021 |
| CHMP Co-Rapporteur Critique circulated on                                            | 5 January 2022   |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | 13 January 2022  |
| Request for supplementary information adopted by the CHMP on                         | 27 January 2022  |
| MAH's responses submitted to the CHMP on                                             | 1 February 2022  |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on | 11 March 2022    |
| CHMP Opinion                                                                         | 24 March 2022    |

## 2. Scientific discussion

## 2.1. Introduction

The scope of this type II variation is to include a new indication for KEYTRUDA in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults, based on the results from KEYNOTE-826 study.

## 2.1.1. Problem statement

## Disease or condition

The initial claimed indication is 'KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults'.

The indication was updated during the procedure to 'KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥ 1'.

## Epidemiology and risk factors, screening tools/prevention

Globally, cervical cancer is the fourth most common cancer in women, with approximately estimated 600,000 new cases in 2020, representing 6.5% of all female cancers (Sung H, 2021). Approximately 350,000 deaths from cervical cancer occurred in 2020, 90% of them in low- and middle-income

<div style=\"page-break-after: always\"></div>

countries. Rates in EU and US are much lower, ranking 20 th  (1%) among all new cancer cases. In Europe, incidence (age standardized rate per 100,000) ranges from 7 in Western Europe to 14.5 in Eastern Europe (Sung H, 2021), yielding roughly 61,000 new cases in 2018. Mortality (per 100,000) ranges from 2.1 (Northern) to 6.6 (Central/Eastern) with nearly 26,000 deaths in 2018 (Ferlay J, 2018).

The most significant cause of cervical cancer is persistent papillomavirus infection. HPV is detected in 99% of cervical tumours, particularly the oncogenic subtypes such as HPV 16 and 18 (ESMO GL Marth C, 2017). Immunization against HPV prevents infection with the types of HPV against which the vaccine is designed and thus is expected to prevent specific HPV cancer in women (NCCN GL). Cervical cancer screening programmes have reduced incidence and death rates. For many years, the Papanicolaou (Pap) test has been the standard method for cervical cancer screening. More recently, an HPV test has been introduced as a screening tool as HPV DNA is present in almost all cervical cancers and it has demonstrated higher sensitivity for high grade cervical intraepithelial neoplasia (CIN2+) than that achieved by cytology in several studies (ESMO GL). The WHO recommends the screening of the general population of women aged 30 to 49 years using HPV DNA detection as the primary screening test at a regular screening interval of every 5 to 10 years. Where HPV DNA testing is not yet operational, WHO suggests a regular screening interval of every 3 years when using visual inspection with acetic acid or cytology as the primary screening test. Screening should be coupled with timely and efficacious treatment of precancerous lesions (WHO, 2021).

Therefore, primary prevention of cervical cancer is possible via immunisation with HPV vaccines and secondary prevention has gained impetus with the advent of sensitive HPV DNA testing to improve traditional Pap cytology screening programmes (Marth C, 2017).

Other important cofactors include smoking, some sexually transmittable infections, a higher number of childbirths, early age of onset of coitus, large number of sexual partners, long-term use of oral contraceptives, and chronic immunosuppression (NCCN GL; Herrero R, 2018).

## Biologic features

Squamous cell carcinomas account for 70%-80% of cervical cancers and adenocarcinomas for 20%25% (ESMO GL). Patients with adenocarcinoma and squamous cell carcinoma undergo the same standard treatment, even though these histologic subtypes differ substantially in terms of HPV and mutation status (HPV16 for SCC, HPV18 for adenocarcinoma), immune infiltrate, response to therapy, and patient outcome. Several retrospective studies showed that patients with adenocarcinoma have a higher risk of developing metastases, resulting in a poorer prognosis (Rotman J, 2020).

Approximately 5-11% of all cervical cancers are reported to be HPV-negative, which can be attributed to truly negative and false-negative results. The truly HPV-negative cervical cancers are almost all cervical adenocarcinomas with unclear aetiology (Xing B, 2021).

## Clinical presentation, diagnosis and stage/prognosis

Due to current screening procedures used in Western countries for the early detection of CIN and cervical cancer, almost half of the newly diagnosed adult cervical cancer patients have Stage I localized cancer, with a 5-year survival rate of over 90%. Five-year survival rates decrease with stage at diagnosis, becoming as low as 15-17% for metastatic disease (Lorin, 2015; Munich cancer registry 2016; SEER Cervical Cancer).

The median age at the diagnosis of cervical cancer is 50 years (CDC statistics).

<div style=\"page-break-after: always\"></div>

## Management

Treatment options for cervical cancer in adults include surgery (conization and hysterectomy), radiation, and chemotherapy alone or in combination, depending on the stage of the disease (NCCN).

Chemotherapy is often recommended for patients with extrapelvic metastases or recurrent disease who are not candidates for RT or exenterative surgery. Patients who develop distant metastases, either at initial presentation or at relapse, are rarely curable, and systemic treatment is provided for palliation, aiming of relieving symptoms and improving quality of life, is indicated if the patient has a performance status (PS) &lt;=2 and no formal contraindications (NCCN, ESMO). Cisplatin-based doublets with topotecan or paclitaxel have demonstrated superiority to cisplatin monotherapy in terms of response rate and PFS, especially in patients previously exposed to CRT where cisplatin was used as radiosensitizer (Moore, 2004; Long, 2005). A large randomised phase III trial (GOG-204) comparing four different cisplatin-based doublets with paclitaxel, topotecan, gemcitabine or vinorelbine was unable to demonstrate the superiority of any regimen. Nevertheless, paclitaxel-cisplatin showed the highest response rate (29%), median PFS (5.8 months) and median OS (12.8 months) and was considered the preferred regimen based on the balance between efficacy and toxicity profile (ESMO GL; Monk BJ, 2009). The GOG-240 study explored the addition of bevacizumab to chemotherapy in a randomised phase III trial with a 2x2 factorial design in which OS was the primary endpoint. Patients with primary stage IVB or recurrent/persistent, PS 0 or 1 and measurable disease were randomised to paclitaxel-cisplatin or paclitaxel-topotecan, both with or without bevacizumab. The median OS was significantly prolonged by the addition of bevacizumab (16.8 vs 13.3 months; HR 0.765; 95% CI: 0.62-0.95; p=0.0068) and non-platinum doublet resulted not superior to cisplatin-paclitaxel, even in the population previously treated with cisplatin. Patients treated with bevacizumab had a higher risk of grade 2 hypertension (25% vs 1.8%), grade 3 venous thromboembolic events (8.2% vs 1.8%) and grade 2 fistula (8.6% vs 1%) (Tewari KS, 2014). A 2017 systemic review and meta-analysis found a trend towards improved OS with the addition of bevacizumab to chemotherapy. Paclitaxel and cisplatin combined with bevacizumab is considered the preferred first-line regimen in metastatic or recurrent cervical cancer, based on the balance between efficacy and toxicity profile (ESMO, NCCN). Based on the results of GOG-240 study, bevacizumab was approved in EU in 2015 with the following indication: 'Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see Section 5.1).' (EPAR Avastin II/72).

The combination of paclitaxel and carboplatin could be considered an alternative for patients that are not candidates for cisplatin, especially in patients who have already received cisplatin based on the results of a Japanese randomised clinical trial (JCOG0505) (ESMO GL, NCCN, Kitagawa 2015). Based on the collective findings of GOG-240 and JCOG0505, the NCCN guidelines added the combination carboplatin/paclitaxel/bevacizumab as an alternative treatment option. Approximately 59% of patients in the US in clinical setting receive a 1L bevacizumab-containing regimen (Kantar Health, cervical cancer U.S., 2021). The single-arm CECILIA study evaluated bevacizumab in combination with carboplatin-paclitaxel for advanced cervical cancer. The study concluded that bevacizumab can be combined with carboplatin-paclitaxel in this population, and the fistula/gastrointestinal perforation incidence was in line with GOG-0240; efficacy results were encouraging, within the limits of the single arm study (Redondo A, 2020).

According to ESMO guidelines, in patients progressing following first-line therapy, different cytostatic agents, including vinorelbine, topotecan, gemcitabine or nanoparticle albumin-bound paclitaxel have been evaluated. However, response rates are low and duration of responses is short. Therefore, no recommendation can be given about the most effective second-line treatment (ESMO GL).

<div style=\"page-break-after: always\"></div>

KEYTRUDA received FDA accelerated approval for second and later lines of treatment for recurrent or metastatic cervical cancer which has progressed on or after chemotherapy in participants who are PDL1 positi ve (CPS ≥1) based on ORR of 14.3% with 91% of responses lasting for at least 6 months based on the results of KEYNOTE-158 (Chung HC, 2019).

To date, a recently completed RCT (EMPOWER-Cervical 1) with another anti-PD1 agent cemiplimab (not yet approved in any country) showed significantly improved OS compared with chemotherapy in recurrent or metastatic cervical cancer following progression after 1L platinum-based chemotherapy. Median OS for cemiplimab was 12.0 months versus 8.5 months for chemotherapy alone (HR 0.69). In this study, patients treated with cemiplimab who had positive PD-L1 expression on tumor cells benefited the most (median OS, 13.9 months) in comparison with those with negative PD-L1 expression (7.7 months) and those treated with chemotherapy (0.70 in PD-L1 positive, 0.98 in PD-L1 negative; PFS HR 0.75 vs 1, and ORR 18.3% vs 11.4% in PD-L1 positive vs negative tumors, respectively) (Tewari KS, 2021).

## 2.1.2. About the product

Pembrolizumab is a highly selective humanized monoclonal antibody that binds to human programmed cell death 1 (PD-1) and blocks the interaction between the PD-1 pathway receptor and its ligands, programmed cell death 1 ligand 1 (PD-L1) and 2 (PD-L2) on antigen presenting tumor cells.

In the EU, pembrolizumab is currently approved, as monotherapy and in combination with other agents, for the treatment of melanoma, NSCLC, RCC, HNSCC, MSI-H or dMMR tumours (CRC, endometrial carcinoma, gastric, small intestine, or biliary cancer), urothelial cancer, oesophageal cancer, breast cancer, endometrial carcinoma and cHL. This is the first extension of indication requested for cervical cancer.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

An overview of the Phase 3 clinical development program for cervical cancer is provided in the table below:

Table 1. Phase 3 Studies of Pembrolizumab Plus Standard of Care in Cervical Cancer

| Study       | Design                                                                                                                                                                                                                           | Participant Population                                                                                                                                                                                                                                                                                   | Primary Endpoint(s)                               | Status                  |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|-------------------------|
| KEYNOTE-826 | Phase 3, Randomized, Double-Blind, Placebo- Controlled Trial of Pembrolizumab (MK- 3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer | 617 participants were randomized (69 CPS <1, 548 CPS ≥1). Participants must have persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which has not been treated with systemic chemotherapy and is not amenable to curative treatment. | PFS per RECIST 1.1 as assessed by investigator OS | Fully enrolled, ongoing |

<div style=\"page-break-after: always\"></div>

| Study                                                                                                                                                                                   | Design                                                                                                                                                                                  | Participant Population                                                                                                                                                                                                                                                                                                                                        | Primary Endpoint(s)                                                                                                                                                                     | Status                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| KEYNOTE-A18                                                                                                                                                                             | Phase 3, Randomized, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer                             | Enrollment ongoing (~980 participants expected to be enrolled). Participants must have locally advanced histologically- confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix which has not previously received any definitive surgical, radiation, or systemic therapy for cervical cancer and is immunotherapy-naïve. | PFS per RECIST 1.1 as assessed by investigator OS                                                                                                                                       | Enrolling, Ongoing                                                                                                                                                                      |
| Abbreviations: BICR = blinded independent central review; CPS = combined positive score; OS = overall survival; PD-L1 = programmed cell death ligand 1; PFS = progression-free survival | Abbreviations: BICR = blinded independent central review; CPS = combined positive score; OS = overall survival; PD-L1 = programmed cell death ligand 1; PFS = progression-free survival | Abbreviations: BICR = blinded independent central review; CPS = combined positive score; OS = overall survival; PD-L1 = programmed cell death ligand 1; PFS = progression-free survival                                                                                                                                                                       | Abbreviations: BICR = blinded independent central review; CPS = combined positive score; OS = overall survival; PD-L1 = programmed cell death ligand 1; PFS = progression-free survival | Abbreviations: BICR = blinded independent central review; CPS = combined positive score; OS = overall survival; PD-L1 = programmed cell death ligand 1; PFS = progression-free survival |

CHMP scientific advice was obtained on the study design of the pivotal study KEYNOTE-826 in EU on 28-JUN-2018 (EMEA/H/SA/2437/23/2018/II). CHMP concluded that the trial may be acceptable as such but would present a difficult case to assess due to the heterogeneity in the study population and the potential that efficacy gains may be offset by toxicity. In the proposed setting, the CHMP considered OS as the preferred primary endpoint, and commented to be in the position to assess mature OS data in order to properly assess the B/R in all subgroups.

The change of primary endpoint PFS from BICR to investigator assessment was discussed with FDA (Meeting type B, 23 Feb 2021, minutes included in the dossier). FDA noted that the proposed change is at the Sponsor's discretion and the acceptability of the approach will be a review issue.

Additionally, a pre-submission meeting was held with the EU Rapporteurs and EMA on 26-JUL-2021, where results from the KEYNOTE-826 study were presented and discussed in view of the planned Type II variation application.

## 2.1.4. General comments on compliance with GCP

The MAH claimed that KEYNOTE-826 study was conducted in conformance with applicable country or local requirements regarding ethical committee review, informed consent, and other statutes or regulations regarding the protection of the rights and welfare of human participants in biomedical research.

The assessment of KEYNOTE-826 data did not raise concern over GCP compliance leading to request for GCP inspection.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.2.1. Ecotoxicity/environmental risk assessment

According to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00) proteins are exempted from the submission of ERA studies because they are unlikely to result in significant risk to the environment. Pembrolizumab is a protein, therefore an ERA has not been submitted by the MAH. This is acceptable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 2. Tabular overview of clinical studies

| Study ID                                  |   Phase | Country/Region                                                                                                                                                                                                      | StudyTitle                                                                                                                                                                                                                             | Study design                                                           | Dosingregimen                                                                                                           | Studypopulation                                                                                                                                                                                                                                                                | Participant exposure           |
|-------------------------------------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| KEYNOTE-826 [Ref. 5.3.5.1: P826V01MK3475] |       3 | Australia Asia (Israel, Japan, South Korea, Taiwan) CentralAmerica (Mexico) Europe (France, Germany, Italy, Spain, Ukraine ) North America (Canada,USA) Russia SouthAmerica (Argentina,Chile, Colombia,Peru) Turkey | A Phase 3 Randomized,Double- Blind,Placebo- Controlled Trial of Pembrolizumab(MK- 3475) Plus ChemotherapyVersus ChemotherapyPlus Placebofor theFirst- Persistent,Recurrent, LineTreatment of orMetastaticCervical Cancer(KEYNOTE- 826) | Randomized, double-blind, placebo-controlled, multicenter,global study | Pembrolizumab:200 mgbyintravenous infusionevery3weeks (Q3 W) Placebo(saline solution): 0 mg by intravenous infusion Q3W | Females Age:22 to82years with persistent, recurrent,ormetastatic squamouscell carcinoma, adenosquamous carcinoma,or adenocarcinomaofthe cervixwhich hadnot beentreatedwith systemicchemotherapy andwas not amenable tocurativetreatment (such as with surgery and/orradiation) | Pembrolizumab: 307 Placebo:309 |

## 2.3.2. Pharmacokinetics

Pembrolizumab PK disposition has been characterized via pooled population PK analyses using serum concentration-time data contributed from subjects across various clinical studies using a time-dependent PK (TDPK) model. The PK reference dataset for monotherapy includes all available PK data from subjects enrolled on KEYNOTE-001, KEYNOTE-002, KEYNOTE-006, KEYNOTE-010, and KEYNOTE-024, with an overall  sample  size  of  2993.  This  serves  as  the  PK  reference  analysis  to  support  descriptions  of pembrolizumab pharmacokinetics in the USPI and EU SmPC.

## Absorption

Pembrolizumab  is  dosed  via  the  intravenous  route  and  therefore  is  immediately  and  completely bioavailable.

<div style=\"page-break-after: always\"></div>

## Distribution

Consistent  with  a  limited  extravascular  distribution,  the  volume  of  distribution  of  pembrolizumab  at steady  state  is  small  (6.0  L;  coefficient  of  variation  [CV]:  20%).  As  expected  for  an  antibody, pembrolizumab does not bind to plasma proteins in a specific manner.

## Elimination

Pembrolizumab  CL  is  approximately  23%  lower  (geometric  mean,  195  mL/day  [CV%:  40%])  after achieving maximal change at steady state compared with the first dose (252 mL/day [CV%: 37%]); this decrease in CL with time is not considered clinically meaningful. The geometric mean value (CV%) for the terminal half-life is 22 days (32%) at steady-state.

## Pharmacokinetic in subjects with cervical cancer

Efficacy and safety data in support of the current submission were obtained from study KEYNOTE-826 where patients were treated with the combination of pembrolizumab plus chemotherapy with or without bevacizumab.

As part of the agreement established in 2017 with the EMA to streamline the clinical pharmacology content in the clinical development program of KEYTRUDA, pharmacokinetic and immunogenicity data were not collected in KEYNOTE-826.

The focus of the clinical pharmacology report is on the clinical PK data from participants with cervical cancer in Group E of study KEYNOTE-158 (a Phase 2, multicohort, open-label, nonrandomized study designed  to  evaluate  the  efficacy  and  safety  of  pembrolizumab  monotherapy  in  participants  with unresectable or metastatic solid tumors).

Data from KEYNOTE-158, Group E are supportive of the proposed pembrolizumab dose of 200 mg Q3W for adults with cervical cancer.

Moreover, the MAH is also applying for the 400 mg Q6W dosing regimen. This dosing regimen was approved in the EU for all adult monotherapy indications (EMEA/H/C/003820/II/0062 [March 2019]) and for all adult indications in combination with other anticancer agents (EMEA/H/C/003820/II/0102 [May 2021]). The dosing regimen of 400 mg Q6W is then applicable across all adult indications, including this proposed indication for cervical cancer, regardless of the combination treatment type.

## PK Data Keynote-158

KEYNOTE-158 is an ongoing , non-randomized, single arm, multi-site, open-label study of pembrolizumab in previously treated participants who have locally advanced unresectable or metastatic rare  cancers  for  whom  prior  standard  first-line  treatment  had  failed.  Eligible  participants  received pembrolizumab 200 mg IV Q3W.

<div style=\"page-break-after: always\"></div>

Figure 1. Study design

ForCohortM,MSI=MSI-Hexcluded.

<!-- image -->

PK schedule in KEYNOTE-158 200 mg Q3W: Predose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycles 1 and 4. Postdose serum concentrations (Cmax) were drawn within approximately 30 minutes after the end of the infusion in Cycle 1.

Summary descriptive statistics of the predose concentrations by cycle are presented in the following table:

| Cycle            |   NOMTAFD (Day) | GM (%CV)       |                         | GM (SD) AM (SD) (μg/mL)   |   Min |   Median |   Max |
|------------------|-----------------|----------------|-------------------------|---------------------------|-------|----------|-------|
| Cycle 1 (Week 0) |           0.021 | 95 71.4 (42.2) | 71.4 (20.2)             | 75.0 (20.2)               |  2.61 |     75   | 199   |
| Cycle 4 (Week 9) |          63     | 59             | 26.1 (47.0) 26.1 (10.4) | 28.3 (10.4)               |  4.75 |     28.4 |  62.5 |

Table 3. Summary Statistics of Pembrolizumab Cycle 1 Postdose and Cycle 4 Predose, Serum Concentration Values Following Administration of Multiple 200 mg I.V. Doses with a 3 Week Dosing Interval in KEYNOTE-158 Cervical Carcinoma Subjects

<!-- image -->

Data Source: [06DF8S: analysis-p158pkdm24cerv]

Observed pembrolizumab concentration data in KEYNOTE-158 group E for pembrolizumab are overlaid on the simulated profile using the reference PK model as shown in the following figure:

<div style=\"page-break-after: always\"></div>

Figure  2.  Observed  Concentration  Data  in  KEYNOTE-158  Group  E  subjects  with  Cervical Carcinoma Receiving 200 mg  Q3W  Pembrolizumab with Reference Model-Predicted Pharmacokinetic Profile for 200 mg/kg Q3W Dose Regimen

KEYNOTE-158 Group E Pembrolizumab Cycle 1 to Cycle 4

<!-- image -->

Note:Pembrolizumabmodel predictions and observedconcentration dataforKEYNOTE-158groupE subjectsAfter1st dose; and at cycle 4, with a 28 day time since last dose sample cut off. Symbols are individual observed data (nominal time); blackdashedlineismedianpredictedconcentrationsfromthemodelfor aregimenof200mgQ3Wandthegreyshaded area represents the 90% predictioninterval; plots are displayed on log scale.Data Source:[06DF8S: analysisp158pkdm24cerv]

Tabular summaries of descriptive statistics and boxplots from early drug treatment at Cycle 1 end of infusion (postdose) and at predose Cycle 4, comparing observed pembrolizumab concentrations of 200 mg every 3 weeks (Q3W) from participants with cervical carcinoma in KEYNOTE-158 group E and monotherapy trials in non-small cell lung cancer (NSCLC, KEYNOTE-024), urothelial cancer (UC, KEYNOTE-045 and KEYNOTE-052), head and neck squamous cell cancer (HNSCC, KEYNOTE-048 and KEYNOTE-055), classical Hodgkin Lymphoma (HL, KEYNOTE-087), microsatellite instability-high cancer (MSI-H, KEYNOTE-158) and MSI-H colorectal cancer (MSI-H-CRC, KEYNOTE-164 and KEYNOTE-177), are presented in the following table and figure.

<div style=\"page-break-after: always\"></div>

Table 4. Summary Statistics of Observed Pembrolizumab Trough Concentrations at Cycle 1 Postdose and Cycle 4 Predose in Various Monotherapy Trials (KEYNOTE-024, -045, -048, -052, -055, -087, 158 MSIH non CRC, -164, -177) and KEYNOTE-158 Group E Cervical Cancer

| point Time       | dose   | Indication Study/   |   N | GM(CV%) (μg/mL)   | (μg/mL) AM(SD)   |   (μg/mL) Min |   (μg/mL) Median |   (μg/mL) Max |
|------------------|--------|---------------------|-----|-------------------|------------------|---------------|------------------|---------------|
| Postdose Cycle 1 | 200mg  | KN024 NSCLC         | 147 | 67.5 (23.1)       | 69.3 (16.2)      |        36.6   |             66.8 |         132   |
| Postdose Cycle 1 | 200mg  | KN045 UC            | 247 | 65.7 (26.2)       | 67.9 (18.2)      |        33.9   |             65.9 |         144   |
| Postdose Cycle 1 | 200mg  | KN048 IL HNSCC      | 495 | 61.8 (28.7)       | 64.2 (17.6)      |         9.48  |             61.7 |         165   |
| Postdose Cycle 1 | 200mg  | KN052 UC            | 298 | 58.0 (27.9)       | 60.2 (17.3)      |        22.8   |             57.4 |         148   |
| Postdose Cycle 1 | 200mg  | KN055HNSCC          |  43 | 56.5 (27.8)       | 58.9 (20.7)      |        33.1   |             54.9 |         162   |
| Postdose Cycle 1 | 200mg  | KN087 HL            | 195 | 60.7 (28.0)       | 63.1 (18.3)      |        31.2   |             61.3 |         183   |
| Postdose Cycle 1 | 200mg  | KN158 Group-E       |  95 | 71.4 (42.2)       | 75.0 (20.2)      |         2.61  |             75   |         199   |
| Postdose Cycle 1 | 200mg  | KN158 MSIH- NonCRC  |  88 | 64.2 (27.3)       | 66.5 (18.4)      |        31.2   |             65.2 |         133   |
| Postdose Cycle 1 | 200mg  | KN164MSIH-CRC       |  56 | 62.2 (27.8)       | 64.6 (19.1)      |        34.9   |             61.2 |         150   |
| Postdose Cycle 1 | 200mg  | KN177 MSIH-CRC      | 115 | 65.0 (25.7)       | 67.1 (17.1)      |        36.4   |             65.7 |         113   |
| Cycle 4 Predose  | 200mg  | KN024 NSCLC         | 105 | 22.5 (51.6)       | 24.7 (9.6)       |         1.35  |             24.5 |          54   |
| Cycle 4 Predose  | 200mg  | KN045 UC            | 169 | 25.3 (51.5)       | 27.7 (10.6)      |         0.677 |             26.6 |          62.1 |
| Cycle 4 Predose  | 200mg  | KN048 IL HNSCC      | 378 | 24.8 (44.1)       | 26.8 (9.8)       |         2.67  |             26.4 |          77.3 |
| Cycle 4 Predose  | 200mg  | KN052 UC            | 170 | 20.6 (51.0)       | 22.8 (9.4)       |         4.41  |             22.4 |          56.1 |
| Cycle 4 Predose  | 200mg  | KN055HNSCC          |  23 | 21.5 (35.6)       | 22.7 (7.3)       |        11.5   |             24.9 |          34.4 |
| Cycle 4 Predose  | 200mg  | KN087 HL            | 183 | 30.3 (40.0)       | 32.3 (11.1)      |         4.93  |             30.7 |          64.7 |
| Cycle 4 Predose  | 200mg  | KN158 Group-E       |  59 | 26.1 (47.0)       | 28.3 (10.4)      |         4.75  |             28.4 |          62.5 |
| Cycle 4 Predose  | 200mg  | KN158 MSIH- NonCRC  |  67 | 25.2 (50.2)       | 27.7 (11.2)      |         6.01  |             26.9 |          49.7 |
| Cycle 4 Predose  | 200mg  | KN164 MSIH-CRC      |  51 | 23.1 (42.2)       | 24.9 (9.4)       |         6.52  |             23.4 |          54.7 |
| Cycle 4 Predose  | 200mg  | KN177MSIH-CRC       |  75 | 26.0 (51.5)       | 28.9 (12.9)      |         7.41  |             27.5 |          67.2 |

GM = Geometric Mean; %CV = Geometric Coefficient of Variation; AM = Arithmetic Mean; SD = Standard Deviation; NSCLC = non-small cell lung cancer; UC = urothelial cancer; HNSCC = head and neck squamous cell carcinoma; HL=Hodgkin lymphoma; MSIH CRC=micro satelliteinstabilityhigh cancer colorectal cancer.

<div style=\"page-break-after: always\"></div>

Figure  3.  Pembrolizumab  Observed  Trough  Pembrolizumab  Concentrations  at  Cycle  1 Postdose and Cycle 4 Predose in Various Monotherapy Trials (KEYNOTE-024, -045, -048, -052, -055, -087, 158 MSIH non CRC, -164, -177) and KEYNOTE-158 Group E

CycleIPostdose

<!-- image -->

Data Source:[06DF8S:analysis-p158pkdm24cerv]

## 2.3.3. Pharmacodynamics

## Mechanism of action

KEYTRUDA is an antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

<div style=\"page-break-after: always\"></div>

## 2.3.4. PK/PD modelling

No new information regarding PK/PD modelling for pembrolizumab is available within this extension of indication.

## 2.3.5. Discussion on clinical pharmacology

While the efficacy and safety data of the current submission are based on the combination of pembrolizumab plus chemotherapy with or without bevacizumab from KEYNOTE-826, the focus on the clinical Pharmacology is on data from participants with cervical cancer in Group E of KEYNOTE-158 a Phase 2 study of pembrolizumab monotherapy in participants with unresectable or metastatic solid tumours, including cervical carcinoma.

The observed serum concentration values in subjects with cervical cancer from KEYNOTE-158 study are contained within the 90% CI of the reference PK model, which indicate that pembrolizumab data from KEYNOTE-158 group E is consistent with the historical data in both cycle 1 postdose and cycle 4 predose. PK concentrations reached ~ 88% of the steady-state concentrations at the end of cycle 3 (timepoint for cycle 4 pre-dose).

Observed pembrolizumab concentration data in KEYNOTE-158 group E for subjects with cervical carcinoma were compared with simulated profiles for female subjects only using the reference PK model and resulted to fall within predicted concentrations.

Tabular summaries of descriptive statistics and boxplots comparing observed pembrolizumab concentrations of 200 mg Q3W from participants with cervical carcinoma in KEYNOTE-158 group E and female subjects in other monotherapy trials, showed consistent concentration values between female subjects with cervical cancer and other approved monotherapy trials in NSCLC, UC, HNSCC, HL and MSI-H.

Although a substantial characterization of the clinical pharmacology and immunogenicity profile of pembrolizumab has been provided in previous applications as monotherapy and in combination with small molecules or chemotherapy, the immunogenicity profile when another biologic drug is administered in combination with pembrolizumab is unknown.

No new ADA data are provided in this submission based on the following consideration argued by the MAH:

- the  existing  immunogenicity  assessment  for  pembrolizumab  for  the  monotherapy  setting  is based  on  a  sufficiently  large  dataset  of  patients  across  several  indications,  with  very  low observed rates of total treatment ADA across different pembrolizumab regimens (1.4 - 3.8%) as well as of neutralizing antibodies (0.4 - 1.6%). This analysis has not demonstrated impact on efficacy or safety, as currently summarized in the EU SmPC and USPI.
- the low rate of immunogenicity has been shown to be consistent across tumor type and no clinically  meaningful  consequences  have  been  observed  in  the  subjects  with  a  positive immunogenicity reading.
- the  incidence  of  ADA  has  not  been  impacted  by  the  presence  of  another  small  molecule  or chemotherapy in combination with pembrolizumab.

In 2017, the MAH was recommended 'to assess immunogenicity for co-administered biologics and also to collect ADA samples for pembrolizumab at least until results form a sufficient number of cases will provide characterization of the pembrolizumab immunogenicity profile in such combinations, making unnecessary further analysis'.

<div style=\"page-break-after: always\"></div>

During this procedure, the Applicant provided data from study KEYNOTE-021 cohort B where 24 patients were treated with pembrolizumab in combination with paclitaxel, carboplatin and bevacizumab.

Among these patients, only 16 subjects were evaluable for immunogenicity and although data showed that only 1 subject/16 was found to be treatment-emergent positive and had no antibodies with neutralizing capacity, the number of analysed subjects is very low and the Applicant is encouraged to further collect PK and ADA samples in study MK-3475-B96/KEYNOTE-B96/ENGOT-ov65 that is still recruiting and to provide data in the context of future procedure.

## 2.3.6. Conclusions on clinical pharmacology

The PK of pembrolizumab when used in combination with chemotherapy has been extensively evaluated in a number of cancer indications and demonstrates that the PK of pembrolizumab is consistent across tumour  types  and  it  is  not  impacted  by  concomitant  chemotherapy.  However,  a  comprehensive characterization of the immunogenicity profile of pembrolizumab in combination with other biologic drugs and in particular with bevacizumab is lacking and should be better defined in future procedures.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No dose-response studies have been conducted specifically for this indication, nor for the combination of pembrolizumab with bevacizumab.

## 2.4.2. Main study(ies)

## Title of Study

A Phase 3 Randomized, Double-Blind, Placebo- Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

<div style=\"page-break-after: always\"></div>

## Methods

## Figure 4. Study Design for KEYNOTE-826

<!-- image -->

Abbreviations: AEs=adverse events; AUC= area under the concentration-time curve; CPS=combined positive score; ECOG PS=Eastern Cooperative Oncology Group Performance Score; IV=intravenous; OS=overall survival; PD-L1=Programmed cell death 1 ligand 1; PFS=progression-free survival; Q3W=every 3 weeks.

## Study participants

## Key inclusion criteria:

- Had persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which has not been treated with systemic chemotherapy and is not amenable to curative treatment (such as with surgery and/or radiation). NOTE: Prior chemotherapy utilized as a radiosensitizing agent and completed at least 2 weeks prior to randomization with resolution of all treatment-related toxicities is allowed. AEs due to previous treatments should be resolved to ≤ Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are eligible.
- Had measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable only if progression has been demonstrated in such lesions.
- Had provided archival tumour tissue sample or newly obtained core or excisional biopsy of a tumour lesion not previously irradiated for prospective determination of PD-L1 status prior to randomization.
- Had an ECOG PS of 0 to 1 within 14 days prior to randomization.
- Have adequate organ function as indicated by the laboratory values within 14 days prior to randomization as defined in the protocol.

## Key exclusion criteria:

<div style=\"page-break-after: always\"></div>

- Had a positive urine pregnancy test within 72 hours prior to randomization (WOCBP only).
- Had known active CNS metastases and/or carcinomatous meningitis. Participants with known brain metastases may participate provided that the brain metastases have been previously treated (except with chemotherapy) and are radiographically stable.
- Had a known additional malignancy that was progressing or had required active treatment within the past 3 years.
- Had a diagnosis of immunodeficiency or was receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization.
- Had received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
- Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
- Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- Has an active infection requiring systemic therapy, known history of HIV, Hepatitis B or known active Hepatitis C, known history of active tuberculosis.
- Had received prior systemic chemotherapy for treatment of cervical cancer (chemotherapy used as a radiosensitizing agent and completed at least 2 weeks prior to randomization was permitted).
- Has received prior radiotherapy within 2 weeks prior to randomization.

## Treatments

Table 5. Study interventions

| Intervention   | Unit Dose and Frequency   | RouteofAdministration   |
|----------------|---------------------------|-------------------------|
| Pembrolizumab  | 200 mg Q3W                | IV                      |
| Placebo        | 0 mg Q3W                  | IV                      |
| Paclitaxel     | 175 mg/m2                 | IV                      |
| Carboplatin    | AUC 5                     | IV                      |
| Cisplatin      | 50 mg/m2                  | IV                      |
| Bevacizumab    | 15 mg/kg                  | IV                      |

IV=intravenous;Q3W=every3weeks;AUC=areaunderthecurve

All drugs were administered on day 1 of each 3-week treatment cycle.

As of protocol amendment 2, the maximum duration of chemotherapy was 6 cycles; patients with ongoing clinical benefit who were tolerating chemotherapy could continue chemotherapy beyond 6 administrations after consultation with the study sponsor.

There was no maximum number of bevacizumab administrations.

The maximum number of pembrolizumab or placebo administrations was 35 (i.e. approximately 2 years).

<div style=\"page-break-after: always\"></div>

## Objectives and endpoints

Table 6. Objectives and endpoints

| Objective/ Hypothesis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Endpoint                                                                                                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                |
| Objective: To compare PFS per RECIST 1.1 as assessed by investigator Hypothesis (H1): The combination of pembrolizumab + chemotherapy is superior to placebo plus chemotherapy with respect to PFS per RECIST 1.1 as assessed by investigator for the CPS ≥ 1 group. Hypothesis (H2): The combination of pembrolizumab + chemotherapy is superior to placebo plus chemotherapy with respect to PFS per RECIST 1.1 as assessed by investigator for all-comers. Hypothesis (H3): The combination of pembrolizumab + chemotherapy is superior to placebo plus chemotherapy with respect to PFS per RECIST 1.1 as assessed by investigator for | PFS: The time from randomization to the first documented disease progression or death due to any cause, whichever occurs first.                                                                                                                |
| Objective: To compare OS Hypothesis (H4): The combination of pembrolizumab + chemotherapy is superior to placebo plus chemotherapy with respect to OS for the CPS ≥ 1 group. Hypothesis (H5): The combination of pembrolizumab + chemotherapy is superior to placebo plus chemotherapy with respect to OS for all-comers. Hypothesis (H6): The combination of pembrolizumab + chemotherapy is superior to placebo plus chemotherapy with respect to OS for the CPS ≥ 10 group.                                                                                                                                                             | OS: The time from randomization to death due to any cause.                                                                                                                                                                                     |
| Secondary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                |
| Objective: To evaluate the ORR, DOR, and 12- month PFS rate per RECIST 1.1 as assessed by investigator.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | OR: Participants who have a best overall response of either confirmed CR or PR. DOR: The time from the first documented evidence of CR or PR until the first documented disease progression or death due to any cause, whichever occurs first. |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                    | PFS-12: The proportion of participants that are PFS event-free at 12 months.                                                                                                                                                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective: To evaluate PFS per RECIST 1.1 as assessed by BICR.                                                                                                                                                                                     | PFS: The time from randomization to the first documented disease progression or death due to any cause, whichever occurs first.                                                                                                                                                                                             |
| Objective: To compare the safety and tolerability by the proportion of AEs.                                                                                                                                                                        | Participants experiencing AEs, serious AEs, and immune-related AEs. Participants discontinuing study treatment due to AEs.                                                                                                                                                                                                  |
| Objective: To evaluate changes in HRQoL assessments using the global score of the EORTC QLQ-C30.                                                                                                                                                   | The EORTC QLQ-C30 global score.                                                                                                                                                                                                                                                                                             |
| Exploratory                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                             |
| Objective: To evaluate the ORR, DOR, and 12- month PFS rate per RECIST 1.1 as assessed by BICR.                                                                                                                                                    | OR: Participants who have a best overall response of either confirmed CR or PR. DOR: The time from the first documented evidence of CR or PR until the first documented disease progression or death due to any cause, whichever occurs first. PFS-12: The proportion of participants that are PFS event-free at 12 months. |
| Objective: To evaluate PFS using iRECIST, as assessed by investigator.                                                                                                                                                                             | PFS per iRECIST is defined as time from the date of randomization to the date of the first documentation of confirmed immune-related progressive disease (iPD) or death (whichever occurs first).                                                                                                                           |
| Objective: To identify molecular (genomic, metabolic, and/or proteomic) biomarkers that may be indicative of clinical response/resistance, safety, pharmacodynamic activity, and/or the mechanism of action of pembrolizumab and other treatments. | Germline genetic variation, genetic (DNA) mutations from tumor, tumor and blood RNA variation, proteomics and IHC, and other biomarkers.                                                                                                                                                                                    |
| To evaluate changes in HRQoL assessments using the EORTC QLQ-C30, EORTC QLQCX24, and European Quality of Life (EuroQoL) EQ-5D- 5L instruments.                                                                                                     | HRQoL will be assessed using the EORTC QLQ- C30 (scores other than global score), EORTC QLQ CX24, and EuroQoL EQ-5D-5L.                                                                                                                                                                                                     |
| To characterize utilities using the EuroQoL EQ- 5D-5L.                                                                                                                                                                                             | Utilities will be assessed using the EuroQoL EQ- 5D-5L.                                                                                                                                                                                                                                                                     |

## Sample size

The study was planned to randomize approximately 600 participants (all-comers) in a 1:1 ratio between the two arms, over a period of 16 months. Approximately 510 participants were expected to be CPS ≥ 1

<div style=\"page-break-after: always\"></div>

and  300  participants  were  expected  to  be  CPS ≥ 10.  The  study  is  event-driven  and  completes  after accumulation of sufficient events to determine efficacy for PFS and for OS.

## Sample Size and Power Calculations for PFS and OS

The study includes dual-primary efficacy endpoints: 1) PFS per RECIST 1.1 as assessed by investigator and 2) OS. The study includes multiple hypotheses testing the superiority of pembrolizumab compared to placebo, and it was to be considered positive if it is positive for either the PFS or OS hypothesis test for any of the 3 groups: CPS ≥ 1 group, all-comers, and CPS ≥ 10 group.

## PFS

The duration of PFS in the control arm is assumed to follow an exponential distribution with a median of 7.1 months based on historical data. The PFS hypothesis testing was designed as follows:

H1: CPS ≥ 1 group (expected N=510): It was expected that with approximately 370 and 435 PFS events at the planned IA1 and IA2 (final analysis for PFS), the trial has a power of 91% to detect a hazard ratio of 0.68 at onesided α = 0.004.

H2: All-comers (N=600): It was expected that with approximately 432 and 508 events at the planned IA1 and IA2 (final analysis for PFS), the trial has a power of 91% to detect a hazard ratio of 0.70 at onesided α = 0.004 (when H1 is rejected).

H3: CPS ≥ 10 group (N=300): It was expected that with approximately 210 and 247 PFS events at the planned IA1 and IA2 (final analysis for PFS), the trial has a power of 92% to detect a hazard ratio of 0.60 at onesided α = 0.005 (when H1 and H2 are rejected).

## OS

The duration of OS in the control arm is assumed to follow an exponential distribution with a median of 15.1 months based on historical data. The OS hypothesis testing was designed as follows:

H4: CPS ≥ 1 group (N=510): It was expected that with approximately 246, 321, and 378 events at the planned IA1, IA2 and final OS analyses, the trial has a power of 90% to detect a hazard ratio of 0.70 at one-sided α = 0.016.

H5: All-comers (N=600): It was expected that with approximately 289, 378, and 445 events at the planned IA1, IA2 and final OS analyses, the trial has a and power of 90% to detect a hazard ratio of 0.72 at onesided α = 0.016 (when H4 is rejected).

H6: CPS ≥ 10 group (N=300): It was expected that with approximately 127, 167, and 196 events at the planned IA1, IA2 and final OS analyses, the trial has a power of 93% to detect a hazard ratio of 0.60 at one-sided α = 0.020 (when H4 and H5 are rejected).

## Software used for sample size calculation

The sample size and power calculations were performed using EAST 6.4 software.

## Randomisation

Randomization occurred centrally using an interactive voice response system / integrated web response system (IVRS/IWRS). There were 2 treatment arms. Participants were assigned randomly in a 1:1 ratio to  pembrolizumab  plus  chemotherapy  or  placebo  plus  chemotherapy,  respectively.  The  choice  of chemotherapy (cisplatin or carboplatin) and +/- bevacizumab was determined prior to randomization and documented in the IVRS/IWRS.

Treatment randomization was stratified based on the following criteria:

<div style=\"page-break-after: always\"></div>

- 1) Metastatic (FIGO [2009] Stage IVB) at initial diagnosis (yes vs. no)
- 2) Investigator decision to use bevacizumab (yes vs. no), and
- 3) PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS ≥ 10).

A total of 12 strata have been utilized in this study.

## Blinding (masking)

A double-blinding technique with in-house blinding has been used. The participant, the investigator, and Sponsor  personnel  or  delegates  who  were  involved  in  the  study  were  unaware  of  treatment  group assignments.  Therefore,  pembrolizumab  and  placebo  were  prepared  and/or  dispensed  in  a  blinded fashion by an unblinded pharmacist or other qualified site personnel, who provided the investigative staff with ready-to-use blinded pembrolizumab or saline infusion solutions, packaged identically to maintain the blinding, for administration at scheduled infusion visits.

Results of the interim analyses were reviewed by an external DMC, which made recommendations for discontinuation of the study or protocol modification to an EOC of the Sponsor, who might have been unblinded to study results at the treatment level together with limited additional Sponsor personnel in order to act on these recommendations or facilitate regulatory filing.

A total of 84 participants discontinued treatment before the IVRS unblinding and the main reason for the unblinding was the progression of the disease.

## Statistical methods

## Protocol Amendments involving statistical methods

In global amendment 03 (31-JAN-2020) and global amendment 04 (02-APR-2020) the objectives and hypotheses were modified with an updated multiplicity  strategy  based  on  updated  results  from  the KEYTRUDA program. Statistical analysis (timing and required events, alpha passing strategy, efficacy boundaries) approach was modified to address changes in primary objectives and hypotheses. Finally, in  global  amendment  05  (30-OCT-2020),  the  objectives  including  primary  efficacy  endpoints  were modified. The primary PFS endpoint per RECIST 1.1 has been assessed by the investigator instead of by BICR (blinded independent central review), the purpose of this amendment was to address discordance between BICR-confirmed progressive disease (PD) and investigator assessed PD that could affect the power of the trial. The table below shows the history of changes.

<div style=\"page-break-after: always\"></div>

Table 7. Summary of Key Revisions to the Protocol Amendments

| Document                               | Date of Issue   | OverallRationale                                                                                                                                                                      |
|----------------------------------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 5/ Global amendment          | 30-OCT-2020     | The objectives including primary efficacy endpoints were modified. The primary PFS endpoint per RECIST 1.1 will be assessed by the mvestigator.                                       |
| Amendment 4/ Global amendment          | 02-APR-2020     | Amendment 4 supersedes Amendment 3. The objectives and hypotheses were modified with an updated multiplicity strategy based on updated resultsfromtheKEYTRUDAprogram.                 |
| Amendment 3/ Global amendment          | 31-JAN-2020     | The objectives and hypotheses were modified with an updated multiplicity strategy based on updatedresults from the KEYTRUDA program.                                                  |
| Amendment 2/ Global amendment          | 25-JUN-2019     | Clarificationofstratificationfactorsandtreatmentduration                                                                                                                              |
| Amendment1/ Germany-specific amendment | 13-NOV-2018     | Insertion of the requirements to perform HIV, hepatitis B and C testing at Screening,monthly pregnancy testing,and urinalysis at every cycle during which bevacizumab is administered |
| Original Protocol                      | 13-JUN-2018     | Not applicable                                                                                                                                                                        |

Amendments 3 and 4 were mainly driven by the new external data from other studies, such as KEYNOTE158 and by additional changes in study procedures, respectively. In Amendment 5, the modification of the primary endpoint to PFS by investigator was intended to protect the study from a loss of power, the BICR assessment was retained as a secondary endpoint.

## Interim Analyses

There are two planned interim analyses (IA) in addition to the final analysis (FA) for this study. The efficacy analyses in this submission are based on IA1. The analyses planned, endpoints evaluated, and drivers of timing are summarized in the table below.

Table 8. Summary of Interim and Final Analyses Strategy

| Analysis                              | Criteria                                                                                                                                                                                                                                                                                                                                                                                                  | Endpoint   | Time after last Subject Randomized   | Primary Purpose of Analysis                                                                                                                                                                        |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA1 (interim analysis for PFS and OS) | PFS IA1 was to be conducted when ~ 370 PFS events for CPS ≥ 1 group has been observed. It is estimated that ~210 PFS events for CPS ≥ 10 group and ~432 PFS events for all-comers will be observed at the same time. OS IA1 was to be conducted at the same time. It is estimated ~246 OS events for CPS ≥ 1 group, ~127 OS events for CPS ≥ 10 group and ~289 OS events for all-comers will be observed. | PFS OS     | ~ 22 months                          | Demonstrate PFS superiority at interim analysis for CPS ≥ 1 group, CPS ≥ 10 group, and all-comers Demonstrate OS superiority at interim analysis for CPS ≥ 1 group, CPS ≥ 10 group, and all-comers |

<div style=\"page-break-after: always\"></div>

| IA2 (final analysis for PFS/interim analysis for OS)   | PFS IA2 will be triggered when at least 435 PFS events for CPS ≥ 1 group have been observed. It is estimated that ~247 PFS events for CPS ≥ 10 group and ~508 PFS events for all-comers will be observed by then. OS IA2 will be performed at the same time. It is estimated ~321 OS events for CPS ≥ 1 group, ~167 OS events for CPS ≥ 10 group and ~378 OS events for all- comers will be observed.   | PFS OS   | ~ 30 months   | Demonstrate PFS superiority for CPS ≥ 1 group, CPS ≥ 10 group, and all-comers Demonstrate OS superiority at interim analysis for CPS ≥ 1 group, CPS ≥ 10 group, and all-comers   |
|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FA                                                     | FA will be triggered when at least 378 OS events for CPS ≥ 1 group has been observed. It is estimated that ~196 OS events for CPS ≥ 10 group and 445 OS events for all-comers will be observed by then.                                                                                                                                                                                                 | OS       | ~ 40 months   | Demonstrate OS superiority for CPS ≥ 1 group, CPS ≥ 10 group, and all-comers                                                                                                     |

IA1 was performed after approximately 355 PFS events had been observed among participants with CPS ≥ 1, of which 157 occurred in pembrolizumab arm and 198 in the placebo arm.

PFS events had been accruing significantly slower than expected at the time the analysis plan was constructed,  but  the  number  of  355  at  IA1  was  considered  sufficiently  close  to  the  target  number (n=370).

## Error probabilities, adjustment for multiplicity

Based on emerging data external to this study, the multiplicity strategy including the testing order among the 6 primary hypotheses was revised in Protocol Amendments 03 and 04. The update of the multiplicity strategy occurred prior to the conduct of efficacy IA1. The overall Type-I error rate among the multiple hypotheses was strongly controlled at 2.5% (one-sided). The study used the graphical method of Maurer and Bretz to provide strong multiplicity control among the hypotheses of PFS and OS for CPS ≥ 1 group, all-comers, and CPS ≥ 10 group. Lan-DeMets O'Brien-Fleming group sequential methods has been used to allocate alpha among the interim and final analyses for the PFS and OS endpoints. The Figures below display the revised multiplicity strategy diagram of the study according to Protocol Amendment 05 on the right side and the former multiplicity strategy diagram of the study according to amendment 02 on the left side.

<div style=\"page-break-after: always\"></div>

Figure 5A. Amendment 2: Multiplicity Graph for     Figure 5B. Amendment 5: Multiplicity

Graph Study Type I Error Control of Study Hypotheses

<!-- image -->

The  initial  one-sided  alpha  allocation  for  each  hypothesis  is  shown  in  the  ellipse  representing  the hypothesis. The weights for re-allocation from each hypothesis to the others are in the boxes on the lines connecting hypotheses. According to this approach, study hypotheses may be tested more than once, and when a particular null hypothesis is rejected, the alpha allocated to that hypothesis can be reallocated to other hypothesis tests.

## PFS

The study initially allocates onesided α =0.005 to test PFS between two treatment groups for CPS ≥ 1 group, all-comers, and CPS ≥ 10 group. If the null hypothesis of PFS for CPS ≥ 1 group was rejected, its α=0.004 was reallocated to the PFS analysis for all -comers, and if the null hypothesis of PFS for allcomers was rejected, its α=0.004 was reallocated to the PFS analysis for CPS ≥ 10 group. The boundary properties  for  each  of  these  alpha-levels  for  the  interim  analyses  were  derived  using  a  Lan-DeMets O'Brien-Fleming spending function. The bounds and boundary properties for PFS testing are shown in the table below.

<div style=\"page-break-after: always\"></div>

| Population   | Analysisa   | Value               | α=0.004   |         |
|--------------|-------------|---------------------|-----------|---------|
| CPS ≥1       | IA1: 85%    | Z                   | 2.911     |         |
|              | N: 510      | p (1-sided)         | 0.002     |         |
|              | Events:370  | ~HR at bound        | 0.739     |         |
|              | Month: 22   | P(Cross) if HR=1    | 0.002     |         |
|              |             | P(Cross) if HR=0.68 | 0.788     |         |
|              | IA2:100%    | Z                   | 2.700     |         |
|              | N: 510      | p (l-sided)         | 0.003     |         |
|              | Events: 435 | ~HR at bound        | 0.772     |         |
|              | Month: 30   | P(Cross) if HR=1    | 0.004     |         |
|              |             | P(Cross) if HR=0.68 | 0.911     |         |
| Population   | Analysisa   | Value               | α=0.004   |         |
| All-comers   | IA1: 85%    | Z                   | 2.911     |         |
|              | N: 600      | p (1-sided)         | 0.002     |         |
|              | Events: 432 | ~HR at bound        | 0.756     |         |
|              | Month: 22   | P(Cross) if HR=1    | 0.002     |         |
|              |             | P(Cross) if HR=0.70 | 0.787     |         |
|              | IA2: 100%   | Z                   | 2.700     |         |
|              | N: 600      | p (l-sided)         | 0.003     |         |
|              | Events: 508 | ~HR at bound        | 0.787     |         |
|              | Month: 30   | P(Cross) if HR=1    | 0.004     |         |
|              |             | P(Cross) if HR=0.70 | 0.910     |         |
| Population   | Analysisa   | Value               | α=0.005   | α=0.001 |
| CPS ≥10      | IA1: 85%    | Z                   | 2.829     | 3.383   |
|              | N: 300      | p (l-sided)         | 0.002     | 0.0004  |
|              | Events: 210 | ~HR at bound        | 0.677     | 0.627   |
|              | Month: 22   | P(Cross) if HR=1    | 0.002     | 0.0004  |
|              |             | P(Cross) if HR=0.60 | 0.808     | 0.625   |
|              | IA2:100%    | Z                   | 2.627     | 3.125   |
|              | N: 300      | p (l-sided)         | 0.004     | 0.001   |
|              | Events: 247 | ~HR at bound        | 0.716     | 0.672   |
|              | Month: 30   | P(Cross) if HR=1    | 0.005     | 0.001   |
|              |             | P(Cross) if HR=0.60 | 0.921     | 0.817   |

Table 8A. Efficacy Boundaries and Properties for PFS Analyses

<!-- image -->

## OS

The study initially allocates onesided α=0.020 to test OS between two treatment groups for CPS ≥ 1 group, all-comers, and CPS ≥ 10 group. The OS hypothesis for CPS ≥ 1 group may be tested at one-sided α=0.016 (initially allocated) or higher if one or more nu ll hypotheses for PFS test are rejected. If the null hypothesis of OS for CPS ≥ 1 group was rejected , its α was allocated to the OS analysis for all -comers, and if the null hypothesis of OS for all-comers was rejected, its α was reallocated to the OS analysis for CPS ≥ 10 group. The table below shows the bounds and boundary properties for OS testing which were derived using a Lan-DeMets O'BrienFleming α -spending function. Further details of statistical analyses were described in the SAP.

<div style=\"page-break-after: always\"></div>

Table 8B. Efficacy Boundaries and Properties for OS Analysis.

<!-- image -->

| Population   | Analysisa    | Parameter                            | α=0.016     |              |
|--------------|--------------|--------------------------------------|-------------|--------------|
| CPS≥1        | IA1: 65%     | Z                                    | 2.767       |              |
|              | N: 510       | p (1-sided)                          | 0.003       |              |
|              | Events: 246  | ~HR at bound                         | 0.703       |              |
|              | Month: 22    | P(Cross) if HR=1                     | 0.003       |              |
|              |              | P(Cross) if HR=0.70                  | 0.512       |              |
|              | IA2: 85%     | Z                                    | 2.405       |              |
|              | N: 510       | p(1-sided)                           | 0.008       |              |
|              | Events: 321  | ~HR at bound                         | 0.765       |              |
|              | Month: 30    | P(Cross) if HR=1                     | 0.009       |              |
|              |              | P(Cross) if HR=0.70                  | 0.791       |              |
|              | Final: 100%  | Z                                    | 2.221       |              |
|              | N: 510       | p (l-sided)                          | 0.013       |              |
|              | Events: 378  | ~HR at bound                         | 0.796       |              |
|              | Month: 40    | P(Cross) if HR=1                     | 0.016       |              |
|              |              | P(Cross)if HR=0.70                   | 0.901       |              |
| Population   | Analysisa    | Parameter                            | α=0.016     |              |
| All-comers   | IA1: 65%     | Z                                    | 2.771       |              |
|              | N: 600       | p (1-sided)                          | 0.003       |              |
|              | Events: 289  | ~HR at bound                         | 0.722       |              |
|              | Month: 22    | P(Cross) if HR=1                     | 0.003       |              |
|              |              | P(Cross) if HR=0.72                  | 0.509       |              |
|              | IA2: 85%     | Z                                    | 2.404       |              |
|              | N: 600       | p (l-sided)                          | 0.008       |              |
|              | Events: 378  | ~HR at bound                         | 0.781       |              |
|              | Month: 30    | P(Cross) if HR=1                     | 0.009       |              |
|              |              | P(Cross) if HR=0.72                  | 0.790       |              |
|              | Final: 100%  | Z                                    | 2.221       |              |
|              | N: 600       | p (1-sided)                          | 0.013       |              |
|              | Events:445   | ~HR at bound                         | 0.810       |              |
|              | Month: 40    | P(Cross) if HR=1                     | 0.016       |              |
|              |              | P(Cross) if HR=0.72                  | 0.901       |              |
| Population   | Analysisa    | Parameter                            | α=0.020     | α=0.004      |
| CPS ≥10      | IA1: 65%     | Z                                    | 2.665       | 3.339        |
|              | N: 300       | p (1-sided)                          | 0.004       | 0.0004       |
| Population   | Analysisa    | Parameter                            | α=0.016     |              |
|              | Events: 127  | ~HR at bound                         | 0.623       | 0.548        |
|              | Month: 22    | P(Cross) if HR=1 P(Cross) if HR=0.60 | 0.004 0.585 | 0.0004 0.304 |
|              | IA2: 85%     | Z                                    | 2.306       | 2.928        |
|              | N: 300       | p (l-sided)                          | 0.011       | 0.002        |
|              |              |                                      |             | 0.636        |
|              | Events: 167  | ~HR at bound                         | 0.700       |              |
|              | Month: 30    | P(Cross) if HR=1                     | 0.012       | 0.002        |
|              |              | P(Cross) if HR=0.60                  | 0.845       | 0.648        |
|              | Final : 100% | Z                                    | 2.137       | 2.704        |
|              | N: 300       | p (l-sided)                          | 0.016       | 0.003        |
|              | Events: 196  | ~HR at bound                         | 0.737       | 0.680        |
|              | Month: 40    | P(Cross) if HR=1                     | 0.020       | 0.004        |
|              |              | P(Cross) if HR=0.60                  | 0.931       | 0.815        |

CPS=combinedpositivescore;HR=hazardratio;IAX=interim analysisX;OS=overallsurvival

p (1-sided): the nominal α for testing.

This column displays the number (Events) and percentage (%) of needed PFS events, the expected sample size (N) and a. the estimatedmonths (Month) after first participant is randomized for each analysis.

~HR at bound: the approximate hazard ratio required to reach an efficacy bound.

P(Cross if HR=1): the probability of crossing a bound at or before each analysis under the null hypothesis

P(Cross if HR=0.70 or 0.72 or 0.60): the probability of crossing a bound at or before each analysis under the altermative hypothesis.

## Efficacy analyses

The Intention-to-Treat (ITT) population served as the population for the primary efficacy analyses. All randomized participants were included in this population. Participants were analysed in the treatment arm to which they are randomized, regardless of whether they received study treatment. A summary of the analysis strategy for key efficacy endpoints is presented in the following table:

<div style=\"page-break-after: always\"></div>

Table 8C. Efficacy Analysis Methods for Key Efficacy Endpoints

| Endpoint/Variable                                  | Statistical Method                                                                                  | Analysis Population   | Missing Data Approach                                        |
|----------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------------------|
| Primary Analyses:                                  | Primary Analyses:                                                                                   | Primary Analyses:     | Primary Analyses:                                            |
| PFS (RECIST 1.1) by investigator                   | Testing:StratifiedLog-ranktest Estimation: Stratified Cox model with Efron's tie handling method    | ITT                   | Censored according to rules in Table 9                       |
| OS                                                 | Testing: Stratified Log-rank test Estimation: Stratified Cox model with Efron's tie handling method | ITT                   | Censored at last known alive date                            |
| Secondary Analyses:                                | Secondary Analyses:                                                                                 | Secondary Analyses:   | Secondary Analyses:                                          |
| ORR (RECIST 1.1) by investigator                   | Estimation:StratifiedMiettinen and Nurminen method                                                  | ITT                   | Participants with missing data are considered non-responders |
| DOR (RECIST 1.1) by investigator                   | Summary statistics using Kaplan- Meier method                                                       | A11 responders in ITT | Non-responders are excluded from the analysis                |
| PFS rate at 12 months (RECIST 1.1) by investigator | Kaplan-Meier estimation with CI                                                                     | ITT                   | Censored according to rules in Table 9                       |
| PFS (RECIST 1.1) by BICR                           | Estimation:StratifiedCoxmodel with Efron's tie handling method                                      | ITT                   | Censored according to rules in Table 9                       |

BICR=blinded independent central review;CI=confidence interval;DOR=duration ofresponse;ITT=Intention-toTreat; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; RECIST 1.1 =Response EvaluationCriteria inSolid Tumors1.1.

Table 9. Censoring rules for Primary and Sensitivity Analysis of Progression-Free Survival

| Situation                                                                                                                                               | Primary Analysis                                                                                                                          | Sensitivity Analysis 1                       | Sensitivity Analysis 2                                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PD or death documented after ≤1 missed disease assessment and before new anti-cancer therapy, if any                                                    | Progressed at date of documented PD or death                                                                                              | Progressed at date of documentedPDordeath    | Progressed at date of documentedPDordeath                                                                                                                                   |
| Death or progression after ≥2 consecutive missed disease assessments without further valid non-PD disease assessments, or after new anti-cancer therapy | Censored at last disease assessmentpriorto theearlierdate of ≥2 consecutive missed disease assessment and new anti-cancer therapy, if any | Progressed at date of documented PD or death | Progressed at date of documentedPDordeath                                                                                                                                   |
| NoPDandnodeath and new anti-cancer treatment is not initiated                                                                                           | Censored at last disease assessment                                                                                                       | Censored at last disease assessment          | Progressed at treatment discontinuation due to reasons other than complete response;otherwisecensored atlastdiseaseassessmentif still on study or completed study treatment |
| No PD and no death; new anti-cancer treatmentisinitiated                                                                                                | Censored at last disease assessment before new anti-cancer treatment                                                                      | Censored at last disease assessment          | Progressed at date of new anti-cancertreatment                                                                                                                              |

<div style=\"page-break-after: always\"></div>

Table 10. Censoring Rules for DOR

| Situation                                                                                                                        | Date of Progression or Censoring                                                                                                 | Outcome                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| No progression nor death, no new anti-cancer therapy initiated                                                                   | Last adequate disease assessment                                                                                                 | Censor (non-event)                                                                                                               |
| No progression nor death, new anti-cancer therapy initiated                                                                      | Last adequate disease assessment before new anti- cancer therapy initiated                                                       | Censor (non-event)                                                                                                               |
| Death or progression after ≥2 consecutive missed disease assessments                                                             | Last adequate disease assessment prior to the ≥2 missed adequate disease assessments                                             | Censor (non-event)                                                                                                               |
| Death or progression after ≤1 missed adequate disease assessments                                                                | PD or death                                                                                                                      | End of response (Event)                                                                                                          |
| A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response. | A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response. | A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response. |

The non-parametric Kaplan-Meier method was used to estimate the PFS and OS curve in each treatment group. The treatment difference in PFS and OS was assessed by the stratified log-rank test. For PFS and OS a stratified Cox proportional hazard model with Efron's method of tie handling was used to assess the magnitude of the treatment difference between the treatment arms. The hazard ratio and its 95% confidence interval from the stratified Cox model with Efron's method of tie handling and with a single treatment covariate was reported. The same stratification factors used for randomization were applied to  both  the  stratified  log-rank  test  and  the  stratified  Cox  model.  Death  is  always  considered  as  a confirmed PD event. Participants who do not experience PFS event were censored at the last disease assessment, while participants without documented death at the time of analysis were censored at the date of last known contact. Restricted Mean Survival Time (RMST) method may be conducted for OS to account for the possible non-proportional hazards effect.

In order to evaluate the robustness of the PFS endpoint, one primary and two sensitivity analyses with a  different  set  of  censoring  rules  were  performed.  The  censoring  rules  for  primary  and  sensitivity analyses are summarized in Table 9.

The stratified Miettinen and Nurminen method was used for the comparison of the ORR between the two treatment groups. The difference in ORR and its 95% confidence interval from the stratified Miettinen and Nurminen method with strata weighting by sample size was reported. The stratification factors used for randomization were applied to the analysis.

DOR was summarised descriptively using Kaplan-Meier medians and quartiles and was assessed using RECIST 1.1 by investigator and BICR, respectively. Only the subset of patients who show a complete response or partial response were included in this analysis. For each DOR analysis, a corresponding summary of the censoring reasons for responding participant were also provided. Censoring rules for DOR are summarized in Table 10.

Sensitivity analyses are adequate.

## Subgroup analyses

Subgroup Analyses and Effect of Baseline Factors are planned. To determine whether the treatment effect is consistent across various subgroups, the between-group treatment effect for PFS and OS (with a nominal 95% CI) was estimated and plotted by treatment group within each category of the following classification variables: Stratification factors, Metastatic at diagnosis (Yes vs. No), Bevacizumab use (Yes vs. No), PD-L1 status (CPS&lt;1 vs. CPS 1 to &lt; 10 vs. CPS ≥ 10), Age group (&lt;65 years vs. ≥ 65 years),

<div style=\"page-break-after: always\"></div>

Race (white, non-white), ECOG performance status (0, 1). A Forest plot was produced, which provides the estimated point estimates and confidence intervals for the treatment effect across the categories of subgroups listed above. The consistency of the treatment effect was assessed descriptively via summary statistics by category for the classification variables listed above.

## Safety analyses

The safety analyses were based on the APaT populations, which included all randomized participants who received at least 1 dose of study treatment. The analysis of safety results followed a tiered approach. There were no Tier 1 endpoints in this study, and Tier 2 parameters were assessed via point estimates with 95% confidence intervals (CIs) provided for differences in the proportion of participants with events; only point estimates by intervention arm were provided for Tier 3 safety parameters. The 95% CIs for the  between-treatment  differences  in  percentages  were  provided  using  the  Miettinen  and  Nurminen method.

## PRO analyses

PRO  analyses  were  based  on  the  PRO  FAS  population,  defined  as  all  randomized  participants  who received at least 1 dose of study intervention and had completed at least 1 PRO assessment. Participants were included in the treatment arm to which they were randomly assigned in the PRO analyses.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 6. Participant flow in all comer participants

<!-- image -->

Abbreviations: APaT=all participants as treated; COVID-19=Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2ECOG=Eastern Cooperative Oncology Group; ITT=intent to treat; RECIST=Response Evaluation Criteria in Solid Tumor.

A total of 266 patients screened were not randomized due to screen failure. The main reason for screen failure were inadequate organ functions per laboratory value (18.9%), lack of measurable disease per RECIST 1.1 (16.6%), not providing informed consent (12.5%), ECOG not 0 or 1 (8.3%), other condition that may confound result or interfere with participation (7.9%).

<div style=\"page-break-after: always\"></div>

Table 11. Disposition of Participants Including Association with COVID-19 (ITT Population)

|                                                     | Pembro Combo   | Pembro Combo   | Control   | Control   | Total   | Total   |
|-----------------------------------------------------|----------------|----------------|-----------|-----------|---------|---------|
|                                                     |                | (%)            |           | (%)       | n       | (%)     |
| Participants in population                          | 308            |                | 309       |           | 617     |         |
| Status for Trial                                    |                |                |           |           |         |         |
| Discontinued                                        | 140            | (45.5)         | 180       | (58.3)    | 320     | (51.9)  |
| Death                                               | 134            | (43.5)         | 171       | (55.3)    | 305     | (49.4)  |
| AssociatedwithCOVID-19                              | 0              | (0.0)          | 1         | (0.3)     | 1       | (0.2)   |
| Lost To Follow-Up                                   | 0              | (0.0)          | 1         | (0.3)     | 1       | (0.2)   |
| Withdrawal By Subject                               | 6              | (1.9)          | 8         | (2.6)     | 14      | (2.3)   |
| COVID-19 association unspecified, Subsequently died | 4              | (1.3)          | 3         | (1.0)     | 7       | (1.1)   |
| Participants Ongoing                                | 168            | (54.5)         | 129       | (41.7)    | 297     | (48.1)  |
| StatusforStudyMedicationinTrial                     |                |                |           |           |         |         |
| Started                                             | 307            |                | 309       |           | 616     |         |
| Completed                                           | 7              | (2.3)          | 0         | (0.0)     | 7       | (1.1)   |
| Discontinued                                        | 196            | (63.8)         | 255       | (82.5)    | 451     | (73.2)  |
| Adverse Event                                       | 38             | (12.4)         | 24        | (7.8)     | 62      | (10.1)  |
| Clinical Progression                                | 12             | (3.9)          | 22        | (7.1)     | 34      | (5.5)   |
| Complete Response                                   | 2              | (0.7)          | 1         | (0.3)     | 3       | (0.5)   |
| Excluded Medication                                 | 1              | (0.3)          | 0         | (0.0)     | 1       | (0.2)   |
| Physician Decision                                  | 4              | (1.3)          | 4         | (1.3)     | 8       | (1.3)   |
| Progressive Disease                                 | 124            | (40.4)         | 181       | (58.6)    | 305     | (49.5)  |
| Protocol Violation                                  | 0              | (0.0)          | 1         | (0.3)     | 1       | (0.2)   |
| Withdrawal BySubject                                | 15             | (4.9)          | 22        | (7.1)     | 37      | (6.0)   |
| AssociatedwithCOVID-19                              | 0              | (0.0)          | 1         | (0.3)     | 1       | (0.2)   |
| Participants Ongoing                                | 104            | (33.9)         | 54        | (17.5)    | 158     | (25.6)  |

Ifthe overall count of participants is calculated and displayed withina section in the fist row, then it is used as the denominator for the percentage calculation.Otherwise,participants in population is used as the denominator for the percentage calculation.

DatabaseCutoffDate:03MAY2021

## Recruitment

This study was conducted at 151 centers in 19 countries. First patient first visit was on 25-OCT-2018. Randomization occurred between 20 November 2018 and 31 January 2020 (Colombo, 2021).

Data Cut-off for IA1 was on 03-MAY-2021.

The last patient randomized was observed for approximately 15 months. The median follow-up was approximately 17 months (see tables below):

Table 12. Summary of Follow-up Duration (CPS&gt;=1 Participants) (ITT Population)

| Follow-upduration(months)a                                                                                                                                      | PembroCombo (N=273)                                                                                                                                             | Control (N=275)                                                                                                                                                 | Total (N=548)                                                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Median (Range)                                                                                                                                                  | 18.3 (0.5,29.4)                                                                                                                                                 | 16.3(0.3,29.2)                                                                                                                                                  | 17.2 (0.3,29.4)                                                                                                                                                 |
| Mean (SD)                                                                                                                                                       | 17.2 (6.9)                                                                                                                                                      | 15.0 (7.3)                                                                                                                                                      | 16.1 (7.1)                                                                                                                                                      |
| Follow-updurationis definedasthetimefromrandomizationtothedate of death or thedatabase cutoff dateif the participantisstill alive. DatabaseCutoffDate:03MAY2021 | Follow-updurationis definedasthetimefromrandomizationtothedate of death or thedatabase cutoff dateif the participantisstill alive. DatabaseCutoffDate:03MAY2021 | Follow-updurationis definedasthetimefromrandomizationtothedate of death or thedatabase cutoff dateif the participantisstill alive. DatabaseCutoffDate:03MAY2021 | Follow-updurationis definedasthetimefromrandomizationtothedate of death or thedatabase cutoff dateif the participantisstill alive. DatabaseCutoffDate:03MAY2021 |

Table 13. Summary of Follow-up Duration (All-comer Participants) (ITT Population)

| Follow-upduration(months)a                                                                                                                              | PembroCombo (N=308)                                                                                                                                     | Control (N=309)                                                                                                                                         | Total (N=617)                                                                                                                                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| Median (Range)                                                                                                                                          | 18.2(0.5,29.4)                                                                                                                                          | 16.3 (0.3,29.2)                                                                                                                                         | 17.2 (0.3,29.4)                                                                                                                                         |
| Mean (SD)                                                                                                                                               | 17.0 (7.0)                                                                                                                                              | 15.1 (7.1)                                                                                                                                              | 16.1 (7.1)                                                                                                                                              |
| Follow-updurationisdefinedasthetimefromrandomizationtothedateofdeathorthedatabasecutoffdateifthe participantisstill alive. DatabaseCutoffDate:03MAY2021 | Follow-updurationisdefinedasthetimefromrandomizationtothedateofdeathorthedatabasecutoffdateifthe participantisstill alive. DatabaseCutoffDate:03MAY2021 | Follow-updurationisdefinedasthetimefromrandomizationtothedateofdeathorthedatabasecutoffdateifthe participantisstill alive. DatabaseCutoffDate:03MAY2021 | Follow-updurationisdefinedasthetimefromrandomizationtothedateofdeathorthedatabasecutoffdateifthe participantisstill alive. DatabaseCutoffDate:03MAY2021 |

<div style=\"page-break-after: always\"></div>

Table 14. Summary of Follow-up Duration (CPS&gt;=10 Participants) (ITT Population)

| Follow-upduration(months)a                                                                                                                                        | PembroCombo (N=158)   | Control (N=159)   | Total (N=317)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------------|-----------------|
| Median(Range)                                                                                                                                                     | 18.3 (0.5,28.4)       | 16.3 (0.9,29.2)   | 17.2(0.5,29.2)  |
| Mean (SD) Follow-updurationisdefinedasthetimefromrandomizationtothedateofdeathorthedatabasecutoffdateif the participantisstillalive. DatabaseCutoffDate:03MAY2021 | 17.2 (6.9)            | 14.9 (7.4)        | 16.0 (7.3)      |

## Conduct of the study

Protocol amendments : original protocol was dated 13 June 2018. A total of 5 global protocol amendments were released by data cut-off date for IA1 (see statistical methods).

Protocol deviations : overall, 6.3% of patients were with one or more not clinically important protocol deviation, 22 (7.1%) vs 17 (5.5%) in the pembro combo vs control arm, respectively. Clinically important protocol deviations were recorded in 14 patients, 5 (1.6%) in the pembro combo arm and 9 (2.9%) in the control arm.

Table 15. Summary of Important Protocol Deviations Considered to be Clinically Important (ITT Population)

|                                                                                                                                                 | Pembro Combo                                                                                                | Pembro Combo                                                                                                | Control                                                                                                     | Control                                                                                                     | Total                                                                                                       | Total                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                 | n                                                                                                           | (%)                                                                                                         | n                                                                                                           | (%)                                                                                                         | n                                                                                                           | (%)                                                                                                         |
| Participants in population                                                                                                                      | 308                                                                                                         |                                                                                                             | 309                                                                                                         |                                                                                                             | 617                                                                                                         |                                                                                                             |
| with one or more clinically important protocol deviations                                                                                       | 5                                                                                                           | (1.6)                                                                                                       | 9                                                                                                           | (2.9)                                                                                                       | 14                                                                                                          | (2.3)                                                                                                       |
| with no clinicallyimportant protocol deviations                                                                                                 | 303                                                                                                         | (98.4)                                                                                                      | 300                                                                                                         | (97.1)                                                                                                      | 603                                                                                                         | (97.7)                                                                                                      |
| Inclusion/ExclusionCriteria                                                                                                                     | +                                                                                                           | (1.3)                                                                                                       | 2                                                                                                           | (0.6)                                                                                                       | 6                                                                                                           | (1.0)                                                                                                       |
| Participant didnot havepersistent,recurrent,ormetastaticsquamous cell carcinoma,adenosquamous carcinoma,or adenocarcinoma ofthe cervix.         | 0                                                                                                           | (0.0)                                                                                                       | 1                                                                                                           | (0.3)                                                                                                       | 1                                                                                                           | (0.2)                                                                                                       |
| Participant waspreviously treatedwithsystemicchemotherapyforthe treatment of cervical cancer.                                                   | 3                                                                                                           | (1.0)                                                                                                       | 0                                                                                                           | (0.0)                                                                                                       | 3                                                                                                           | (0.5)                                                                                                       |
| Participants entered into the trial who did not have the correct tumor histology per the I/E criteria.                                          |                                                                                                             | (0.3)                                                                                                       |                                                                                                             | (0.3)                                                                                                       | 2                                                                                                           | (0.3)                                                                                                       |
| InformedConsent                                                                                                                                 | 0                                                                                                           | (0.0)                                                                                                       | 1                                                                                                           | (0.3)                                                                                                       | 1                                                                                                           | (0.2)                                                                                                       |
| Participant had nodocumentedinitial consent toenter the trial.                                                                                  | 0                                                                                                           | (0.0)                                                                                                       | 1                                                                                                           | (0.3)                                                                                                       | 1                                                                                                           | (0.2)                                                                                                       |
| SafetyReporting                                                                                                                                 | 1                                                                                                           | (0.3)                                                                                                       | 1                                                                                                           | (0.3)                                                                                                       | 2                                                                                                           | (0.3)                                                                                                       |
| Participant had areportableSafetyEvent and/orfollow upSafetyEvent infonmation that was not reported per the timelines outlined in the protocol. | 1                                                                                                           | (0.3)                                                                                                       |                                                                                                             | (0.3)                                                                                                       | 2                                                                                                           | (0.3)                                                                                                       |
| StudyIntervention                                                                                                                               | 0                                                                                                           | (0.0)                                                                                                       | 6                                                                                                           | (1.9)                                                                                                       | 6                                                                                                           | (1.0)                                                                                                       |
| Participant was administered improperly stored study intervention that was deemed unacceptablefor use.                                          | 0                                                                                                           | (0.0)                                                                                                       | 6                                                                                                           | (1.9)                                                                                                       | 6                                                                                                           | (1.0)                                                                                                       |
| Every participant is counted a single time for each applicable row and column. DatabaseCutoffDate:03MAY2021                                     | Every participant is counted a single time for each applicable row and column. DatabaseCutoffDate:03MAY2021 | Every participant is counted a single time for each applicable row and column. DatabaseCutoffDate:03MAY2021 | Every participant is counted a single time for each applicable row and column. DatabaseCutoffDate:03MAY2021 | Every participant is counted a single time for each applicable row and column. DatabaseCutoffDate:03MAY2021 | Every participant is counted a single time for each applicable row and column. DatabaseCutoffDate:03MAY2021 | Every participant is counted a single time for each applicable row and column. DatabaseCutoffDate:03MAY2021 |

<div style=\"page-break-after: always\"></div>

Table  16.  Accounting  of  Selected  Protocol  Deviations  Associated  With  COVID-19  (ITT Population)

|                                                                   | Pembro Combo   | Pembro Combo   | Control   | Control   | Total   | Total   |
|-------------------------------------------------------------------|----------------|----------------|-----------|-----------|---------|---------|
|                                                                   | n              | (%)            | n         | (%)       | n       | (%)     |
| Participants in population                                        | 308            |                | 309       |           | 617     |         |
| Subjects with >=1 Disease Assessment deviation                    | 2              | (0.6)          | 2         | (0.6)     | 4       | (0.6)   |
| >=1 Disease Assessment Alternate Method- AltemativeLocation       | 0              | (0.0)          | 2         | (0.6)     | 2       | (0.3)   |
| >=1 Disease Assessment Missed                                     | 1              | (0.3)          | 0         | (0.0)     | 1       | (0.2)   |
| >=1 Disease Assessment Partially Missed                           | 1              | (0.3)          | 0         | (0.0)     | 1       | (0.2)   |
| Subjects with >=1 Dose deviation                                  | 6              | (1.9)          | 3         | (1.0)     | 9       | (1.5)   |
| >=1 Dose Delayed                                                  | 6              | (1.9)          | 3         | (1.0)     | 9       | (1.5)   |
| Subjectswith>=1 ImagingScan deviation                             | 27             | (8.8)          | 13        | (4.2)     | 40      | (6.5)   |
| >=1 Imaging Scan Delayed                                          | 23             | (7.5)          | I         | (3.6)     | 34      | (5.5)   |
| >=1 Imaging Scan Missed                                           | 4              | (1.3)          | 2         | (0.6)     | 6       | (1.0)   |
| Subjectswith>=1Patient-Reported Outcome deviation                 | 14             | (4.5)          | 20        | (6.5)     |         | (5.5)   |
| >=1 Patient-Reported Outcome Altermate Method-AlternativeLocation |                | (3.6)          | 10        | (3.2)     | 21      | (3.4)   |
| >=1 Patient -Reported Outcome Missed                              | 5              | (1.6)          | 13        | (4.2)     | 18      | (2.9)   |
| >=1 Patient -Reported OutcomePartially Missed                     | 0              | (0.0)          | 2         | (0.6)     | 2       | (0.3)   |
| Subjectswith>=1Procedure deviation                                | 17             | (5.5)          | 13        | (4.2)     | 30      | (4.9)   |
| >=1Procedure Altermate Method                                     | 3              | (1.0)          | 2         | (0.6)     | 5       | (0.8)   |
| >=1Procedure Altemate Process                                     | 3              | (1.0)          | 0         | (0.0)     | 3       | (0.5)   |
| >=1 Procedure Delayed                                             | 5              | (1.6)          | 4         | (1.3)     | 9       | (1.5)   |
| >=1 Procedure Missed                                              | 6              | (1.9)          | 6         | (1.9)     | 12      | (1.9)   |
| >=1 Procedure Telemedicine                                        | 2              | (0.6)          | 2         | (0.6)     | 4       | (0.6)   |
| Subjects with>=1SafetyAssessment deviation                        | 12             | (3.9)          | 6         | (1.9)     | 18      | (2.9)   |
| >=1 Safety Assessment Alternate Method- Altermative Location      | 4              | (1.3)          | 2         | (0.6)     | 6       | (1.0)   |
| >=1 SafetyAssessment Delayed                                      | 1              | (0.3)          | 0         | (0.0)     | 1       | (0.2)   |
| >=1 Safety Assessment Missed                                      | 6              | (1.9)          | 3         | (1.0)     | 9       | (1.5)   |
| >=1 Safety Assessment Other                                       | 1              | (0.3)          | 1         | (0.3)     | 2       | (0.3)   |
| Subjects with >=1 Scan deviation                                  | 4              | (1.3)          | 3         | (1.0)     | 7       | (1.1)   |
| >=1 Scan Delayed                                                  | 3              | (1.0)          | 2         | (0.6)     | 5       | (0.8)   |
| >=1 Scan Missed                                                   | 1              | (0.3)          | 1         | (0.3)     | 2       | (0.3)   |
| Subjects with >=1 Visit deviation                                 | 47             | (15.3)         | 42        | (13.6)    | 89      | (14.4)  |
| >=1 Visit Altermate Method-Altermative Location                   | 13             | (4.2)          | 5         | (1.6)     | 18      | (2.9)   |
| >=1 Visit Delayed                                                 | 33             | (10.7)         | 34        | (11.0)    | 67      | (10.9)  |
| >=1 Visit Missed                                                  | 5              | (1.6)          | 6         | (1.9)     | 11      | (1.8)   |
| >=1Visit Telemedicine                                             | 8              | (2.6)          | 4         | (1.3)     | 12      | (1.9)   |

Database CutoffDate:03MAY2021

This tablereflects all protocol deviations reported as associated with COVID-19 that are deemed to have the potential to impact interpretation of study results.

Each block of rows (i.e., within horizontal grid lines) reflects deviations recorded according to the bolded text (e.g., visit, dose).Impacts of COVID-19 counted in the blocks of rows subsequent to visit deviations may or may not alsobe counted within the block of rows for visit deviations,and vice versa,depending on whether the impacts were reportedboth asvisit deviations and as other deviations.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 17 . Participant Characteristics (CPS≥1 Participants) (ITT Population)

|                                                               | Pembro Combo   | Pembro Combo   | Control   | Control   | Total    | Total   |
|---------------------------------------------------------------|----------------|----------------|-----------|-----------|----------|---------|
|                                                               |                | (%)            | 1         | (%)       | 1        | (%)     |
| Participants in population                                    | 273            |                | 275       |           | 548      |         |
| Sex                                                           |                |                |           |           |          |         |
| Female                                                        | 273            | (100.0)        | 275       | (100.0)   | 548      | (100.0) |
| Age (Years)                                                   |                |                |           |           |          |         |
| <50                                                           | 123            | (45.1)         | 124       | (45.1)    | 247      | (45.1)  |
| 50 to 64                                                      | 109            | (39.9)         | 105       | (38.2)    | 214      | (39.1)  |
| 65 to 74                                                      | 32             | (11.7)         | 37        | (13.5)    | 69       | (12.6)  |
| >=75                                                          | 9              | (3.3)          | 9         | (3.3)     | 18       | (3.3)   |
| Mean                                                          | 51.2           |                | 50.7      |           | 51.0     |         |
| SD                                                            | 12.0           |                | 12.6      |           | 12.3     |         |
| Median                                                        | 51.0           |                | 51.0      |           | 51.0     |         |
| Range                                                         | 25 to 82       |                | 22 to 78  |           | 22 to 82 |         |
| Race                                                          |                |                |           |           |          |         |
| AmericanIndian Or Alaska Native                               | 13             | (4.8)          | 17        | (6.2)     | 30       | (5.5)   |
| Asian                                                         | 57             | (20.9)         | 41        | (14.9)    | 98       | (17.9)  |
| Black Or African American                                     | 4              | (1.5)          | 2         | (0.7)     | 6        | (1.1)   |
| Multiple                                                      | 28             | (10.3)         | 27        | (9.8)     | 55       | (10.0)  |
| American Indian Or AlaskaNative And Black Or African American | 7              | (2.6)          | 7         | (2.5)     | 14       | (2.6)   |
| AmericanIndianOrAlaskaNative And White                        | 15             | (5.5)          | 13        | (4.7)     | 28       | (5.1)   |
| American Indian Or Alaska Native And White And Asian          | 0              | (0.0)          | 1         | (0.4)     | 1        | (0.2)   |
| Black Or African AmericanAnd White                            | 6              | (2.2)          | 6         | (2.2)     | 12       | (2.2)   |
| Not Applicablea                                               | 17             | (6.2)          | 16        | (5.8)     | 33       | (6.0)   |
| White                                                         | 153            | (56.0)         | 172       | (62.5)    | 325      | (59.3)  |
| Missing                                                       | 1              | (0.4)          | 0         | (0.0)     | 1        | (0.2)   |
| Ethnicity                                                     |                |                |           |           |          |         |
| Hispanic Or Latino                                            | 97             | (35.5)         | 106       | (38.5)    | 203      | (37.0)  |

<div style=\"page-break-after: always\"></div>

| Not Hispanic Or Latino Not Reported                           | 170   | (62.3)   | 165   | (60.0)   | 335   | (61.1)   |
|---------------------------------------------------------------|-------|----------|-------|----------|-------|----------|
|                                                               | 5     | (1.8)    | 4     | (1.5)    | 9     | (1.6)    |
| Unknown                                                       | 1     | (0.4)    | 0     | (0.0)    | 1     | (0.2)    |
| Geographic Region                                             |       |          |       |          |       |          |
| Asia Pacific                                                  | 54    | (19.8)   | 38    | (13.8)   | 92    | (16.8)   |
| EU/EMEA                                                       | 91    | (33.3)   | 98    | (35.6)   | 189   | (34.5)   |
| North America                                                 | 35    | (12.8)   | 38    | (13.8)   | 73    | (13.3)   |
| Latin America                                                 | 93    | (34.1)   | 101   | (36.7)   | 194   | (35.4)   |
| ECOGPerformanceScale                                          |       |          |       |          |       |          |
| 0                                                             | 160   | (58.6)   | 148   | (53.8)   | 308   | (56.2)   |
| 1                                                             | 111   | (40.7)   | 127   | (46.2)   | 238   | (43.4)   |
| 乙                                                             | 1     | (0.4)    | 0     | (0.0)    | 1     | (0.2)    |
| Missing                                                       | 1     | (0.4)    | 0     | (0.0)    | 1     | (0.2)    |
| Stage at Initial Diagnosisb                                   |       |          |       |          |       |          |
| I                                                             | 55    | (20.1)   | 48    | (17.5)   | 103   | (18.8)   |
|                                                               | 76    | (27.8)   | 85    | (30.9)   | 161   | (29.4)   |
| IⅢI                                                           | 5     | (1.8)    | 7     | (2.5)    | 12    | (2.2)    |
| IIIA                                                          | 4     | (1.5)    | 7     | (2.5)    | 11    | (2.0)    |
| IIIB                                                          | 41    | (15.0)   | 37    | (13.5)   | 78    | (14.2)   |
| IVA                                                           | 6     | (2.2)    | 3     | (1.1)    | 9     | (1.6)    |
| IVB                                                           | 86    | (31.5)   | 88    | (32.0)   | 174   | (31.8)   |
| DiseaseStatus at StudyEntry                                   |       |          |       |          |       |          |
| Metastaticc                                                   | 56    | (20.5)   | 59    | (21.5)   | 115   | (21.0)   |
| Persistent orRecurrentwith distant metastases at study entry  | 170   | (62.3)   | 156   | (56.7)   | 326   | (59.5)   |
| PersistentorRecurrentwithoutdistant metastases at study entry | 47    | (17.2)   | 60    | (21.8)   | 107   | (19.5)   |
| Histologyof Subtypeof Cervical Cancer                         |       |          |       |          |       |          |
| Adenocarcinoma                                                | 47    | (17.2)   | 66    | (24.0)   | 113   | (20.6)   |
| Adenosquamous/Both-Squamous And Adenocarcinoma                | 13    | (4.8)    | 12    | (4.4)    | 25    | (4.6)    |
| Epidermoide Carcinom                                          | 1     | (0.4)    | 0     | (0.0)    | 1     | (0.2)    |
| Indiferenciated Carcinoma                                     | 1     | (0.4)    | 0     | (0.0)    | 1     | (0.2)    |
| Squamous Cell/Squamous Cell Carcinoma                         | 211   | (77.3)   | 197   | (71.6)   | 408   | (74.5)   |
| PD-L1 Status                                                  |       |          |       |          |       |          |
| 1=<CPS<10                                                     | 115   | (42.1)   | 116   | (42.2)   | 231   | (42.2)   |
| CPS>=10                                                       | 158   | (57.9)   | 159   | (57.8)   | 317   | (57.8)   |
| BevacizumabUse                                                |       |          |       |          |       |          |
| Yes                                                           | 175   | (64.1)   | 171   | (62.2)   | 346   | (63.1)   |
| No                                                            | 98    | (35.9)   | 104   | (37.8)   | 202   | (36.9)   |
| Prior Therapy                                                 |       |          |       |          |       |          |
| Chemoradiation (CRT) and Surgery                              | 43    | (15.8)   | 48    | (17.5)   | 91    | (16.6)   |
| Radiation and Surgery                                         | 18    | (6.6)    | 21    | (7.6)    | 39    | (7.1)    |
| CRT Only                                                      | 112   | (41.0)   | 103   | (37.5)   | 215   | (39.2)   |
| Radiation Only                                                | 28    | (10.3)   | 21    | (7.6)    | 49    | (8.9)    |
| Surgery Only                                                  | 16    | (5.9)    | 23    | (8.4)    | 39    | (7.1)    |
| None                                                          | 56    | (20.5)   | 59    | (21.5)   | 115   | (21.0)   |

Database Cutoff Date:03MAY2021

a Participants in France cannot report race by law.

c Metastatic includes participants with para-aortic lymph node involvement.

b Stage at Initial Diagnosis determined using FIGO 2009/ NCCN 2017 criteria.

<div style=\"page-break-after: always\"></div>

Table 18. Participant Characteristics (All-comer Participants) (ITT Population)

<!-- image -->

|                                                                      | Pembro Combo                                                 | Pembro Combo                                                 | Control                                                      | Control                                                      | Total                                                        | Total                                                        |
|----------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
|                                                                      |                                                              | (%)                                                          | 11                                                           | (%)                                                          |                                                              | (%)                                                          |
| Participants in population                                           | 308                                                          |                                                              | 309                                                          |                                                              | 617                                                          |                                                              |
| Sex                                                                  |                                                              |                                                              |                                                              |                                                              |                                                              |                                                              |
| Female                                                               | 308                                                          | (100.0)                                                      | 309                                                          | (100.0)                                                      | 617                                                          | (100.0)                                                      |
| Age (Years)                                                          |                                                              |                                                              |                                                              |                                                              |                                                              |                                                              |
| OS>                                                                  | 134                                                          | (43.5)                                                       | 143                                                          | (46.3)                                                       | 277                                                          | (44.9)                                                       |
| 50 to 64                                                             | 126                                                          | (40.9)                                                       | 114                                                          | (36.9)                                                       | 240                                                          | (38.9)                                                       |
| 65 to 74                                                             | 38                                                           | (12.3)                                                       | 42                                                           | (13.6)                                                       | 80                                                           | (13.0)                                                       |
| >=75                                                                 | 10                                                           | (3.2)                                                        | 10                                                           | (3.2)                                                        | 20                                                           | (3.2)                                                        |
| Mean                                                                 |                                                              |                                                              | 50.7                                                         |                                                              | 51.2                                                         |                                                              |
| SD                                                                   | 51.7                                                         |                                                              |                                                              |                                                              | 12.3                                                         |                                                              |
|                                                                      | 11.9                                                         |                                                              | 12.7                                                         |                                                              |                                                              |                                                              |
| Median                                                               | 51.0                                                         |                                                              | 50.0                                                         |                                                              | 51.0                                                         |                                                              |
| Range                                                                | 25 to 82                                                     |                                                              | 22 to 79                                                     |                                                              | 22 to 82                                                     |                                                              |
| Race                                                                 |                                                              |                                                              |                                                              |                                                              |                                                              |                                                              |
| AmericanIndian OrAlaskaNative                                        | 18                                                           | (5.8)                                                        | 21                                                           | (6.8)                                                        | 39                                                           | (6.3)                                                        |
| Asian                                                                | 65                                                           | (21.1)                                                       | 45                                                           | (14.6)                                                       | 110                                                          | (17.8)                                                       |
| Black Or African American                                            | 4                                                            | (1.3)                                                        | 2                                                            | (0.6)                                                        | 6                                                            | (1.0)                                                        |
| Multiple                                                             | 32                                                           | (10.4)                                                       | 34                                                           | (11.0)                                                       | 66                                                           | (10.7)                                                       |
| AmericanIndian OrAlaska Native                                       | 7                                                            | (2.3)                                                        | 7                                                            | (2.3)                                                        | 14                                                           | (2.3)                                                        |
| And Black Or African American                                        | 17                                                           | (5.5)                                                        | 19                                                           | (6.1)                                                        | 36                                                           | (5.8)                                                        |
| AmericanIndian OrAlaskaNative And White AmericanIndianOrAlaskaNative | 0                                                            | (0.0)                                                        | 1                                                            | (0.3)                                                        | 1                                                            | (0.2)                                                        |
| And White And Asian Black Or AfricanAmerican And White               | 8                                                            | (2.6)                                                        | 7                                                            | (2.3)                                                        | 15                                                           | (2.4)                                                        |
| Not Applicablea                                                      | 18                                                           | (5.8)                                                        | 17                                                           | (5.5)                                                        | 35                                                           | (5.7)                                                        |
| White                                                                | 170                                                          | (55.2)                                                       | 190                                                          | (61.5)                                                       | 360                                                          | (58.3)                                                       |
| Missing                                                              | 1                                                            | (0.3)                                                        | 0                                                            | (0.0)                                                        | 1                                                            | (0.2)                                                        |
| Ethnicity                                                            |                                                              |                                                              |                                                              |                                                              |                                                              |                                                              |
| Hispanic Or Latino                                                   | 110                                                          | (35.7)                                                       | 121                                                          | (39.2)                                                       | 231                                                          | (37.4)                                                       |
| Not Hispanic Or Latino                                               | 192                                                          | (62.3)                                                       | 184                                                          | (59.5)                                                       | 376                                                          | (60.9)                                                       |
| Not Reported                                                         | 5                                                            | (1.6)                                                        | 4                                                            | (1.3)                                                        | 9                                                            | (1.5)                                                        |
| Unknown                                                              | 1                                                            | (0.3)                                                        | 0                                                            | (0.0)                                                        | 1                                                            | (0.2)                                                        |
| Geographic Region                                                    |                                                              |                                                              |                                                              |                                                              |                                                              |                                                              |
| Asia Pacific                                                         | 63                                                           | (20.5)                                                       | 42                                                           | (13.6)                                                       | 105                                                          | (17.0)                                                       |
| EU/EMEA                                                              | 103                                                          | (33.4)                                                       | 108                                                          | (35.0)                                                       | 211                                                          | (34.2)                                                       |
| North America                                                        | 39                                                           | (12.7)                                                       | 43                                                           | (13.9)                                                       | 82                                                           | (13.3)                                                       |
| Latin America                                                        | 103                                                          | (33.4)                                                       | 116                                                          | (37.5)                                                       | 219                                                          | (35.5)                                                       |
| ECOGPerformanceScale                                                 |                                                              |                                                              |                                                              |                                                              |                                                              |                                                              |
| 0                                                                    | 178                                                          | (57.8)                                                       | 170                                                          | (55.0)                                                       | 348                                                          | (56.4)                                                       |
| 1                                                                    | 128                                                          | (41.6)                                                       | 139                                                          | (45.0)                                                       | 267                                                          | (43.3)                                                       |
| 2                                                                    | 1                                                            | (0.3)                                                        | 0                                                            | (0.0)                                                        | 1                                                            | (0.2)                                                        |
| Missing                                                              |                                                              | (0.3)                                                        | 0                                                            | (0.0)                                                        | 1                                                            | (0.2)                                                        |
| Stage atInitial Diagnosisb                                           |                                                              |                                                              |                                                              |                                                              |                                                              |                                                              |
| I                                                                    | 67                                                           | (21.8)                                                       | 58                                                           | (18.8)                                                       | 125                                                          | (20.3)                                                       |
| II                                                                   | 85                                                           | (27.6)                                                       | 93                                                           | (30.1)                                                       | 178                                                          | (28.8)                                                       |
| III                                                                  | 5                                                            | (1.6)                                                        | 8                                                            | (2.6)                                                        | 13                                                           | (2.1)                                                        |
| IIIA                                                                 | 4                                                            | (1.3)                                                        | 8                                                            | (2.6)                                                        | 12                                                           | (1.9)                                                        |
| IIIB                                                                 | 46                                                           | (14.9)                                                       | 42                                                           | (13.6)                                                       | 88                                                           | (14.3)                                                       |
| IVA                                                                  | 7                                                            | (2.3)                                                        | 4                                                            | (1.3)                                                        | 11                                                           | (1.8)                                                        |
| IVB                                                                  | 94                                                           | (30.5)                                                       | 96                                                           | (31.1)                                                       | 190                                                          | (30.8)                                                       |
| DiseaseStatus at StudyEntry                                          |                                                              |                                                              |                                                              |                                                              |                                                              |                                                              |
| Metastaticc                                                          | 58                                                           | (18.8)                                                       | 64                                                           | (20.7)                                                       | 122                                                          | (19.8)                                                       |
| PersistentorRecurrentwithdistant                                     | 199                                                          | (64.6)                                                       | 179                                                          | (57.9)                                                       | 378                                                          | (61.3)                                                       |
| metastases at study entry Persistent orRecurrent withoutdistant      | 51                                                           | (16.6)                                                       | 66                                                           | (21.4)                                                       | 117                                                          | (19.0)                                                       |
| metastases at study entry HistologyofSubtypeofCervicalCancer         | metastases at study entry HistologyofSubtypeofCervicalCancer | metastases at study entry HistologyofSubtypeofCervicalCancer | metastases at study entry HistologyofSubtypeofCervicalCancer | metastases at study entry HistologyofSubtypeofCervicalCancer | metastases at study entry HistologyofSubtypeofCervicalCancer | metastases at study entry HistologyofSubtypeofCervicalCancer |
| Adenocarcinoma                                                       | 56                                                           | (18.2)                                                       | 84                                                           | (27.2)                                                       | 140                                                          | (22.7)                                                       |

<div style=\"page-break-after: always\"></div>

| Adenosquamous/Both-Squamous And Adenocarcinoma   | 15     | (4.9)         | 14     | (4.5)         | 29     | (4.7)         |
|--------------------------------------------------|--------|---------------|--------|---------------|--------|---------------|
| Epidermoide Carcinom                             | 1      | (0.3)         | 0      | (0.0)         | 1      | (0.2)         |
| Indiferenciated Carcinoma                        | 1      | (0.3)         | 0      | (0.0)         | 1      | (0.2)         |
| Squamous Cell/Squamous Cell Carcinoma            | 235    | (76.3)        | 211    | (68.3)        | 446    | (72.3)        |
| PD-L1 Status                                     |        |               |        |               |        |               |
| CPS<1 1=<CPS<10                                  | 35 115 | (11.4) (37.3) | 34 116 | (11.0) (37.5) | 69 231 | (11.2) (37.4) |
| BevacizumabUse                                   |        |               |        |               |        |               |
| Yes                                              | 196    | (63.6)        | 193    | (62.5)        | 389    | (63.0)        |
| No                                               | 112    | (36.4)        | 116    | (37.5)        | 228    | (37.0)        |
| Prior Therapy                                    |        |               |        |               |        |               |
| Chemoradiation (CRT) and Surgery                 | 49     | (15.9)        | 56     | (18.1)        | 105    | (17.0)        |
| Radiation and Surgery                            | 22     | (7.1)         | 23     | (7.4)         | 45     | (7.3)         |
| CRT Only                                         | 125    | (40.6)        | 118    | (38.2)        | 243    | (39.4)        |
| Radiation Only                                   | 31     | (10.1)        | 24     | (7.8)         | 55     | (8.9)         |
| Surgery Only                                     | 23     | (7.5)         | 24     | (7.8)         | 47     | (7.6)         |
| None                                             |        | (18.8)        | 64     | (20.7)        |        |               |
|                                                  | 58     |               |        |               | 122    | (19.8)        |

Database Cutoff Date: 03MAY2021

a Participants in France cannot report race by law.

b Stage at Initial Diagnosis determined using FIGO 2009/ NCCN 2017 criteria.

Metastatic includesparticipants withpara-aorticlymph node involvement.These patients are the participants diagnosed with stage IVB disease and enter the study without any prior treatment for their cervical cancer.

In the CPS≥10 participants, demographics and other baseline characteristics were generally consistent with those of the all-comer participants.

## Numbers analysed

A total of 617 participants were randomized (308 to pembrolizumab + chemotherapy ± bevacizumab, 309 to placebo + chemotherapy ± bevacizumab). All randomized participants were included in the Intention-to-Treat (ITT) population, which served as the population for the primary efficacy analyses.

Table 18A. Populations analysed per ITT, CPS≥1 and CPS≥10

| Pembro      | combo       | Placebo control   | Total          |
|-------------|-------------|-------------------|----------------|
| ITT 308     | 309         |                   | 617            |
| 273 (88.6%) | 275 (89%)   | 548 (88.8%)       | PD-L1 CPS ≥1   |
| 158 (51.3%) | 159 (51.5%) | 317 (51.4%)       | PD-L1 CPS ≥1 0 |

## Outcomes and estimation

The efficacy analyses were based on IA1 (database cutoff: 03-MAY-2021), which was the first interim analysis of PFS and OS in all-comer participants and participants whose tumours express PD-L1 (CPS ≥1 and CPS ≥10).

<div style=\"page-break-after: always\"></div>

## PDL1 CPS ≥1 Participants

Table 19. Summary of Key Efficacy Results in Participants With CPS≥1 Persistent, Recurrent, or Metastatic Cervical Cancer (ITT Population)

| Endpoint                                       | Pembrolizumab + Chemotherapy ± Bevacizumab (N=273)   | Placebo + Chemotherapy ± Bevacizumab (N=275)   |
|------------------------------------------------|------------------------------------------------------|------------------------------------------------|
| PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1       | PFS as Assessed by Investigator per RECIST 1.1 |
| Number of Events (%)                           | 157 (57.5)                                           | 198 (72.0)                                     |
| Median PFS a , months (95% CI)                 | 10.4 (9.7, 12.3)                                     | 8.2 (6.3, 8.5)                                 |
| HR (95% CI) b p-value c,d                      | 0.62 (0.50, 0.77) <0.0001                            | 0.62 (0.50, 0.77) <0.0001                      |
| OS                                             |                                                      |                                                |
| Number of Events (%)                           | 118 (43.2)                                           | 154 (56.0)                                     |
| Median OS a , months (95% CI)                  | NR (19.8, NR)                                        | 16.3 (14.5, 19.4)                              |
| HR (95% CI) b p-value c,e                      | 0.64 (0.50, 0.81) 0.0001                             | 0.64 (0.50, 0.81) 0.0001                       |
| ORR, %(95% CI)                                 | 68.1 (62.2, 73.6)                                    | 50.2 (44.1, 56.2)                              |
| ORR Difference %(95% CI) f                     | 18.0 (10.1, 25.7)                                    | 18.0 (10.1, 25.7)                              |
| DOR , (months), median (range) a               | 18.0 (1.3+, 24.2+)                                   | 10.4 (1.5+, 22.0+)                             |
| PFS as Assessed by BICR per RECIST 1.1         | PFS as Assessed by BICR per RECIST 1.1               | PFS as Assessed by BICR per RECIST 1.1         |
| Median PFS a , months (95% CI)                 | 12.8 (10.4, 20.6)                                    | 8.3 (7.7, 9.2)                                 |
| HR (95% CI) b                                  | 0.60 (0.48, 0.75)                                    | 0.60 (0.48, 0.75)                              |

Abbreviations: BICR = blinded independent central review; CI = confidence interval; CPS = Combined Positive Score; HR = hazard ratio; ITT = intent-to-treat; NR = not reached; OS = overall survival; PFS = progression-free survival; PD-L1 = programmed cell death ligand 1; RECIST = Response Evaluation Criteria In Solid Tumors

a  From product-limit (Kaplan-Meier) method for censored data.

b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS ≥10).

- c One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PDL1 status (CPS &lt;1, CPS 1 to &lt;10, CPS ≥10).
- d  Based on stratified log-rank test (compared to an alpha boundary of 0.0014426).
- e  Based on stratified log-rank test (compared to an alpha boundary of 0.0054906).
- f  Based on Miettinen &amp; Nurminen method stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PDL1 status (CPS &lt;1, CPS 1 to &lt;10, CPS ≥10).

Database Cutoff Date: 03-MAY-2021

## All-comer Participants

Table  20.  Summary  of  Key  Efficacy  Results  in  All-comer  Participants  With  Persistent, Recurrent, or Metastatic Cervical Cancer (ITT Population)

| Endpoint                                       | Pembrolizumab + Chemotherapy ± Bevacizumab (N=308)   | Placebo + Chemotherapy ± Bevacizumab (N=309)   |
|------------------------------------------------|------------------------------------------------------|------------------------------------------------|
| PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1       |                                                |
| Number of Events (%)                           | 180 (58.4)                                           | 226 (73.1)                                     |
| Median PFS a , months (95% CI)                 | 10.4 (9.1, 12.1)                                     | 8.2 (6.4, 8.4)                                 |
| HR (95% CI) b p-value c,d                      | 0.65 (0.53, 0.79) <0.0001                            | 0.65 (0.53, 0.79) <0.0001                      |

<div style=\"page-break-after: always\"></div>

| Endpoint                               | Pembrolizumab + Chemotherapy ± Bevacizumab (N=308)   | Placebo + Chemotherapy ± Bevacizumab (N=309)   |
|----------------------------------------|------------------------------------------------------|------------------------------------------------|
| OS                                     |                                                      |                                                |
| Number of Events (%)                   | 138 (44.8)                                           | 174 (56.3)                                     |
| Median OS a , months (95% CI)          | 24.4 (19.2, NR)                                      | 16.5 (14.5, 19.4)                              |
| HR (95% CI) b p-value c,e              | 0.67 (0.54, 0.84) 0.0003                             | 0.67 (0.54, 0.84) 0.0003                       |
| ORR, %(95% CI)                         | 65.9 (60.3, 71.2)                                    | 50.8 (45.1, 56.5)                              |
| ORR Difference %(95% CI) f             | 15.3 (7.8, 22.6)                                     | 15.3 (7.8, 22.6)                               |
| DOR , (months), median (range) a       | 18.0 (1.3+, 24.2+)                                   | 10.4 (1.5+, 22.0+)                             |
| PFS as Assessed by BICR per RECIST 1.1 | PFS as Assessed by BICR per RECIST 1.1               |                                                |
| Median PFS a , months (95% CI)         | 12.3 (10.3, 17.9)                                    | 8.3 (8.1, 9.0)                                 |
| HR (95% CI) b                          | 0.63 (0.51, 0.77)                                    | 0.63 (0.51, 0.77)                              |

Abbreviations: BICR = blinded independent central review; CI = confidence interval; CPS = Combined Positive Score; HR = hazard ratio; ITT = intent-to-treat; NR = not reached; OS = overall survival; PFS = progression-free survival; PD-L1 = programmed cell death ligand 1; RECIST = Response Evaluation Criteria In Solid Tumors

a  From product-limit (Kaplan-Meier) method for censored data.

b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS ≥10).

- c One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PDL1 status (CPS &lt;1, CPS 1 to &lt;10, CPS ≥10).
- d  Based on stratified log-rank test (compared to an alpha boundary of 0.0012843).
- e  Based on stratified log-rank test (compared to an alpha boundary of 0.0049074).
- f  Based on Miettinen &amp; Nurminen method stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PDL1 status (CPS &lt;1, CPS 1 to &lt;10, CPS ≥10).

Database Cutoff Date: 03-MAY-2021

## PDL1 CPS ≥10 Participants

Table 21 . Summary of Key Efficacy Results in Participants With CPS≥10 Persistent, Recurrent, or Metastatic Cervical Cancer (ITT Population)*

| Endpoint                                       | Pembrolizumab + Chemotherapy ± Bevacizumab (N=158)   | Placebo + Chemotherapy ± Bevacizumab (N=159)   |
|------------------------------------------------|------------------------------------------------------|------------------------------------------------|
| PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1       | PFS as Assessed by Investigator per RECIST 1.1 |
| Number of Events (%)                           | 87 (55.1)                                            | 116 (73.0)                                     |
| Median PFS, months (95% CI)                    | 10.4 (8.9, 15.1)                                     | 8.1 (6.2, 8.8)                                 |
| HR (95% CI) p-value                            | 0.58 (0.44, 0.77) <0.0001                            | 0.58 (0.44, 0.77) <0.0001                      |
| OS                                             |                                                      |                                                |
| Number of Events (%)                           | 66 (41.8)                                            | 88 (55.3)                                      |
| Median OS, months (95% CI)                     | NR (19.1, NR)                                        | 16.4 (14.0, 25.0)                              |
| HR (95% CI) p-value                            | 0.61 (0.44, 0.84) 0.0013                             | 0.61 (0.44, 0.84) 0.0013                       |
| ORR by inv, %(95% CI)                          | 69.6 (61.8, 76.7)                                    | 49.1 (41.1, 57.1)                              |
| ORR Difference %(95% CI)                       | 20.5 (10.1, 30.5)                                    | 20.5 (10.1, 30.5)                              |
| DOR by inv , (months), median (range)          | 21.1 (1.3+, 24.2+)                                   | 9.4 (2.1+, 21.5+)                              |

<div style=\"page-break-after: always\"></div>

| Endpoint                                                                                                                                                                                                                                                                                                                                                               | Pembrolizumab + Chemotherapy ± Bevacizumab (N=158)                                                                                                                                                                                                                                                                                                                     | Placebo + Chemotherapy ± Bevacizumab (N=159)                                                                                                                                                                                                                                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PFS as Assessed by BICR per RECIST 1.1                                                                                                                                                                                                                                                                                                                                 | PFS as Assessed by BICR per RECIST 1.1                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                        |
| Median PFS, months (95% CI)                                                                                                                                                                                                                                                                                                                                            | 15.1 (8.9, NR)                                                                                                                                                                                                                                                                                                                                                         | 8.3 (7.1, 10.2)                                                                                                                                                                                                                                                                                                                                                        |
| HR (95% CI)                                                                                                                                                                                                                                                                                                                                                            | 0.55 (0.41, 0.74)                                                                                                                                                                                                                                                                                                                                                      | 0.55 (0.41, 0.74)                                                                                                                                                                                                                                                                                                                                                      |
| Abbreviations: BICR = blinded independent central review; CI = confidence interval; CPS = Combined Positive Score; HR = hazard ratio; ITT = intent-to-treat; NR = not reached; OS = overall survival; PFS = progression-free survival; PD-L1 = programmed cell death ligand 1; RECIST = Response Evaluation Criteria In Solid Tumors Database Cutoff Date: 03-MAY-2021 | Abbreviations: BICR = blinded independent central review; CI = confidence interval; CPS = Combined Positive Score; HR = hazard ratio; ITT = intent-to-treat; NR = not reached; OS = overall survival; PFS = progression-free survival; PD-L1 = programmed cell death ligand 1; RECIST = Response Evaluation Criteria In Solid Tumors Database Cutoff Date: 03-MAY-2021 | Abbreviations: BICR = blinded independent central review; CI = confidence interval; CPS = Combined Positive Score; HR = hazard ratio; ITT = intent-to-treat; NR = not reached; OS = overall survival; PFS = progression-free survival; PD-L1 = programmed cell death ligand 1; RECIST = Response Evaluation Criteria In Solid Tumors Database Cutoff Date: 03-MAY-2021 |

* Summary presented by the assessment team

Results in the CPS 1-&lt;10 subgroup: OS HR 0.67 (0.46, 0.97); PFS by inv HR 0.68 (0.49, 0.94); ORR difference 14.58 (2.24, 26.5).

## Dual primary endpoint - Overall survival

Pembrolizumab + chemotherapy ± bevacizumab provided a statistically significant improvement in OS compared with placebo + chemotherapy ± bevacizumab in participants with PD-L1 CPS ≥ 1, all-comer participants and in patients whose tumors express PD-L1 CPS ≥ 10.

## CPS ≥

1

## Table 22. Analysis of Overall Survival (CPS&gt;=1 Participants) (ITT Population)

|                                                                          | Pembro Combo (N=273)    | Control (N=275)          |
|--------------------------------------------------------------------------|-------------------------|--------------------------|
| Number of Events (%) DEATH                                               | 118 (43.2) 118 (43.2)   | 154 (56.0) 154 (56.0)    |
| Kaplan-Meier Estimates (months)a Median (95% CI) [Q1, Q3]                | NR (19.8, NR) [12.0, ]  | 16.3 (14.5, 19.4) [9.0,] |
| Person-months                                                            | 4559.1                  | 3988.5                   |
| Event Rate/100Person-months                                              | 2.6                     | 3.9                      |
| p-valuec OS Rate at month 6 (%) (95% CI) OS Rate at month 12 (%)(95% CI) | 0.0001 91.9 (88.0,94.6) | 85.5 (80.7,89.1)         |
|                                                                          | 75.3 (69.7, 80.0)       | 63.1 (57.0, 68.5)        |
| OS Rate atmonth 18(%)(95%CI)                                             | 60.8 (54.6, 66.4)       | 47.1 (41.0, 53.0)        |
| OS Rate atmonth 24(%)(95%CI)                                             | 53.0 (46.0, 59.4)       | 41.7 (34.9, 48.2)        |

b Based on Cox regression model with Efron's method of tie handling with trea tment as a covariate stratified by metastatic atinitial diagnosis (FIGO [2009] stage IVB)(yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS&lt;1, CPS 1 to &lt;10, CPS &gt;=10).

a From product-limit(Kaplan-Meier) method for censored data.

c One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB)(yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10). NR = Not reached.

Database Cutoff Date: 03MAY2021

<div style=\"page-break-after: always\"></div>

Figure 7. Kaplan-Meier Estimates of Overall Survival (CPS&gt;=1 Participants) (ITT Population)

<!-- image -->

DatabaseCutoffDate:03MAY2021

Figure  8.  Forest  Plot  of  Overall  Survival  Hazard  Ratio  by  Subgroup  Factors  (CPS&gt;=1 Participants) (ITT Population)

<!-- image -->

|                              | #Events/N   | HR   |              | 95% CI   |
|------------------------------|-------------|------|--------------|----------|
| Overall                      | 272/548     | 0.64 | (0.50, 0.81) |          |
| MetastaticatInitialDiagnosis |             |      |              |          |
| Yes                          | 91/174      | 0.88 | (0.58, 1.35) |          |
| No                           | 181/374     | 0.56 | (0.41, 0.75) |          |
| BevacizumabUse               |             |      |              |          |
| Yes                          | 143/346     | 0.62 | (0.45, 0.87) |          |
| No                           | 129/202     | 0.67 | (0.47, 0.96) |          |
| Age                          |             |      |              |          |
| < 65 Years                   | 230/461     | 0.62 | (0.48, 0.81) |          |
| >= 65 Years                  | 42/87       | 0.74 | (0.38, 1.45) |          |
| Race                         |             |      |              |          |
| White                        | 169/325     | 0.61 | (0.45, 0.84) |          |
| AllOthers                    | 87/189      | 0.73 | (0.48, 1.13) |          |
| ECOG                         |             |      |              |          |
| 0                            | 119/308     | 0.66 | (0.46, 0.95) |          |
|                              | 151/238     | 0.64 | (0.46, 0.89) |          |
|                              |             |      |              | 0.1 0.5  |

NR = Not Reached. Based on Cox regression model with Efrons method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10). If total number of participants in one level of a subgroup is &lt;20, that particular level will not be displayed. Database Cutoff Date: 03MAY2021

<div style=\"page-break-after: always\"></div>

## All-comers

Table 23. Analysis of Overall Survival (All-comer Participants) (ITT Population)

|                                                                  | Pembro Combo (N=308)                | Control (60≤=N)          |
|------------------------------------------------------------------|-------------------------------------|--------------------------|
| Number of Events (%) DEATH                                       | 138 (44.8) 138 (44.8)               | 174 (56.3) 174 (56.3)    |
| Kaplan-Meier Estimates (months)a Median (95% CI) [Q1, Q3]        | 24.4 (19.2, NR) [12.0, ]            | 16.5 (14.5, 19.4) [9.1,] |
| Person-months                                                    | 5055.9                              | 4516.2                   |
| EventRate/100Person-months                                       | 2.7                                 | 3.9                      |
| vs Control Hazard Ratio (95% CI)b p-valuec                       | 0.67 (0.54, 0.84) 0.0003            | 86.7 (82.4, 90.1)        |
| OS Rate at month 6 (%) (95% CI) OS Rate at month 12 (%) (95% CI) | 90.5 (86.7, 93.3) 74.8 (69.5, 79.3) | 63.6 (57.9, 68.7)        |
| OS Rate at month 18 (%)(95% CI)                                  | 60.2 (54.3, 65.5)                   | 48.3 (42.6, 53.9)        |
| OS Rate at month 24 (%) (95% CI)                                 |                                     |                          |
|                                                                  | 50.4 (43.8, 56.6)                   | 40.4 (34.0, 46.6)        |

aFrom product-limit (Kaplan-Meier)method for censored data.

bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic atinitial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no)and PD-L1 status (CPS &lt;1,CPS 1 to &lt;10,CPS &gt;=10).

c One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10). NR =Notreached.

Database Cutoff Date:03MAY2021

Figure 9. Kaplan-Meier Estimates of Overall Survival (All-comer Participants) (ITT Population)

<!-- image -->

DatabaseCutoffDate:03MAY2021

<div style=\"page-break-after: always\"></div>

Figure  10.  Forest  Plot  of  Overall  Survival  Hazard  Ratio  by  Subgroup  Factors  (All-comer Participants) (ITT Population)

<!-- image -->

## CPS ≥ 10

Table 24. Analysis of Overall Survival (CPS&gt;=10 Participants) (ITT Population)

|                                                                | Pembro Combo (N=158)                       | Control (N=159)          |
|----------------------------------------------------------------|--------------------------------------------|--------------------------|
| Number of Events (%) DEATH                                     | 66 (41.8) 66 (41.8)                        | 88 (55.3) 88 (55.3)      |
| Kaplan-Meier Estimates (months)a Median (95% CI) [Q1, Q3]      | NR (19.1, NR) [12.6,]                      | 16.4 (14.0, 25.0) [8.3,] |
| Person-months                                                  | 2627.9                                     | 2271.4                   |
| Event Rate/100Person-months                                    | 2.5                                        | 3.9                      |
| vs Control Hazard Ratio (95% CIb p-valuec                      | 0.61 (0.44, 0.84) 0.0013 91.7 (86.2, 95.1) | 84.9 (78.3, 89.6)        |
| OS Rate at month 6 (%) (95% CI) OS Rate atmonth 12 (%)(95% CI) | 75.7 (68.2, 81.7)                          | 61.5 (53.4, 68.6)        |
| OS Rate at month 18 (%) (95% CI)                               | 61.2 (52.9, 68.5)                          | 48.4 (40.2, 56.1)        |
| OS Rate at month 24 (%)(95% CI)                                | 54.4 (45.5, 62.4)                          | 44.6 (36.3, 52.5)        |

a From product-limit (Kaplan-Meier) method for censored data.

bBased on Cox regression model with Efron's method oftie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

c One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10). NR =Notreached.

Database Cutoff Date: 03MAY2021

<div style=\"page-break-after: always\"></div>

Figure 11. Kaplan-Meier Estimates of Overall Survival (CPS&gt;=10  Participants) (ITT Population)

<!-- image -->

DatabaseCutoffDate:03MAY2021

Figure  12.  Forest  Plot  of  Overall  Survival  Hazard  Ratio  by  Subgroup  Factors  (CPS&gt;=10 Participants) (ITT Population)

<!-- image -->

|                               | #Events/NHR   |      |              | 95% CI                     |
|-------------------------------|---------------|------|--------------|----------------------------|
| Overall                       | 154/317       | 0.61 | (0.44, 0.84) |                            |
| MetastaticatInitial Diagnosis |               |      |              |                            |
| Yes                           | 44/94         | 0.91 | (0.49, 1.70) |                            |
| No                            | 110/223       | 0.54 | (0.37, 0.79) |                            |
| BevacizumabUse                |               |      |              |                            |
| Yes                           | 79/199        | 0.64 | (0.41, 1.00) |                            |
| No                            | 75/118        | 0.59 | (0.37, 0.96) |                            |
| Age                           |               |      |              |                            |
| < 65 Yeais                    | 135/278       | 0.66 | (0.47, 0.93) |                            |
| >= 65 Years                   | 19/39         | 0.40 | (0.15, 1.10) |                            |
| Race                          |               |      |              |                            |
| White                         | 100/199       | 0.58 | (0.39, 0.88) |                            |
| AllOthers                     | 46/99         | 0.72 | (0.40, 1.29) |                            |
| ECOG                          |               |      |              |                            |
| 0                             | 62/170        | 0.64 | (0.38, 1.07) |                            |
|                               | 90/145        | 0.59 | (0.38, 0.91) |                            |
|                               |               |      |              | 0.1 0.5 1.5 2              |
|                               |               |      |              | Estimated Hazard Ratio(HR) |

## Dual primary endpoint - Progression free survival (by investigator)

Pembrolizumab + chemotherapy ± bevacizumab was superior to placebo + chemotherapy ± bevacizumab with a statistically significant improvement in PFS per RECIST 1.1 as assessed by

<div style=\"page-break-after: always\"></div>

investigator in participants with persistent, recurrent, or metastatic cervical cancer whose tumors express PDL1 CPS ≥1, in all -comer participants as well as in PDL1 CPS ≥10 population.

## CPS ≥ 1

Table 25. Analysis of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1 (Primary Analysis) (CPS&gt;=1 Participants) (ITT Population)

|                                                                    | Pembro Combo (N=273)      | Control (N=275)            |
|--------------------------------------------------------------------|---------------------------|----------------------------|
| Number of Events (%) DEATH                                         | 157 (57.5) 25 (9.2)       | 198 (72.0) 26 (9.5)        |
| Median (95% CI) [Q1, Q3]                                           |                           |                            |
| DOCUMENTEDPROGRESSION                                              | 132 (48.4)                | 172 (62.5)                 |
| Kaplan-MeierEstimates (months)a                                    | 10.4 (9.7,12.3) [6.2,]    | 8.2 (6.3, 8.5) [4.2, 17.1] |
| Person-months Event Rate/100Person-months                          | 3110.2                    | 2460.4                     |
| vs Control Hazard Ratio (95% CI)b                                  | 5.0                       | 8.0                        |
| p-valuee                                                           | 0.62 (0.50, 0.77) <0.0001 |                            |
| PFS Rate at month 6 (%) (95% CI) PFS Rate at month 12 (%) (95% CI) | 81.5 (76.2, 85.7)         | 67.1 (61.0, 72.4)          |
| PFSRate at month18(%)(95%Cl)                                       | 39.3 (33.2, 45.4)         | 34.1 (28.3,40.0)           |
|                                                                    | 45.5 (39.2, 51.5)         | 23.8 (18.6, 29.4)          |
| PFS Rate at month 24 (%)(95% CI)                                   | 33.1 (25.7, 40.7)         | 14.0 (7.7,22.3)            |

From product-limit (Kaplan-Meier) method for censored data.

Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic atinitial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to&lt;10,CPS &gt;=10).

One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10). NR =Notreached.

Database Cutoff Date: 03MAY2021

PFS by BICR (secondary endpoint) in the CPS ≥1 population was median PFS 12.8 (10.4, 20.6) vs 8.3 (7.7, 9.2), Hazard Ratio 0.60 (95%CI 0.48, 0.75).

PFS sensitivity analyses in the CPS ≥1 population were consistent with primary analysis (sensitivity 1 HR 0.62, sensitivity 2 HR 0.66).

Figure  13.  Kaplan-Meier  Estimates  of  Progression-Free  Survival  Based  on  Investigator Assessment per RECIST 1.1 (Primary Analysis) (CPS&gt;=1 Participants) (ITT Population)

<!-- image -->

DatabaseCutoffDate:03MAY2021

<div style=\"page-break-after: always\"></div>

Figure 14. Forest Plot of Progression-Free Survival Hazard Ratio by Subgroup Factors Based on Investigator Assessment per RECIST 1.1 (Primary Analysis) (CPS&gt;=1 Participants) (ITT Population)

<!-- image -->

NR = Not Reached. Based on Cox regression model with Efrons method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10). If total number of participants in one level of a subgroup is &lt;20, that particular level will not be displayed. Database Cutoff Date: 03MAY2021

## All-comers

## Table 26. Analysis of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1 (Primary Analysis) (All-comer Participants) (ITT Population)

|                                                                    | Pembro Combo (N=308)                | Control (N=309)            |
|--------------------------------------------------------------------|-------------------------------------|----------------------------|
| Number of Events (%)                                               | 180 (58.4)                          | 226 (73.1) 27 (8.7)        |
| DEATH                                                              | 27 (8.8)                            |                            |
| DOCUMENTEDPROGRESSION                                              | 153 (49.7)                          | 199 (64.4)                 |
| Kaplan-MeierEstimates(months)a Median (95% CI) [Q1, Q3]            | 10.4 (9.1, 12.1) [6.2,]             | 8.2 (6.4, 8.4) [4.3, 15.5] |
| Person-months EventRate/100Person-months                           |                                     |                            |
|                                                                    | 3412.5                              | 2753.4                     |
| vs Control Hazard Ratio (95% C1)b p-valuec                         | 5.3 0.65 (0.53, 0.79) <0.0001       | 8.2                        |
| PFS Rate at month 6 (%) (95% CI) PFS Rate at month 12 (%) (95% CI) | 80.5 (75.4, 84.6) 44.7 (38.8, 50.4) | 68.5 (62.8, 73.4)          |
| PFSRate at month18 (%)(95%CI)                                      | 38.0 (32.3,43.7)                    | 33.5 (28.0,39.1)           |
|                                                                    |                                     | 21.7 (16.9,26.9)           |
| PFS Rate at month 24 (%) (95% CI)                                  | 31.6 (24.7, 38.8)                   | 12.8 (7.0, 20.4)           |

a From product-limit (Kaplan-Meier) method for censored data.

bBased on CoxregressionmodelwithEfron'smethodoftiehandlingwith treatment as acovariate stratified by metastatic at initial diagnosis (FIGO[2009] stage IVB)(yes or no),bevacizumab use(yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

c One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10). NR = Not reached.

DatabaseCutoffDate:03MAY2021

PFS by BICR in the all-comer population was median PFS 12.3 (10.3, 17.9) vs 8.3 (8.1, 9.0), Hazard Ratio 0.63 (95% CI 0.51, 0.77).

PFS sensitivity analyses were consistent with primary analysis (sensitivity 1 HR 0.65, sensitivity 2 HR 0.69).

<div style=\"page-break-after: always\"></div>

Figure  15.  Kaplan-Meier  Estimates  of  Progression-Free  Survival  Based  on  Investigator Assessment per RECIST 1.1 (Primary Analysis) (All-comer Participants) (ITT Population)

<!-- image -->

DatabaseCutoffDate:03MAY2021

Figure 16. Forest Plot of Progression-Free Survival Hazard Ratio by Subgroup Factors Based on Investigator Assessment per RECIST 1.1 (Primary Analysis) (All-comer Participants) (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## CPS ≥ 10

## Table 27. Analysis of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1 (Primary Analysis) (CPS&gt;=10 Participants) (ITT Population)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pembro Combo (N=158)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Control (N=159)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number of Events (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 87 (55.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 116 (73.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| DEATH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16 (10.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16 (10.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| DOCUMENTEDPROGRESSION                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 71 (44.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 100 (62.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Kaplan-Meier Estimates (months)a                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Median (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 10.4 (8.9, 15.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 8.1 (6.2, 8.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| [Q1, Q3]                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | [6.3,]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | [4.2, 15.4]                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Person-months                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1777.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1364.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Event Rate/100Person-months                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 4.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 8.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| vs Control                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hazard Ratio (95% CI)b p-valuec                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.58 (0.44, 0.77) <0.0001                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PFS Rate at month 6 (%) (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 84.6 (77.7, 89.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 64.7 (56.5, 71.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| PFS Rate at month 12 (%)(95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 44.6 (36.3, 52.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 33.5 (25.9, 41.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| PFS Rate at month 18 (%) (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 40.6 (32.4, 48.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 22.2 (15.6,29.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PFSRate at month 24 (%)(95%CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 35.8 (26.4, 45.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NR (NR, NR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| From product-limit (Kaplan-Meier) method for censored data.                                                                                                                                                                                                                                                                                                                                                                                                                            | From product-limit (Kaplan-Meier) method for censored data.                                                                                                                                                                                                                                                                                                                                                                                                                            | From product-limit (Kaplan-Meier) method for censored data.                                                                                                                                                                                                                                                                                                                                                                                                                            |
| bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes orno)and PD-L1 status (CPS<1,CPS 1 to<10,CPS>=10).  One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS <1, CPS 1 to <10, CPS >=10). NR=Notreached. | bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes orno)and PD-L1 status (CPS<1,CPS 1 to<10,CPS>=10).  One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS <1, CPS 1 to <10, CPS >=10). NR=Notreached. | bBased on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes orno)and PD-L1 status (CPS<1,CPS 1 to<10,CPS>=10).  One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS <1, CPS 1 to <10, CPS >=10). NR=Notreached. |

PFS by BICR in the CPS≥10 population was median PFS 15.1 (8.9, NR) vs 8.3 (7.1, 10.2), Hazard Ratio 0.55 (95%CI 0.41, 0.74).

PFS sensitivity analyses in the CPS≥10 pop ulation were consistent with primary analysis (sensitivity 1 HR 0.59, sensitivity 2 HR 0.61).

<div style=\"page-break-after: always\"></div>

Figure  17.  Kaplan-Meier  Estimates  of  Progression-Free  Survival  Based  on  Investigator Assessment per RECIST 1.1 (Primary Analysis) (CPS&gt;=10 Participants) (ITT Population)

<!-- image -->

DatabaseCutoffDate:03MAY2021

Figure 18. Forest Plot of Progression-Free Survival Hazard Ratio by Subgroup Factors Based on Investigator Assessment per RECIST 1.1 (Primary Analysis) (CPS&gt;=10 Participants) (ITT Population)

<!-- image -->

## Secondary endpoint - Overall response rate (by investigator)

Pembrolizumab + chemotherapy ± bevacizumab provided improvement in ORR (per RECIST 1.1 by the investigator, confirmed response) compared with placebo + chemotherapy ± bevacizumab in participants whose tumors express PD-L1 CPS ≥ 1 (68.1% vs 50.2%), all-comers (65.9% vs 50.8%) and CPS ≥ 10 (69.6% vs 49.1%).

<div style=\"page-break-after: always\"></div>

## CPS ≥ 1

Table  28.  Summary  of  Best  Objective  Response  (Confirmed)  Based  on  Investigator Assessment per RECIST 1.1 (CPS&gt;=1 Participants) (ITT Population)

|                                  |   Pembro Combo | Pembro Combo   | Pembro Combo   |   Control | Control   | Control      |
|----------------------------------|----------------|----------------|----------------|-----------|-----------|--------------|
|                                  |             11 | (%)            | (95% CI)a      |        11 | (%)       | (95% CI)a    |
| NumberofParticipantsinPopulation |            273 |                |                |       275 |           |              |
| Complete Response (CR)           |             62 | (22.7)         | (17.9,28.1)    |        36 | (13.1)    | (9.3, 17.7)  |
| Partial Response (PR)            |            124 | (45.4)         | (39.4, 51.5)   |       102 | (37.1)    | (31.4, 43.1) |
| ObjectiveResponse(CR+PR)         |            186 | (68.1)         | (62.2, 73.6)   |       138 | (50.2)    | (44.1, 56.2) |
| Stable Disease (SD)              |             58 | (21.2)         | (16.5, 26.6)   |        88 | (32.0)    | (26.5, 37.9) |
| Progressive Disease (PD)         |              9 | (3.3)          | (1.5,6.2)      |        29 | (10.5)    | (7.2,14.8)   |
| Not Evaluable (NE)               |              1 | (0.4)          | (0.0, 2.0)     |         2 | (0.7)     | (0.1, 2.6)   |
| No Assessment (NA)               |             19 | (7.0)          | (4.2, 10.7)    |        18 | (6.5)     | (3.9, 10.1)  |

aBased onbinomialexact confidenceinterval method.

Investigator assessed responses per RECIST 1.1 (confirmed)are included in this table.

DatabaseCutoffDate:03MAY2021

Confirmed ORR per BICR in the CPS ≥ 1 participants was 64.8% (58.9,70.5) vs 53.1% (47.0,59.1) in the pembro combo vs control arm, respectively.

## All comers

Table  29.  Summary  of  Best  Objective  Response  (Confirmed)  Based  on  Investigator Assessment per RECIST 1.1 (All-comer Participants) (ITT Population)

|                                  |   Pembro Combo | Pembro Combo   | Pembro Combo   |   Control | Control   | Control      |
|----------------------------------|----------------|----------------|----------------|-----------|-----------|--------------|
|                                  |             11 | (%)            | (95% CI)a      |        11 | (%)       | (95%CI)a     |
| NumberofParticipantsinPopulation |            308 |                |                |       309 |           |              |
| Complete Response (CR)           |             66 | (21.4)         | (17.0, 26.4)   |        40 | (12.9)    | (9.4, 17.2)  |
| PartialResponse(PR)              |            137 | (44.5)         | (38.8, 50.2)   |       117 | (37.9)    | (32.4, 43.5) |
| ObjectiveResponse(CR+PR)         |            203 | (65.9)         | (60.3,71.2)    |       157 | (50.8)    | (45.1, 56.5) |
| Stable Disease (SD)              |             69 | (22.4)         | (17.9, 27.5)   |        99 | (32.0)    | (26.9, 37.6) |
| Progressive Disease (PD)         |             15 | (4.9)          | (2.8, 7.9)     |        33 | (10.7)    | (7.5, 14.7)  |
| Not Evaluable (NE)               |              1 | (0.3)          | (0.0, 1.8)     |         2 | (0.6)     | (0.1, 2.3)   |
| NoAssessment (NA)                |             20 | (6.5)          | (4.0, 9.9)     |        18 | (5.8)     | (3.5, 9.1)   |

aBasedonbinomialexactconfidenceintervalmethod.

Investigator assessed responses per RECIST 1.1 (confirmed) are included in this table. DatabaseCutoffDate:03MAY2021

Confirmed ORR per BICR in the all-comer population was 61.7% (56.0, 67.1) vs 53.7% (48.0, 59.4) in the pembro combo vs control arm, respectively.

Table 30. Summary of Best Objective Response (Confirmed) Based on BICR Assessment per RECIST 1.1 (All-comer Participants) (ITT Population)

|                                  | PembroCombo   | PembroCombo   | PembroCombo   |   Control | Control   | Control      |
|----------------------------------|---------------|---------------|---------------|-----------|-----------|--------------|
|                                  | n1            | (%)           | (95% CI)a     |        11 | (%)       | (95% CI)a    |
| NumberofParticipantsinPopulation | 308           |               |               |       309 |           |              |
| Complete Response (CR)           | 105           | (34.1)        | (28.8, 39.7)  |        64 | (20.7)    | (16.3, 25.7) |
| Partial Response (PR)            | 85            | (27.6)        | (22.7,33.0)   |       102 | (33.0)    | (27.8, 38.6) |
| ObjectiveResponse(CR+PR)         | 190           | (61.7)        | (56.0, 67.1)  |       166 | (53.7)    | (48.0, 59.4) |
| Stable Disease (SD)              | 77            | (25.0)        | (20.3, 30.2)  |        89 | (28.8)    | (23.8, 34.2) |
| Progressive Disease (PD)         | 13            | (4.2)         | (2.3,7.1)     |        30 | (9.7)     | (6.6, 13.6)  |
| Not Evaluable (NE)               | 10            | (3.2)         | (1.6, 5.9)    |         8 | (2.6)     | (1.1, 5.0)   |
| No Assessment (NA)               | 18            | (5.8)         | (3.5, 9.1)    |        16 | (5.2)     | (3.0, 8.3)   |

Basedonbinomialexactconfidenceintervalmethod. BICR assessed responses per RECIST 1.1 (confirmed) are included in this table. DatabaseCutoffDate:03MAY2021

<div style=\"page-break-after: always\"></div>

Table 31. Concordance of Progression Events (Investigator vs. BICR) (All-comer Participants) (ITT Population)

|                                      | Pembro Combo   | Control     | Total       |
|--------------------------------------|----------------|-------------|-------------|
| Number of Subjects in Population     | 308            | 309         | 617         |
| Investigator Assessment - PD         | 155            | 204         | 359         |
| BICR Agreed                          | 119 (76.8%)    | 161 (78.9%) | 280 (78.0%) |
| BICR and Investigator agreed on time | 60 (38.7%)     | 90 (44.1%)  | 150 (41.8%) |
| BICR has earlier time                | 31 (20.0%)     | 41 (20.1%)  | 72 (20.1%)  |
| BICR has later time                  | 28 (18.1%)     | 30 (14.7%)  | 58 (16.2%)  |
| BICR Disagreed                       | 35 (22.6%)     | 42 (20.6%)  | 77 (21.4%)  |
| No BICR Assessment                   | 1 (0.6%)       | 1 (0.5%)    | 2 (0.6%)    |
| Investigator Assessment - Non PD     | 133            | 85          | 218         |
| BICR Agreed                          | 122 (91.7%)    | 70 (82.4%)  | 192 (88.1%) |
| BICR Disagreed                       | 6 (4.5%)       | 10 (11.8%)  | 16 (7.3%)   |
| No BICR Assessment                   | 5 (3.8%)       | 5 (5.9%)    | 10 (4.6%)   |

PD: Progressive Disease.

BICR: Blinded Independent Central Review.

Database Cutoff Date: 03MAY2021

## CPS ≥ 10

Table  32.  Summary  of  Best  Objective  Response  (Confirmed)  Based  on  Investigator Assessment per RECIST 1.1 (CPS&gt;=10 Participants) (ITT Population)

|                                  |   Pembro Combo | Pembro Combo   | Pembro Combo   | Control   | Control   | Control      |
|----------------------------------|----------------|----------------|----------------|-----------|-----------|--------------|
|                                  |             11 | (%)            | (95% CI)a      |           | (%)       | (95% CI)a    |
| NumberofParticipantsinPopulation |            158 |                |                | 159       |           |              |
| Complete Response (CR)           |             35 | (22.2)         | (15.9, 29.4)   | 18        | (11.3)    | (6.8, 17.3)  |
| Partial Response (PR)            |             75 | (47.5)         | (39.5, 55.6)   | 60        | (37.7)    | (30.2, 45.8) |
| ObjectiveResponse(CR+PR)         |            110 | (69.6)         | (61.8, 76.7)   | 78        | (49.1)    | (41.1, 57.1) |
| Stable Disease (SD)              |             29 | (18.4)         | (12.7,25.3)    | 53        | (33.3)    | (26.1,41.2)  |
| Progressive Disease (PD)         |              4 | (2.5)          | (0.7, 6.4)     | 16        | (10.1)    | (5.9, 15.8)  |
| Not Evaluable (NE)               |              1 | (0.6)          | (0.0, 3.5)     | 2         | (1.3)     | (0.2,4.5)    |
| No Assessment (NA)               |             14 | (8.9)          | (4.9, 14.4)    | 10        | (6.3)     | (3.1, 11.3)  |

aBasedonbinomialexactconfidenceintervalmethod.

Investigator assessed responses per RECIST 1.1 (confirmed) areincluded in this table.

DatabaseCutoffDate:03MAY2021

Confirmed ORR per BICR in the CPS ≥ 10 participants was 70.3% (62.5,77.3) vs 52.8% (44.8,60.8) in the pembro combo vs control arm, respectively.

<div style=\"page-break-after: always\"></div>

## Secondary endpoint - Duration of response (by investigator)

## CPS ≥ 1

Table 33. Summary of Time to Response and Duration of Response Based on Investigator Assessment per RECIST 1.1 in Participants with Confirmed Response (CPS&gt;=1 Participants) (ITT Population)

|                                                       | PembroCombo (N=273)   | Control (N=275)    | Total (N=548)       |
|-------------------------------------------------------|-----------------------|--------------------|---------------------|
| Number of participants with responsea                 | 186                   | 138                | 324                 |
| Time to Response (months)                             |                       |                    |                     |
| Mean (SD)                                             | 2.8 (2.1)             | 2.4 (0.9)          | 2.6 (1.7)           |
| Median (Range)                                        | 2.1 (1.7-20.6)        | 2.1 (1.3-7.1)      | 2.1 (1.3-20.6)      |
| ResponseDurationb(months)                             |                       |                    |                     |
| Median (Range)                                        | 18.0 (1.3+ -24.2+)    | 10.4 (1.5+ -22.0+) | 13.2 (1.3+ - 24.2+) |
| Number(%b)ofParticipantswithExtendedResponseDuration: |                       |                    |                     |
| ≥6 months                                             | 147 (82.7)            | 105 (79.8)         | 252 (81.4)          |
| ≥12 months                                            | 93 (55.7)             | 56 (46.0)          | 149 (51.6)          |
| ≥18 months                                            | 39 (49.6)             | 19 (35.4)          | 58 (43.5)           |
| ≥24 months                                            | 4 (46.7)              | 0 (NR)             | 4 (38.2)            |

Includes participants with best objective response with confirmation as complete response or partial response

From product-limit (Kaplan-Meier) method for censored data.

\"+\" indicates there is no progressive disease by the time of last disease assessment.

NR = Not Reached.

DatabaseCutoffDate:03MAY2021

Figure 19. Kaplan-Meier Estimates of Duration of Response Based on Investigator Assessment per RECIST 1.1 (CPS&gt;=1 Participants) (ITT Population)

<!-- image -->

DatabaseCutoff Date:03MAY2021

<div style=\"page-break-after: always\"></div>

## All comers

Table 34. Summary of Time to Response and Duration of Response Based on Investigator Assessment per RECIST 1.1 in Participants with Confirmed Response (All-comer Participants) (ITT Population)

|                                                       | PembroCombo (N=308)   | Control (N=309)   | Total (N=617)       |
|-------------------------------------------------------|-----------------------|-------------------|---------------------|
| Number of participants with responsea                 | 203                   | 157               | 360                 |
| Time toResponse(months)                               |                       |                   |                     |
| Mean (SD)                                             | 2.8 (2.0)             | 2.4 (1.0)         | 2.6 (1.6)           |
| Median (Range)                                        | 2.1 (1.7-20.6)        | 2.1 (1.3-8.8)     | 2.1 (1.3-20.6)      |
| ResponseDurationb(months)                             |                       |                   |                     |
| Median (Range)                                        | 18.0 (1.3+-24.2+)     | 10.4 (1.5+-22.0+) | 13.2 (1.3+ - 24.2+) |
| Number(%b)ofParticipantswithExtendedResponseDuration: |                       |                   |                     |
| ≥6 months                                             | 161 (82.6)            | 119 (80.7)        | 280 (81.8)          |
| ≥12 months                                            | 101 (55.0)            | 63 (46.3)         | 164 (51.3)          |
| ≥18 months                                            | 43 (49.4)             | 19 (31.9)         | 62 (41.7)           |
| ≥24 months                                            | 4 (45.5)              | 0 (NR)            | 4 (36.1)            |

Includes participants withbest objective response with confirmation as complete response or partial response

b From product-limit (Kaplan-Meier) method for censored data.

\"+\" indicates there is no progressive disease by the time of last disease assessment.

NR = Not Reached.

DatabaseCutoffDate:03MAY2021

Figure 20. Kaplan-Meier Estimates of Duration of Response Based on Investigator Assessment per RECIST 1.1 (All-comer Participants) (ITT Population)

<!-- image -->

DatabaseCutoffDate:03MAY2021

<div style=\"page-break-after: always\"></div>

## CPS ≥ 10

Table 35. Summary of Time to Response and Duration of Response Based on Investigator Assessment per RECIST 1.1 in Participants with Confirmed Response (CPS&gt;=10 Participants) (ITT Population)

|                                                       | Pembro Combo (N=158)   | Control (N=159)   | Total (N=317)      |
|-------------------------------------------------------|------------------------|-------------------|--------------------|
| Number of participants with responsea                 | 110                    | 78                | 188                |
| TimetoResponse(months)                                |                        |                   |                    |
| Mean (SD)                                             | 2.6 (1.2)              | 2.4 (1.0)         | 2.5 (1.1)          |
| Median (Range)                                        | 2.2 (1.7-8.4)          | 2.1 (1.3-7.1)     | 2.1 (1.3-8.4)      |
| ResponseDurationb(months)                             |                        |                   |                    |
| Median (Range)                                        | 21.1 (1.3+ - 24.2+)    | 9.4 (2.1+-21.5+)  | 13.3 (1.3+- 24.2+) |
| Number(%b)ofParticipantswithExtendedResponseDuration: |                        |                   |                    |
| ≥6 months                                             | 88 (83.8)              | 58 (76.6)         | 146 (80.8)         |
| ≥12months                                             | 56 (58.3)              | 31 (43.9)         | 87 (52.3)          |
| ≥18 months                                            | 21 (53.3)              | 6 (31.6)          | 27 (44.3)          |
| ≥24 months                                            | 3 (48.5)               | 0 (NR)            | 3 (39.2)           |

Includes participants with best objective response with confirmation as complete response or partial response

From product-limit (Kaplan-Meier) method for censored data.

\"+\" indicates there is no progressive disease by the time of last disease assessment.

NR =Not Reached.

DatabaseCutoffDate:03MAY2021

Figure 21. Kaplan-Meier Estimates of Duration of Response Based on Investigator Assessment per RECIST 1.1 (CPS&gt;=10 Participants) (ITT Population)

<!-- image -->

Database Cutoff Date:03MAY2021

## Ancillary analyses

## PD-L1 CPS &lt;1 Participants (post-hoc analysis)

In KEYNOTE-826, of the total of 617 participants, 69 (approximately 11%) were in the CPS &lt;1 subgroup (35 in pembrolizumab + chemotherapy ± bevacizumab group and 34 in placebo + chemotherapy ± bevacizumab group). Efficacy in this group was explored via post hoc efficacy analyses at the Agency's request. KEYNOTE-826 was not designed or powered to make the comparison of pembrolizumab + chemotherapy ± bevacizumab versus placebo + chemotherapy ± bevacizumab in participants whose tumors express CPS &lt;1.

<div style=\"page-break-after: always\"></div>

Table 36. Summary of Key Efficacy Results in Participants With CPS&lt;1 Persistent, Recurrent, or Metastatic Cervical Cancer (ITT Population)*

| Endpoint                                       | Pembrolizumab + Chemotherapy ± Bevacizumab (N=35)   | Placebo + Chemotherapy ± Bevacizumab (N=34)    |
|------------------------------------------------|-----------------------------------------------------|------------------------------------------------|
| PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1      | PFS as Assessed by Investigator per RECIST 1.1 |
| Number of Events (%)                           | 23 (65.7)                                           | 28 (82.4)                                      |
| Median PFS, months (95% CI)                    | 8.1 (6.1, 12.6)                                     | 8.2 (6.2, 10.4)                                |
| HR (95% CI)                                    | 0.94 (0.52, 1.70)                                   | 0.94 (0.52, 1.70)                              |
| OS                                             |                                                     |                                                |
| Number of Events (%)                           | 20 (57.1)                                           | 20 (58.8)                                      |
| Median OS, months (95% CI)                     | 19.0 (12.6, 21.4)                                   | 18.9 (11.7, 21.3)                              |
| HR (95% CI)                                    | 1.00 (0.53, 1.89)                                   | 1.00 (0.53, 1.89)                              |
| ORR by inv, %(95% CI)                          | 48.6 (31.4,66.0)                                    | 55.9 (37.9,72.8)                               |
| ORR Difference %(95% CI)                       | -6.4 (-29.0,16.7)                                   | -6.4 (-29.0,16.7)                              |
| DOR by inv , (months), median (range)          | 10.7 (4.2 - 21.6+)                                  | 8.5 (2.4+ - 17.3+)                             |

Abbreviations: BICR = blinded independent central review; CI = confidence interval; CPS = Combined Positive Score; HR = hazard ratio; ITT = intent-to-treat; NR = not reached; OS = overall survival; PFS = progression-free survival; PD-L1 = programmed cell death ligand 1; RECIST = Response Evaluation Criteria In Solid Tumors

Database Cutoff Date: 03-MAY-2021

* Summary presented by the assessment team

<div style=\"page-break-after: always\"></div>

Table 37. Analysis of Progression-Free Survival Based on Investigator Assessment per RECIST 1.1 (CPS&lt;1 Participants) (ITT Population)

|                                                           | Pembro Combo (N=35)                 | Control (N=34)              |
|-----------------------------------------------------------|-------------------------------------|-----------------------------|
| Number of Events (%)                                      | 23 (65.7)                           | 28 (82.4)                   |
| DEATH                                                     | 2 (5.7)                             | 1 (2.9)                     |
| DOCUMENTEDPROGRESSION                                     | 21 (60.0)                           | 27 (79.4)                   |
| Kaplan-Meier Estimates (months)a Median (95% CI) [Q1, Q3] | 8.1 (6.1, 12.6) [3.9, 20.7]         | 8.2 (6.2, 10.4) [6.1, 15.2] |
| Person-months Event Rate/100 Person-months                | 302.3 7.6                           | 9.6                         |
|                                                           |                                     | 293.0                       |
| vs Control Hazard Ratio (95% C1)b p-valuec                | 0.94 (0.52, 1.70) 0.4185            |                             |
| PFS Rate at month 6 (%) (95% CI)                          | 72.3 (53.5, 84.5)                   | 79.2 (61.2, 89.5)           |
| PFS Rate at month 18 (%) (95% CI)                         | 37.9 (21.0, 54.7) 27.1 (12.7, 43.8) | 28.2 (13.5, 44.8)           |
| PFS Rate at month 12 (%)(95% CI)                          |                                     | 4.4 (0.3, 18.0)             |
| PFS Rate at month 24 (%) (95% CI)                         | NR (NR, NR)                         | NR (NR, NR)                 |

a From product-limit (Kaplan-Meier) method for censored data.

b Based on Cox regression model with Efron's method oftie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1,CPS 1 to &lt;10,CPS &gt;=10).

c One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10). NR = Not reached.

Database Cutoff Date: 03MAY2021

Figure  22.  Kaplan-Meier  Estimates  of  Progression-Free  Survival  Based  on  Investigator Assessment per RECIST 1.1 (CPS&lt;1 Participants) (ITT Population)

<!-- image -->

DatabaseCutoffDate:03MAY2021

<div style=\"page-break-after: always\"></div>

Table 38. Analysis of Overall Survival (CPS&lt;1 Participants) (ITT Population)

|                                  | Pembro Combo (N=35)         | Control (N=34)               |
|----------------------------------|-----------------------------|------------------------------|
| Number of Events (%) DEATH       | 20 (57.1) 20 (57.1)         | 20 (58.8) 20 (58.8)          |
| Kaplan-Meier Estimates (months)a |                             |                              |
| Median (95% CI) [Q1, Q3]         | 19.0 (12.6, 21.4) [8.5, NR] | 18.9 (11.7, 21.3) [10.8, NR] |
| Person-months                    | 496.8                       | 527.7                        |
| Event Rate/100 Person-months     | 4.0                         | 3.8                          |
| vs Control                       |                             |                              |
| Hazard Ratio (95% CI)b p-valuec  | 1.00 (0.53, 1.89) 0.5026    |                              |
| OS Rate at month 6 (%)(95% CI)   | 79.5 (61.7, 89.6)           | 97.1 (80.9, 99.6)            |
| OS Rate at month 12 (%) (95% CI) | 70.6 (52.3, 83.0)           | 67.6 (49.2, 80.6)            |
| OS Rate at month 18 (%)(95% CI)  | 54.8 (36.4, 69.9)           | 58.7 (40.4, 73.1)            |
| OS Rate at month 24 (%)(95% CI)  | 28.3 (11.6, 47.7)           | 30.0 (12.5, 49.9)            |

aFrom product-limit(Kaplan-Meier)method for censored data.

bBased on Cox regression model with Efron's method oftie handlingwith treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

c One-sided p-value based on log-rank test stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10). NR = Not reached.

Database Cutoff Date:03MAY2021

Figure 23. Kaplan-Meier Estimates of Overall Survival (CPS&lt;1 Participants) (ITT Population)

<!-- image -->

DatabaseCutoffDate:03MAY2021

<div style=\"page-break-after: always\"></div>

Table 39. Analysis of Confirmed Objective Response Based on Investigator Assessment per RECIST 1.1 (CPS&lt;1 Participants) (ITT Population)

|             |    |                                    |                                    | DifferenceinPercentagePembroCombovs.Control   | DifferenceinPercentagePembroCombovs.Control   |
|-------------|----|------------------------------------|------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Treatment   | N  | NumberofConfimed ObjectiveResponse | ObjectiveResponseRate (%) (95% CI) | Estimate(95%C1)a                              | p-Valueb                                      |
| PembroCombo | 35 | 17                                 | 48.6 (31.4,66.0)                   | -6.4 (-29.0,16.7)                             | 0.7037                                        |
| Control     | 34 | 19                                 | 55.9(37.9,72.8)                    |                                               |                                               |

Based on Miettinen&amp;Nurminenmethod stratified bymetastatic atinitial diagnosis(FIGO[2009]stage IVB)(yesorno),bevacizumabuse(yesorno)and PD-L1status(CPS&lt;1,CPS1to&lt;10,CPS&gt;=10).

bOne-sided p-value for testing.H0:difference in %=0versus H1:differencein %&gt;0.

DatabaseCutoffDate:03MAY2021

Table  40.  Summary  of  Best  Objective  Response  (Confirmed)  Based  on  Investigator Assessment per RECIST 1.1 (CPS&lt;1 Participants) (ITT Population)

|                                  |   PembroCombo | PembroCombo   | PembroCombo   |   Control | Control   | Control      |
|----------------------------------|---------------|---------------|---------------|-----------|-----------|--------------|
|                                  |            11 | (%)           | (95% CI)a     |        11 | (%)       | (95% CI)a    |
| NumberofParticipantsinPopulation |            35 |               |               |        34 |           |              |
| Complete Response (CR)           |             4 | (11.4)        | (3.2,26.7)    |         4 | (11.8)    | (3.3,27.5)   |
| Partial Response (PR)            |            13 | (37.1)        | (21.5, 55.1)  |        15 | (44.1)    | (27.2, 62.1) |
| ObjectiveResponse(CR+PR)         |            17 | (48.6)        | (31.4, 66.0)  |        19 | (55.9)    | (37.9, 72.8) |
| Stable Disease (SD)              |            11 | (31.4)        | (16.9, 49.3)  |        11 | (32.4)    | (17.4, 50.5) |
| Progressive Disease (PD)         |             6 | (17.1)        | (6.6, 33.6)   |         4 | (11.8)    | (3.3,27.5)   |
| Not Evaluable (NE)               |             0 | (0.0)         | (0.0, 10.0)   |         0 | (0.0)     | (0.0, 10.3)  |
| No Assessment (NA)               |             1 | (2.9)         | (0.1, 14.9)   |         0 | (0.0)     | (0.0,10.3)   |

aBasedonbinomialexactconfidenceintervalmethod

Investigator assessed responses per RECIST 1.1 (confirmed) are included in this table. DatabaseCutoffDate:03MAY2021

Table 41. Summary of Time to Response and Duration of Response Based on Investigator Assessment per RECIST 1.1 in Participants with Confirmed Response (CPS&lt;1 Participants) (ITT Population)

|                                                                                                                                                   | Pembro Combo (N=35)                                                                                                                               | Control (N=34)                                                                                                                                    | Total (N=69)                                                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Number ofparticipantswith responsea                                                                                                               | 17                                                                                                                                                | 19                                                                                                                                                | 36                                                                                                                                                |
| TimetoResponse(months)                                                                                                                            |                                                                                                                                                   |                                                                                                                                                   |                                                                                                                                                   |
| Mean (SD)                                                                                                                                         | 2.2 (0.5)                                                                                                                                         | 2.5 (1.5)                                                                                                                                         | 2.3 (1.2)                                                                                                                                         |
| Median (Range)                                                                                                                                    | 2.1 (1.9-4.0)                                                                                                                                     | 2.1 (1.9-8.8)                                                                                                                                     | 2.1 (1.9-8.8)                                                                                                                                     |
| ResponseDurationb(months)                                                                                                                         |                                                                                                                                                   |                                                                                                                                                   |                                                                                                                                                   |
| Median (Range)                                                                                                                                    | 10.7 (4.2 - 21.6+)                                                                                                                                | 8.5 (2.4+ - 17.3+)                                                                                                                                | 10.7 (2.4+ -21.6+)                                                                                                                                |
| Number(%b)of ParticipantswithExtended ResponseDuration:                                                                                           |                                                                                                                                                   |                                                                                                                                                   |                                                                                                                                                   |
| ≥6 months                                                                                                                                         | 14 (82.4)                                                                                                                                         | 14 (88.9)                                                                                                                                         | 28 (85.4)                                                                                                                                         |
| ≥12 months                                                                                                                                        | 8 (47.1)                                                                                                                                          | 7 (49.4)                                                                                                                                          | 15 (48.1)                                                                                                                                         |
| ≥18months                                                                                                                                         | 4 (47.1)                                                                                                                                          | 0 (NR)                                                                                                                                            | 4 (26.0)                                                                                                                                          |
| Includes participants with best objective response with confirmation as complete response or partial response                                     | Includes participants with best objective response with confirmation as complete response or partial response                                     | Includes participants with best objective response with confirmation as complete response or partial response                                     | Includes participants with best objective response with confirmation as complete response or partial response                                     |
| From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. | From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. | From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. | From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. |

<div style=\"page-break-after: always\"></div>

Figure  24.    Kaplan-Meier  Estimates  of  Duration  of  Response  Based  on  Investigator Assessment per RECIST 1.1 (CPS&lt;1 Participants) (ITT Population)

<!-- image -->

## Results according to bevacizumab use

The use of bevacizumab (yes/no) was a stratification factor. Subgroup analyses according to bevacizumab use were pre-specified. Approximately 60% of patients received bevacizumab.

<div style=\"page-break-after: always\"></div>

Table 42. Summary of Efficacy Results in All-comer Participants by Bevacizumab Use (ITT Population)

|                                                | With Bevacizumab                               | With Bevacizumab                               | Without Bevacizumab                            | Without Bevacizumab                            |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Endpoint                                       | Pembrolizumab + Chemotherapy (N=196)           | Placebo + Chemotherapy (N=193)                 | Pembrolizumab + Chemotherapy (N=112)           | Placebo + Chemotherapy (N=116)                 |
| PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 |
| Median PFS a , months (95% CI)                 | 15.2 (10.5, 21.3)                              | 10.2 (8.3, 12.3)                               | 6.3 (6.1, 8.3)                                 | 6.2 (4.4, 6.3)                                 |
| HR (95% CI) b                                  | 0.61 (0.47, 0.79)                              | 0.61 (0.47, 0.79)                              | 0.74 (0.54, 1.01)                              | 0.74 (0.54, 1.01)                              |
| OS                                             | OS                                             | OS                                             | OS                                             | OS                                             |
| Median OS a , months (95% CI)                  | NR (24.4, NR)                                  | 24.7 (16.4, 26.0)                              | 16.8 (14.2, 19.8)                              | 12.6 (10.0, 14.8)                              |
| HR (95% CI) b                                  | 0.63 (0.47, 0.87)                              | 0.63 (0.47, 0.87)                              | 0.74 (0.53, 1.04)                              | 0.74 (0.53, 1.04)                              |
| Objective Response Rate                        | Objective Response Rate                        | Objective Response Rate                        | Objective Response Rate                        | Objective Response Rate                        |
| ORR (%) (95% CI)                               | 75.5 (68.9, 81.4)                              | 60.6 (53.3, 67.6)                              | 49.1 (39.5, 58.7)                              | 34.5 (25.9, 43.9)                              |
| ORR Difference% (95% CI) c                     | 15.1 (5.8, 24.3)                               | 15.1 (5.8, 24.3)                               | 14.6 (1.8, 27.0)                               | 14.6 (1.8, 27.0)                               |
| DOR                                            | DOR                                            | DOR                                            | DOR                                            | DOR                                            |
| DOR a , (months), median (range)               | 21.1 (1.3+ - 24.2+)                            | 12.9 (2.1+ - 22.0+)                            | 8.2 (1.9+ - 24.1+)                             | 6.3 (1.5+ - 18.6+)                             |

CI=confidence interval; CPS=combined positive score; HR=hazard ratio; ITT=intent-to-treat; NR=not reached;

OS=overall survival; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; RECIST

1.1=response evaluation criteria in solid tumors version 1.1.

a  From product-limit (Kaplan-Meier) method for censored data.

b Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

c Based on Miettinen &amp; Nurminen method stratified by metastatic at initial diagnosis (FIGO [2009] stage   IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

\"+\" indicates there is no progressive disease by the time of last disease assessment.

Database Cutoff Date: 03MAY2021

<div style=\"page-break-after: always\"></div>

Figure  25.  Kaplan-Meier  Estimates  of  Progression-Free  Survival  Based  on  Investigator Assessment per RECIST 1.1 (Primary Analysis) (All-comer Participants by Bevacizumab Use) (ITT Population)

<!-- image -->

Figure 26. Kaplan-Meier Estimates of Overall Survival (All-comer Participants by Bevacizumab Use) (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table  43 . Summary of Efficacy Results in CPS ≥1 Participants by Bevacizumab Use (ITT Population)

0.66 (0.47, 0.92)

(9.7, 14.5)

0.67 (0.47, 0.96)

|                                                | With Bevacizumab                               | With Bevacizumab                               | Without Bevacizumab                            | Without Bevacizumab                            |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Endpoint                                       | Pembrolizumab + Chemotherapy (N=175)           | Placebo + Chemotherapy (N=171)                 | Pembrolizumab + Chemotherapy (N=98)            | Placebo + Chemotherapy (N=104)                 |
| PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 |
| Median PFS a , months (95% CI)                 | 15.3 (10.5, 23.5)                              | 10.3 (8.4, 12.3)                               | 7.0 (6.2, 9.1)                                 | 6.0 (4.3, 6.3)                                 |
| HR (95% CI) b                                  | 0.61 (0.46, 0.80)                              | 0.61 (0.46, 0.80)                              | 0.66 (0.47, 0.92)                              | 0.66 (0.47, 0.92)                              |
| OS                                             | OS                                             | OS                                             | OS                                             | OS                                             |
| Median OS a , months (95% CI)                  | NR (24.4, NR)                                  | 25.0 (16.3, NR)                                | 17.1 (14.9, 20.0)                              | 11.9 (9.7, 14.5)                               |
| HR (95% CI) b                                  | 0.62 (0.45, 0.87)                              | 0.62 (0.45, 0.87)                              | 0.67 (0.47, 0.96)                              | 0.67 (0.47, 0.96)                              |
| Objective Response Rate                        | Objective Response Rate                        | Objective Response Rate                        | Objective Response Rate                        | Objective Response Rate                        |
| ORR (%) (95% CI)                               | 77.1 (70.2, 83.1)                              | 60.2 (52.5, 67.6)                              | 52.0 (41.7, 62.2)                              | 33.7 (24.7, 43.6)                              |
| ORR Difference% (95% CI) c                     | 17.3 (7.5, 26.9)                               | 17.3 (7.5, 26.9)                               | 18.3 (4.7, 31.3)                               | 18.3 (4.7, 31.3)                               |
| DOR                                            | DOR                                            | DOR                                            | DOR                                            | DOR                                            |
| DOR a , (months), median (range)               | 21.1 (1.3+ - 24.2+)                            | 12.6 (2.1+ - 22.0+)                            | 8.5 (1.9+ - 24.1+)                             | 6.3 (1.5+ - 18.6+)                             |

CI=confidence interval; CPS=combined positive score; DOR= duration of response; HR=hazard ratio; ITT=intentto-treat; NR=not reached; OS=overall survival; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; RECIST 1.1=response evaluation criteria in solid tumors version 1.1.

a  From product-limit (Kaplan-Meier) method for censored data.

b Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

c Based on Miettinen &amp; Nurminen method stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

\"+\" indicates there is no progressive disease by the time of last disease assessment.

NR = Not reached.

Database Cutoff Date: 03MAY2021

<div style=\"page-break-after: always\"></div>

Figure  27.  Kaplan-Meier  Estimates  of  Progression-Free  Survival  Based  on  Investigator Assessment per RECIST 1.1 (Primary Analysis) (CPS ≥1 Participants by Bev acizumab Use) (ITT Population)

<!-- image -->

Figure 28. KaplanMeier Estimates of Overall Survival (CPS ≥1 Participants by Bev acizumab Use) (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Results by histology

Table 44. PD-L1 Expression in All-comer Participants by Histology (ITT Population)

|                            | Participants with Squamous Cell Carcinoma   | Participants with Squamous Cell Carcinoma   | Participants with Non-squamous Cell Carcinoma   | Participants with Non-squamous Cell Carcinoma   | Participants with Non-squamous Cell Carcinoma   |
|----------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                            | Pembrolizumab + Chemotherapy                | Placebo + Chemotherapy                      | Pembrolizumab + Chemotherapy                    | Placebo + Chemotherapy                          | Placebo + Chemotherapy                          |
|                            | n (%)                                       | n (%)                                       | n                                               | (%) n                                           | (%)                                             |
| Participants in population | 236                                         | 211                                         | 71                                              | 98                                              |                                                 |
| PD-L1 Status               |                                             |                                             |                                                 |                                                 |                                                 |
| CPS <1                     | 24 (10.2)                                   | 14 (6.6)                                    | 11 (15.5)                                       | 20                                              | (20.4)                                          |
| 1 ≤ CPS <10                | 78 (33.1)                                   | 77 (36.5)                                   | 36 (50.7)                                       | 39                                              | (39.8)                                          |
| CPS ≥ 10                   | 134 (56.8)                                  | 120 (56.9)                                  | 24                                              | (33.8) 39                                       | (39.8)                                          |

CPS=combined positive score; ITT=intent-to-treat; PD-L1=programmed cell death ligand 1. Non-squamous subgroup included participants with Adenocarcinoma and Adenosquamous. One participant with Epidermoide Carcinoma was included in Squamous subgroup.

PFS and OS results by histology in the all comers and PDL1 CPS≥1 population are presented in the tables below:

Table 45. Progression-Free Survival Based on Investigator Assessment per RECIST 1.1 by Subgroup Factors (All-comers)

|                                           | Pembro Combo (N=308)   | Pembro Combo (N=308)   | Pembro Combo (N=308)   | Control (N=309)   | Control (N=309)   | Control (N=309)   | Pembro Combo vs. Control Hazard Ratio (95% CI)   |
|-------------------------------------------|------------------------|------------------------|------------------------|-------------------|-------------------|-------------------|--------------------------------------------------|
|                                           | N                      | Number of Events       | (%)                    | N                 | Number of Events  | (%)               | a                                                |
| Overall                                   | 308                    | 180                    | (58.4)                 | 309               | 226               | (73.1)            | 0.65 (0.53, 0.79)                                |
| Histology of Subtype of Cervical Cancer b |                        |                        |                        |                   |                   |                   |                                                  |
| Non-squamous                              | 71                     | 41                     | (57.7)                 | 98                | 67                | (68.4)            | 0.66 (0.43, 1.00)                                |
| Squamous                                  | 236                    | 138                    | (58.5)                 | 211               | 159               | (75.4)            | 0.63 (0.50, 0.80)                                |

NR = Not Reached

a Based on Cox regression model with Efrons method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

b  Non-squamous subgroup included participants with Adenocarcinoma and Adenosquamous. One participant with Epidermoide Carcinoma was included in Squamous subgroup.

Database Cutoff Date: 03MAY2021

<div style=\"page-break-after: always\"></div>

Table 46. Overall Survival by Subgroup Factors

|                                           | Pembro Combo (N=308)   | Pembro Combo (N=308)   | Pembro Combo (N=308)   | Control (N=309)   | Control (N=309)   | Control (N=309)   | Pembro Combo vs. Control Hazard Ratio (95% CI) a   |
|-------------------------------------------|------------------------|------------------------|------------------------|-------------------|-------------------|-------------------|----------------------------------------------------|
|                                           | N                      | Number of Events       | (%)                    | N                 | Number of Events  | (%)               | Pembro Combo vs. Control Hazard Ratio (95% CI) a   |
| Overall                                   | 308                    | 138                    | (44.8)                 | 309               | 174               | (56.3)            | 0.67 (0.54, 0.84)                                  |
| Histology of Subtype of Cervical Cancer b |                        |                        |                        |                   |                   |                   |                                                    |
| Non-squamous                              | 71                     | 29                     | (40.8)                 | 98                | 46                | (46.9)            | 0.76 (0.47, 1.23)                                  |
| Squamous                                  | 236                    | 109                    | (46.2)                 | 211               | 128               | (60.7)            | 0.61 (0.47, 0.80)                                  |

NR = Not Reached

a Based on Cox regression model with Efrons method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

b  Non-squamous subgroup included participants with Adenocarcinoma and Adenosquamous. One participant with Epidermoide Carcinoma was included in Squamous subgroup.

Database Cutoff Date: 03MAY2021

Table 47. Summary of Efficacy Results in CPS ≥1 Participants by Histology (ITT Population)

0.59 (0.37, 0.93)

0.70 (0.41, 1.20)

|                                                | Participants with Squamous Cell Carcinoma      | Participants with Squamous Cell Carcinoma      | Participants with Non-squamous Cell Carcinoma   | Participants with Non-squamous Cell Carcinoma   |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Endpoint                                       | Pembrolizumab + Chemotherapy (N=212)           | Placebo + Chemotherapy (N=197)                 | Pembrolizumab + Chemotherapy (N=60)             | Placebo + Chemotherapy (N=78)                   |
| PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1  | PFS as Assessed by Investigator per RECIST 1.1  |
| Median PFS a , months (95% CI)                 | 10.4 (8.6, 12.3)                               | 6.6 (6.2, 8.3)                                 | 11.8 (9.6, NR)                                  | 8.5 (7.0, 11.5)                                 |
| HR (95% CI) b                                  | 0.61 (0.48, 0.78)                              | 0.61 (0.48, 0.78)                              | 0.59 (0.37, 0.93)                               | 0.59 (0.37, 0.93)                               |
| OS                                             | OS                                             | OS                                             | OS                                              | OS                                              |
| Median OS a , months (95% CI)                  | 24.4 (19.1, NR)                                | 14.2 (12.1, 18.4)                              | NR (17.3, NR)                                   | 23.5 (16.3, NR)                                 |
| HR (95% CI) b                                  | 0.60 (0.46, 0.79)                              | 0.60 (0.46, 0.79)                              | 0.70 (0.41, 1.20)                               | 0.70 (0.41, 1.20)                               |
| Objective Response Rate                        | Objective Response Rate                        | Objective Response Rate                        | Objective Response Rate                         | Objective Response Rate                         |
| ORR (%) (95% CI)                               | 67.0 (60.2, 73.3)                              | 46.2 (39.1, 53.4)                              | 71.7 (58.6, 82.5)                               | 60.3 (48.5, 71.2)                               |
| ORR Difference %(95% CI) c                     | 20.4 (11.1, 29.4)                              | 20.4 (11.1, 29.4)                              | 13.8 (-2.2, 28.1)                               | 13.8 (-2.2, 28.1)                               |

CI=confidence interval; CPS=combined positive score; HR=hazard ratio; ITT=intent-to-treat; NR=not reached; ORR=objective response rate; OS=overall survival; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; RECIST 1.1=response evaluation criteria in solid tumors version 1.1.

a  From product-limit (Kaplan-Meier) method for censored data.

- b Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).
- c Based on Miettinen &amp; Nurminen method stratified by metastatic at initial diagnosis (FIGO [2009] stage   IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).
- \"+\" indicates there is no progressive disease by the time of last disease assessment.

Database Cutoff Date: 03MAY2021

<div style=\"page-break-after: always\"></div>

## Results by platinum compound

Approximately 20% of patients received cisplatin. Summary of efficacy results in all-comer participants by platinum compound used are provided in Table 48.

Table 48. Summary of Efficacy Results in All-comer Participants by Platinum Compound Used (ITT Population)

7.4 (6.3, 8.4)

15.9 (13.4, 18.8)

21.3 (16.0, NR)

| Endpoint                                       | Pembrolizumab + Chemotherapy ± Bevacizumab     | Placebo + Chemotherapy ± Bevacizumab           |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Participants Treated with Carboplatin          | Participants Treated with Carboplatin          | Participants Treated with Carboplatin          |
|                                                | (N=246)                                        | (N=249)                                        |
| PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 |
| Median PFS a , months (95% CI)                 | 10.2 (8.3, 10.6)                               | 7.4 (6.3, 8.4)                                 |
| HR (95% CI) b                                  | 0.69 (0.55, 0.86)                              | 0.69 (0.55, 0.86)                              |
| OS                                             | OS                                             | OS                                             |
| Median OS a , months (95% CI)                  | 21.4 (18.7, NR)                                | 15.9 (13.4, 18.8)                              |
| HR (95% CI) b                                  | 0.69 (0.54, 0.89)                              | 0.69 (0.54, 0.89)                              |
| ORR                                            | ORR                                            | ORR                                            |
| Objective Response Rate (%) (95% CI)           | 62.2 (55.8, 68.3)                              | 48.6 (42.2, 55.0)                              |
| ORR Difference %(95% CI) c                     | 14.0 (5.4, 22.3)                               | 14.0 (5.4, 22.3)                               |
| Participants Treated with Cisplatin            | Participants Treated with Cisplatin            | Participants Treated with Cisplatin            |
|                                                | (N=61)                                         | (N=59)                                         |
| PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 | PFS as Assessed by Investigator per RECIST 1.1 |
| Median PFS a , months (95% CI)                 | 15.2 (10.5, NR)                                | 8.4 (6.4, 12.3)                                |
| HR (95% CI) b                                  | 0.47 (0.28, 0.77)                              | 0.47 (0.28, 0.77)                              |
| OS                                             | OS                                             | OS                                             |
| Median OS a , months (95% CI)                  | NR (20.9, NR)                                  | 21.3 (16.0, NR)                                |
| HR (95% CI) b                                  | 0.59 (0.32, 1.09)                              | 0.59 (0.32, 1.09)                              |
| ORR                                            | ORR                                            | ORR                                            |
| Objective Response Rate (%) (95% CI)           | 82.0 (70.0, 90.6)                              | 61.0 (47.4, 73.5)                              |
| ORR Difference %(95% CI) c                     | 19.6 (3.5, 35.2)                               | 19.6 (3.5, 35.2)                               |

CI=confidence interval; CPS=combined positive score; HR=hazard ratio; NR = not reached; ORR=objective response rate;

OS=overall survival; PFS=progression-free survival; RECIST 1.1=response evaluation criteria in solid tumors version 1.1.

a  From product-limit (Kaplan-Meier) method for censored data.

b  Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS ≥10).

c  Based on Miettinen &amp; Nurminen method stratified by metastatic at initial diagnosis (FIGO [2009] stage IVB) (yes or no), bevacizumab use (yes or no) and PD-L1 status (CPS &lt;1, CPS 1 to &lt;10, CPS &gt;=10).

Database Cutoff Date: 03MAY2021

## Patient-reported Outcomes

More participants treated with pembrolizumab + chemotherapy ± bevacizumab had improved or stable health status/QoL using the EQ-5D-5L compared with participants receiving placebo + chemotherapy ± bevacizumab (78.3% vs 71.7%, nominal p =0.033, not adjusted for multiplicity). A prolonged time to deterioration in EQ-5D-5L was observed for patients treated with pembrolizumab + chemotherapy ± bevacizumab compared to those treated with placebo + chemotherapy ± bevacizumab (HR 0.75; 95% CI: 0.58, 0.97; nominal p =0.027, not adjusted for multiplicity). Differences in the EORTC QLQ-C30 global health status score were not statistically different between the 2 groups.

<div style=\"page-break-after: always\"></div>

Figure 29. Empirical Mean Change from Baseline and 95% CI for the EORTC QLQ-C30 Global Health Status/QoL Over Time by Treatment Group (CPS &gt;=1 Full Analysis Set)

<!-- image -->

DatabaseCutoffDate:03MAY2021

Figure 30. Empirical Mean Change from Baseline and 95% CI for the EORTC QLQ-C30 Global Health Status/QoL Over Time by Treatment Group (All-comer Full Analysis Set)

<!-- image -->

Database CutoffDate:03MAY2021

## Subsequent systemic anticancer treatment

After discontinuation of study treatment, a similar proportion of all-comer participants in the pembrolizumab + chemotherapy ± bevacizumab and the placebo + chemotherapy ± bevacizumab groups received subsequent systemic anti-cancer treatment.

<div style=\"page-break-after: always\"></div>

Table 49. Summary of Subsequent Systemic Anti-Cancer Treatment (All-comer Participants) (ITT Population)

616 (99.8)

255 (82.5)

451 (73.1)

96 (31.1)

176 (28.5)

15 (4.9)

18 (2.9)

1 (0.3)

1 (0.2)

1 (0.3)

1 (0.2)

1 (0.3)

1 (0.2)

1 (0.3)

2 (0.3)

1 (0.3)

1 (0.2)

11 (3.6)

13 (2.1)

17 (5.5)

26 (4.2)

17 (5.5)

26 (4.2)

81 (26.2)

158 (25.6)

2 (0.6)

4 (0.6)

30 (9.7)

58 (9.4)

17 (5.5)

31 (5.0)

0 (0.0)

1 (0.2)

2 (0.6)

4 (0.6)

0 (0.0)

2 (0.3)

2 (0.6)

6 (1.0)

29 (9.4)

48 (7.8)

1 (0.3)

5 (0.8)

1 (0.3)

1 (0.2)

8 (2.6)

18 (2.9)

1 (0.3)

1 (0.2)

19 (6.1)

51 (8.3)

2 (0.6)

3 (0.5)

0 (0.0)

1 (0.2)

12 (3.9)

25 (4.1)

6 (1.9)

12 (1.9)

4 (1.3)

6 (1.0)

1 (0.3)

1 (0.2)

0 (0.0)

1 (0.2)

0 (0.0)

1 (0.2)

1 (0.3)

1 (0.2)

1 (0.3)

1 (0.2)

1 (0.3)

1 (0.2)

1 (0.3)

1 (0.2)

1 (0.3)

1 (0.2)

1 (0.3)

1 (0.2)

3 (1.0)

3 (0.5)

3 (1.0)

3 (0.5)

2 (0.6)

2 (0.3)

1 (0.3)

1 (0.2)

1 (0.3)

1 (0.2)

14 (4.5)

19 (3.1)

|                                                      | Pembro Combo (N=308)   | Control (N=309)   | Total (N=617)   |
|------------------------------------------------------|------------------------|-------------------|-----------------|
| Started Study Treatment                              | 307 (99.7)             | 309 (100.0)       | 616 (99.8)      |
| Discontinued Study Treatment                         | 196 (63.6)             | 255 (82.5)        | 451 (73.1)      |
| Received Any Subsequent Systemic Anti-cancer Therapy | 80 (26.0)              | 96 (31.1)         | 176 (28.5)      |
| Subsequent systemic therapy by type                  |                        |                   |                 |
| Any PD1/PD-L1 checkpoint                             | 3 (1.0)                | 15 (4.9)          | 18 (2.9)        |
| Atezolizumab                                         | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Cemiplimab                                           | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Dostarlimab                                          | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Durvalumab                                           | 1 (0.3)                | 1 (0.3)           | 2 (0.3)         |
| Nivolumab                                            | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Pembrolizumab                                        | 2 (0.6)                | 11 (3.6)          | 13 (2.1)        |
| Any VEGF/VEGFR inhibitor                             | 9 (2.9)                | 17 (5.5)          | 26 (4.2)        |
| Bevacizumab                                          | 9 (2.9)                | 17 (5.5)          | 26 (4.2)        |
| Chemotherapy                                         | 77 (25.0)              | 81 (26.2)         | 158 (25.6)      |
| Capecitabine                                         | 2 (0.6)                | 2 (0.6)           | 4 (0.6)         |
| Carboplatin                                          | 28 (9.1)               | 30 (9.7)          | 58 (9.4)        |
| Cisplatin                                            | 14 (4.5)               | 17 (5.5)          | 31 (5.0)        |
| Cyclophosphamide                                     | 1 (0.3)                | 0 (0.0)           | 1 (0.2)         |
| Docetaxel                                            | 2 (0.6)                | 2 (0.6)           | 4 (0.6)         |
| Doxorubicin                                          | 2 (0.6)                | 0 (0.0)           | 2 (0.3)         |
| Fluorouracil                                         | 4 (1.3)                | 2 (0.6)           | 6 (1.0)         |
| Gemcitabine                                          | 19 (6.2)               | 29 (9.4)          | 48 (7.8)        |
| Gemcitabine Hydrochloride                            | 4 (1.3)                | 1 (0.3)           | 5 (0.8)         |
| Ifosfamide                                           | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Irinotecan                                           | 10 (3.2)               | 8 (2.6)           | 18 (2.9)        |
| Oxaliplatin                                          | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Paclitaxel                                           | 32 (10.4)              | 19 (6.1)          | 51 (8.3)        |
| Pemetrexed Disodium                                  | 1 (0.3)                | 2 (0.6)           | 3 (0.5)         |
| Platinum                                             | 1 (0.3)                | 0 (0.0)           | 1 (0.2)         |
| Topotecan                                            | 13 (4.2)               | 12 (3.9)          | 25 (4.1)        |
| Vinorelbine Tartrate                                 | 6 (1.9)                | 6 (1.9)           | 12 (1.9)        |
| Targeted therapy                                     | 2 (0.6)                | 4 (1.3)           | 6 (1.0)         |
| Cabozantinib                                         | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Everolimus                                           | 1 (0.3)                | 0 (0.0)           | 1 (0.2)         |
| Obinutuzumab                                         | 1 (0.3)                | 0 (0.0)           | 1 (0.2)         |
| Selumetinib                                          | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Temsirolimus                                         | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Tremelimumab                                         | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Hormonal therapy                                     | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Letrozole                                            | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Megestrol Acetate                                    | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| ADC                                                  | 0 (0.0)                | 3 (1.0)           | 3 (0.5)         |
| Tisotumab Vedotin                                    | 0 (0.0)                | 3 (1.0)           | 3 (0.5)         |
| PARP inhibitor                                       | 0 (0.0)                | 2 (0.6)           | 2 (0.3)         |
| Niraparib                                            | 0 (0.0)                | 1 (0.3)           | 1 (0.2)         |
| Other                                                | 5 (1.6)                | 14 (4.5)          | 19 (3.1)        |

<div style=\"page-break-after: always\"></div>

1 (0.3)

1 (0.2)

0 (0.0)

1 (0.2)

8 (2.6)

12 (1.9)

5 (1.6)

5 (0.8)

| Dimesna                         | 0 (0.0)   | 1 (0.3)   | 1 (0.2)   |
|---------------------------------|-----------|-----------|-----------|
| Naptumomab Estafenatox          | 1 (0.3)   | 0 (0.0)   | 1 (0.2)   |
| Unspecified                     | 4 (1.3)   | 8 (2.6)   | 12 (1.9)  |
| Unspecified Monoclonal Antibody | 0 (0.0)   | 5 (1.6)   | 5 (0.8)   |
| Database Cutoff Date: 03MAY2021 |           |           |           |

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 50. Summary of Efficacy for trial KEYNOTE-826

| Title:                    | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)   | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)   | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)   |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier          | Study identifier                                                                                                                                                                                                                                | IND: 126191; EudraCT: 2018-001440-53                                                                                                                                                                                                            | IND: 126191; EudraCT: 2018-001440-53                                                                                                                                                                                                            |
| Design                    | Design                                                                                                                                                                                                                                          | Phase 3, multicenter, double-blind, placebo-controlled, interventional study                                                                                                                                                                    | Phase 3, multicenter, double-blind, placebo-controlled, interventional study                                                                                                                                                                    |
|                           |                                                                                                                                                                                                                                                 | Duration of Main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                  | Approximately 2 years Not applicable Not applicable                                                                                                                                                                                             |
| Hypothesis                | Hypothesis                                                                                                                                                                                                                                      | Superiority                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                     |
| Treatment groups          | Treatment groups                                                                                                                                                                                                                                | Pembrolizumab + chemotherapy ± bevacizumab                                                                                                                                                                                                      | Pembrolizumab 200 mg by IV infusion plus chemotherapy (with or without bevacizumab) Q3W for up to 35 cycles (approximately 2 years) 308 participants randomized (ITT population)                                                                |
|                           |                                                                                                                                                                                                                                                 | Placebo + chemotherapy ± bevacizumab                                                                                                                                                                                                            | Placebo by IV infusion plus chemotherapy (with or without bevacizumab) Q3W for up to 35 cycles (approximately 2 years) 309 participants randomized (ITT population)                                                                             |
| Endpoints and definitions | Endpoints and definitions                                                                                                                                                                                                                       | Dual primary endpoint PFS (Investigator assessed)                                                                                                                                                                                               | Defined as time from randomization to the first documented disease progression per RECIST 1.1 as assessed by investigator or death due to any cause, whichever occurs first                                                                     |
|                           |                                                                                                                                                                                                                                                 | Dual primary endpoint OS                                                                                                                                                                                                                        | Defined as the time from randomization to death due to any cause                                                                                                                                                                                |
|                           |                                                                                                                                                                                                                                                 | Secondary Endpoint ORR                                                                                                                                                                                                                          | Defined as the proportion of participants who have a best overall response of either confirmed CR or PR per RECIST 1.1 as assessed by investigator                                                                                              |
|                           |                                                                                                                                                                                                                                                 | Secondary Endpoint DOR                                                                                                                                                                                                                          | Defined as the time from the first documented evidence of CR or PR until the first documented disease progression assessed per RECIST 1.1 by investigator or death due to any cause, whichever occurs first.                                    |
|                           |                                                                                                                                                                                                                                                 | Secondary Endpoint PFS (Assessed BICR)                                                                                                                                                                                                          | by Defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by BICR or death due to any cause, whichever occurs first.                                                                     |

<div style=\"page-break-after: always\"></div>

| Database lock                                   | 28-MAY-2021                                                                       | 28-MAY-2021                                                                       | 28-MAY-2021                                                                       |
|-------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Results and Analysis                            | Results and Analysis                                                              | Results and Analysis                                                              | Results and Analysis                                                              |
| Analysis Description                            | Primary Analysis (CPS ≥1, all - comer, CPS ≥10 participants) - interim analysis 1 | Primary Analysis (CPS ≥1, all - comer, CPS ≥10 participants) - interim analysis 1 | Primary Analysis (CPS ≥1, all - comer, CPS ≥10 participants) - interim analysis 1 |
| Analysis population and time point description  | Intent-to-treat population (IA1; data cutoff 03-MAY-2021)                         | Intent-to-treat population (IA1; data cutoff 03-MAY-2021)                         | Intent-to-treat population (IA1; data cutoff 03-MAY-2021)                         |
| Descriptive statistics and estimate variability | Treatment group                                                                   | Pembrolizumab + chemotherapy ± bevacizumab                                        | Placebo + chemotherapy ± bevacizumab                                              |
|                                                 | CPS ≥1 Participants                                                               | CPS ≥1 Participants                                                               | CPS ≥1 Participants                                                               |
|                                                 | Number of subjects                                                                | 273                                                                               | 275                                                                               |
|                                                 | PFS (Investigator Assessed) Median, months (95% CI)                               | 10.4 (9.7, 12.3)                                                                  | 8.2 (6.3, 8.5)                                                                    |
|                                                 | OS Median, months (95% CI)                                                        | NR (19.8, NR)                                                                     | 16.3 (14.5, 19.4)                                                                 |
|                                                 | ORR %(95% CI)                                                                     | 68.1 (62.2, 73.6)                                                                 | 50.2 (44.1, 56.2)                                                                 |
|                                                 | DOR Median months (range)                                                         | 18.0 (1.3+ - 24.2+)                                                               | 10.4 (1.5+ - 22.0+)                                                               |
|                                                 | PFS by BICR Median, months (95% CI)                                               | 12.8 (10.4, 20.6)                                                                 | 8.3 (7.7, 9.2)                                                                    |
|                                                 | All-comer Participants                                                            | All-comer Participants                                                            | All-comer Participants                                                            |
|                                                 | Number of subjects                                                                | 308                                                                               | 309                                                                               |
|                                                 | PFS (Investigator Assessed) Median, months (95% CI)                               | 10.4 (9.1, 12.1)                                                                  | 8.2 (6.4, 8.4)                                                                    |
|                                                 | OS Median, months (95% CI)                                                        | 24.4 (19.2, NR)                                                                   | 16.5 (14.5, 19.4)                                                                 |
|                                                 | ORR %(95% CI)                                                                     | 65.9 (60.3, 71.2)                                                                 | 50.8 (45.1, 56.5)                                                                 |
|                                                 | DOR Median, months (range)                                                        | 18.0 (1.3+ - 24.2+)                                                               | 10.4 (1.5+ - 22.0+)                                                               |
|                                                 | PFS by BICR Median, months (95% CI) 12.3 (10.3, 17.9) 8.3 (8.1, 9.0)              | PFS by BICR Median, months (95% CI) 12.3 (10.3, 17.9) 8.3 (8.1, 9.0)              | PFS by BICR Median, months (95% CI) 12.3 (10.3, 17.9) 8.3 (8.1, 9.0)              |
|                                                 | Number of subjects                                                                | 158                                                                               |                                                                                   |
|                                                 | CPS ≥10 Participants                                                              | CPS ≥10 Participants                                                              | CPS ≥10 Participants                                                              |
|                                                 |                                                                                   |                                                                                   | 159                                                                               |
|                                                 | PFS (Investigator Assessed) Median, months (95% CI)                               | 10.4 (8.9, 15.1)                                                                  | 8.1 (6.2, 8.8)                                                                    |
|                                                 | OS Median, months (95% CI)                                                        | NR (19.1, NR)                                                                     | 16. 4 (14.0, 25.0)                                                                |

<div style=\"page-break-after: always\"></div>

|                                | %(95% CI)                                          | 69.6 (61.8, 76.7)      | 49.1 (41.1, 57.1)                                                                   |
|--------------------------------|----------------------------------------------------|------------------------|-------------------------------------------------------------------------------------|
|                                | DOR                                                |                        |                                                                                     |
|                                | Median, months (range)                             | 21.1 (1.3+ - 24.2+)    | 9.4 (2.1+ - 21.5+)                                                                  |
|                                | PFS by BICR                                        |                        |                                                                                     |
|                                | Median, months (95% CI)                            | 15.1 (8.9, NR)         | 8.3 (7.1, 10.2)                                                                     |
| Effect estimate per comparison | CPS ≥1 Participants                                | CPS ≥1 Participants    | CPS ≥1 Participants                                                                 |
|                                |                                                    | Comparison groups      | Pembrolizumab + Chemotherapy ± Bevacizumab vs. Placebo + Chemotherapy ± Bevacizumab |
|                                | Dual primary endpoint: PFS (Investigator Assessed) | Hazard ratio           | 0.62                                                                                |
|                                |                                                    | 95% CI                 | (0.50, 0.77)                                                                        |
|                                |                                                    | P-value                | <0.0001                                                                             |
|                                | Dual primary endpoint: OS                          | Hazard ratio           | 0.64                                                                                |
|                                |                                                    | 95% CI                 | (0.50, 0.81)                                                                        |
|                                |                                                    | P-value                | 0.0001                                                                              |
|                                | Secondary Endpoint: ORR                            | Difference%            | 18.0                                                                                |
|                                |                                                    | 95% CI                 | (10.1, 25.7)                                                                        |
|                                | Secondary Endpoint:                                | Hazard ratio           | 0.60                                                                                |
|                                | PFS by BICR                                        | 95% CI                 | (0.48, 0.75)                                                                        |
|                                | All-comer Participants                             | All-comer Participants | All-comer Participants                                                              |
|                                |                                                    | Comparison groups      | Pembrolizumab + Chemotherapy ± Bevacizumab vs. Placebo + Chemotherapy ± Bevacizumab |
|                                | Dual primary endpoint: PFS (Investigator Assessed) | Hazard ratio           | 0.65                                                                                |
|                                |                                                    | 95% CI                 | (0.53, 0.79)                                                                        |
|                                |                                                    | P-value                | <0.0001                                                                             |
|                                | Dual primary endpoint: OS                          | Hazard ratio           | 0.67                                                                                |
|                                |                                                    | 95% CI                 | (0.54, 0.84)                                                                        |
|                                |                                                    | P-value                | 0.0003                                                                              |
|                                | Secondary Endpoint: ORR                            | Difference%            | 15.3                                                                                |
|                                |                                                    | 95% CI                 | (7.8, 22.6)                                                                         |
|                                | Secondary Endpoint:                                | Hazard ratio           | 0.63                                                                                |
|                                | PFS by BICR                                        | 95% CI                 | (0.51, 0.77)                                                                        |
|                                | CPS ≥10 Participants                               | CPS ≥10 Participants   | CPS ≥10 Participants                                                                |

<div style=\"page-break-after: always\"></div>

|                                                    | Comparison groups   | Pembrolizumab + Chemotherapy ± Bevacizumab vs. Placebo + Chemotherapy ± Bevacizumab   |
|----------------------------------------------------|---------------------|---------------------------------------------------------------------------------------|
| Dual primary endpoint: PFS (Investigator Assessed) | Hazard ratio        | 0.58                                                                                  |
|                                                    | 95% CI              | (0.44, 0.77)                                                                          |
|                                                    | P-value             | <0.0001                                                                               |
| Dual primary endpoint: OS                          | Hazard ratio        | 0.61                                                                                  |
|                                                    | 95% CI              | (0.44, 0.84)                                                                          |
|                                                    | P-value             | 0.0013                                                                                |
| Secondary Endpoint: ORR                            | Difference%         | 20.5                                                                                  |
|                                                    | 95% CI              | (10.1, 30.5)                                                                          |
| Secondary Endpoint: PFS by BICR                    | Hazard ratio        | 0.55                                                                                  |
|                                                    | 95% CI              | (0.41, 0.74)                                                                          |

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

## Clinical studies in special populations

None performed.

## Supportive study(ies)

A brief summary of efficacy data, based on clinical study reports for KEYNOTE-028 and KEYNOTE-158 which have been included in the dossier by the MAH to support safety assessment, is presented below.

KEYNOTE-028 is an ongoing, Phase 1b, multicenter, nonrandomized, multicohort study of pembrolizumab (10 mg/kg every 2 weeks) in participants with PD-L1 positive metastatic/refractory solid tumours. Cohort B4 enrolled participants with cervical squamous cell cancer (N=24). Efficacy data are related only to PD-L1 positive population. ORR by investigator assessment of all subjects in Cohort B4 (n=24) was 16.7% (95% CI: 4.7, 37.4) and included 4 subjects with a confirmed PR. ORR by central radiology assessment (n=20) was 10.0% (95% CI: 1.2, 31.7), with 2 subjects with confirmed PR.

KEYNOTE-158 is an ongoing, Phase 2, multicenter, nonrandomized, multicohort study of pembrolizumab (200 mg every 3 weeks) as monotherapy in previously treated participants with advanced solid tumours, independent of PD-L1 status. The study included 13 cohorts in various advanced solid tumour indications; Cohort E enrolled participants with cervical cancer (N=98). Of the 98 participants in the ASaT population, PD-L1 IHC test results were available for 97 participants. Cervical carcinoma specimens from 82 (84.5%) participants expressed PD-L1 at a CPS ≥ 1, while specimens from 15 (15.5%) participants were negative for PD-L1 expression. All participants with confirmed response (CR or PR) had tumours that were positive for PD-L1 expression (ORR 17.1%, 14/82).

<div style=\"page-break-after: always\"></div>

Table 51. Summary of Best Objective Response Based on RECIST 1.1 per Central Radiology Assessment  (Baseline  PD-L1  Positive  vs.  PD-L1  Negative)  (Cohort  E:  Cervical  Carcinoma) (MK3475 200mg Q3W) (ASaT Population)

| Response Evaluation        | Baseline PD-L1 Positive (N=82)   | Baseline PD-L1 Positive (N=82)   | Baseline PD-L1 Positive (N=82)   | Baseline PD-L1 Negative (N=15)   | Baseline PD-L1 Negative (N=15)   | Baseline PD-L1 Negative (N=15)   |
|----------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                            | n                                | %                                | 95% CIT                          |                                  | %                                | II %$6                           |
| Complete Response (CR)     | 5                                | 6.1                              | (2.0, 13.7)                      | 0                                | 0.0                              | (0.0, 21.8)                      |
| Partial Response (PR)      | 9                                | 11.0                             | (5.1, 19.8)                      | 0                                | 0.0                              | (0.0, 21.8)                      |
| Objective Response (CR+PR) | 14                               | 17.1                             | (9.7, 27.0)                      | 0                                | 0.0                              | (0.0, 21.8)                      |
| Stable Disease (SD)        | 13                               | 15.9                             | (8.7, 25.6)                      | 3                                | 20.0                             | (4.3, 48.1)                      |
| Progressive Disease (PD)   | 44                               | 53.7                             | (42.3, 64.7)                     | 10                               | 66.7                             | (38.4, 88.2)                     |
| Non-evaluable (NE)         | 3                                | 3.7                              | (0.8, 10.3)                      | 1                                | 6.7                              | (0.2, 31.9)                      |
| No Assessment              | 8                                | 9.8                              | (4.3, 18.3)                      | 1                                | 6.7                              | (0.2, 31.9)                      |

Central radiology assessed responses per RECIST 1.1 (confirmed) are included in this table.

IBased on binomial exact confidenceinterval method.

No Assessment' (NA) counts subjects who had a baseline assessment evaluated by the central radiology assessment post-baseline scan.

(Database Cutoff Date: 27JUN2019).

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

KEYNOTE-826 is a phase 3 randomized, double-blind, placebo-controlled trial of pembrolizumab plus chemotherapy (cisplatin or carboplatin plus paclitaxel) with or without bevacizumab vs placebo plus chemotherapy with or without bevacizumab for the 1L treatment of persistent, recurrent, or metastatic cervical cancer.

In study KEYNOTE-826, patients not amenable to radical treatment and who have not received prior systemic chemotherapy (with the exception of radiosensitizing cisplatin) were allowed. All histologies were included and disease should be measurable. Patients were fit (ECOG 0-1) and have the usual exclusion criteria for immunotherapy. Overall, the enrolment criteria were acceptable. Stratification was made according to stage at initial diagnosis, use of bevacizumab and PD-L1 status, which is acceptable.

Maximum 6 cycles of platinum-based chemotherapy were allowed. Participants with on-going clinical benefit and who were tolerating combination chemotherapy were allowed to continue chemotherapy beyond 6 cycles after Sponsor consultation. Bevacizumab and pembrolizumab/placebo (max 2 years) were to be continued until disease progression. Bevacizumab demonstrated overall survival advantage when added to chemotherapy compared to chemotherapy alone in GOG-240 study, so it is considered the preferred first line regimen by international guidelines (ESMO, NCCN). It is however acknowledged that its use might not always be feasible related to the safety profile of this drug. In this study, approximately 63% of patients received bevacizumab. Baseline characteristics by bevacizumab use showed less older patients (over 75) treated with bevacizumab, as well as more patients with ECOG 0. This is comprehensible. It is noted that bevacizumab was less used in EU, as compared to North America and Asia.

In the EU, bevacizumab is approved for 1L cervical cancer with cisplatin plus paclitaxel, and not with carboplatin; it is acknowledged though that carboplatin is considered an alternative to cisplatin in subjects who are not candidate to cisplatin by ESMO guidelines, and the triplet combination with

<div style=\"page-break-after: always\"></div>

carboplatin is included as an alternative in the NCCN guidelines. As discussed in the Scientific Advice, population in KEYNOTE-826 was randomised to receive a number of treatment options that are expected to impact differently in terms of efficacy/safety.

Dual primary endpoints were PFS and OS, and the study was considered positive if it was positive for either the PFS or OS hypothesis test for any of the 3 groups: CPS ≥ 1, all-comers, and CPS ≥ 10. Regarding PFS, the primary endpoint was modified from assessment by independent review (BICR) to by investigator (inv) with Amendment 5, released after enrolment was completed but before any formal study analysis. The rate of discordance was 21.4% when investigator assessed PD was not confirmed by independent assessment based on IA1, which was attributed by the MAH to the investigators' ability to determine radiographic progression with greater sensitivity than assessment by BICR. Since PD event determination in metastatic cervical cancer takes into consideration symptoms and other clinical findings in addition to imaging, investigators with all evidence at their disposal, are anticipated to corroborate radiographic changes as progressive disease. Additional clinical input beyond imaging is used to assess progression, suggesting that BICR-determined PFS alone may not have adequate sensitivity to identify PD (disease progression) events. Clinical progression without radiographic evidence did not have any significant impact on the discordance. Overall, this explanation can be followed. The MAH declared that the modification of the primary endpoint to PFS by investigator was intended to protect the study from a loss of power while the important and objective assessment by BICR was retained as a secondary endpoint. Considering the consistent PFS benefit between the assessments by investigators and BICR, this issue can be considered solved. The MAH clarified that external pembrolizumab data from KEYNOTE-158 in 2L cervical cancer and from KEYNOTE-048 in 1L head and neck cancer motivated the change of hierarchical testing order. Overall, the MAH got greater confidence that the PD-L1 positive patient population as defined by the CPS ≥ 1 cutoff would derive sufficient benefit. By that, the hypothesis testing in this population was prioritized above the testing in the CPS ≥ 10 population. This can be followed.

The used methods for the statistical analysis were appropriate and the type one-error was overall controlled at the one-sided 0.025 level.

## Efficacy data and additional analyses

Results have been provided for the interim analysis 1 (data cut-off date 3 May 2021), after a median follow up of approximately 17 months (last patient randomized was observed for 15 months at least). Although an interim analysis, the overall number of PFS and OS events were about 65% and 50%, respectively. Data are considered of sufficient maturity for B/R assessment.

A total of 617 patients were enrolled (308 in the pembro combo and 309 in the control arm). At the data cut-off date, 63.8% and 82.5% in the experimental and control arm have discontinued treatment, with higher rate of progression in the control arm, while discontinuation due to adverse events were more frequent in the pembro combo arm (12.4% vs 7.8%). Important protocol deviations occurred at a limited and similar rate in both arms and are not considered impacting relevantly on study results.

The majority of women were white with a median age of 51 years (16% were over 65). About 80% had distant metastases; of those, 31% had primary metastatic disease. Most patients (~70%) had squamous cell carcinoma and 20% adenocarcinoma, consistent with epidemiology of this cancer. Prior chemoradiation was received by more than half of the patient. Baseline characteristics were similar in both treatment arms, although adenocarcinomas were slightly less represented in the pembrolizumab arm (18.2% vs 27.2%).

At the interim analysis 1, PFS by investigator and OS results were statistically significant in all the 3 populations analysed (CPS ≥ 1, all comers, CPS ≥ 10).

<div style=\"page-break-after: always\"></div>

The results in the all-comers showed statistically significant and clinically relevant improvement in OS with the addition of pembrolizumab to chemotherapy +/- bevacizumab, with HR of 0.67 (95%CI 0.54, 0.84) and a gain in median OS was approximately 8 months (from 16.5 to 24.4 months); 12 months OS rate increased of 10% (from 64 to 75%). The OS KM curves separated at 4.5 months and remained separated throughout the evaluation period in favour of pembrolizumab combination. PFS by investigator was also improved in the pembro combo arm (HR 0.65, 95%CI 0.53, 0.79), with median PFS 10.4 vs 8.2 months. Improvement was also observed in ORR [65.9% (95%CI 60.3, 71.2) vs 50.8% (95%CI 45.1, 56.5)] and median DOR (18 vs 10.4 months).

Overall 89% of all comers expressed PD-L1 as CPS ≥ 1 (273 and 275 patients in pembro and control arm), and 51.4% of the population has high PD-L1 expression, defined as CPS ≥ 10 (158 and 159 patients). Baseline characteristics of these two subpopulations were overall consistent with all comers.

In the CPS ≥ 1 population , results were consistent with the overall population, showing statistically significant and clinically relevant benefit for the pembrolizumab combination arm vs placebo combination arm. OS HR was 0.64 (0.5, 0.81), with median OS NR in the experimental arm (19.8, NR) vs 16.3 months (14.5, 19.4) in the control arm. The OS KM curves separated in favour of the pembro combo arm at month 3. HR for PFS by inv was 0.62 (95%CI 0.50, 0.77), median PFS was 10.4 vs 8.2 months. Higher ORR by inv was shown in the pembro combo arm (68.1% vs 50.2%) as well as longer median DOR (18 vs 10.4 months).

The advantage for pembrolizumab + standard treatment over standard treatment was more pronounced in the CPS ≥ 10 population with respect to all-comers: OS HR 0.61, PFS by inv HR 0.58, ORR by inv 69.6% vs 49.1% (95%CI 41.1, 57.1), median DOR 21.1 vs 9.4.

A post hoc efficacy analysis in the PD-L1 negative population ( CPS&lt;1 subgroup ) was also performed, which included approximately 11% of all comers (35 in the pembrolizumab arm and 34 in the placebo arm). The results in this subgroup showed hazard ratio for PFS by investigator of 0.94 (95%CI 0.52, 1.70), with KM curves roughly superimposed; number of PFS events were more in the control arm though (65.7% vs 82.4%). OS HR was 1.00 (95%CI 0.53, 1.89), with almost same event rate in both treatment arms (57.1% vs 58.8%). OS KM curves initially are in favour of the control arm, then overlap. ORR difference was slightly in favour of the control arm (ORR 48.6% vs 55.9%). Slight advantage in median DOR is instead seen in the pembrolizumab arm (10.7 vs 8.5 months).

It is acknowledged that the study was not designed or powered to make comparison in the CPS&lt;1 population, which has not been prespecified in the hierarchical testing, and results in this small subgroup should be interpreted with caution. This cannot however be raised as a sufficient argument against the validity of the results considering that the complementary population of CPS&gt;1 has been pre-specified. The available data did not suggest a benefit in this subgroup of patients (and detriment cannot be excluded). This is further supported by the apparent lack of activity of pembrolizumab monotherapy in CPS&lt;1 patients in KEYNOTE-158 in cervical cancer: no objective responses among the 15 PD-L1 negative patients were seen, as compared to ORR 17.1% (14/82) in PD-L1 positive tumours. Another recent RCT in more advanced cervical cancer with an anti PD1 inhibitor showed differential benefit based on PD-L1 expression (Tewari KS, 2021). The low prevalence of PD-L1 negative patient population is acknowledged in this indication; however, the biological rationale of PD-L1 expression status and the lack of benefit for the PD-L1 negative subgroup are supported by the external data in 2L cervical cancer above. PD-L1 expression was determined centrally (Neogenomics Laboratories) using a validated assay (the investigational PD-L1 IHC 22C3 pharmDx kit). There were no missing data. PD-L1 expression status was a stratification factor resulting in a balanced distribution of PD-L1 expression status between treatment arms. In conclusion, the CHMP considers the evidence of the subgroup results sufficiently reliable to draw conclusions.

<div style=\"page-break-after: always\"></div>

In addition, as this is an add-on treatment, patients would be inevitably exposed to supplementary pembrolizumab toxicity.

Taking everything into account, the use of pembrolizumab in combination of chemotherapy+/bevacizumab does not appear justified in the CPS&lt;1 population, in whom the B/R is not considered favourable. Following CHMP request, the MAH restricted the indication to the PD-L1 CPS ≥ 1 population.

With regard to subgroup analyses, the treatment benefit observed in the primary analysis populations was generally consistent across all subgroups analysed, with the exception of CPS&lt;1 as discussed above, and patients who have metastatic disease at study entry, showing lower efficacy in primary metastatic disease (PFS HR 0.92, OS HR 0.84). The MAH noted that Stage IVB newly diagnosed is an independent poor prognostic factor. Based on additional analyses provided, it does not appear justified to exclude difficult to treat patients with newly diagnosed metastatic disease from the proposed indication.

With regard to subgroup according to bevacizumab use (received by 63% of patients), as already discussed during the EMA SA, it is considered unfortunate that the study design does not allow to fully evaluate the benefit/risk of the additional and rather toxic treatment compound bevacizumab. It is observed that in the control arm the outcome of patients not using bevacizumab is inferior in all endpoints (OS, PFS, ORR, DOR) as compared to subjects treated with bevacizumab. This is consistent with the survival advantage showed with the addition of bevacizumab to chemotherapy in GOG-240 study, supporting the approval of bevacizumab in 1L cervical cancer. Patients receiving bevacizumab with chemotherapy in the control arm appear to have even better outcome than patients receiving pembrolizumab with chemotherapy. However, there is a subset of patients who do not receive bevacizumab due to risk posed by side effect of bevacizumab. The benefit of adding pembrolizumab to backbone chemotherapy is consistent in subgroups with and without bevacizumab.

The MAH provided subgroup analysis by platinum compound (about 20% of patients received cisplatin). Considering that the investigator's choice of carboplatin vs cisplatin might possibly select a heterogeneous patient population regarding prognostic patient and disease characteristics, it is reassuring that results by platinum agent are consistent. These data would be also considered relevant to support the general indication 'in combination with chemotherapy'.

Approximately 70% of patients had squamous cell carcinoma, and about 25% were adenocarcinoma, which reflects the real distribution of histology. Histology was not used as stratification factor. In baseline characteristics there was indeed no complete balance among treatment arms by histology in the all comers and in the CPS&gt;=1 population. PD-L1 expression by histology data showed lower PD-L1 positivity in adenocarcinoma. In the updated sought indication in CPS&gt;=1 population, benefit of pembrolizumab addition was consistent in both histologies, which is reassuring.

## 2.4.4. Conclusions on the clinical efficacy

KEYNOTE-826 study showed statistically significant improvement in PFS at the interim analysis in all the primary populations analysed (all-comers, CPS ≥ 1 and CPS ≥ 10), together with statistically significant and clinically relevant improvement in OS with the addition of pembrolizumab to platinum/paclitaxel chemotherapy +/- bevacizumab as first line treatment of persistent, recurrent or metastatic cervical cancer patients not amenable to curative treatment. This was supported by improvement in ORR and DOR. However, no benefit is seen in the small PD-L1 negative subgroup, in whom the addition of pembrolizumab to standard treatment does not appear justified. As a result, per CHMP request, the indication was restricted to CPS≥1 population.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

Safety results were presented from the following datasets:

Table 52. Safety Datasets and Treatment Group Nomenclature

| Dataset                                                 | Population                                                                                                                                                                                                                                                                    | Treatment                                                                                           | Nomenclature in Tables                                   | Nomenclature in Text                             |
|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------|
| KEYNOTE- 826 pembrolizumab + chemotherapy ± bevacizumab | N=307: Safety data from participants with persistent, recurrent, or metastatic cervical cancer, who received pembrolizumab in combination with chemotherapy with or without bevacizumab in KEYNOTE-826                                                                        | Pembrolizumab + chemotherapy (paclitaxel plus cisplatin or carboplatin) with or without bevacizumab | KN826 Pembrolizumab + Chemotherapy a                     | Pembrolizumab + chemotherapy ± bevacizumab group |
| KEYNOTE- 826 placebo + chemotherapy ± bevacizumab       | N=309: Safety data from participants with persistent, recurrent, or metastatic cervical cancer, who received placebo in combination with chemotherapy with or without bevacizumab in KEYNOTE-826                                                                              | Placebo + chemotherapy (paclitaxel plus cisplatin or carboplatin) with or without bevacizumab       | KN826 Placebo + Chemotherapy b                           | Placebo + chemotherapy ± bevacizumab group       |
| Pooled pembrolizumab + chemotherapy                     | N=2033: Pooled safety data from participants treated with pembrolizumab + chemotherapy, including participants with NSCLC in KEYNOTE-021 Cohorts A, C, and G, KEYNOTE-189 and KEYNOTE-407, HNSCC in KEYNOTE-048, TNBC in KEYNOTE-355, and esophageal carcinoma in KEYNOTE-590 | Pembrolizumab + chemotherapy                                                                        | Pooled Safety Dataset for Pembrolizumab + Chemotherapy c | Pooled pembrolizumab + chemotherapy group        |
| Advanced cervical cancer pembrolizumab monotherapy      | N=122: Pooled safety data from participants with advanced cervical cancer treated with pembrolizumab monotherapy in Cohort B4 of KEYNOTE-028 and Cohort E of KEYNOTE-158                                                                                                      | Pembrolizumab monotherapy                                                                           | Cervical Safety Dataset for Pembrolizumab Monotherapy d  | Advanced cervical cancer monotherapy group       |

<div style=\"page-break-after: always\"></div>

| Dataset                                    | Population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Treatment                 | Nomenclature in Tables                               | Nomenclature in Text          |
|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|------------------------------------------------------|-------------------------------|
| Pembrolizumab monotherapy reference safety | N=6185: Pooled safety data from participants treated with pembrolizumab monotherapy in the following populations and studies: melanoma (n=2076) in KEYNOTE- 001, KEYNOTE-002, KEYNOTE- 006 and KEYNOTE-054; NSCLC (n=2022) in KEYNOTE- 001, KEYNOTE-010, KEYNOTE-024 and KEYNOTE-042; HNSCC (n=909) in KEYNOTE-012 (Cohorts B and B2), KEYNOTE-040, KEYNOTE-048 and KEYNOTE 055; HL (n=389) in KEYNOTE-013 Cohort 3), KEYNOTE-087 and KEYNOTE-204; bladder (n=636) in KEYNOTE-045 and KEYNOTE- 052; CRC (n=153) in KEYNOTE- 177 | Pembrolizumab monotherapy | Pembrolizumab Monotherapy Reference Safety Dataset e | Pembrolizumab monotherapy RSD |

Abbreviations: CRC=colorectal cancer; HL=Hodgkin lymphoma; HNSCC=head and neck squamous cell carcinoma; ISS = Integrated Summary of Safety; N = number; NSCLC = Non-small cell lung cancer; RSD = reference safety dataset, TNBC=triple-negative breast cancer.

- a  Includes all participants who received at least 1 dose of pembrolizumab or chemotherapy in KEYNOTE-826.
- b Includes all participants who received at least 1 dose of placebo or chemotherapy in KEYNOTE-826.
- c  Includes all participants who received at least 1 dose of pembrolizumab combination therapy in KEYNOTE-021 Cohorts A, C and G, KEYNOTE-048, KEYNOTE-189, KEYNOTE-355, KEYNOTE-407, and KEYNOTE590.
- d  Includes all participants who received at least 1 dose of pembrolizumab in Cohort B4 of KEYNOTE-028 and Cohort E of KEYNOTE-158.
- e The studies that comprise the Pembrolizumab Monotherapy RSD are listed in the footnotes of the data tables in this document and in the ISS.

Additional subsets of the KEYNOTE-826 datasets were provided by bevacizumab use:

<div style=\"page-break-after: always\"></div>

Table 53. Additional Safety Datasets for KEYNOTE-826 by Bevacizumab Use

| Dataset                                                       | Population                                                                                                                                                                                     | Treatment                                                                                   | Nomenclature in Tables                               | Nomenclature in Text                                   |
|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------------------------------------------|--------------------------------------------------------|
| KEYNOTE- 826 pembrolizumab + chemotherapy with bevacizumab    | N=196: Safety data from participants with persistent, recurrent, or metastatic cervical cancer, who received pembrolizumab in combination with chemotherapy plus bevacizumab in KEYNOTE-826    | Pembrolizumab + chemotherapy (paclitaxel plus cisplatin or carboplatin) with bevacizumab    | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab a  | Pembrolizumab + chemotherapy with bevacizumab group    |
| KEYNOTE- 826 pembrolizumab + chemotherapy without bevacizumab | N=111: Safety data from participants with persistent, recurrent, or metastatic cervical cancer, who received pembrolizumab in combination with chemotherapy without bevacizumab in KEYNOTE-826 | Pembrolizumab + chemotherapy (paclitaxel plus cisplatin or carboplatin) without bevacizumab | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab b | Pembrolizumab + chemotherapy without bevacizumab group |
| KEYNOTE- 826 placebo + chemotherapy with bevacizumab          | N=193: Safety data from participants with persistent, recurrent, or metastatic cervical cancer, who received placebo in combination with chemotherapy with bevacizumab in KEYNOTE-826          | Placebo + chemotherapy (paclitaxel plus cisplatin or carboplatin) with bevacizumab          | KN826 Placebo + Chemotherapy w/ Bevacizumab c        | Placebo + chemotherapy with bevacizumab group          |
| KEYNOTE- 826 placebo + chemotherapy without bevacizumab       | N=116: Safety data from participants with persistent, recurrent, or metastatic cervical cancer, who received placebo in combination with chemotherapy without bevacizumab in KEYNOTE-826       | Placebo + chemotherapy (paclitaxel plus cisplatin or carboplatin) without bevacizumab       | KN826 Placebo + Chemotherapy w/o Bevacizumab d       | Placebo + chemotherapy without bevacizumab group       |

Abbreviations:  N=number; w/=with; w/o=without.

Note: Pembrolizumab Monotherapy Reference Safety Dataset is also included in additional safety dataset tables. a Includes all participants who received at least 1 dose of pembrolizumab or chemotherapy and bevacizumab in KEYNOTE-826.

b Includes all participants who received at least 1 dose of pembrolizumab or chemotherapy in KEYNOTE-826.

c  Includes all participants who received at least 1 dose of placebo or chemotherapy and bevacizumab in KEYNOTE826.

d Includes all participants who received at least 1 dose of placebo or chemotherapy in KEYNOTE-826.

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Table 54. Drug Exposure Summary (APaT Population)

|                              | KN826 Pembrolizumab + Chemotherapy (N=307)   | KN826 Placebo + Chemotherapy (N=309)   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f (N=2033)   | Cervical Safety Dataset for Pembrolizumab Monotherapy d (N=122)   | Pembrolizumab Monotherapy Reference Safety Dataset e (N=6185)   |
|------------------------------|----------------------------------------------|----------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------|
| Duration of Exposure (month) | Duration of Exposure (month)                 | Duration of Exposure (month)           | Duration of Exposure (month)                                        | Duration of Exposure (month)                                      | Duration of Exposure (month)                                    |
| n                            | 307                                          | 309                                    | 2033                                                                | 122                                                               | 6185                                                            |
| Mean                         | 11.79                                        | 9.42                                   | 9.02                                                                | 5.53                                                              | 7.52                                                            |
| Median                       | 9.99                                         | 7.66                                   | 6.28                                                                | 2.84                                                              | 4.90                                                            |
| SD                           | 8.047                                        | 6.788                                  | 7.802                                                               | 7.042                                                             | 7.029                                                           |
| Range                        | 0.03 to 26.88                                | 0.03 to 27.37                          | 0.03 to 48.00                                                       | 0.03 to 40.05                                                     | 0.03 to 30.62                                                   |
| Number of Cycles             | Number of Cycles                             | Number of Cycles                       | Number of Cycles                                                    | Number of Cycles                                                  | Number of Cycles                                                |
| n                            | 307                                          | 309                                    | 2033                                                                | 122                                                               | 6185                                                            |
| Mean                         | 16.53                                        | 13.37                                  | 12.77                                                               | 8.91                                                              | 11.96                                                           |
| Median                       | 14.00                                        | 11.00                                  | 9.00                                                                | 5.00                                                              | 8.00                                                            |
| SD                           | 11.014                                       | 9.167                                  | 10.587                                                              | 9.489                                                             | 10.403                                                          |

Duration of exposure is the time from the first dose date to the last dose date.

d Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

e Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

f Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

6185

7.029

0.03 to 30.62

6185

<div style=\"page-break-after: always\"></div>

Table 55. Drug Exposure by Duration (APaT Population)

|                      | KN826 Pembrolizumab + Chemotherapy (N=307)   | KN826 Pembrolizumab + Chemotherapy (N=307)   | KN826 Pembrolizumab + Chemotherapy (N=307)   | KN826 Placebo + Chemotherapy (N=309)   | KN826 Placebo + Chemotherapy (N=309)   | KN826 Placebo + Chemotherapy (N=309)   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f (N=2033)   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f (N=2033)   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f (N=2033)   | Cervical Safety Dataset for Pembrolizumab Monotherapy d (N=122)   | Cervical Safety Dataset for Pembrolizumab Monotherapy d (N=122)   | Cervical Safety Dataset for Pembrolizumab Monotherapy d (N=122)   | Pembrolizumab Monotherapy Reference Safety Dataset e (N=6185)   | Pembrolizumab Monotherapy Reference Safety Dataset e (N=6185)   | Pembrolizumab Monotherapy Reference Safety Dataset e (N=6185)   |
|----------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                      | n                                            | (%)                                          | Person- years                                | n                                      | (%)                                    | Person- years                          | n                                                                   | (%)                                                                 | Person- years                                                       | n                                                                 | (%)                                                               | Person- years                                                     | n                                                               | (%)                                                             | Person- years                                                   |
| Duration of exposure |                                              |                                              |                                              |                                        |                                        |                                        |                                                                     |                                                                     |                                                                     |                                                                   |                                                                   |                                                                   |                                                                 |                                                                 |                                                                 |
| >0m                  | 307                                          | (100.0 )                                     | (301.7)                                      | 309                                    | (100.0 )                               | (242.4)                                | 2,033                                                               | (100.0 )                                                            | (1,528.7)                                                           | 122                                                               | (100.0 )                                                          | (56.2)                                                            | 6,185                                                           | (100.0 )                                                        | (3,875.4)                                                       |
| >=1 m                | 280                                          | (91.2)                                       | (301.2)                                      | 288                                    | (93.2)                                 | (241.9)                                | 1,846                                                               | (90.8)                                                              | (1,522.4)                                                           | 103                                                               | (84.4)                                                            | (55.7)                                                            | 5,314                                                           | (85.9)                                                          | (3,846.7)                                                       |
| >=3 m                | 256                                          | (83.4)                                       | (297.1)                                      | 257                                    | (83.2)                                 | (236.8)                                | 1,562                                                               | (76.8)                                                              | (1,473.2)                                                           | 57                                                                | (46.7)                                                            | (48.2)                                                            | 3,860                                                           | (62.4)                                                          | (3,604.5)                                                       |
| >=6 m                | 209                                          | (68.1)                                       | (278.4)                                      | 186                                    | (60.2)                                 | (209.2)                                | 1,068                                                               | (52.5)                                                              | (1,288.4)                                                           | 29                                                                | (23.8)                                                            | (38.3)                                                            | 2,808                                                           | (45.4)                                                          | (3,222.1)                                                       |
| >=12m                | 139                                          | (45.3)                                       | (228.6)                                      | 96                                     | (31.1)                                 | (145.5)                                | 550                                                                 | (27.1)                                                              | (923.8)                                                             | 18                                                                | (14.8)                                                            | (30.2)                                                            | 1,431                                                           | (23.1)                                                          | (2,179.8)                                                       |

Each participant is counted once on each applicable duration category row.

Duration of exposure is the time from the first dose date to the last dose date.

d Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

- e Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

f Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

(3,875.4)

(3,846.7)

(3,604.5)

(3,222.1)

(2,179.8)

<div style=\"page-break-after: always\"></div>

Table 56. Drug Exposure Summary (APaT Population)

|                              | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab (N=196)   | KN826 Pembrolizimab + Chemotherapy w/o Bevacizumab (N=111)   | KN826 Placebo + Chemotherapy w/Bevacizumab (N=193)   | KN826 Placebo + Chemotherapy w/o Bevacizumab (N=116)   | Pembrolizumab Monotherapy Reference SafetyDataset (N=6185)   |
|------------------------------|------------------------------------------------------------|--------------------------------------------------------------|------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------|
| Duration of Exposure (month) |                                                            |                                                              |                                                      |                                                        |                                                              |
| n Mean Median SD Range       | 196 13.36 13.91 7.841 0.03 to 26.88                        | 111 9.02 6.31 7.681 0.03 to 25.43                            | 193 11.05 9.69 6.918 0.03 to 27.37                   | 116 6.69 5.39 5.612 0.03 to 22.05                      | 6185 7.52 4.90 7.029 0.03 to 30.62                           |
| Number of Cycles             |                                                            |                                                              |                                                      |                                                        |                                                              |
| n                            | 196 18.66                                                  | 111 12.78 9.00                                               | 193 15.61 14.00                                      | 116 9.66                                               | 6185                                                         |
| Mean Median                  | 18.00                                                      |                                                              | 9.373                                                | 8.00                                                   | 11.96 8.00                                                   |
| SD Range                     | 10.884 1.00 to 39.00                                       | 10.257 1.00 to 35.00                                         | 1.00 to 38.00                                        | 7.488 1.00 to 31.00                                    | 10.403 1.00 to 59.00                                         |

Durationof exposure is thetimefrom thefirstdose datetothelastdosedate.

Includes allparticipants whoreceived atleastone dose ofpembrolizumab inKN001Part B1,B2,B3,D,C,F1,F2,F3,KN002 (original phase),KN006,KN010,KN012 cohortB and B2,KN013 cohort 3,KN024,KN040,KN042,KN045,KN048,KN052, KN054,KN055,KN087,KN177, and KN204.

DatabasecutoffdateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054: 03APR2020)

Database cutoff dateforLung (KN001-NSCLC:23JAN2015,KN010: 30SEP2015,KN024:10JUL2017,KN042:04SEP2018) Databasecutoff dateforHNSCC(KN012cohortB andB2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018,KN087: 21MAR2019,KN204: 16JAN2020)

Database cutoff dateforBladder (KN045:26OCT2017,KN052: 26SEP2018)

Database cutoff date forCRC (KN177: 19FEB2020)

Databasecutoff dateforCervical(KN826:03MAY2021)

Source:[ISS: adam-adsl; adexsum]

|                      | KN826Pembrolizumab + Chemotherapy w/Bevacizumab (96I=N)   | KN826Pembrolizumab + Chemotherapy w/Bevacizumab (96I=N)   | KN826Pembrolizumab + Chemotherapy w/Bevacizumab (96I=N)   | KN826Pembrolizumab + Chemotherapy w/o Bevacizumab (N=111)   | KN826Pembrolizumab + Chemotherapy w/o Bevacizumab (N=111)   | KN826Pembrolizumab + Chemotherapy w/o Bevacizumab (N=111)   | KN826Placebo+Chemotherapy w/ Bevacizumab (N=193)   | KN826Placebo+Chemotherapy w/ Bevacizumab (N=193)   | KN826Placebo+Chemotherapy w/ Bevacizumab (N=193)   | KN826 Placebo +Chemotherapy w/oBevacizimab (N=116)   | KN826 Placebo +Chemotherapy w/oBevacizimab (N=116)   | KN826 Placebo +Chemotherapy w/oBevacizimab (N=116)   | PembrolizumabMonotherapy ReferenceSafety Dataset (N=6185)   | PembrolizumabMonotherapy ReferenceSafety Dataset (N=6185)   | PembrolizumabMonotherapy ReferenceSafety Dataset (N=6185)   |
|----------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                      | n                                                         | (%)                                                       | Person-years                                              | n                                                           | (%)                                                         | Person-years                                                | n                                                  | (%)                                                | Person-years                                       | n                                                    | (%)                                                  | Person-years                                         | n                                                           | (%)                                                         | Person-years                                                |
| Duration of exposure |                                                           |                                                           |                                                           |                                                             |                                                             |                                                             |                                                    |                                                    |                                                    |                                                      |                                                      |                                                      |                                                             |                                                             |                                                             |
| >0 m                 | 196                                                       | (100.0)                                                   | (218.3)                                                   |                                                             | (100.0)                                                     | (83.4)                                                      | 193                                                | (100.0)                                            | (177.8)                                            | 116                                                  | (100.0)                                              | (64.6)                                               | 6,185                                                       | (100.0)                                                     | (3,875.4)                                                   |
| >=1 m                | 183                                                       | (93.4)                                                    | (218.1)                                                   | 97                                                          | (87.4)                                                      | (83.0)                                                      | 183                                                | (94.8)                                             | (177.5)                                            | 105                                                  | (90.5)                                               | (64.5)                                               | 5,314                                                       | (85.9)                                                      | (3,846.7)                                                   |
| >=3m                 | 173                                                       | (88.3)                                                    | (216.4)                                                   | 83                                                          | (74.8)                                                      | (80.7)                                                      | 172                                                | (89.1)                                             | (175.5)                                            | 85                                                   | (73.3)                                               | (61.3)                                               | 3,860                                                       | (62.4)                                                      | (3,604.5)                                                   |
| >=6m                 | 151                                                       | (77.0)                                                    | (207.7)                                                   | 58                                                          | (52.3)                                                      | (70.7)                                                      | 137                                                | (71.0)                                             | (161.7)                                            | 49                                                   | (42.2)                                               | (47.5)                                               | 2,808                                                       | (45.4)                                                      | (3,222.1)                                                   |
| >=12 m               | 107                                                       | (54.6)                                                    | (175.5)                                                   | 32                                                          | (28.8)                                                      | (53.1)                                                      | 79                                                 | (40.9)                                             | (120.0)                                            | 17                                                   | (14.7)                                               | (25.5)                                               | 1,431                                                       | (23.1)                                                      | (2,179.8)                                                   |

Table 57. Drug Exposure by Duration by Bevacizumab use (APaT Population)

<!-- image -->

Source: [ISS: adam-adsl; adexsum]

<div style=\"page-break-after: always\"></div>

## Adverse events

## Table 58. Participant Characteristics (APaT Population)

|                                           | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Cervical Safety Dataset for Pembrolizumab Monotherapy d   | Cervical Safety Dataset for Pembrolizumab Monotherapy d   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|-------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                           | n                                    | (%)                                  | n                              | (%)                            | n                                                          | (%)                                                        | n                                                         | (%)                                                       | n                                                      | (%)                                                    |
| Participants in population                | 307                                  |                                      | 309                            |                                | 2,033                                                      |                                                            | 122                                                       |                                                           | 6,185                                                  |                                                        |
| Sex                                       |                                      |                                      |                                |                                |                                                            |                                                            |                                                           |                                                           |                                                        |                                                        |
| Male                                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1,041                                                      | (51.2)                                                     | 0                                                         | (0.0)                                                     | 4,039                                                  | (65.3)                                                 |
| Female                                    | 307                                  | (100.0)                              | 309                            | (100.0)                        | 992                                                        | (48.8)                                                     | 122                                                       | (100.0)                                                   | 2,146                                                  | (34.7)                                                 |
| Age (Years)                               |                                      |                                      |                                |                                |                                                            |                                                            |                                                           |                                                           |                                                        |                                                        |
| <65                                       | 259                                  | (84.4)                               | 257                            | (83.2)                         | 1,218                                                      | (59.9)                                                     | 114                                                       | (93.4)                                                    | 3,587                                                  | (58.0)                                                 |
| >=65                                      | 48                                   | (15.6)                               | 52                             | (16.8)                         | 815                                                        | (40.1)                                                     | 8                                                         | (6.6)                                                     | 2,598                                                  | (42.0)                                                 |
| Mean                                      | 51.7                                 |                                      | 50.7                           |                                | 60.2                                                       |                                                            | 46.7                                                      |                                                           | 60.2                                                   |                                                        |
| SD                                        | 11.9                                 |                                      | 12.7                           |                                | 11.4                                                       |                                                            | 11.0                                                      |                                                           | 13.6                                                   |                                                        |
| Median                                    | 51.0                                 |                                      | 50.0                           |                                | 62.0                                                       |                                                            | 45.0                                                      |                                                           | 62.0                                                   |                                                        |
| Range                                     | 25 to 82                             |                                      | 22 to 79                       |                                | 20 to 94                                                   |                                                            | 24 to 75                                                  |                                                           | 15 to 94                                               |                                                        |
| Race                                      |                                      |                                      |                                |                                |                                                            |                                                            |                                                           |                                                           |                                                        |                                                        |
| American Indian Or Alaska Native          | 18                                   | (5.9)                                | 21                             | (6.8)                          | 23                                                         | (1.1)                                                      | 1                                                         | (0.8)                                                     | 30                                                     | (0.5)                                                  |
| Asian                                     | 65                                   | (21.2)                               | 45                             | (14.6)                         | 472                                                        | (23.2)                                                     | 16                                                        | (13.1)                                                    | 695                                                    | (11.2)                                                 |
| Black Or African American                 | 4                                    | (1.3)                                | 2                              | (0.6)                          | 66                                                         | (3.2)                                                      | 2                                                         | (1.6)                                                     | 121                                                    | (2.0)                                                  |
| Multiracial                               | 32                                   | (10.4)                               | 34                             | (11.0)                         | 19                                                         | (0.9)                                                      | 1                                                         | (0.8)                                                     | 70                                                     | (1.1)                                                  |
| Native Hawaiian Or Other Pacific Islander | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                          | (0.0)                                                      | 1                                                         | (0.8)                                                     | 5                                                      | (0.1)                                                  |
| White                                     | 169                                  | (55.0)                               | 190                            | (61.5)                         | 1,416                                                      | (69.7)                                                     | 93                                                        | (76.2)                                                    | 4,673                                                  | (75.6)                                                 |
| Missing                                   | 19                                   | (6.2)                                | 17                             | (5.5)                          | 36                                                         | (1.8)                                                      | 8                                                         | (6.6)                                                     | 591                                                    | (9.6)                                                  |
| Ethnicity                                 |                                      |                                      |                                |                                |                                                            |                                                            |                                                           |                                                           |                                                        |                                                        |
| Hispanic Or Latino                        | 109                                  | (35.5)                               | 121                            | (39.2)                         | 235                                                        | (11.6)                                                     | 3                                                         | (2.5)                                                     | 424                                                    | (6.9)                                                  |
| Not Hispanic Or Latino                    | 192                                  | (62.5)                               | 184                            | (59.5)                         | 1,695                                                      | (83.4)                                                     | 103                                                       | (84.4)                                                    | 4,927                                                  | (79.7)                                                 |
| Not Reported                              | 5                                    | (1.6)                                | 4                              | (1.3)                          | 54                                                         | (2.7)                                                      | 10                                                        | (8.2)                                                     | 708                                                    | (11.4)                                                 |
| Unknown                                   | 1                                    | (0.3)                                | 0                              | (0.0)                          | 46                                                         | (2.3)                                                      | 2                                                         | (1.6)                                                     | 117                                                    | (1.9)                                                  |
| Missing                                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 3                                                          | (0.1)                                                      | 4                                                         | (3.3)                                                     | 9                                                      | (0.1)                                                  |
| Age Category (year)                       |                                      |                                      |                                |                                |                                                            |                                                            |                                                           |                                                           |                                                        |                                                        |
| <65                                       | 259                                  | (84.4)                               | 257                            | (83.2)                         | 1,218                                                      | (59.9)                                                     | 114                                                       | (93.4)                                                    | 3,587                                                  | (58.0)                                                 |
| 65-74                                     | 38                                   | (12.4)                               | 42                             | (13.6)                         | 653                                                        | (32.1)                                                     | 7                                                         | (5.7)                                                     | 1,797                                                  | (29.1)                                                 |
| 75-84                                     | 10                                   | (3.3)                                | 10                             | (3.2)                          | 157                                                        | (7.7)                                                      | 1                                                         | (0.8)                                                     | 694                                                    | (11.2)                                                 |
| >=85                                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 5                                                          | (0.2)                                                      | 0                                                         | (0.0)                                                     | 107                                                    | (1.7)                                                  |
| ECOG Performance Status                   |                                      |                                      |                                |                                |                                                            |                                                            |                                                           |                                                           |                                                        |                                                        |
| [0] Normal Activity                       | 178                                  | (58.0)                               | 170                            | (55.0)                         | 913                                                        | (44.9)                                                     | 40                                                        | (32.8)                                                    | 2,942                                                  | (47.6)                                                 |
| [1] Symptoms, but ambulatory              | 127                                  | (41.4)                               | 139                            | (45.0)                         | 1,116                                                      | (54.9)                                                     | 82                                                        | (67.2)                                                    | 3,069                                                  | (49.6)                                                 |
| Other/Missing                             | 2                                    | (0.7)                                | 0                              | (0.0)                          | 4                                                          | (0.2)                                                      | 0                                                         | (0.0)                                                     | 174                                                    | (2.8)                                                  |
| Geographic Region                         |                                      |                                      |                                |                                |                                                            |                                                            |                                                           |                                                           |                                                        |                                                        |
| EU                                        | 103                                  | (33.6)                               | 108                            | (35.0)                         | 690                                                        | (33.9)                                                     | 61                                                        | (50.0)                                                    | 2,217                                                  | (35.8)                                                 |
| Ex-EU                                     | 204                                  | (66.4)                               | 201                            | (65.0)                         | 1,343                                                      | (66.1)                                                     | 61                                                        | (50.0)                                                    | 3,968                                                  | (64.2)                                                 |

(64.2)

<div style=\"page-break-after: always\"></div>

d  Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

f  Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590. Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

Table 59. Participant Characteristics by Bevacizumab use (APaT Population)

|                                       | KN826 Pembrolizumab + Chemotherapy w/ Bevacizimab   | KN826 Pembrolizumab + Chemotherapy w/ Bevacizimab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|---------------------------------------|-----------------------------------------------------|-----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                       | n                                                   | (%)                                                 | n                                                    | (%)                                                  | n                                             | (%)                                           | n                                              | (%)                                            | n                                                    | (%)                                                  |
| Participants in population            | 196                                                 |                                                     | 111                                                  |                                                      | 193                                           |                                               | 116                                            |                                                | 6,185                                                |                                                      |
| Sex                                   |                                                     |                                                     |                                                      |                                                      |                                               |                                               |                                                |                                                |                                                      |                                                      |
| Male                                  | 0                                                   | (0.0)                                               | 0                                                    | (0.0)                                                | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 4,039                                                | (65.3)                                               |
| Female                                | 196                                                 | (100.0)                                             | 111                                                  | (100.0)                                              | 193                                           | (100.0)                                       | 116                                            | (100.0)                                        | 2,146                                                | (34.7)                                               |
| Age (Years)                           |                                                     |                                                     |                                                      |                                                      |                                               |                                               |                                                |                                                |                                                      |                                                      |
| <65                                   | 170                                                 | (86.7)                                              | 89                                                   | (80.2)                                               | 165                                           | (85.5)                                        | 92                                             | (79.3)                                         | 3,587                                                | (58.0)                                               |
| >=65                                  | 26                                                  | (13.3)                                              | 22                                                   | (19.8)                                               | 28                                            | (14.5)                                        | 24                                             | (20.7)                                         | 2,598                                                | (42.0)                                               |
| Mean                                  | 50.9                                                |                                                     | 53.1                                                 |                                                      | 49.9                                          |                                               | 52.1                                           |                                                | 60.2                                                 |                                                      |
| SD                                    | 11.5                                                |                                                     | 12.5                                                 |                                                      | 12.7                                          |                                               | 12.6                                           |                                                | 13.6                                                 |                                                      |
| Median                                | 51.0                                                |                                                     | 53.0                                                 |                                                      | 50.0                                          |                                               | 50.0                                           |                                                | 62.0                                                 |                                                      |
| Range                                 | 25 to 82                                            |                                                     | 30 to 82                                             |                                                      | 22 to 77                                      |                                               | 31 to 79                                       |                                                | 15 to 94                                             |                                                      |
| Race                                  |                                                     |                                                     |                                                      |                                                      |                                               |                                               |                                                |                                                |                                                      |                                                      |
| AmericanIndianOrAlaskaNative          | 9                                                   | (4.6)                                               | 9                                                    | (8.1)                                                | 10                                            | (5.2)                                         | 11                                             | (9.5)                                          | 30                                                   | (0.5)                                                |
| Asian                                 | 49                                                  | (25.0)                                              | 16                                                   | (14.4)                                               | 37                                            | (19.2)                                        | 8                                              | (6.9)                                          | $69                                                  | (11.2)                                               |
| Black Or African American             | 4                                                   | (2.0)                                               | 0                                                    | (0.0)                                                | 2                                             | (1.0)                                         | 0                                              | (0.0)                                          | 121                                                  | (2.0)                                                |
| Multiracial                           | 22                                                  | (11.2)                                              | 10                                                   | (9.0)                                                | 22                                            | (11.4)                                        | 12                                             | (10.3)                                         | 70                                                   | (1.1)                                                |
| NativeHawaiianOr OtherPacificIslander | 0                                                   | (0.0)                                               | 0                                                    | (0.0)                                                | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 5                                                    | (0.1)                                                |
| White                                 | 103                                                 | (52.6)                                              | 66                                                   | (59.5)                                               | 115                                           | (59.6)                                        | 75                                             | (64.7)                                         | 4,673                                                | (75.6)                                               |
| Missing                               | 9                                                   | (4.6)                                               | 10                                                   | (9.0)                                                | 7                                             | (3.6)                                         | 10                                             | (8.6)                                          | 591                                                  | (9.6)                                                |
| Ethnicity                             |                                                     |                                                     |                                                      |                                                      |                                               |                                               |                                                |                                                |                                                      |                                                      |
| Hispanic Or Latino                    | 72                                                  | (36.7)                                              | 37                                                   | (33.3)                                               | 81                                            | (42.0)                                        | 40                                             | (34.5)                                         | 424                                                  | (6.9)                                                |

|                             | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab   | KN826Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-----------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                             | n                                                   | (%)                                                 | n                                                   | (%)                                                 | n                                             | (%)                                           | n                                              | (%)                                            | n                                                    | (%)                                                  |
| Not Hispanic Or Latino      | 121                                                 | (61.7)                                              | 71                                                  | (64.0)                                              | 111                                           | (57.5)                                        | 73                                             | (62.9)                                         | 4,927                                                | (79.7)                                               |
| Not Reported                | 2                                                   | (1.0)                                               | 3                                                   | (2.7)                                               | 1                                             | (0.5)                                         | 3                                              | (2.6)                                          | 708                                                  | (11.4)                                               |
| Unknown                     | 1                                                   | (0.5)                                               | 0                                                   | (0.0)                                               | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 117                                                  | (1.9)                                                |
| Missing                     | 0                                                   | (0.0)                                               | 0                                                   | (0.0)                                               | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 9                                                    | (0.1)                                                |
| Age Category (year)         |                                                     |                                                     |                                                     |                                                     |                                               |                                               |                                                |                                                |                                                      |                                                      |
| <65                         | 170                                                 | (86.7)                                              | 89                                                  | (80.2)                                              | 165                                           | (85.5)                                        | 92                                             | (79.3)                                         | 3,587                                                | (58.0)                                               |
| 65-74                       | 22                                                  | (11.2)                                              | 16                                                  | (14.4)                                              | 24                                            | (12.4)                                        | 18                                             | (15.5)                                         | 1,797                                                | (29.1)                                               |
| 75-84                       | 4                                                   | (2.0)                                               | 6                                                   | (5.4)                                               | 4                                             | (2.1)                                         | 6                                              | (5.2)                                          | 694                                                  | (11.2)                                               |
| >=85                        | 0                                                   | (0.0)                                               | 0                                                   | (0.0)                                               | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 107                                                  | (1.7)                                                |
| ECoGPerformanceStatus       |                                                     |                                                     |                                                     |                                                     |                                               |                                               |                                                |                                                |                                                      |                                                      |
| [0] Normal Activity         | 127                                                 | (64.8)                                              | 51                                                  | (45.9)                                              | 107                                           | (55.4)                                        | 63                                             | (54.3)                                         | 2,942                                                | (47.6)                                               |
| [1]Symptoms, but ambulatory | 68                                                  | (34.7)                                              | 59                                                  | (53.2)                                              | 86                                            | (44.0)                                        | 53                                             | (45.7)                                         | 3,069                                                | (49.6)                                               |
| Other/Missing               | 1                                                   | (0.5)                                               | 1                                                   | (0.9)                                               | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 174                                                  | (2.8)                                                |
| Geographic Region           |                                                     |                                                     |                                                     |                                                     |                                               |                                               |                                                |                                                |                                                      |                                                      |
| EU                          | 55                                                  | (28.1)                                              | 48                                                  | (43.2)                                              | 50                                            | (25.9)                                        | 58                                             | (50.0)                                         | 2,217                                                | (35.8)                                               |

<div style=\"page-break-after: always\"></div>

|       | KN826Pembrolizumab+ Chemotherapy w/ Bevacizimab   | KN826Pembrolizumab+ Chemotherapy w/o Bevacizimab   | KN826Placebo+ Chemotherapyw/ Bevacizumab   | KN826Placebo+ Chemotherapyw/o Bevacizumab   | Pembrolizumab MonotherapyReference SafetyDataset   |
|-------|---------------------------------------------------|----------------------------------------------------|--------------------------------------------|---------------------------------------------|----------------------------------------------------|
| Ex-EU | n (%) 141 (71.9)                                  | n (%) 63 (56.8)                                    | n (%) 143 (74.1)                           | n (%) 58 (50.0)                             | n (%) 3,968 (64.2)                                 |

Includes allparticipants whoreceived atleastone dose ofpembrolizumabinKN001Part B1,B2,B3,D,C,F1,F2,F3,KN002(original phase),KN006,KN010,KN012cohortB andB2,KN013 cohort 3,KN024, KN040,KN042,KN045,KN048,KN052,KN054,KN055,KN087,KN177,andKN204.

DatabasecutoffdateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:03APR2020)

Databasecutoff dateforLung(KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:04SEP2018)

DatabasecutoffdateforHNSCC(KN012cohortBandB2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoffdateforcHL(KN013cohort3:28SEP2018,KN087:21MAR2019,KN204:16JAN2020)

Databasecutoff dateforBladder(KN045:26OCT2017,KN052:26SEP2018)

DatabasecutoffdateforCRC(KN177:19FEB2020)

DatabasecutoffdateforCervical(KN826:03MAY2021)

Source:[ISS:adam-adsl]

## Table 60. Adverse Event Summary (APaT Population)

|                                                                   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Cervical Safety Dataset for Pembrolizumab Monotherapy d   | Cervical Safety Dataset for Pembrolizumab Monotherapy d   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|-------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                                   | n                                    | (%)                                  | n                              | (%)                            | n                                                          | (%)                                                        | n                                                         | (%)                                                       | n                                                      | (%)                                                    |
| Participants in population                                        | 307                                  |                                      | 309                            |                                | 2,033                                                      |                                                            | 122                                                       |                                                           | 6,185                                                  |                                                        |
| with one or more adverse events                                   | 305                                  | (99.3)                               | 307                            | (99.4)                         | 2,015                                                      | (99.1)                                                     | 119                                                       | (97.5)                                                    | 5,989                                                  | (96.8)                                                 |
| with no adverse event                                             | 2                                    | (0.7)                                | 2                              | (0.6)                          | 18                                                         | (0.9)                                                      | 3                                                         | (2.5)                                                     | 196                                                    | (3.2)                                                  |
| with drug-related a adverse events                                | 298                                  | (97.1)                               | 300                            | (97.1)                         | 1,948                                                      | (95.8)                                                     | 82                                                        | (67.2)                                                    | 4,366                                                  | (70.6)                                                 |
| with toxicity grade 3-5 adverse events                            | 251                                  | (81.8)                               | 232                            | (75.1)                         | 1,583                                                      | (77.9)                                                     | 65                                                        | (53.3)                                                    | 2,984                                                  | (48.2)                                                 |
| with toxicity grade 3-5 drug- related adverse events              | 210                                  | (68.4)                               | 198                            | (64.1)                         | 1,285                                                      | (63.2)                                                     | 17                                                        | (13.9)                                                    | 975                                                    | (15.8)                                                 |
| with serious adverse events                                       | 153                                  | (49.8)                               | 131                            | (42.4)                         | 962                                                        | (47.3)                                                     | 52                                                        | (42.6)                                                    | 2,371                                                  | (38.3)                                                 |
| with serious drug-related adverse events                          | 93                                   | (30.3)                               | 71                             | (23.0)                         | 550                                                        | (27.1)                                                     | 12                                                        | (9.8)                                                     | 701                                                    | (11.3)                                                 |
| who died                                                          | 14                                   | (4.6)                                | 14                             | (4.5)                          | 139                                                        | (6.8)                                                      | 4                                                         | (3.3)                                                     | 321                                                    | (5.2)                                                  |
| who died due to a drug-related adverse event                      | 2                                    | (0.7)                                | 4                              | (1.3)                          | 43                                                         | (2.1)                                                      | 0                                                         | (0.0)                                                     | 39                                                     | (0.6)                                                  |
| discontinued any drug due to an adverse event                     | 115                                  | (37.5)                               | 82                             | (26.5)                         | 551                                                        | (27.1)                                                     | 11                                                        | (9.0)                                                     | 832                                                    | (13.5)                                                 |
| discontinued pembrolizumab or placebo                             | 46                                   | (15.0)                               | 25                             | (8.1)                          | 345                                                        | (17.0)                                                     | 11                                                        | (9.0)                                                     | 832                                                    | (13.5)                                                 |
| discontinued all drugs                                            | 18                                   | (5.9)                                | 15                             | (4.9)                          | 125                                                        | (6.1)                                                      | 11                                                        | (9.0)                                                     | 832                                                    | (13.5)                                                 |
| discontinued any drug due to a drug-related adverse event         | 96                                   | (31.3)                               | 69                             | (22.3)                         | 434                                                        | (21.3)                                                     | 6                                                         | (4.9)                                                     | 444                                                    | (7.2)                                                  |
| discontinued pembrolizumab or placebo                             | 31                                   | (10.1)                               | 12                             | (3.9)                          | 234                                                        | (11.5)                                                     | 6                                                         | (4.9)                                                     | 444                                                    | (7.2)                                                  |
| discontinued all drugs                                            | 10                                   | (3.3)                                | 6                              | (1.9)                          | 76                                                         | (3.7)                                                      | 6                                                         | (4.9)                                                     | 444                                                    | (7.2)                                                  |
| discontinued any drug due to a serious adverse event              | 51                                   | (16.6)                               | 32                             | (10.4)                         | 327                                                        | (16.1)                                                     | 9                                                         | (7.4)                                                     | 598                                                    | (9.7)                                                  |
| discontinued pembrolizumab or placebo                             | 33                                   | (10.7)                               | 16                             | (5.2)                          | 268                                                        | (13.2)                                                     | 9                                                         | (7.4)                                                     | 598                                                    | (9.7)                                                  |
| discontinued all drugs                                            | 17                                   | (5.5)                                | 11                             | (3.6)                          | 110                                                        | (5.4)                                                      | 9                                                         | (7.4)                                                     | 598                                                    | (9.7)                                                  |
| discontinued any drug due to a serious drug-related adverse event | 39                                   | (12.7)                               | 23                             | (7.4)                          | 220                                                        | (10.8)                                                     | 4                                                         | (3.3)                                                     | 265                                                    | (4.3)                                                  |
| discontinued pembrolizumab or placebo                             | 22                                   | (7.2)                                | 8                              | (2.6)                          | 167                                                        | (8.2)                                                      | 4                                                         | (3.3)                                                     | 265                                                    | (4.3)                                                  |
| discontinued all drugs                                            | 10                                   | (3.3)                                | 4                              | (1.3)                          | 63                                                         | (3.1)                                                      | 4                                                         | (3.3)                                                     | 265                                                    | (4.3)                                                  |

(96.8)

(3.2)

(70.6)

(48.2)

(15.8)

(38.3)

(5.2)

(0.6)

(7.2)

(7.2)

(7.2)

(9.7)

(9.7)

(9.7)

(4.3)

(4.3)

(4.3)

<div style=\"page-break-after: always\"></div>

- a  Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

- MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCI CTCAE version 4.0.

- d  Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.
- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.
- f  Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055:

22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

Table 61. Adverse Event Summary by Bevacizumab use (APaT Population)

|                                                                   | KN826Pembrolizumab+ Chemotherapy w/ Bevacizumab   | KN826Pembrolizumab+ Chemotherapy w/ Bevacizumab   | KN826Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safely Dataset   | Pembrolizumab Monotherapy Reference Safely Dataset   |
|-------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                   | n                                                 | (%)                                               | n                                                   | (%)                                                 | n                                             | (%)                                           | n                                              | (%)                                            | n                                                    | (%)                                                  |
| Participants in population                                        | 196                                               |                                                   | 111                                                 |                                                     | 193                                           |                                               | 116                                            |                                                | 6,185                                                |                                                      |
| with one ormore adverse events                                    | 196                                               | (100.0)                                           | 109                                                 | (98.2)                                              | 193                                           | (100.0)                                       | 114                                            | (98.3)                                         | 5,989                                                | (96.8)                                               |
| with no adverse event                                             | 0                                                 | (0.0)                                             | 2                                                   | (1.8)                                               | 0                                             | (0.0)                                         | 2                                              | (1.7)                                          | 196                                                  | (3.2)                                                |
| with drug-related’adverse events                                  | 191                                               | (97.4)                                            | 107                                                 | (96.4)                                              | 190                                           | (98.4)                                        | 110                                            | (94.8)                                         | 4,366                                                | (70.6)                                               |
| with toxicity grade 3-5 adverse events                            | 164                                               | (83.7)                                            | 87                                                  | (78.4)                                              | 144                                           | (74.6)                                        | 88                                             | (75.9)                                         | 2,984                                                | (48.2)                                               |
| with toxicity grade3-5 drug-related adverse events                | 143                                               | (73.0)                                            | 67                                                  | (60.4)                                              | 126                                           | (65.3)                                        | 72                                             | (62.1)                                         | 975                                                  | (15.8)                                               |
| with serious adverse evenls                                       | 99                                                | (50.5)                                            | 54                                                  | (48.6)                                              | 87                                            | (45.1)                                        | 44                                             | (37.9)                                         | 2,371                                                | (38.3)                                               |
| with serious drug-related adverse events                          | 65                                                | (33.2)                                            | 28                                                  | (25.2)                                              | 48                                            | (24.9)                                        | 23                                             | (19.8)                                         | 701                                                  | (11.3)                                               |
| who died                                                          | 10                                                | (5.1)                                             | 4                                                   | (3.6)                                               | 11                                            | (5.7)                                         | 3                                              | (2.6)                                          | 321                                                  | (5.2)                                                |
| who died due to a drug-related adverse event                      | 1                                                 | (0.5)                                             | 1                                                   | (0.9)                                               | 3                                             | (1.6)                                         | 1                                              | (0.9)                                          | 39                                                   | (0.6)                                                |
| discontinued any drug due to an adverse event                     | 88                                                | (44.9)                                            | 27                                                  | (24.3)                                              | 61                                            | (31.6)                                        | 21                                             | (18.1)                                         | 832                                                  | (13.5)                                               |
| discontinuedpembrolizumaborplacebo                                | 35                                                | (17.9)                                            | 11                                                  | (9.9)                                               | 12                                            | (6.2)                                         | 13                                             | (11.2)                                         | 832                                                  | (13.5)                                               |
| discontinued all drugs                                            | 14                                                | (7.1)                                             | 4                                                   | (3.6)                                               | 7                                             | (3.6)                                         | 8                                              | (6.9)                                          | 832                                                  | (13.5)                                               |
| discontinued any drug due to a drug-related adverse event         | 74                                                | (37.8)                                            | 22                                                  | (19.8)                                              | 55                                            | (28.5)                                        | 14                                             | (12.1)                                         | 444                                                  | (7.2)                                                |
| discontinued pembrolizumab orplacebo                              | 25                                                | (12.8)                                            | 6                                                   | (5.4)                                               | 6                                             | (3.1)                                         | 6                                              | (5.2)                                          | 444                                                  | (7.2)                                                |
| discontinued all drugs                                            | 8                                                 | (4.1)                                             | 2                                                   | (1.8)                                               | 2                                             | (1.0)                                         | 4                                              | (3.4)                                          | 444                                                  | (7.2)                                                |
| discontinued any drug due to a serious adverse event              | 41                                                | (20.9)                                            | 10                                                  | (9.0)                                               | 26                                            | (13.5)                                        | 6                                              | (5.2)                                          | 598                                                  | (9.7)                                                |
| discontinued pembrolizumab orplacebo                              | 27                                                | (13.8)                                            | 6                                                   | (5.4)                                               | 11                                            | (5.7)                                         | 5                                              | (4.3)                                          | 598                                                  | (9.7)                                                |
| discontinued all drugs                                            | 13                                                | (6.6)                                             | 4                                                   | (3.6)                                               | 6                                             | (3.1)                                         | 5                                              | (4.3)                                          | 598                                                  | (9.7)                                                |
| discontinued any drug due to a serious drug-related adverse event | 31                                                | (15.8)                                            | 8                                                   | (7.2)                                               | 20                                            | (10.4)                                        | 3                                              | (2.6)                                          | 265                                                  | (4.3)                                                |
| discontinued pembrolizumab orplacebo                              | 19                                                | (9.7)                                             | 3                                                   | (2.7)                                               | 6                                             | (3.1)                                         | 2                                              | (1.7)                                          | 265                                                  | (4.3)                                                |

|                        | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab   | KN826Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab MonotherapyReference Safety Datasel   |
|------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------|------------------------------------------------|-----------------------------------------------------|
|                        | n (%)                                               | n (%)                                               | n (%)                                         | n (%)                                          | (%)                                                 |
| discontinued all drugs | 8 (4.1)                                             | 2 (1.8)                                             | 2 (1.0)                                       | 2 (1.7)                                        | 265 (4.3)                                           |

*Determined by the investigatortobe related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms\"NeoplasmProgression\",“Malignant Neoplasm Progression\"and \"Disease Progression\"notrelated to the drug are excluded.

Grades are based on NCICTCAE version4.0.

Includes allparticipants whoreceivedatleast one dose ofpembrolizumabinKN001Part B1,B2,B3,D,C,F1,F2,F3,KN002(originalphase),KN006,KN010,KN012cohort BandB2,KN013cohont3,KN024, KN040,KN042,KN045,KN048,KN052,KN054,KN055,KN087,KN177,andKN204.

DatabasecutoffdateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:03APR2020)

Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024: 10JUL2017,KN042:04SEP2018)

Database cutoffdate forHNSCC(KN012 cohortB andB2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoffdateforcHL (KN013cohort3:28SEP2018,KN087:21MAR2019,KN204:16JAN2020)

Database cutoffdate forBladder(KN045:26OCT2017,KN052:26SEP2018)

Database cutoff date forCRC (KN177: 19FEB2020)

Database cutoffdate for Cervical (KN826: 03MAY2021)

Souce:[ISS:adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table  62.  Exposure-Adjusted  Adverse  Event  Summary  (Including  Multiple  Occurrences  of Events) (APaT Population)

|                                                                          | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)         | Event Count and Rate (Events/100 person-years)      | Event Count and Rate (Events/100 person-years)      |
|--------------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                                          | KN826 Pembrolizumab + Chemotherapy               | KN826Placebo+ Chemotherapy                       | Pooled Safety Dataset for Pembrolizumab + Chemotherapy | CervicalSafetyDataset for Pembrolizumab Monotherapy | Pembrolizumab Monotherapy Reference Safety Datasete |
| Number of subjects exposed                                               | 307                                              | 309                                              | 2033                                                   | 122                                                 | 6185                                                |
| Total exposure in person-years                                           | 322.11                                           | 265.35                                           | 1688.88                                                | 66.15                                               | 4336.02                                             |
| Total events (rate)                                                      |                                                  |                                                  |                                                        |                                                     |                                                     |
| adverse events                                                           | 6260 (1943.41)                                   | 5628 (2120.94)                                   | 40308 (2386.67)                                        | 1110 (1678.05)                                      | 64173 (1480.00)                                     |
| drug-related adverse events                                              | 3661 (1136.55)                                   | 3152 (1187.85)                                   | 23303 (1379.79)                                        | 280 (423.29)                                        | 20041 (462.20)                                      |
| toxicity grade 3-5 adverse events                                        | 1009 (313.24)                                    | 851 (320.70)                                     | 6238 (369.30)                                          | 152 (229.79)                                        | 6478 (149.40)                                       |
| toxicity grade 3-5 drug-related adverse events                           | 660 (204.90)                                     | 505 (190.31)                                     | 4288 (253.90)                                          | 22 (33.26)                                          | 1467 (33.83)                                        |
| serious adverse events                                                   | 340 (105.55)                                     | 266 (100.24)                                     | 1939 (114.81)                                          | 86 (130.01)                                         | 4264 (98.34)                                        |
| serious drug-related adverse events                                      | 151 (46.88)                                      | 106 (39.95)                                      | 887 (52.52)                                            | 15 (22.68)                                          | 971 (22.39)                                         |
| adverse events leading to death                                          | 14 (4.35)                                        | 14 (5.28)                                        | 143 (8.47)                                             | 4 (6.05)                                            | 328 (7.56)                                          |
| drug-related adverse events leading to death                             | 2 (0.62)                                         | 4 (1.51)                                         | 43 (2.55)                                              | 0(0.00)                                             | 39 (0.90)                                           |
| adverse events resulting in drug discontinuation                         | 151 (46.88)                                      | 104 (39.19)                                      | 656 (38.84)                                            | 11 (16.63)                                          | 904 (20.85)                                         |
| drug-related adverse events resulting in drug                            | 122 (37.87)                                      | 87 (32.79)                                       | 515 (30.49)                                            | 6(9.07)                                             | 481 (11.09)                                         |
| discontinuation serious adverse events resulting in drug discontinuation | 58 (18.01)                                       | 38 (14.32)                                       | 363 (21.49)                                            | 9 (13.61)                                           | 635 (14.64)                                         |

|                                                                       | Event Count and Rate (Events/100 person-years)*   | Event Count and Rate (Events/100 person-years)*   | Event Count and Rate (Events/100 person-years)*       | Event Count and Rate (Events/100 person-years)*      | Event Count and Rate (Events/100 person-years)*     |
|-----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------|
|                                                                       | KN826 Pembrolizumab + Chemotherapy                | KN826 Placebo + Chemotherapy                      | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy | Cervical SafetyDataset for Pembrolizumab Monotherapy | Pembrolizumab Monotherapy Reference Safety Dataset? |
| serious drug-related adverse events resulting in drug discontinuation | 42 (13.04)                                        | 29 (10.93)                                        | 242 (14.33)                                           | 4 (6.05)                                             | 279 (6.43)                                          |

aEvent rate per100person-years of exposure=event count *100/person-years of exposure.

bDrug exposure is defined asthe time from the first dose dateto the earlier of the last dose date + 30 or the database cut-off date.

Determined by the investigator to berelated to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to90 days of last dose are included.

MedDRA preferred terms \"Neoplasm progression\",\"Malignant neoplasm progression\"and \"Disease progression\" not related to the drug are excluded. Grades are based on NCI CTCAE version 4.0.

d Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3,KN024, KN040, KN042,KN045,KN048,KN052,KN054,KN055, KN087, KN177, and KN204.

f Includes allsubjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

DatabasecutoffdateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024: 10JUL2017, KN042: 04SEP2018,KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019) Database cutoff date for HNSCC (KN012 cohort B and B2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018,KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date forBladder(KN045:26OCT2017,KN052:26SEP2018)

Database cutoff date forEsophageal (KN590: 02JUL2020)

Database cutoff datefor CRC(KN177:19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Source:[ISS: adam-adsl; adae]

Table  63.  Exposure-Adjusted  Adverse  Event  Summary  by  Bevacizumab  use  (Including Multiple Occurrences of Events) (APaT Population)

|                                                               | Event Count and Rate (Events/100 person-years)    | Event Count and Rate (Events/100 person-years)     | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)      |
|---------------------------------------------------------------|---------------------------------------------------|----------------------------------------------------|--------------------------------------------------|--------------------------------------------------|-----------------------------------------------------|
|                                                               | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab | KN826 Placebo + Chemotherapy w/ Bevacizumab      | KN826 Placebo + Chemotherapy w/o Bevacizumab     | Pembrolizumab Monotherapy Reference Safety Datasete |
| Number of subjects exposed                                    | 196                                               |                                                    | 193                                              | 116                                              | 6185                                                |
| Total exposure in person-years                                | 230.72                                            | 91.39                                              | 191.67                                           | 73.69                                            | 4336.02                                             |
| Total events(rate)                                            |                                                   |                                                    |                                                  |                                                  |                                                     |
| adverse events                                                | 4410 (1911.41)                                    | 1850 (2024.19) 1085 (1187.16)                      | 3862 (2014.97) 2165 (1129.57)                    | 1766 (2396.57) 987 (1339.42)                     | 64173 (1480.00) 20041 (462.20)                      |
| drug-related adverse events                                   | 2576 (1116.51)                                    |                                                    |                                                  |                                                  |                                                     |
| toxicity grade 3-5 adverse events                             | 670 (290.40)                                      | 339 (370.92)                                       | 560 (292.18)                                     | 291 (394.91)                                     | 6478 (149.40)                                       |
| toxicity grade 3-5 drug-related adverse events                | 444 (192.44)                                      | 216 (236.34)                                       | 342 (178.44)                                     | 163 (221.20)                                     | 1467 (33.83)                                        |
| serious adverse events                                        | 227 (98.39)                                       | 113 (123.64)                                       | 180 (93.91)                                      | 86 (116.71)                                      | 4264 (98.34)                                        |
| serious drug-related adverse events                           | 106 (45.94)                                       | 45 (49.24)                                         | 76 (39.65)                                       | 30 (40.71)                                       | 971 (22.39)                                         |
| adverse events leading to death                               | 10 (4.33)                                         | 4 (4.38)                                           | 11 (5.74)                                        | 3 (4.07)                                         | 328 (7.56)                                          |
| drug-related adverse events leading to death                  | 1 (0.43)                                          | (60'D) 1                                           | 3 (1.57)                                         | 1 (1.30)                                         | 39 (0.90)                                           |
| adverse events resulting in drug discontinuation              | 118 (51.14)                                       | 33 (36.11)                                         | 79 (41.22)                                       | 25 (33.93)                                       | 904 (20.85)                                         |
| drug-related adverse events resulting in drug discontinuation | 96 (41.61)                                        | 26 (28.45)                                         | 70 (36.52)                                       | 17 (23.07)                                       | 481 (11.09)                                         |
| serious adverse events resulting in drug discontinuation      | 47 (20.37)                                        | 11 (12.04)                                         | 32 (16.70)                                       | 6 (8.14)                                         | 635 (14.64)                                         |

<div style=\"page-break-after: always\"></div>

|                                                                       | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   |
|-----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                                       | KN826Pembrolizumab + Chemotherapy w/ Bevacizumab  | KN826Pembrolizumab+ Chemotherapy w/o Bevacizimab  | KN826 Placebo + Chemotherapy w/ Bevacizumab       | KN826 Placebo + Chemotherapy w/o Bevacizumab      | Pembrolizumab MonotherapyReference Safety Dataset |
| serious drug-related adverse events resulting in drug discontinuation | 34 (14.74)                                        | 8 (8.75)                                          | 26 (13.57)                                        | 3 (4.07)                                          | 279 (6.43)                                        |

Event rate per 100 person-years of exposure=event count *100/person-years of exposure.

Determined by the investigator toberelated to the drug.

Drug exposure is defined as the time from the first dose date to the earlier of the last dose date + 30 or the database cut-off date.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\"and \"Disease progression\"not related to the drug are excluded. Grades are based on NCI CTCAE version 4.0.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2,B3,D,C,F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2,KN013 cohort3,KN024,KN040,KN042,KN045,KN048,KN052,KN054,KN055,KN087,KN177,andKN204.

Database cutoff dateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:03APR2020)

Database cutoff date for Lung(KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017, KN042:04SEP2018)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoff datefor cHL (KN013 cohort 3:28SEP2018,KN087: 21MAR2019,KN204:16JAN2020)

Database cutoff date for Bladder(KN045:26OCT2017,KN052:26SEP2018)

Database cutoff datefor CRC(KN177:19FEB2020)

Databasecutoff dateforCervical(KN826:03MAY2021)

Source:[ISS: adam-adsl; adae]

Table 64 . Participants With Adverse Events by Decreasing Incidence (Incidence ≥ 10% in One or More Treatment Groups) (APaT Population)

|                                    | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy f   | Cervical Safety Dataset for Pembrolizumab Monotherapy d   | Cervical Safety Dataset for Pembrolizumab Monotherapy d   | Pembrolizumab Monotherapy Reference Safety Dataset e   | Pembrolizumab Monotherapy Reference Safety Dataset e   |
|------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                    | n                                    | (%)                                  | n                              | (%)                            | n                                                          | (%)                                                        | n                                                         | (%)                                                       | n                                                      | (%)                                                    |
| Participants in population         | 307                                  |                                      | 309                            |                                | 2,033                                                      |                                                            | 122                                                       |                                                           | 6,185                                                  |                                                        |
| with one or more adverse events    | 305                                  | (99.3)                               | 307                            | (99.4)                         | 2,015                                                      | (99.1)                                                     | 119                                                       | (97.5)                                                    | 5,989                                                  | (96.8)                                                 |
| with no adverse events             | 2                                    | (0.7)                                | 2                              | (0.6)                          | 18                                                         | (0.9)                                                      | 3                                                         | (2.5)                                                     | 196                                                    | (3.2)                                                  |
| Anaemia                            | 188                                  | (61.2)                               | 165                            | (53.4)                         | 1,053                                                      | (51.8)                                                     | 36                                                        | (29.5)                                                    | 872                                                    | (14.1)                                                 |
| Alopecia                           | 173                                  | (56.4)                               | 179                            | (57.9)                         | 449                                                        | (22.1)                                                     | 1                                                         | (0.8)                                                     | 98                                                     | (1.6)                                                  |
| Nausea                             | 122                                  | (39.7)                               | 135                            | (43.7)                         | 1,051                                                      | (51.7)                                                     | 22                                                        | (18.0)                                                    | 1,282                                                  | (20.7)                                                 |
| Diarrhoea                          | 109                                  | (35.5)                               | 92                             | (29.8)                         | 644                                                        | (31.7)                                                     | 27                                                        | (22.1)                                                    | 1,295                                                  | (20.9)                                                 |
| Fatigue                            | 88                                   | (28.7)                               | 84                             | (27.2)                         | 744                                                        | (36.6)                                                     | 28                                                        | (23.0)                                                    | 1,967                                                  | (31.8)                                                 |
| Constipation                       | 87                                   | (28.3)                               | 102                            | (33.0)                         | 692                                                        | (34.0)                                                     | 21                                                        | (17.2)                                                    | 1,032                                                  | (16.7)                                                 |
| Arthralgia                         | 82                                   | (26.7)                               | 80                             | (25.9)                         | 363                                                        | (17.9)                                                     | 14                                                        | (11.5)                                                    | 1,149                                                  | (18.6)                                                 |
| Neuropathy peripheral              | 81                                   | (26.4)                               | 79                             | (25.6)                         | 221                                                        | (10.9)                                                     | 0                                                         | (0.0)                                                     | 123                                                    | (2.0)                                                  |
| Vomiting                           | 81                                   | (26.4)                               | 84                             | (27.2)                         | 560                                                        | (27.5)                                                     | 24                                                        | (19.7)                                                    | 784                                                    | (12.7)                                                 |
| Hypertension                       | 74                                   | (24.1)                               | 71                             | (23.0)                         | 120                                                        | (5.9)                                                      | 2                                                         | (1.6)                                                     | 318                                                    | (5.1)                                                  |
| Urinary tract infection            | 73                                   | (23.8)                               | 80                             | (25.9)                         | 147                                                        | (7.2)                                                      | 18                                                        | (14.8)                                                    | 414                                                    | (6.7)                                                  |
| Neutropenia                        | 72                                   | (23.5)                               | 60                             | (19.4)                         | 663                                                        | (32.6)                                                     | 1                                                         | (0.8)                                                     | 62                                                     | (1.0)                                                  |
| Peripheral sensory neuropathy      | 71                                   | (23.1)                               | 79                             | (25.6)                         | 166                                                        | (8.2)                                                      | 0                                                         | (0.0)                                                     | 71                                                     | (1.1)                                                  |
| Asthenia                           | 63                                   | (20.5)                               | 66                             | (21.4)                         | 379                                                        | (18.6)                                                     | 21                                                        | (17.2)                                                    | 692                                                    | (11.2)                                                 |
| Decreased appetite                 | 61                                   | (19.9)                               | 52                             | (16.8)                         | 611                                                        | (30.1)                                                     | 25                                                        | (20.5)                                                    | 1,181                                                  | (19.1)                                                 |
| Thrombocytopenia                   | 61                                   | (19.9)                               | 62                             | (20.1)                         | 401                                                        | (19.7)                                                     | 3                                                         | (2.5)                                                     | 100                                                    | (1.6)                                                  |
| Myalgia                            | 57                                   | (18.6)                               | 59                             | (19.1)                         | 151                                                        | (7.4)                                                      | 6                                                         | (4.9)                                                     | 446                                                    | (7.2)                                                  |
| Hypothyroidism                     | 56                                   | (18.2)                               | 28                             | (9.1)                          | 260                                                        | (12.8)                                                     | 12                                                        | (9.8)                                                     | 699                                                    | (11.3)                                                 |
| Neutrophil count decreased         | 56                                   | (18.2)                               | 48                             | (15.5)                         | 374                                                        | (18.4)                                                     | 0                                                         | (0.0)                                                     | 42                                                     | (0.7)                                                  |
| Pyrexia                            | 55                                   | (17.9)                               | 44                             | (14.2)                         | 354                                                        | (17.4)                                                     | 28                                                        | (23.0)                                                    | 802                                                    | (13.0)                                                 |
| Abdominal pain                     | 50                                   | (16.3)                               | 53                             | (17.2)                         | 161                                                        | (7.9)                                                      | 20                                                        | (16.4)                                                    | 527                                                    | (8.5)                                                  |
| Platelet count decreased           | 49                                   | (16.0)                               | 41                             | (13.3)                         | 250                                                        | (12.3)                                                     | 1                                                         | (0.8)                                                     | 76                                                     | (1.2)                                                  |
| Headache                           | 48                                   | (15.6)                               | 57                             | (18.4)                         | 290                                                        | (14.3)                                                     | 13                                                        | (10.7)                                                    | 747                                                    | (12.1)                                                 |
| Rash                               | 47                                   | (15.3)                               | 35                             | (11.3)                         | 363                                                        | (17.9)                                                     | 12                                                        | (9.8)                                                     | 936                                                    | (15.1)                                                 |
| Alanine aminotransferase increased | 43                                   | (14.0)                               | 28                             | (9.1)                          | 283                                                        | (13.9)                                                     | 5                                                         | (4.1)                                                     | 429                                                    | (6.9)                                                  |
| Proteinuria                        | 41                                   | (13.4)                               | 27                             | (8.7)                          | 32                                                         | (1.6)                                                      | 8                                                         | (6.6)                                                     | 60                                                     | (1.0)                                                  |
| Back pain                          | 40                                   | (13.0)                               | 44                             | (14.2)                         | 230                                                        | (11.3)                                                     | 13                                                        | (10.7)                                                    | 709                                                    | (11.5)                                                 |
| Cough Leukopenia                   | 40 40                                | (13.0) (13.0)                        | 31 33                          | (10.0) (10.7)                  | 426 229                                                    | (21.0) (11.3)                                              | 12 2                                                      | (9.8) (1.6)                                               | 1,200 46                                               | (19.4) (0.7)                                           |
| Pruritus                           | 38                                   | (12.4)                               | 26                             | (8.4)                          | 283                                                        | (13.9)                                                     | 10                                                        | (8.2)                                                     | 1,111                                                  | (18.0)                                                 |
| White blood cell count decreased   | 37                                   | (12.1)                               | 22                             | (7.1)                          | 314                                                        | (15.4)                                                     | 0                                                         | (0.0)                                                     | 58                                                     | (0.9)                                                  |
| Pain in extremity                  | 36                                   | (11.7)                               |                                | (8.1)                          | 161                                                        | (7.9)                                                      | 7                                                         | (5.7)                                                     | 421                                                    | (6.8)                                                  |
| Aspartate aminotransferase         |                                      |                                      | 25                             |                                |                                                            | (13.2)                                                     |                                                           |                                                           |                                                        |                                                        |
| increased                          | 34                                   | (11.1)                               | 22                             | (7.1)                          | 269                                                        |                                                            | 7                                                         | (5.7)                                                     | 422                                                    | (6.8)                                                  |

(96.8)

(3.2)

(14.1)

(1.6)

(20.7)

(20.9)

(31.8)

(16.7)

(18.6)

(2.0)

(12.7)

(5.1)

(1.0)

(1.1)

(11.2)

(19.1)

(1.6)

(7.2)

(11.3)

(0.7)

(13.0)

(1.2)

(12.1)

(15.1)

(6.9)

(1.0)

(11.5)

(19.4)

(0.7)

(18.0)

(0.9)

(6.8)

(6.8)

<div style=\"page-break-after: always\"></div>

(7.2)

(9.3)

(1.4)

(4.7)

(0.3)

(2.6)

(7.4)

(1.6)

(16.5)

(0.8)

(7.3)

| Insomnia                   |   33 | (10.7)   |   26 | (8.4)   |   206 | (10.1)   |   6 | (4.9)   | 447   | (7.2)   |
|----------------------------|------|----------|------|---------|-------|----------|-----|---------|-------|---------|
| Weight decreased           |   33 | (10.7)   |   35 | (11.3)  |   275 | (13.5)   |   6 | (4.9)   | 574   | (9.3)   |
| Epistaxis                  |   31 | (10.1)   |   42 | (13.6)  |   112 | (5.5)    |   2 | (1.6)   | 86    | (1.4)   |
| Hypokalaemia               |   31 | (10.1)   |   30 | (9.7)   |   216 | (10.6)   |   9 | (7.4)   | 288   | (4.7)   |
| Vaginal haemorrhage        |   30 | (9.8)    |   35 | (11.3)  |     8 | (0.4)    |  11 | (9.0)   | 20    | (0.3)   |
| Blood creatinine increased |   28 | (9.1)    |   30 | (9.7)   |   241 | (11.9)   |  13 | (10.7)  | 268   | (4.3)   |
| Oedema peripheral          |   26 | (8.5)    |   27 | (8.7)   |   251 | (12.3)   |  18 | (14.8)  | 539   | (8.7)   |
| Stomatitis                 |   22 | (7.2)    |   21 | (6.8)   |   288 | (14.2)   |   4 | (3.3)   | 159   | (2.6)   |
| Dizziness                  |   21 | (6.8)    |   24 | (7.8)   |   224 | (11.0)   |   4 | (3.3)   | 460   | (7.4)   |
| Mucosal inflammation       |   21 | (6.8)    |   10 | (3.2)   |   230 | (11.3)   |   1 | (0.8)   | 99    | (1.6)   |
| Dyspnoea                   |   20 | (6.5)    |   30 | (9.7)   |   306 | (15.1)   |  13 | (10.7)  | 1,020 | (16.5)  |
| Pelvic pain                |   18 | (5.9)    |   35 | (11.3)  |    13 | (0.6)    |   6 | (4.9)   | 47    | (0.8)   |
| Pneumonia                  |    7 | (2.3)    |   15 | (4.9)   |   218 | (10.7)   |   1 | (0.8)   | 451   | (7.3)   |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

- d  Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.
- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

f  Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

<div style=\"page-break-after: always\"></div>

Table  65.  Participants  with  Adverse  Events  by  System  Organ  Class  and  Preferred  Term (Incidence &gt;0% in One or More Treatment Groups (APaT Population)

|                                        | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset°   | Pembrolizumab Monotherapy Reference Safety Dataset°   |
|----------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                        | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                     | (%)                                                   |
| Participants in population             | 307                                  |                                      | 309                            |                                | 2,033                                                    |                                                          | 122                                                      |                                                          | 6,185                                                 |                                                       |
| with one or more adverse events        | 305                                  | (99.3)                               | 307                            | (99.4)                         | 2,015                                                    | (99.1)                                                   | 611                                                      | (97.5)                                                   | 5,989                                                 | (96.8)                                                |
| with no adverse events                 | 2                                    | (0.7)                                | 2                              | (0.6)                          | 18                                                       | (0.9)                                                    | 3                                                        | (2.5)                                                    | 196                                                   | (3.2)                                                 |
| Blood and lymphatic system disorders   | 222                                  | (72.3)                               | 207                            | (67.0)                         | 1,373                                                    | (67.5)                                                   | 45                                                       | (36.9)                                                   | 1,183                                                 | (19.1)                                                |
| Anaemia                                | 188                                  | (61.2)                               | 165                            | (53.4)                         | 1,053                                                    | (51.8)                                                   | 36                                                       | (29.5)                                                   | 872                                                   | (14.1)                                                |
| Anaemia macrocytic                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                     | (0.0)                                                 |
| Anaemia of chronic disease             | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                     | (0.0)                                                 |
| Anaemia of malignant disease           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                       | (0.1)                                                 |
| Autoimmune haemolytic anaemia          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                       | (0.0)                                                 |
| Bicytopenia                            |                                      | (0.3)                                | 1                              | (0.3)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                     | (0.0)                                                 |
| Blood loss anaemia                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                     | (0.0)                                                 |
| Bone marrow failure                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                     | (0.0)                                                 |
| Bone marrow oedema                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                     | (0.0)                                                 |
| Coagulopathy                           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 2                                                     | (0.0)                                                 |
| Disseminated intravascular coagulation | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                     | (0.1)                                                 |
| Eosinopenia                            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                     | (0.0)                                                 |
| Eosinophilia                           | 12                                   | (3.9)                                | 0                              | (0.0)                          | 4                                                        | (0.2)                                                    | 0                                                        | (0.0)                                                    | 40                                                    | (0.6)                                                 |
| Febrile neutropenia                    | 24                                   | (7.8)                                | 14                             | (4.5)                          | 94                                                       | (4.6)                                                    | 0                                                        | (0.0)                                                    | 10                                                    | (0.2)                                                 |
| Haemolytic anaemia                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                       | (0.0)                                                 |
| Haemorrhagic diathesis                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                     | (0.0)                                                 |
| Hypercoagulation                       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                     | (0.1)                                                 |
| Hypochromic anaemia                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                     | (0.0)                                                 |
| Hypofibrinogenaemia                    | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                     | (0.0)                                                 |

|                                      | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy'   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy'   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataser   | Pembrolizumab Monotherapy Reference Safety Dataser   |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                      | n                                    | (%)                                  | n                              | (%)                            | n                                                         | (%)                                                       | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Blood and lymphatic system disorders | 222                                  | (72.3)                               | 207                            | (67.0)                         | 1,373                                                     | (67.5)                                                    | 45                                                       | (36.9)                                                   | 1,183                                                | (19.1)                                               |
| Immune thrombocytopenia              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 6                                                    | (0.1)                                                |
| Increased tendency to bruise         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Iron deficiency anaemia              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 4                                                         | (0.2)                                                     | 1                                                        | (0.8)                                                    | 10                                                   | (0.2)                                                |
| Leukaemoid reaction                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Leukocytosis                         | 2                                    | (0.7)                                | 4                              | (1.3)                          | 18                                                        | (0.9)                                                     | 4                                                        | (3.3)                                                    | 55                                                   | (0.9)                                                |
| Leukopenia                           | 40                                   | (13.0)                               | 33                             | (10.7)                         | 229                                                       | (11.3)                                                    | 2                                                        | (1.6)                                                    | 46                                                   | (0.7)                                                |
| Lymph node pain                      | 0                                    | (0.0)                                |                                | (0.3)                          | 6                                                         | (0.3)                                                     | 1                                                        | (0.8)                                                    | 23                                                   | (0.4)                                                |
| Lymphadenitis                        |                                      | (0.3)                                | 0                              | (0.0)                          | 3                                                         | (0.1)                                                     | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Lymphadenopathy                      | 0                                    | (0.0)                                |                                | (0.3)                          | 8                                                         | (0.4)                                                     | 1                                                        | (0.8)                                                    | 22                                                   | (0.4)                                                |
| Lymphadenopathy mediastinal          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Lymphatic obstruction                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Lymphocytosis                        | 0                                    | (0.0)                                |                                | (0.3)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Lymphoid tissue hyperplasia          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Lymphopenia                          | 13                                   | (4.2)                                | 6                              | (6'1)                          | 55                                                        | (2.7)                                                     | I                                                        | (0.8)                                                    | 73                                                   | (1.2)                                                |
| Macrocytosis                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Microcytic anaemia                   | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                           | (0.0)                                                     | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Monocytopenia                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Myelosuppression                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Neutropenia                          | 72                                   | (23.5)                               | 60                             | (19.4)                         | 663                                                       | (32.6)                                                    | 1                                                        | (0.8)                                                    | 62                                                   | (1.0)                                                |
| Neutrophilia                         | 1                                    | (0.3)                                | 2                              | (0.6)                          | 6                                                         | (0.3)                                                     | 0                                                        | (0.0)                                                    | 9                                                    | (0.1)                                                |
| Normocytic anaemia                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Pancytopenia                         | 3                                    | (1.0)                                | 4                              | (1.3)                          | 14                                                        | (0.7)                                                     | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Pemicious anaemia                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |

|                                          | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                          | n (%)                                | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Cardiac disorders                        | 26 (8.5)                             | 27                             | (8.7)                          | 210                                                      | (10.3)                                                   | 9                                                        | (7.4)                                                    | 505                                                  | (8.2)                                                |
| Tachycardia                              | 5 (1.6)                              | 10                             | (3.2)                          | 37                                                       | (1.8)                                                    | 6                                                        | (4.9)                                                    | 92                                                   | (1.5)                                                |
| Ventricular arrhythmia                   | 0                                    | (0.0)                          | 0 (0.0)                        | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Ventricular extrasystoles                | 0                                    | (0.0)                          | 0 (0.0)                        | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Ventricular fibrillation                 | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Ventricular tachycardia                  | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Wolff-Parkinson-White syndrome           | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Congenital,familialand genetic disorders | 0                                    | (0.0)                          | 0 (0.0)                        | 6                                                        | (0.3)                                                    | 0                                                        | (0.0)                                                    | 11                                                   | (0.2)                                                |
| Accessory spleen                         | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Hepato-lenticular degeneration           | 0                                    | (0.0)                          | 0 (0.0)                        |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Ichthyosis                               | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Naevus flammeus                          | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Peutz-Jeghers syndrome                   | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Phimosis                                 | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Preauricular cyst                        | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Pseudohypoparathyroidism                 | 0                                    | (0.0)                          | 0 (0.0)                        |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Pyloric stenosis                         | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Syndactyly                               | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Tracheo-oesophageal fistula              | 0                                    | (0.0)                          | 0 (0.0)                        | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Type V hyperlipidaemia                   | 0                                    | (0.0)                          | 0 (0.0)                        | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Earand labyrinth disorders               | 17                                   | (5.5) 12                       | (3.9)                          | 206                                                      | (10.1)                                                   | 2                                                        | (1.6)                                                    | 299                                                  | (4.8)                                                |
| Auricular swelling                       | 0                                    | (0.0)                          | 0 (0.0)                        | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |

<div style=\"page-break-after: always\"></div>

|                                    | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                    | n                                    | (%)                                  | n                              | (%)                            | n                                                       | (%)                                                     |                                                          | (%)                                                      | n                                                    | (%)                                                  |
| Ear and labyrinth disorders        | 17                                   | (5.5)                                | 12                             | (3.9)                          | 206                                                     | (10.1)                                                  | 2                                                        | (1.6)                                                    | 299                                                  | (4.8)                                                |
| Paraesthesia ear                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Presbyacusis                       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Tinnitus                           | 7                                    | (2.3)                                | 5                              | (1.6)                          | 74                                                      | (3.6)                                                   | 0                                                        | (0.0)                                                    | 57                                                   | (0.9)                                                |
| Tympanic membrane perforation      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Vertigo                            | 6                                    | (2.0)                                | 3                              | (1.0)                          | 60                                                      | (3.0)                                                   | 1                                                        | (0.8)                                                    | 95                                                   | (1.5)                                                |
| Vertigo positional                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 3                                                       | (0.1)                                                   | 0                                                        | (0.0)                                                    | 8                                                    | (0.1)                                                |
| Vestibular disorder                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Endocrine disorders                | 79                                   | (25.7)                               | 39                             | (12.6)                         | 359                                                     | (17.7)                                                  | 17                                                       | (13.9)                                                   | 949                                                  | (15.3)                                               |
| Addison's disease                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Adrenal disorder                   | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                         | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Adrenal haemorrhage                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Adrenal insufficiency              | 4                                    | (1.3)                                | 0                              | (0.0)                          | 15                                                      | (0.7)                                                   | 0                                                        | (0.0)                                                    | 47                                                   | (0.8)                                                |
| Adrenocortical insufficiency acute | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Autoimmune thyroiditis             | 1                                    | (0.3)                                | 0                              | (0.0)                          | 3                                                       | (0.1)                                                   | 0                                                        | (0.0)                                                    | 16                                                   | (0.3)                                                |
| Basedow's disease                  | I                                    | (0.3)                                | 0                              | (0.0)                          |                                                         | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Cushing's syndrome                 | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                         | (0.0)                                                   | 0                                                        | (0.0)                                                    | I                                                    | (0.0)                                                |
| Cushingoid                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 7                                                       | (0.3)                                                   | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Diabetes insipidus                 | 0                                    | (0.0)                                | 1                              | (0.3)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Endocrine disorder                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Euthyroid sick syndrome            | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                         | (0.0)                                                   | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Glucocorticoid deficiency          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Goitre                             | 1                                    | (0.3)                                |                                | (0.3)                          | 2                                                       | (0.1)                                                   | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |

|                                   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-----------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                   | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Eye disorders                     | 23                                   | (7.5)                                | 23                             | (7.4)                          | 333                                                      | (16.4)                                                   | 7                                                        | (5.7)                                                    | 663                                                  | (10.7)                                               |
| Abnormal sensation in eye         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Accommodation disorder            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| A ge-related macular degeneration | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Altered visual depth perception   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Amaurosis                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Angle closure glaucoma            | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Anterior chamber inflammation     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Asthenopia                        |                                      | (0.3)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Blepharitis                       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 7                                                        | (0.3)                                                    | 0                                                        | (0.0)                                                    | 8                                                    | (0.1)                                                |
| Blepharospasm                     | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Blindness                         | 0                                    | (0.0)                                |                                | (0.3)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Blindness unilateral              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Cataract                          | I                                    | (0.3)                                | 1                              | (0.3)                          | 15                                                       | (0.7)                                                    | 0                                                        | (0.0)                                                    | 46                                                   | (0.7)                                                |
| Chalazion                         | 0                                    | (0.0)                                |                                | (0.3)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Choroidal neovascularisation      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Ciliary muscle spasm              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Conjunctival deposit              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Conjunctival haemorrhage          | 0                                    | (0.0)                                | 1                              | (0.3)                          | 9                                                        | (0.4)                                                    | 0                                                        | (0.0)                                                    | 12                                                   | (0.2)                                                |
| Conjunctival hyperaemia           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 8                                                    | (0.1)                                                |
| Conjunctival irritation           | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Conjunctival oedema               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Conjunctivalisation               | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Conjunctivitis allergic           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 9                                                    | (0.1)                                                |

|                                      | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                      | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Gastrointestinal disorders           | 241                                  | (78.5)                               | 236                            | (76.4)                         | 1,641                                                    | (80.7)                                                   | 76                                                       | (62.3)                                                   | 3,565                                                | (57.6)                                               |
| Change of bowel habit                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Chapped lips                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    |                                                          | (0.8)                                                    | 1                                                    | (0.0)                                                |
| Cheilitis                            |                                      | (0.3)                                | 0                              | (0.0)                          | 7                                                        | (0.3)                                                    | 0                                                        | (0.0)                                                    | 10                                                   | (0.2)                                                |
| Chronic gastritis                    | 0                                    | (0.0)                                |                                | (0.3)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Coating in mouth                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Colitis                              | 12                                   | (3.9)                                | 3                              | (1.0)                          | 44                                                       | (2.2)                                                    | 3                                                        | (2.5)                                                    | 105                                                  | (1.7)                                                |
| Colitis microscopic                  | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Colonic fistula                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 2                                                        | (1.6)                                                    | 1                                                    | (0.0)                                                |
| Constipation                         | 87                                   | (28.3)                               | 102                            | (33.0)                         | 692                                                      | (34.0)                                                   | 21                                                       | (17.2)                                                   | 1,032                                                | (16.7)                                               |
| Defaecation urgency                  |                                      | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Dental caries                        | 4                                    | (1.3)                                | 0                              | (0.0)                          | 10                                                       | (0.5)                                                    | 0                                                        | (0.0)                                                    | 25                                                   | (0.4)                                                |
| Dental discomfort                    | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Diaphragmatic hernia                 | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Diarhoea                             | 109                                  | (35.5)                               | 92                             | (29.8)                         | 644                                                      | (31.7)                                                   | 27                                                       | (22.1)                                                   | 1,295                                                | (20.9)                                               |
| Diarrhoea haemorrhagic               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Diverticular perforation             | 0                                    | (0.0)                                | 0                              | (0.0)                          | I                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Diverticulum                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 7                                                    | (0.1)                                                |
| Diverticulum gastric                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Diverticulum intestinal              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Diverticulum intestinal haemorrhagic | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Dry mouth                            | 5                                    | (1.6)                                | 8                              | (2.6)                          | 16                                                       | (4.5)                                                    | 3                                                        | (2.5)                                                    | 304                                                  | (4.9)                                                |
| Dumping syndrome                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Duodenal obstruction                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |

<div style=\"page-break-after: always\"></div>

|                                                      | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                      | n                                    | (%)                                  |                                | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| General disorders and administration site conditions | 192                                  | (62.5)                               | 189                            | (61.2)                         | 1,498                                                    | (73.7)                                                   | 80                                                       | (65.0)                                                   | 3,760                                                | (60.8)                                               |
| Vascular device occlusion                            | 1                                    | (0.3)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Vessel puncture site pain                            | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Withdrawal syndrome                                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 1                                                        | (0.8)                                                    | 0                                                    | (0.0)                                                |
| Xerosis                                              | 0                                    | (0.0)                                |                                | (0.3)                          | 7                                                        | (0.3)                                                    |                                                          | (0.8)                                                    | 29                                                   | (0.5)                                                |
| Hepatobiliary disorders                              | 19                                   | (6.2)                                | 15                             | (4.9)                          | 84                                                       | (4.1)                                                    | 7                                                        | (5.7)                                                    | 205                                                  | (3.3)                                                |
| Acute hepatic failure                                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Alcoholic liver disease                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Autoimmune hepatitis                                 | 1                                    | (0.3)                                | 0                              | (0.0)                          | 12                                                       | (0.6)                                                    | 0                                                        | (0.0)                                                    | 26                                                   | (0.4)                                                |
| Bile duct stenosis                                   | 0                                    | (0.0)                                | 1                              | (0.3)                          | 0                                                        | (0.0)                                                    |                                                          | (0.8)                                                    |                                                      | (0.0)                                                |
| Bile duct stone                                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Biliary colic                                        | 1                                    | (0.3)                                |                                | (0.3)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Biliary dilatation                                   | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Biliary obstruction                                  | 0                                    | (0.0)                                |                                | (0.3)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Cholangitis                                          | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.1)                                                    | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Cholangitis sclerosing                               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Cholecystitis                                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 10                                                   | (0.2)                                                |
| Cholecystitis acute                                  | 0                                    | (0.0)                                | 1                              | (0.3)                          |                                                          | (0.0)                                                    | 1                                                        | (0.8)                                                    | 2                                                    | (0.0)                                                |
| Cholecystitis chronic                                | 0                                    | (0.0)                                |                                | (0.3)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Cholelithiasis                                       | 1                                    | (0.3)                                |                                | (0.3)                          | 5                                                        | (0.2)                                                    | 0                                                        | (0.0)                                                    | 6                                                    | (0.1)                                                |
| Cholestasis                                          | 2                                    | (0.7)                                | 2                              | (0.6)                          | 3                                                        | (0.1)                                                    | 1                                                        | (0.8)                                                    | 20                                                   | (0.3)                                                |
| Drug-induced liver injury                            | 0                                    | (0.0)                                |                                | (0.3)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 7                                                    | (0.1)                                                |
| Gallbladder enlargement                              |                                      | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |

|                                          | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                          | I                                    | (%)                                  |                                | (%)                            | I1                                                       | (%)                                                      | n                                                        | (%)                                                      | I                                                    | (%)                                                  |
| Immune system disorders                  | 27                                   | (8.8)                                | 31                             | (10.0)                         | 69                                                       | (3.4)                                                    | 1                                                        | (0.8)                                                    | 180                                                  | (2.9)                                                |
| Food allergy                             | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Hypersensitivity                         | 14                                   | (4.6)                                | 16                             | (5.2)                          | 22                                                       | (1.1)                                                    |                                                          | (0.8)                                                    | 51                                                   | (0.8)                                                |
| Hypogammaglobulinaemia                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Immune system disorder                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Iodine allergy                           | 1                                    | (0.3)                                | 2                              | (0.6)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Sarcoidosis                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 10                                                   | (0.2)                                                |
| Seasonal allergy                         | 1                                    | (0.3)                                | 0                              | (0.0)                          | 18                                                       | (0.9)                                                    | 0                                                        | (0.0)                                                    | 35                                                   | (0.6)                                                |
| Serum sickness                           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Type Il immune complex mediated reaction | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Infections and infestations              | 166                                  | (54.1)                               | 176                            | (57.0)                         | 1,092                                                    | (53.7)                                                   | 41                                                       | (33.6)                                                   | 2,769                                                | (44.8)                                               |
| Abdominal abscess                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Abdominal infection                      |                                      | (0.3)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Abdominal sepsis                         | 0                                    | (0.0)                                | 1                              | (0.3)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Abdominal wall abscess                   | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Abscess                                  |                                      | (0.3)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Abscess jaw                              | 1                                    | (0.3)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Abscess limb                             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Abscess neck                             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Abscess oral                             | 1                                    | (0.3)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Acarodermatitis                          | 0                                    | (0.0)                                |                                | (0.3)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Acinetobacter infection                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Acne pustular                            | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |

|                                              | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy'   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy'   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|----------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                              | n                                    | (%)                                  | n                              | (%)                            | n                                                         | (%)                                                       | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Injury,poisoning andprocedural complications | 69                                   | (22.5)                               | 58                             | (18.8)                         | 270                                                       | (13.3)                                                    | 13                                                       | (10.7)                                                   | 778                                                  | (12.6)                                               |
| Back injury                                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Bone contusion                               | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Brain hemiation                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bun oesophageal                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Bum oral cavity                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Buns second degree                           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Cervical vertebral fracture                  | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Chest injury                                 | 0                                    | (0.0)                                | 1                              | (0.3)                          |                                                           | (0.1)                                                     | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Chillblains                                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Clavicle fracture                            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 6                                                    | (0.1)                                                |
| Concussion                                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                         | (0.1)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Contrast media toxicity                      | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Contusion                                    | 3                                    | (1.0)                                | 5                              | (1.6)                          | 31                                                        | (1.5)                                                     | 0                                                        | (0.0)                                                    | 63                                                   | (1.0)                                                |
| Cormeal abrasion                             | 0                                    | (0.0)                                | 1                              | (0.3)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | I                                                    | (0.0)                                                |
| Craniocerebral injury                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Cystitis radiation                           | 3                                    | (1.0)                                | 1                              | (0.3)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Dental restoration failure                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Dislocation of vertebra                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Ear canal abrasion                           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Epicondylitis                                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Eschar                                       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Eye contusion                                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Eye injury                                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |

<div style=\"page-break-after: always\"></div>

|                                           | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                           | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Investigations                            | 180                                  | (58.6)                               | 165                            | (53.4)                         | 1,170                                                    | (57.6)                                                   | 36                                                       | (29.5)                                                   | 2,090                                                | (33.8)                                               |
| Aortic bruit                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Aspartate aminotransferase                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Aspartate aminotransferase increased      | 34                                   | (11.1)                               | 22                             | (7.1)                          | 269                                                      | (13.2)                                                   | 7                                                        | (5.7)                                                    | 422                                                  | (6.8)                                                |
| Autoantibody positive                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Bacterial test positive                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Band neutrophil count decreased           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Band neutrophil count increased           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Base excess increased                     | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Basophil count decreased                  | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Basophil percentage increased             | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Bilirubin conjugated increased            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 6                                                        | (0.3)                                                    | 0                                                        | (0.0)                                                    | 17                                                   | (0.3)                                                |
| Bilirubin urine present                   | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Biopsy skin                               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Blood 25-hydroxycholecalciferol decreased | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Blood acid phosphatase increased          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Blood albumin decreased                   | 1                                    | (0.3)                                | 2                              | (0.6)                          | 17                                                       | (0.8)                                                    | 0                                                        | (0.0)                                                    | 25                                                   | (0.4)                                                |
| Blood albumin increased                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Blood alkaline phosphatase                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Blood alkaline phosphatase decreased      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Blood alkaline phosphatase increased      | 27                                   | (8.8)                                | 18                             | (5.8)                          | 104                                                      | (5.1)                                                    | 12                                                       | (9.8)                                                    | 266                                                  | (4.3)                                                |
| Blood bicarbonate decreased               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Blood bicarbonate increased               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 11                                                   | (0.2)                                                |
| Blood bilirubin                           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |

|                                                 | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                 | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Metabolism and nutrition disorders              | 135                                  | (44.0)                               | 124                            | (40.1)                         | 1,073                                                    | (52.8)                                                   | 51                                                       | (41.8)                                                   | 2,347                                                | (37.9)                                               |
| Food intolerance                                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Glucose tolerance impaired                      | 0                                    | (0.0)                                | 1                              | (0.3)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Gout                                            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 8                                                        | (0.4)                                                    | 0                                                        | (0.0)                                                    | 25                                                   | (0.4)                                                |
| Hyperalbuminaemia                               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Hyperammonaemia                                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Hyperamylasaemia                                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Hypercalcaemia                                  | 8                                    | (2.6)                                | 7                              | (2.3)                          | 46                                                       | (2.3)                                                    | 10                                                       | (8.2)                                                    | 185                                                  | (3.0)                                                |
| Hyperchloraemia                                 | 2                                    | (0.7)                                | 1                              | (0.3)                          | 4                                                        | (0.2)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Hypercholesterolaemia                           | 3                                    | (1.0)                                | 3                              | (1.0)                          | 7                                                        | (0.3)                                                    | 0                                                        | (0.0)                                                    | 31                                                   | (0.5)                                                |
| Hypercreatininaemia                             | 1                                    | (0.3)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Hyperglycaemia                                  | 14                                   | (4.6)                                | 18                             | (5.8)                          | 122                                                      | (6.0)                                                    | 1                                                        | (0.8)                                                    | 303                                                  | (4.9)                                                |
| Hyperglycaemic hyperosmolar nonketotic syndrome | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Hyperkalaemia                                   | 14                                   | (4.6)                                | 12                             | (3.9)                          | 82                                                       | (4.0)                                                    | 1                                                        | (0.8)                                                    | 158                                                  | (2.6)                                                |
| Hyperlipasaemia                                 | 0                                    | (0.0)                                |                                | (0.3)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Hyperlipidaemia                                 | 4                                    | (1.3)                                | 1                              | (0.3)                          | 5                                                        | (0.2)                                                    | 0                                                        | (0.0)                                                    | 10                                                   | (0.2)                                                |
| Hypermagnesaemia                                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 4                                                        | (0.2)                                                    | 0                                                        | (0.0)                                                    | 23                                                   | (0.4)                                                |
| Hypematraemia                                   | 0                                    | (0.0)                                | 4                              | (1.3)                          | 13                                                       | (0.6)                                                    | 0                                                        | (0.0)                                                    | 18                                                   | (0.3)                                                |
| Hyperphagia                                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Hyperphosphataemia                              | 5                                    | (1.6)                                |                                | (0.3)                          | 9                                                        | (0.4)                                                    | 1                                                        | (0.8)                                                    | 7                                                    | (0.1)                                                |
| Hyperproteinaemia                               | 2                                    | (0.7)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Hypertriglyceridaemia                           |                                      | (0.3)                                | 3                              | (1.0)                          | 8                                                        | (0.4)                                                    | 0                                                        | (0.0)                                                    | 88                                                   | (1.4)                                                |
| Hyperuricaemia                                  | 4                                    | (1.3)                                | 3                              | (1.0)                          | 37                                                       | (1.8)                                                    | 3                                                        | (2.5)                                                    | 104                                                  | (1.7)                                                |
| Hypervolaemia                                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |

|                                               | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-----------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                               | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Musculoskeletaland connectivetissue disorders | 172                                  | (56.0)                               | 161                            | (52.1)                         | 890                                                      | (43.8)                                                   | 41                                                       | (33.6)                                                   | 2,721                                                | (44.0)                                               |
| Axillary mass                                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Back disorder                                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Back pain                                     | 40                                   | (13.0)                               | 44                             | (14.2)                         | 230                                                      | (11.3)                                                   | 13                                                       | (10.7)                                                   | 709                                                  | (11.5)                                               |
| Bone fistula                                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Bone lesion                                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Bone loss                                     | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Bone pain                                     | 21                                   | (6.8)                                | 19                             | (6.1)                          | 57                                                       | (2.8)                                                    |                                                          | (0.8)                                                    | 611                                                  | (1.9)                                                |
| Bone swelling                                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Bursa disorder                                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | I                                                    | (0.0)                                                |
| Bursitis                                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 25                                                   | (0.4)                                                |
| Cervical spinal stenosis                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Chest wall haematoma                          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Chest wall mass                               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Chondrocalcinosis pyrophosphate               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Chondropathy                                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Chondrosis                                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Clubbing                                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Coccydynia                                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Connective tissue disorder                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Costochondritis                               | 1                                    | (0.3)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Crystal arthropathy                           | 0                                    | (0.0)                                | 1                              | (0.3)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Dupuytren's contracture                       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Enthesopathy                                  |                                      | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |

<div style=\"page-break-after: always\"></div>

|                                                                   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-------------------------------------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                   | n (%)                                | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Neoplasms benign, malignant and unspecified (incl cysts (sdod pue | 6 (2.0)                              | 7                              | (2.3)                          | 109                                                      | (5.4)                                                    | 4                                                        | (3.3)                                                    | 581                                                  | (9.4)                                                |
| Acrochordon                                                       | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Adenocarcinoma                                                    | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Adenocarcinoma gastric                                            | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Adenocarcinoma of colon                                           | 0 (0.0)                              | 0                              | (0.0)                          | I                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Anogenital warts                                                  | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Appendix cancer                                                   | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Astrocytoma, low grade                                            | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Basal cell carcinoma                                              | 0 (0.0)                              | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 48                                                   | (0.8)                                                |
| Basosquamous carcinoma                                            | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Benign lung neoplasm                                              | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Benign lymph node neoplasm                                        | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Benign neoplasm                                                   | 0 (0.0)                              | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Benign neoplasm of skin                                           | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Benign neoplasm of testis                                         | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bladder cancer                                                    | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bladder neoplasm                                                  | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bladder papilloma                                                 | 0 (0.0)                              | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Bladder transitional cell carcinoma                               | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bone cancer metastatic                                            | 0                                    | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bowen's disease                                                   | (0.0) 0 (0.0)                        | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 7                                                    | (0.1)                                                |
| Breast cancer                                                     | 0 (0.0)                              | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Cancer pain                                                       | 3 (1.0)                              | 3                              | (1.0)                          | 29                                                       | (1.4)                                                    | 2                                                        | (1.0)                                                    | 71                                                   | (1.1)                                                |

|                                    | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                    | n                                    | (%)                                  |                                | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      |                                                      | (%)                                                  |
| Nervous system disorders           | 210                                  | (68.4)                               | 203                            | (65.7)                         | 1,075                                                    | (52.9)                                                   | 35                                                       | (28.7)                                                   | 1,995                                                | (32.3)                                               |
| Ataxia                             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 4                                                        | (0.2)                                                    | 1                                                        | (0.8)                                                    | 15                                                   | (0.2)                                                |
| Auditory nerve disorder            |                                      | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Autoimmune neuropathy              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Axonal neuropathy                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Balance disorder                   | 2                                    | (0.7)                                | 1                              | (0.3)                          | 8                                                        | (0.4)                                                    | 1                                                        | (0.8)                                                    | 31                                                   | (0.5)                                                |
| Bell's palsy                       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 6                                                    | (0.1)                                                |
| Brachial plexopathy                | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Brain oedema                       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 7                                                        | (0.3)                                                    | 0                                                        | (0.0)                                                    | 12                                                   | (0.2)                                                |
| Brain stem infarction              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Brown-Sequard syndrome             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Buming sensation                   | 5                                    | (1.6)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 9                                                    | (0.1)                                                |
| Carotid arteriosclerosis           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Carotid artery occlusion           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Carotid artery perforation         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Carotid artery stenosis            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Carotid artery thrombosis          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Carpal tunnel syndrome             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 4                                                        | (0.2)                                                    | 0                                                        | (0.0)                                                    | I1                                                   | (0.2)                                                |
| Cauda equina syndrome              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Central nervous system haemorrhage | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Central nervous system lesion      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Central nervous system necrosis    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Central nervous system vasculitis  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Cerebellar infarction              |                                      | (0.3)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |

|                                         | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-----------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                         | n                                    | (%)                                  | n                              | (%)                            | n                                                        | %)                                                       | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Psychiatric disorders                   | 52                                   | (16.9)                               | 46                             | (14.9)                         | 397                                                      | (19.5)                                                   | 14                                                       | (11.5)                                                   | 1,043                                                | (16.9)                                               |
| Abnormal dreams                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Abulia                                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Adjustment disorder                     | 0                                    | (0.0)                                |                                | (0.3)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Adjustment disorder with depressed mood | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Affect lability                         | 1                                    | (0.3)                                | 1                              | (0.3)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Affective disorder                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    |                                                          | (0.8)                                                    | 3                                                    | (0.0)                                                |
| Aggression                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Agitation                               | 2                                    | (0.7)                                | 0                              | (0.0)                          | 11                                                       | (0.5)                                                    |                                                          | (0.8)                                                    | 35                                                   | (0.6)                                                |
| Anhedonia                               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Anxiety                                 | 15                                   | (4.9)                                | I1                             | (3.6)                          | 89                                                       | (4.4)                                                    | 2                                                        | (1.6)                                                    | 264                                                  | (4.3)                                                |
| Anxiety disorder                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Apathy                                  | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Autoscopy                               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Behaviour disorder                      | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Binge eating                            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Bipolar disorder                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Bradyphrenia                            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Bruxism                                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | I                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Bulimia nervosa                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Claustrophobia                          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Completed suicide                       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Confusional state                       | 1                                    | (0.3)                                | 2                              | (0.6)                          | 25                                                       | (1.2)                                                    |                                                          | (0.8)                                                    | 104                                                  | (1.7)                                                |
| Delirium                                | 2                                    | (0.7)                                |                                | (0.3)                          | 14                                                       | (0.7)                                                    | 0                                                        | (0.0)                                                    | 36                                                   | (0.6)                                                |

<div style=\"page-break-after: always\"></div>

|                                      | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy'   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy'   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                      |                                      | (%)                                  | n                              | (%)                            | n                                                         | (%)                                                       | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Psychiatric disorders                | 52                                   | (16.9)                               | 46                             | (14.9)                         | 397                                                       | (19.5)                                                    | 14                                                       | (11.5)                                                   | 1,043                                                | (16.9)                                               |
| Substance-induced psychotic disorder | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Suicidal ideation                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 7                                                    | (0.1)                                                |
| Suicide attempt                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                         | (0.1)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Tension                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Thermophobia                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Trance                               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Renal and urinary disorders          | 114                                  | (37.1)                               | 115                            | (37.2)                         | 325                                                       | (16.0)                                                    | 25                                                       | (20.5)                                                   | 728                                                  | (11.8)                                               |
| Acute kidney injury                  | 19                                   | (6.2)                                | 14                             | (4.5)                          | 86                                                        | (4.2)                                                     | 4                                                        | (3.3)                                                    | 122                                                  | (2.0)                                                |
| Autoimmune nephritis                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Azotaemia                            | 3                                    | (1.0)                                |                                | (0.3)                          | 2                                                         | (0.1)                                                     | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Bilirubinuria                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Bladder cyst                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bladder discomfort                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bladder diverticulum                 | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Bladder irritation                   | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Bladder neck obstruction             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bladder obstruction                  | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                           | (0.0)                                                     | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Bladder pain                         | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Bladder prolapse                     | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                           | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Bladder spasm                        | 3                                    | (1.0)                                | 6                              | (1.9)                          | I                                                         | (0.0)                                                     |                                                          | (0.8)                                                    | 6                                                    | (0.1)                                                |
| Calculus bladder                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Calculus urinary                     | 0                                    | (0.0)                                |                                | (0.3)                          | 0                                                         | (0.0)                                                     | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |

|                                          | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                          | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      |                                                      | (%)                                                  |
| Reproductive system and breast disorders | 84                                   | (27.4)                               | 98                             | (31.7)                         | 119                                                      | (5.9)                                                    | 22                                                       | (18.0)                                                   | 290                                                  | (4.7)                                                |
| Breast inflammation                      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Breast mass                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 4                                                        | (0.2)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Breast oedema                            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Breast pain                              | 1                                    | (0.3)                                | 0                              | (0.0)                          | 30                                                       | (1.5)                                                    | 1                                                        | (0.8)                                                    | 21                                                   | (0.3)                                                |
| Breast swelling                          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 6                                                    | (0.1)                                                |
| Breast tenderness                        | 0                                    | (0.0)                                | 1                              | (0.3)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Breast ulceration                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Cervical discharge                       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Cervical polyp                           | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Cervix disorder                          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Cervix enlargement                       | 0                                    | (0.0)                                |                                | (0.3)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Cervix oedema                            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Coital bleeding                          | 0                                    | (0.0)                                | 2                              | (0.6)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Dysmenorrhoea                            | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Dyspareunia                              | 0                                    | (0.0)                                |                                | (0.3)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Ejaculation disorder                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Endometrial hyperplasia                  | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Endometrial hypertrophy                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Endometriosis                            | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Erectile dysfunction                     | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 24                                                   | (0.4)                                                |
| Female genital tract fistula             | 11                                   | (3.6)                                | 18                             | (5.8)                          | 0                                                        | (0.0)                                                    | 1                                                        | (0.8)                                                    | 1                                                    | (0.0)                                                |
| Female reproductive tract disorder       | 1                                    | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Galactorrhoea                            | 2                                    | (0.7)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |

Every participant is counted a single time for each applicable row and column.

- A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

d  Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

f  Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

- Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)
- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)
- Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

<div style=\"page-break-after: always\"></div>

Database cutoff date for CRC (KN177: 19FEB2020) Database cutoff date for TNBC (KN355: 11DEC2019) Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E:

27JUN2019)

As requested, exposure adjusted AE tables were reported by period and the incidence of AEs in the first two intervals (0-3 months and 3-6 months) to take into account the time windows for chemotherapy administration. Results showed that the AE profiles of the treatment arms are in alignment with the overall findings and no new safety concerns are raised when the exposure is adjusted for chemotherapy duration. As expected, some AEs related to myelosuppression (such as anemia, leukopenia, neutropenia, and thrombocytopenia) were seen predominantly in the first 6 months as these are associated with the chemotherapy components of the combination treatment.

<div style=\"page-break-after: always\"></div>

Table  66.  Participants  with  Adverse  Events  by  Decreasing  Incidence  by  Bevacizumab  use (Incidence ≥10% in One or More Treatment Groups) (APaT Population)

|                                      | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|--------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                      | n                                                  | (%)                                                | 1n (%)                                               | 1n (%)                                               | 1n                                           | (%)                                          | n                                              | (%)                                            | n                                                     | (%)                                                   |
| Participants in population           | 196                                                |                                                    | 111                                                  |                                                      | 193                                          |                                              | 116                                            |                                                | 6,185                                                 |                                                       |
| withoneormore adverseevents          | 196                                                | (100.0)                                            | 109                                                  | (98.2)                                               | 193                                          | (100.0)                                      | 114                                            | (98.3)                                         | 5,989                                                 | (96.8)                                                |
| with no adverse events               | 0                                                  | (0.0)                                              | 2                                                    | (1.8)                                                | 0                                            | (0.0)                                        | 2                                              | (1.7)                                          | 196                                                   | (3.2)                                                 |
| Alopecia                             | 113                                                | (57.7)                                             | 60                                                   | (54.1)                                               | 121                                          | (62.7)                                       | 58                                             | (50.0)                                         | 98                                                    | (1.6)                                                 |
| Anaemia                              | 108                                                | (55.1)                                             | 80                                                   | (72.1)                                               | 94                                           | (48.7)                                       | 71                                             | (61.2)                                         | 872                                                   | (14.1)                                                |
| Nausea                               | 81                                                 | (41.3)                                             | 41                                                   | (36.9)                                               | 80                                           | (41.5)                                       | 55                                             | (47.4)                                         | 1,282                                                 | (20.7)                                                |
| Diarrhoea                            | 76                                                 | (38.8)                                             | 33                                                   | (29.7)                                               | 66                                           | (34.2)                                       | 26                                             | (22.4)                                         | 1,295                                                 | (20.9)                                                |
| Fatigue                              | 69                                                 | (35.2)                                             | 19                                                   | (17.1)                                               | 56                                           | (29.0)                                       | 28                                             | (24.1)                                         | 1,967                                                 | (31.8)                                                |
| Hypertension                         | 68                                                 | (34.7)                                             | 6                                                    | (5.4)                                                | 65                                           | (33.7)                                       | 6                                              | (5.2)                                          | 318                                                   | (5.1)                                                 |
| Arthralgia                           | 61                                                 | (31.1)                                             | 21                                                   | (18.9)                                               | 54                                           | (28.0)                                       | 26                                             | (22.4)                                         | 1,149                                                 | (18.6)                                                |
| Constipation                         | 61                                                 | (31.1)                                             | 26                                                   | (23.4)                                               | 70                                           | (36.3)                                       | 32                                             | (27.6)                                         | 1,032                                                 | (16.7)                                                |
| Neuropathy peripheral                | 59                                                 | (30.1)                                             | 22                                                   | (19.8)                                               | 54                                           | (28.0)                                       | 25                                             | (21.6)                                         | 123                                                   | (2.0)                                                 |
| Vomiting                             | 59                                                 | (30.1)                                             | 22                                                   | (19.8)                                               | 53                                           | (27.5)                                       | 31                                             | (26.7)                                         | 784                                                   | (12.7)                                                |
| Urinary tract infection              | 52                                                 | (26.5)                                             | 21                                                   | (18.9)                                               | 51                                           | (26.4)                                       | 29                                             | (25.0)                                         | 414                                                   | (6.7)                                                 |
| Peripheral sensory neuropathy        | 46                                                 | (23.5)                                             | 25                                                   | (22.5)                                               | 51                                           | (26.4)                                       | 28                                             | (24.1)                                         | 71                                                    | (1.1)                                                 |
| Hypothyroidism                       | 43                                                 | (21.9)                                             | 13                                                   | (11.7)                                               | 21                                           | (10.9)                                       | 7                                              | (6.0)                                          | 699                                                   | (11.3)                                                |
| Neutropenia                          | 42                                                 | (21.4)                                             | 30                                                   | (27.0)                                               | 38                                           | (19.7)                                       | 22                                             | (19.0)                                         | 62                                                    | (1.0)                                                 |
| Decreased appetite                   | 41                                                 | (20.9)                                             | 20                                                   | (18.0)                                               | 33                                           | (17.1)                                       | 19                                             | (16.4)                                         | 1,181                                                 | (19.1)                                                |
| Asthenia                             | 40                                                 | (20.4)                                             | 23                                                   | (20.7)                                               | 39                                           | (20.2)                                       | 27                                             | (23.3)                                         | 692                                                   | (11.2)                                                |
| Neutrophilcountdecreased             | 39                                                 | (19.9)                                             | 17                                                   | (15.3)                                               | 34                                           | (17.6)                                       | 14                                             | (12.1)                                         | 42                                                    | (0.7)                                                 |
| Proteinuria                          | 39                                                 | (19.9)                                             | 2                                                    | (1.8)                                                | 25                                           | (13.0)                                       | 2                                              | (1.7)                                          | 60                                                    | (1.0)                                                 |
| Abdominal pain                       | 38                                                 | (19.4)                                             | 12                                                   | (10.8)                                               | 37                                           | (19.2)                                       | 16                                             | (13.8)                                         | 527                                                   | (8.5)                                                 |
| Headache                             | 37                                                 | (18.9)                                             | 11                                                   | (9.9)                                                | 44                                           | (22.8)                                       | 13                                             | (11.2)                                         | 747                                                   | (12.1)                                                |
| Rash                                 | 36                                                 | (18.4)                                             | 11                                                   | (9.9)                                                | 29                                           | (15.0)                                       | 6                                              | (5.2)                                          | 936                                                   | (15.1)                                                |
| Myalgia                              | 35                                                 | (17.9)                                             | 22                                                   | (19.8)                                               | 35                                           | (18.1)                                       | 24                                             | (20.7)                                         | 446                                                   | (7.2)                                                 |
| Platelet count decreased             | 35                                                 | (17.9)                                             | 14                                                   | (12.6)                                               | 31                                           | (16.1)                                       | 10                                             | (8.6)                                          | 76                                                    | (1.2)                                                 |
| Pyrexia                              | 35                                                 | (17.9)                                             | 20                                                   | (18.0)                                               | 26                                           | (13.5)                                       | 18                                             | (15.5)                                         | 802                                                   | (13.0)                                                |
| Thrombocytopenia                     | 33                                                 | (16.8)                                             | 28                                                   | (25.2)                                               | 33                                           | (17.1)                                       | 29                                             | (25.0)                                         | 100                                                   | (1.6)                                                 |
| Alanine aminotransferase increased   | 32                                                 | (16.3)                                             | 11                                                   | (9.9)                                                | 22                                           | (11.4)                                       | 6                                              | (5.2)                                          | 429                                                   | (6.9)                                                 |
| Cough                                | 30                                                 | (15.3)                                             | 10                                                   | (9.0)                                                | 23                                           | (11.9)                                       | 8                                              | (6.9)                                          | 1,200                                                 | (19.4)                                                |
| Back pain                            | 27                                                 | (13.8)                                             | 13                                                   | (11.7)                                               | 28                                           | (14.5)                                       | 16                                             | (13.8)                                         | 709                                                   | (11.5)                                                |
| Epistaxis Pruritus                   | 27 27                                              | (13.8) (13.8)                                      | 4 11                                                 | (3.6) (9.9)                                          | 41 17                                        | (21.2) (8.8)                                 | 1 9                                            | (0.9) (7.8)                                    | 86 1,111                                              | (1.4) (18.0)                                          |
| Aspartate aminotransferase increased | 25                                                 | (12.8)                                             | 9                                                    | (8.1)                                                | 20                                           | (10.4)                                       | 2                                              | (1.7)                                          | 422                                                   | (6.8)                                                 |
| Insomnia                             | 25                                                 | (12.8)                                             | 8                                                    | (7.2)                                                | 21                                           | (10.9)                                       | 5                                              | (4.3)                                          | 447                                                   | (7.2)                                                 |
| Pain in extremity                    | 25                                                 | (12.8)                                             | 11                                                   | (9.9)                                                | 17                                           | (8.8)                                        | 8                                              | (6.9)                                          | 421                                                   | (6.8)                                                 |
| Weight decreased                     | 25                                                 | (12.8)                                             | 8                                                    | (7.2)                                                | 23                                           | (11.9)                                       |                                                | (10.3)                                         | 574                                                   | (9.3)                                                 |
|                                      |                                                    |                                                    |                                                      |                                                      |                                              |                                              | 12                                             |                                                |                                                       |                                                       |

<div style=\"page-break-after: always\"></div>

|                                      | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|--------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                      | n                                                  | (%)                                                | n                                                    | (%)                                                  | 1n                                           | (%)                                          | 1n                                             | (%)                                            | 1                                                     | (%)                                                   |
| Whiteblood cell count decreased      | 24                                                 | (12.2)                                             | 13                                                   | (11.7)                                               | 15                                           | (7.8)                                        | 7                                              | (6.0)                                          | 58                                                    | (0.9)                                                 |
| Abdominal pain upper                 | 22                                                 | (11.2)                                             | 8                                                    | (7.2)                                                | 20                                           | (10.4)                                       | 8                                              | (6.9)                                          | 239                                                   | (3.9)                                                 |
| Leukopenia                           | 22                                                 | (11.2)                                             | 18                                                   | (16.2)                                               | 19                                           | (9.8)                                        | 14                                             | (12.1)                                         | 46                                                    | (0.7)                                                 |
| Blood alkaline phosphatase increased | 20                                                 | (10.2)                                             | 7                                                    | (6.3)                                                | 9                                            | (4.7)                                        | 9                                              | (7.8)                                          | 266                                                   | (4.3)                                                 |
| Paraesthesia                         | 20                                                 | (10.2)                                             | 7                                                    | (6.3)                                                | 14                                           | (7.3)                                        | 13                                             | (11.2)                                         | 169                                                   | (2.7)                                                 |
| Vaginal haemorrhage                  | 19                                                 | (9.7)                                              | 11                                                   | (9.9)                                                | 23                                           | (11.9)                                       | 12                                             | (10.3)                                         | 20                                                    | (0.3)                                                 |
| Hypokalaemia                         | 18                                                 | (9.2)                                              | 13                                                   | (11.7)                                               | 16                                           | (8.3)                                        | 14                                             | (12.1)                                         | 288                                                   | (4.7)                                                 |
| Blood creatinine increased           | 17                                                 | (8.7)                                              | 11                                                   | (9.9)                                                | 23                                           | (11.9)                                       | 7                                              | (6.0)                                          | 268                                                   | (4.3)                                                 |
| Dyspnoea                             | 14                                                 | (7.1)                                              | 6                                                    | (5.4)                                                | 22                                           | (11.4)                                       | 8                                              | (6.9)                                          | 1,020                                                 | (16.5)                                                |
| Pelvic pain                          | 14                                                 | (7.1)                                              | 4                                                    | (3.6)                                                | 25                                           | (13.0)                                       | 10                                             | (8.6)                                          | 47                                                    | (0.8)                                                 |
| Vaginal discharge                    | 12                                                 | (6.1)                                              | 4                                                    | (3.6)                                                | 10                                           | (5.2)                                        | 14                                             | (12.1)                                         | 14                                                    | (0.2)                                                 |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Databasecutoff dateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

DatabasecutoffdateforHNSCC(KN012cohortBandB2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055: 22APR2016)

Databasecutoff dateforcHL(KN013cohort3:28SEP2018,KN087:21MAR2019,KN204:16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for CRC (KN177:19FEB2020)

Database cutoff date for Cervical (KN826: 03MAY2021)

Sonrce:[ISS·adam-adsl·adael

<div style=\"page-break-after: always\"></div>

Table  67.  Exposure-Adjusted  Adverse  Event  by  Decreasing  Incidence  (including  Multiple Occurrences of Events) APaT Population

|                                 | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a     |
|---------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-----------------------------------------------------|
|                                 | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab | KN826 Pembrolizumab + Chemotherapy w/oBevacizumab | KN826 Placebo + Chemotherapy w/ Bevacizumab       | KN826 Placebo + Chemotherapy w/oBevacizumab       | Pembrolizumab Monotherapy Reference Safety Datasete |
| Number of subjects exposed      | 196                                               | 111                                               | 193                                               | 116                                               | 6185                                                |
| Total exposureb in person-years | 230.72                                            | 91.39                                             | 191.67                                            | 73.69                                             | 4336.02                                             |
| Total events (rate)             | 4410 (1911.41)                                    | 1850 (2024.19)                                    | 3862 (2014.97)                                    | 1766 (2396.57)                                    | 64173 (1480.00)                                     |
| Anaemia                         | 156 (67.6)                                        | 116 (126.9)                                       | 140 (73.0)                                        | 114 (154.7)                                       | 1078 (24.9)                                         |
| Nausea                          | 156 (67.6)                                        | 100 (109.4)                                       | 163 (85.0)                                        | 121 (164.2)                                       | 1602 (36.9)                                         |
| Diarrhoea                       | 125 (54.2)                                        | 59 (64.6)                                         | 115 (60.0)                                        | 47 (63.8)                                         | 1971 (45.5)                                         |
| Alopecia                        | 113 (49.0)                                        | 60 (65.6)                                         | 122 (63.7)                                        | 58 (78.7)                                         | 102 (2.4)                                           |
| Neutrophil count decreased      | 105 (45.5)                                        | 47 (51.4)                                         | 99 (51.7)                                         | 41 (55.6)                                         | 63 (1.5)                                            |
| Fatigue                         | 102 (44.2)                                        | 45 (49.2)                                         | 89 (46.4)                                         | 56 (76.0)                                         | 2453 (56.6)                                         |
| Hypertension                    | 101 (43.8)                                        | 6 (6.6)                                           | 84 (43.8)                                         | 7 (9.5)                                           | 456 (10.5)                                          |
| Urinary tract infection         | 92 (39.9)                                         | 38 (41.6)                                         | 76 (39.7)                                         | 43 (58.4)                                         | 545 (12.6)                                          |
| Arthralgia                      | 91 (39.4)                                         | 34 (37.2)                                         | 90 (47.0)                                         | 36 (48.9)                                         | 1590 (36.7)                                         |
| Constipation                    | 90 (39.0)                                         | 44 (48.1)                                         | 100 (52.2)                                        | 43 (58.4)                                         | 1210 (27.9)                                         |
| Neutropenia                     | 89 (38.6)                                         | 57 (62.4)                                         | 70 (36.5)                                         | 47 (63.8)                                         | 98 (2.3)                                            |
| Vomiting                        | 87 (37.7)                                         | 40 (43.8)                                         | 94 (49.0)                                         | 47 (63.8)                                         | 1038 (23.9)                                         |
| Asthenia                        | 84 (36.4)                                         | 34 (37.2)                                         | 85 (44.3)                                         | 44 (59.7)                                         | 930 (21.4)                                          |
| Neuropathy peripheral           | 77 (33.4)                                         | 29 (31.7)                                         | 63 (32.9)                                         | 32 (43.4)                                         | 142 (3.3)                                           |
| Platelet count decreased        | 68 (29.5)                                         | 32 (35.0)                                         | 55 (28.7)                                         | 12 (16.3)                                         | 94 (2.2)                                            |
| Whiteblood cell count decreased | 68 (29.5)                                         | 41 (44.9)                                         | 44 (23.0)                                         | 17 (23.1)                                         | 82 (1.9)                                            |

<div style=\"page-break-after: always\"></div>

|                                      | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a     |
|--------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-----------------------------------------------------|
|                                      | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab | KN826 Pembrolizumab + Chemotherapy w/oBevacizumab | KN826 Placebo + Chemotherapy w/ Bevacizumab       | KN826 Placebo + Chemotherapy w/oBevacizumab       | Pembrolizumab Monotherapy Reference Safety Datasete |
| Decreased appetite                   | 65 (28.2)                                         | 28 (30.6)                                         | 49 (25.6)                                         | 25 (33.9)                                         | 1337 (30.8)                                         |
| Myalgia                              | 60 (26.0)                                         | 39 (42.7)                                         | 71 (37.0)                                         | 42 (57.0)                                         | 530 (12.2)                                          |
| Peripheral sensory neuropathy        | 57 (24.7)                                         | 25 (27.4)                                         | 55 (28.7)                                         | 34 (46.1)                                         | 80 (1.8)                                            |
| Proteinuria                          | 55 (23.8)                                         | 3 (3.3)                                           | 31 (16.2)                                         | 3 (4.1)                                           | 72 (1.7)                                            |
| Headache                             | 53 (23.0)                                         | 17 (18.6)                                         | 77 (40.2)                                         | 15 (20.4)                                         | 993 (22.9)                                          |
| Thrombocytopenia                     | 53 (23.0)                                         | 43 (47.0)                                         | 55 (28.7)                                         | 47 (63.8)                                         | 126 (2.9)                                           |
| Rash                                 | 52 (22.5)                                         | 14 (15.3)                                         | 39 (20.3)                                         | 6 (8.1)                                           | 1304 (30.1)                                         |
| Pyrexia                              | 49 (21.2)                                         | 32 (35.0)                                         | 34 (17.7)                                         | 23 (31.2)                                         | 1056 (24.4)                                         |
| Alanine aminotransferase increased   | 47 (20.4)                                         | 14 (15.3)                                         | 29 (15.1)                                         | 7 (9.5)                                           | 520 (12.0)                                          |
| Epistaxis                            | 46 (19.9)                                         | 6 (6.6)                                           | 59 (30.8)                                         | 1 (1.4)                                           | 102 (2.4)                                           |
| Hypothyroidism                       | 46 (19.9)                                         | 14 (15.3)                                         | 25 (13.0)                                         | 7 (9.5)                                           | 772 (17.8)                                          |
| Abdominal pain                       | 45 (19.5)                                         | 17 (18.6)                                         | 49 (25.6)                                         | 24 (32.6)                                         | 646 (14.9)                                          |
| Leukopenia                           | 43 (18.6)                                         | 26 (28.4)                                         | 32 (16.7)                                         | 23 (31.2)                                         | 66 (1.5)                                            |
| Pain in extremity                    | 43 (18.6)                                         | 12 (13.1)                                         | 28 (14.6)                                         | 12 (16.3)                                         | 490 (11.3)                                          |
| Aspartate aminotransferase increased | 41 (17.8)                                         | 13 (14.2)                                         | 27 (14.1)                                         | 2 (2.7)                                           | 513 (11.8)                                          |
| Pruritus                             | 41 (17.8)                                         | 15 (16.4)                                         | 25 (13.0)                                         | 13 (17.6)                                         | 1489 (34.3)                                         |
| Cough                                | 36 (15.6)                                         | 12 (13.1)                                         | 29 (15.1)                                         | 8 (10.9)                                          | 1492 (34.4)                                         |
| Back pain                            | 32 (13.9)                                         | 17 (18.6)                                         | 35 (18.3)                                         | 19 (25.8)                                         | 805 (18.6)                                          |
| Vaginalhaemorrhage                   | 30 (13.0)                                         | 12 (13.1)                                         | 29 (15.1)                                         | 16 (21.7)                                         | 21 (0.5)                                            |
| Abdominal pain upper                 | 29 (12.6)                                         | 15 (16.4)                                         | 28 (14.6)                                         | 10 (13.6)                                         | 263 (6.1)                                           |

|                                      | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a     |
|--------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-----------------------------------------------------|
|                                      | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab | KN826 Pembrolizumab + Chemotherapy w/oBevacizumab | KN826 Placebo + Chemotherapy w/ Bevacizumab       | KN826Placebo + Chemotherapy W/oBevacizumab        | Pembrolizumab Monotherapy Reference Safety Datasete |
| Paraesthesia                         | 28 (12.1)                                         | 9 (9.8)                                           | 14 (7.3)                                          | 21 (28.5)                                         | 184 (4.2)                                           |
| Blood creatinine increased           | 27 (11.7)                                         | 15 (16.4)                                         | 26 (13.6)                                         | 10 (13.6)                                         | 343 (7.9)                                           |
| Hypokalaemia                         | 27 (11.7)                                         | 18 (19.7)                                         | 18 (9.4)                                          | 16 (21.7)                                         | 394 (9.1)                                           |
| Dysphonia                            | 26 (11.3)                                         | 0 (0.0)                                           | 8 (4.2)                                           | 0 (0.0)                                           | 136 (3.1)                                           |
| Insomnia                             | 26 (11.3)                                         | 8 (8.8)                                           | 22 (11.5)                                         | 6 (8.1)                                           | 474 (10.9)                                          |
| Mucosalinflammation                  | 25 (10.8)                                         | 2 (2.2)                                           | 12 (6.3)                                          | 2 (2.7)                                           | 114 (2.6)                                           |
| Weight decreased                     | 25 (10.8)                                         | 8 (8.8)                                           | 23 (12.0)                                         | 13 (17.6)                                         | 623 (14.4)                                          |
| Hypomagnesaemia                      | 23 (10.0)                                         | 13 (14.2)                                         | 16 (8.3)                                          | 14 (19.0)                                         | 200 (4.6)                                           |
| Stomatitis                           | 23 (10.0)                                         | 3 (3.3)                                           | 21 (11.0)                                         | 6 (8.1)                                           | 180 (4.2)                                           |
| Blood alkaline phosphatase increased | 22 (9.5)                                          | 9 (9.8)                                           | 9 (4.7)                                           | 11 (14.9)                                         | 310 (7.1)                                           |
| Rectal haemorrhage                   | 21 (9.1)                                          | 7 (7.7)                                           | 11 (5.7)                                          | 8 (10.9)                                          | 43 (1.0)                                            |
| Bone pain                            | 20 (8.7)                                          | 3 (3.3)                                           | 20 (10.4)                                         | 3 (4.1)                                           | 131 (3.0)                                           |
| Febrile neutropenia                  | 20 (8.7)                                          | 9 (9.8)                                           | 13 (6.8)                                          | 2 (2.7)                                           | 10 (0.2)                                            |
| Oedema peripheral                    | 20 (8.7)                                          | 11 (12.0)                                         | 21 (11.0)                                         | 10 (13.6)                                         | 604 (13.9)                                          |
| Dyspnoea                             | 19 (8.2)                                          | 8 (8.8)                                           | 26 (13.6)                                         | 8 (10.9)                                          | 1185 (27.3)                                         |
| Dysuria                              | 19 (8.2)                                          | 5 (5.5)                                           | 18 (9.4)                                          | 10 (13.6)                                         | 108 (2.5)                                           |
| Dyspepsia                            | 17 (7.4)                                          | 3 (3.3)                                           | 15 (7.8)                                          | 1 (1.4)                                           | 190 (4.4)                                           |
| Gingival bleeding                    | 17 (7.4)                                          | 1 (1.1)                                           | 6 (3.1)                                           | 0 (0.0)                                           | 10 (0.2)                                            |
| Haematuria                           | 17 (7.4)                                          | 8 (8.8)                                           | 12 (6.3)                                          | 8 (10.9)                                          | 200 (4.6)                                           |
| Hyperthyroidism                      | 17 (7.4)                                          | 5 (5.5)                                           | 6 (3.1)                                           | 4 (5.4)                                           | 282 (6.5)                                           |
| Infusion related reaction            | 17 (7.4)                                          | 9 (9.8)                                           | 14 (7.3)                                          | 4 (5.4)                                           | 73 (1.7)                                            |

<div style=\"page-break-after: always\"></div>

|                              | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a     |
|------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-----------------------------------------------------|
|                              | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab | KN826 Pembrolizumab + Chemotherapy w/oBevacizumab | KN826Placebo + Chemotherapy w/ Bevacizumab        | KN826 Placebo + Chemotherapy w/oBevacizumab       | Pembrolizumab Monotherapy Reference Safety Datasete |
| Gastritis                    | 11 (4.8)                                          | 2 (2.2)                                           | 12 (6.3)                                          | 1 (1.4)                                           | 44 (1.0)                                            |
| Sepsis                       | 11 (4.8)                                          | 1 (1.1)                                           | 6 (3.1)                                           | 0 (0.0)                                           | 55 (1.3)                                            |
| Lymphopenia                  | 10 (4.3)                                          | 12 (13.1)                                         | 3 (1.6)                                           | 3 (4.1)                                           | 94 (2.2)                                            |
| Urticaria                    | 10 (4.3)                                          | 0 (0.0)                                           | 4 (2.1)                                           | 1 (1.4)                                           | 64 (1.5)                                            |
| Dysgeusia                    | 9 (3.9)                                           | 8 (8.8)                                           | 19 (9.9)                                          | 5 (6.8)                                           | 133 (3.1)                                           |
| Fall                         | 9 (3.9)                                           | 3 (3.3)                                           | 0 (0.0)                                           | 1 (1.4)                                           | 169 (3.9)                                           |
| Female genital tract fistula | 9 (3.9)                                           | 3 (3.3)                                           | 11 (5.7)                                          | 8 (10.9)                                          | 1 (0.0)                                             |
| Hypoalbuminaemia             | 9 (3.9)                                           | 7 (7.7)                                           | 7 (3.7)                                           | 3 (4.1)                                           | 223 (5.1)                                           |
| Proctalgia                   | 9 (3.9)                                           | 2 (2.2)                                           | 5 (2.6)                                           | 3 (4.1)                                           | 16 (0.4)                                            |
| Pain                         | 8 (3.5)                                           | 0 (0.0)                                           | 3 (1.6)                                           | 2 (2.7)                                           | 197 (4.5)                                           |
| Anal haemorrhage             | 7 (3.0)                                           | 0 (0.0)                                           | 9 (4.7)                                           | 1 (1.4)                                           | 7 (0.2)                                             |
| Colitis                      | 7 (3.0)                                           | 7 (7.7)                                           | 1 (0.5)                                           | 2 (2.7)                                           | 141 (3.3)                                           |
| Cystitis                     | 7 (3.0)                                           | 5 (5.5)                                           | 7 (3.7)                                           | 11 (14.9)                                         | 69 (1.6)                                            |
| Dermatitis                   | 7 (3.0)                                           | 0 (0.0)                                           | 4 (2.1)                                           | 2 (2.7)                                           | 70 (1.6)                                            |
| Haemorrhoids                 | 7 (3.0)                                           | 1 (1.1)                                           | 12 (6.3)                                          | 2 (2.7)                                           | 49 (1.1)                                            |
| Hypoaesthesia                | 7 (3.0)                                           | 7 (7.7)                                           | 0 (0.0)                                           | 2 (2.7)                                           | 100 (2.3)                                           |
| Hypocalcaemia                | 7 (3.0)                                           | 2 (2.2)                                           | 6 (3.1)                                           | 3 (4.1)                                           | 141 (3.3)                                           |
| Malaise                      | 7 (3.0)                                           | 5 (5.5)                                           | 4 (2.1)                                           | 0 (0.0)                                           | 142 (3.3)                                           |
| Palpitations                 | 7 (3.0)                                           | 4 (4.4)                                           | 7 (3.7)                                           | 1 (1.4)                                           | 58 (1.3)                                            |
| Peripheral motor neuropathy  | 7 (3.0)                                           | 5 (5.5)                                           | 1 (0.5)                                           | 4 (5.4)                                           | 9 (0.2)                                             |
| Pneumonia                    | 7 (3.0)                                           | 1 (1.1)                                           | 13 (6.8)                                          | 3 (4.1)                                           | 523 (12.1)                                          |
| Radiation proctitis          | 7 (3.0)                                           | 3 (3.3)                                           | 3 (1.6)                                           | 1 (1.4)                                           | 1 (0.0)                                             |
| Thyroiditis                  | 7 (3.0)                                           | 3 (3.3)                                           | 1 (0.5)                                           | 0 (0.0)                                           | 45 (1.0)                                            |

a  Event rate per 100 person-years of exposure=event count *100/person-years of exposure.

- b  Drug exposure is defined as the time from the first dose date to the earlier of the last dose date + 30 or the database cut-off date. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.
- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for Cervical (KN826: 03MAY2021)

<div style=\"page-break-after: always\"></div>

## Drug-related AEs

## Table 68. Participants with Drug-Related Adverse Events by Decreasing Incidence (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

|                                 | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapy   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|---------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                 | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                       | (%)                                                     | n                                                    | (%)                                                  |
| Participants in population      | 307                                  |                                      | 309                            |                                | 2,033                                                    |                                                          | 122                                                     |                                                         | 6,185                                                |                                                      |
| with one or more adverse events | 298                                  | (97.1)                               | 300                            | (97.1)                         | 1,948                                                    | (95.8)                                                   | 82                                                      | (67.2)                                                  | 4,366                                                | (70.6)                                               |
| with no adverse events          | 9                                    | (2.9)                                | 9                              | (2.9)                          | 85                                                       | (4.2)                                                    | 40                                                      | (32.8)                                                  | 1,819                                                | (29.4)                                               |
| Alopecia                        | 171                                  | (55.7)                               | 172                            | (55.7)                         | 430                                                      | (21.2)                                                   | 1                                                       | (0.8)                                                   | 51                                                   | (0.8)                                                |
| Anaemia                         | 149                                  | (48.5)                               | 132                            | (42.7)                         | 887                                                      | (43.6)                                                   | 3                                                       | (2.5)                                                   | 212                                                  | (3.4)                                                |
| Nausea                          | 104                                  | (33.9)                               | 120                            | (38.8)                         | 914                                                      | (45.0)                                                   | 7                                                       | (5.7)                                                   | 561                                                  | (9.1)                                                |
| Diarrhoea                       | 76                                   | (24.8)                               | 58                             | (18.8)                         | 431                                                      | (21.2)                                                   | 10                                                      | (8.2)                                                   | 681                                                  | (11.0)                                               |
| Neuropathy peripheral           | 75                                   | (24.4)                               | 76                             | (24.6)                         | 180                                                      | (8.9)                                                    | 0                                                       | (0.0)                                                   | 45                                                   | (0.7)                                                |
| Fatigue                         | 70                                   | (22.8)                               | 77                             | (24.9)                         | 639                                                      | (31.4)                                                   | 13                                                      | (10.7)                                                  | 1,216                                                | (19.7)                                               |
| Peripheral sensory neuropathy   | 69                                   | (22.5)                               | 78                             | (25.2)                         | 154                                                      | (7.6)                                                    | 0                                                       | (0.0)                                                   | 32                                                   | (0.5)                                                |
| Neutropenia                     | 68                                   | (22.1)                               | 57                             | (18.4)                         | 641                                                      | (31.5)                                                   |                                                         | (0.8)                                                   | 35                                                   | (0.6)                                                |
| Vomiting                        | 63                                   | (20.5)                               | 66                             | (21.4)                         | 430                                                      | (21.2)                                                   | 7                                                       | (5.7)                                                   | 208                                                  | (3.4)                                                |
| Neutrophil count decreased      | 56                                   | (18.2)                               | 47                             | (15.2)                         | 362                                                      | (17.8)                                                   | 0                                                       | (0.0)                                                   | 30                                                   | (0.5)                                                |
| Thrombocytopenia                | 55                                   | (17.9)                               | 58                             | (18.8)                         | 376                                                      | (18.5)                                                   | 1                                                       | (0.8)                                                   | 49                                                   | (0.8)                                                |
| Hypertension                    | 54                                   | (17.6)                               | 55                             | (17.8)                         | 19                                                       | (0.9)                                                    | 1                                                       | (0.8)                                                   | 32                                                   | (0.5)                                                |
| Arthralgia                      | 53                                   | (17.3)                               | 57                             | (18.4)                         | 141                                                      | (6.9)                                                    | 7                                                       | (5.7)                                                   | 490                                                  | (7.9)                                                |
| Myalgia                         | 53                                   | (17.3)                               | 53                             | (17.2)                         | 107                                                      | (5.3)                                                    | 4                                                       | (3.3)                                                   | 236                                                  | (3.8)                                                |
| Hypothyroidism                  | 52                                   | (16.9)                               | 25                             | (8.1)                          | 220                                                      | (10.8)                                                   | 12                                                      | (9.8)                                                   | 605                                                  | (9.8)                                                |
| Asthenia                        | 51                                   | (16.6)                               | 56                             | (18.1)                         | 273                                                      | (13.4)                                                   | 10                                                      | (8.2)                                                   | 376                                                  | (6.1)                                                |
| Constipation                    | 49                                   | (16.0)                               | 49                             | (15.9)                         | 272                                                      | (13.4)                                                   | 4                                                       | (3.3)                                                   | 160                                                  | (2.6)                                                |
| Platelet count decreased        | 49                                   | (16.0)                               | 40                             | (12.9)                         | 240                                                      | (11.8)                                                   | 1                                                       | (0.8)                                                   | 35                                                   | (0.6)                                                |
| Decreased appetite              | 45                                   | (14.7)                               | 33                             | (10.7)                         | 463                                                      | (22.8)                                                   | 9                                                       | (7.4)                                                   | 479                                                  | (7.7)                                                |
| Leukopenia                      | 38                                   | (12.4)                               | 31                             | (10.0)                         | 220                                                      | (10.8)                                                   | 0                                                       | (0.0)                                                   | 29                                                   | (0.5)                                                |
| Proteinuria                     | 38                                   | (12.4)                               | 22                             | (7.1)                          | 18                                                       | (0.9)                                                    | 4                                                       | (3.3)                                                   | 16                                                   | (0.3)                                                |

|                                      | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                      | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                     | (%)                                                   |
| White blood cell count decreased     | 37                                   | (12.1)                               | 21                             | (6.8)                          | 297                                                      | (14.6)                                                   | 0                                                        | (0.0)                                                    | 29                                                    | (0.5)                                                 |
| Rash                                 | 33                                   | (10.7)                               | 27                             | (8.7)                          | 267                                                      | (13.1)                                                   | 9                                                        | (7.4)                                                    | 702                                                   | (11.4)                                                |
| Alanine aminotransferase increased   | 31                                   | (10.1)                               | 23                             | (7.4)                          | 219                                                      | (10.8)                                                   | 1                                                        | (0.8)                                                    | 254                                                   | (4.1)                                                 |
| Pruritus                             | 29                                   | (9.4)                                | 17                             | (5.5)                          | 202                                                      | (9.9)                                                    | 8                                                        | (6.6)                                                    | 871                                                   | (14.1)                                                |
| Epistaxis                            | 26                                   | (8.5)                                | 36                             | (11.7)                         | 53                                                       | (2.6)                                                    | 1                                                        | (0.8)                                                    | 6                                                     | (0.1)                                                 |
| Paraesthesia                         | 26                                   | (8.5)                                | 24                             | (7.8)                          | 69                                                       | (3.4)                                                    | 0                                                        | (0.0)                                                    | 43                                                    | (0.7)                                                 |
| Aspartate aminotransferase increased | 22                                   | (7.2)                                | 16                             | (5.2)                          | 207                                                      | (10.2)                                                   | 4                                                        | (3.3)                                                    | 244                                                   | (3.9)                                                 |
| Febrile neutropenia                  | 21                                   | (6.8)                                | 13                             | (4.2)                          | 85                                                       | (4.2)                                                    | 0                                                        | (0.0)                                                    | 0                                                     | (0.0)                                                 |
| Mucosal inflammation                 | 20                                   | (6.5)                                | 9                              | (2.9)                          | 207                                                      | (10.2)                                                   | 0                                                        | (0.0)                                                    | 52                                                    | (0.8)                                                 |
| Stomatitis                           | 20                                   | (6.5)                                | 15                             | (4.9)                          | 256                                                      | (12.6)                                                   | 2                                                        | (1.6)                                                    | 80                                                    | (1.3)                                                 |
| Hyperthyroidism                      | 19                                   | (6.2)                                | 7                              | (2.3)                          | 92                                                       | (4.5)                                                    | 9                                                        | (7.4)                                                    | 231                                                   | (3.7)                                                 |
| Pain in extremity                    | 17                                   | (5.5)                                | 11                             | (3.6)                          | 49                                                       | (2.4)                                                    | 2                                                        | (1.6)                                                    | 73                                                    | (1.2)                                                 |
| Rash maculo-papular                  | 17                                   | (5.5)                                | 8                              | (2.6)                          | 73                                                       | (3.6)                                                    | 3                                                        | (2.5)                                                    | 166                                                   | (2.7)                                                 |
| Weight decreased                     | 17                                   | (5.5)                                | 15                             | (4.9)                          | 134                                                      | (6.6)                                                    | 1                                                        | (0.8)                                                    | 143                                                   | (2.3)                                                 |
| Blood creatinine increased           | 16                                   | (5.2)                                | 13                             | (4.2)                          | 174                                                      | (8.6)                                                    | 3                                                        | (2.5)                                                    | 70                                                    | (1.1)                                                 |
| Infusion related reaction            | 16                                   | (5.2)                                | 13                             | (4.2)                          | 24                                                       | (1.2)                                                    | 3                                                        | (2.5)                                                    | 61                                                    | (1.0)                                                 |
| Pyrexia                              | 16                                   | (5.2)                                | 9                              | (2.9)                          | 137                                                      | (6.7)                                                    | I1                                                       | (9.0)                                                    | 287                                                   | (4.6)                                                 |
| Urinary tract infection              | 16                                   | (5.2)                                | 12                             | (3.9)                          | 23                                                       | (1.1)                                                    | 1                                                        | (0.8)                                                    | 14                                                    | (0.2)                                                 |
| Abdominal pain                       | 15                                   | (4.9)                                | 19                             | (6.1)                          | 45                                                       | (2.2)                                                    | 6                                                        | (4.9)                                                    | 123                                                   | (2.0)                                                 |
| Headache                             | 15                                   | (4.9)                                | 19                             | (6.1)                          | 75                                                       | (3.7)                                                    | 4                                                        | (3.3)                                                    | 199                                                   | (3.2)                                                 |

|           | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|-----------|--------------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
|           | n (%)                                | n (%)                          | n (%)                                                    | n (%)                                                    | n (%)                                                 |
| Dysgeusia | 12 (3.9)                             | 19 (6.1)                       | 158 (7.8)                                                | (0.8)                                                    | 63 (1.0)                                              |

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Every participant is counted a single time for each applicable row and column.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

d Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040,KN042,KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015,KN006: 03MAR2015, KN054: 03APR2020)

f Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018,KN021: 19AUG2019, KN189: 20MAY2019,KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017,KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

Source:[ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Table  69.  Participants  With  Drug-Related  Adverse  Events  by  Decreasing  Incidence  by Bevacizumab Use (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

|                                      | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|--------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                      | 11                                                 | (%)                                                | n (%)                                                | n (%)                                                | n (%)                                        | n (%)                                        | 1n (%)                                         | 1n (%)                                         | 11 (%)                                                | 11 (%)                                                |
| Participants in population           | 196                                                |                                                    | 111                                                  |                                                      | 193                                          |                                              | 116                                            |                                                | 6,185                                                 |                                                       |
| with one or more adverse events      | 191                                                | (97.4)                                             | 107                                                  | (96.4)                                               | 190                                          | (98.4)                                       | 110                                            | (94.8)                                         | 4,366                                                 | (70.6)                                                |
| with no adverse events               | 5                                                  | (2.6)                                              | 4                                                    | (3.6)                                                | 3                                            | (1.6)                                        | 6                                              | (5.2)                                          | 1,819                                                 | (29.4)                                                |
| Alopecia                             |                                                    | (56.6)                                             | 60                                                   | (54.1)                                               | 118                                          | (61.1)                                       | 54                                             | (46.6)                                         | 51                                                    | (0.8)                                                 |
| Anaemia                              | 81                                                 | (41.3)                                             | 68                                                   | (61.3)                                               | 74                                           | (38.3)                                       | 58                                             | (50.0)                                         | 212                                                   | (3.4)                                                 |
| Nausea                               | 66                                                 | (33.7)                                             | 38                                                   | (34.2)                                               | 72                                           | (37.3)                                       | 48                                             | (41.4)                                         | 561                                                   | (9.1)                                                 |
| Fatigue                              | 54                                                 | (27.6)                                             | 16                                                   | (14.4)                                               | 50                                           | (25.9)                                       | 27                                             | (23.3)                                         | 1,216                                                 | (19.7)                                                |
| Hypertension                         | 54                                                 | (27.6)                                             | 0                                                    | (0.0)                                                | 54                                           | (28.0)                                       | 1                                              | (0.9)                                          | 32                                                    | (0.5)                                                 |
| Diarrhoea                            | 53                                                 | (27.0)                                             | 23                                                   | (20.7)                                               | 38                                           | (19.7)                                       | 20                                             | (17.2)                                         | 681                                                   | (0:1D)                                                |
| Neuropathy peripheral                | 53                                                 | (27.0)                                             | 22                                                   | (19.8)                                               | 53                                           | (27.5)                                       | 23                                             | (19.8)                                         | 45                                                    | (0.7)                                                 |
| Peripheral sensory neuropathy        | 45                                                 | (23.0)                                             | 24                                                   | (21.6)                                               | 51                                           | (26.4)                                       | 27                                             | (23.3)                                         | 32                                                    | (0.5)                                                 |
| Vomiting                             | 44                                                 | (22.4)                                             | 19                                                   | (17.1)                                               | 43                                           | (22.3)                                       | 23                                             | (19.8)                                         | 208                                                   | (3.4)                                                 |
| Hypothyroidism                       | 41                                                 | (20.9)                                             |                                                      | (9.9)                                                | 19                                           | (9.8)                                        | 6                                              | (5.2)                                          | 605                                                   | (9.8)                                                 |
| Neutropenia                          | 39                                                 | (19.9)                                             | 29                                                   | (26.1)                                               | 36                                           | (18.7)                                       | 21                                             | (18.1)                                         | 35                                                    | (0.6)                                                 |
| Neutrophil count decreased           | 39                                                 | (19.9)                                             | 17                                                   | (15.3)                                               | 33                                           | (17.1)                                       | 14                                             | (12.1)                                         | 30                                                    | (0.5)                                                 |
| Proteinuria                          | 37                                                 | (18.9)                                             | 1                                                    | (0.9)                                                | 22                                           | (11.4)                                       | 0                                              | (0.0)                                          | 16                                                    | (0.3)                                                 |
| Arthralgia                           | 36                                                 | (18.4)                                             | 17                                                   | (15.3)                                               | 35                                           | (18.1)                                       | 77                                             | (19.0)                                         | 490                                                   | (7.9)                                                 |
| Platelet count decreased             | 35                                                 | (17.9)                                             | 14                                                   | (12.6)                                               | 31                                           | (16.1)                                       | 9                                              | (7.8)                                          | 35                                                    | (0.6)                                                 |
| Asthenia                             | 33                                                 | (16.8)                                             | 18                                                   | (16.2)                                               | 34                                           | (17.6)                                       | 22                                             | (19.0)                                         | 376                                                   | (6.1)                                                 |
| Constipation                         | 33                                                 | (16.8)                                             | 16                                                   | (14.4)                                               | 34                                           | (17.6)                                       | 15                                             | (12.9)                                         | 160                                                   | (2.6)                                                 |
| Decreased appetite                   | 32                                                 | (16.3)                                             | 13                                                   | (11.7)                                               | 20                                           | (10.4)                                       | 13                                             | (11.2)                                         | 479                                                   | (7.7)                                                 |
| Myalgia                              | 32                                                 | (16.3)                                             | 21                                                   | (18.9)                                               | 30                                           | (15.5)                                       | 23                                             | (19.8)                                         | 236                                                   | (3.8)                                                 |
| Thrombocytopenia                     | 29                                                 | (14.8)                                             | 26                                                   | (23.4)                                               | 31                                           | (16.1)                                       | 27                                             | (23.3)                                         | 49                                                    | (0.8)                                                 |
| Rash                                 | 26                                                 | (13.3)                                             | 7                                                    | (6.3)                                                | 22                                           | (11.4)                                       | 5                                              | (4.3)                                          | 702                                                   | (11.4)                                                |
| Epistaxis                            | 24                                                 | (12.2)                                             | 2                                                    | (1.8)                                                | 36                                           | (18.7)                                       | 0                                              | (0.0)                                          | 6                                                     | (0.1)                                                 |
| Whiteblood cell count decreased      | 24                                                 | (12.2)                                             | 13                                                   | (11.7)                                               | 14                                           | (7.3)                                        | 7                                              | (6.0)                                          | 29                                                    | (0.5)                                                 |
| Alanine aminotransferase increased   | 21                                                 | (10.7)                                             | 10                                                   | (9.0)                                                | 19                                           | (9.8)                                        | 4                                              | (3.4)                                          | 254                                                   | (4.1)                                                 |
| Leukopenia                           | 21                                                 | (10.7)                                             | 17                                                   | (15.3)                                               | 17                                           | (8.8)                                        | 14                                             | (12.1)                                         | 29                                                    | (0.5)                                                 |
| Paraesthesia Pruritus                | 20 20                                              | (10.2) (10.2)                                      | 6                                                    | (5.4) (8.1)                                          | 12 10                                        | (6.2) (5.2)                                  | 12 7                                           | (10.3) (6.0)                                   | 43 871                                                | (0.7) (14.1)                                          |
|                                      | 18                                                 | (9.2)                                              | 9                                                    |                                                      | 8                                            |                                              | 1                                              | (0.9)                                          | 52                                                    |                                                       |
| Mucosal inflammation                 |                                                    |                                                    | 2                                                    | (1.8)                                                |                                              | (4.1)                                        |                                                |                                                |                                                       | (0.8)                                                 |
| Stomatitis                           | 17                                                 | (8.7)                                              | 3                                                    | (2.7)                                                | 10                                           | (5.2)                                        | 5                                              | (4.3)                                          | 80                                                    | (1.3)                                                 |
| Aspartate aminotransferase increased | 14                                                 | (7.1)                                              | 8                                                    | (7.2)                                                | 15                                           | (7.8)                                        | 1                                              | (0.9)                                          | 244                                                   | (3.9)                                                 |
| Febrile neutropenia                  | 14                                                 | (7.1)                                              | 7                                                    | (6.3)                                                | 11                                           | (5.7)                                        | 乙                                              | (1.7)                                          | 0                                                     | (0.0)                                                 |
| Hyperthyroidism                      | 14                                                 | (7.1)                                              | 5                                                    | (4.5)                                                | 4                                            | (2.1)                                        | 3                                              | (2.6)                                          | 231 73                                                | (3.7)                                                 |
| Pain in extremity                    | 14                                                 | (7.1)                                              | 3                                                    | (2.7)                                                | 8                                            | (4.1)                                        | 3                                              | (2.6)                                          |                                                       | (1.2)                                                 |
| Weight decreased                     | 14                                                 | (7.1)                                              | 3                                                    | (2.7)                                                | 8                                            | (4.1)                                        | 7                                              | (6.0)                                          | 143                                                   | (2.3)                                                 |

<div style=\"page-break-after: always\"></div>

|                                      | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   |   KN826 Placebo + Chemotherapy w/o Bevacizumab | KN826 Placebo + Chemotherapy w/o Bevacizumab   |   Pembrolizumab Monotherapy Reference Safety Datasete | Pembrolizumab Monotherapy Reference Safety Datasete   |
|--------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                      |                                                    | (%)                                                | n                                                    | (%)                                                  | 1n                                           | (%)                                          |                                              1 | (%)                                            |                                                     1 | (%)                                                   |
| Dysphonia                            | 13                                                 | (6.6)                                              | 0                                                    | (0.0)                                                | 4                                            | (2.1)                                        |                                              0 | (0.0)                                          |                                                    17 | (0.3)                                                 |
| Headache                             | 13                                                 | (6.6)                                              | 2                                                    | (1.8)                                                | 17                                           | (8.8)                                        |                                              2 | (1.7)                                          |                                                   199 | (3.2)                                                 |
| Blood creatinine increased           | 12                                                 | (6.1)                                              | 4                                                    | (3.6)                                                | 11                                           | (5.7)                                        |                                              2 | (1.7)                                          |                                                    70 | (1.1)                                                 |
| Pyrexia                              | 12                                                 | (6.1)                                              | 4                                                    | (3.6)                                                | 4                                            | (2.1)                                        |                                              5 | (4.3)                                          |                                                   287 | (4.6)                                                 |
| Urinary tract infection              | 12                                                 | (6.1)                                              | 4                                                    | (3.6)                                                | 9                                            | (4.7)                                        |                                              3 | (2.6)                                          |                                                    14 | (0.2)                                                 |
| Rash maculo-papular                  |                                                    | (5.6)                                              | 6                                                    | (5.4)                                                | 6                                            | (3.1)                                        |                                              2 | (1.7)                                          |                                                   166 | (2.7)                                                 |
| Abdominal pain                       | 10                                                 | (5.1)                                              | 5                                                    | (4.5)                                                | 13                                           | (6.7)                                        |                                              6 | (5.2)                                          |                                                   123 | (2.0)                                                 |
| Blood alkaline phosphatase increased | 10                                                 | (5.1)                                              | 4                                                    | (3.6)                                                | 6                                            | (3.1)                                        |                                              3 | (2.6)                                          |                                                   100 | (1.6)                                                 |
| Bone pain                            | 10                                                 | (5.1)                                              | 1                                                    | (0.9)                                                | 8                                            | (4.1)                                        |                                              2 | (1.7)                                          |                                                    25 | (0.4)                                                 |
| Hypomagnesaemia                      | 9                                                  | (4.6)                                              | 6                                                    | (5.4)                                                | 3                                            | (1.6)                                        |                                              6 | (5.2)                                          |                                                    32 | (0.5)                                                 |
| Infusion related reaction            | 8                                                  | (4.1)                                              | 8                                                    | (7.2)                                                | 9                                            | (4.7)                                        |                                              4 | (3.4)                                          |                                                    61 | (1.0)                                                 |
| Hypersensitivity                     | 7                                                  | (3.6)                                              | 4                                                    | (3.6)                                                | 10                                           | (5.2)                                        |                                              2 | (1.7)                                          |                                                    16 | (0.3)                                                 |
| Hypokalaemia                         | 7                                                  | (3.6)                                              | 6                                                    | (5.4)                                                | 4                                            | (2.1)                                        |                                              3 | (2.6)                                          |                                                    40 | (0.6)                                                 |
| Dysgeusia                            | 6                                                  | (3.1)                                              | 6                                                    | (5.4)                                                | 16                                           | (8.3)                                        |                                              3 | (2.6)                                          |                                                    63 | (1.0)                                                 |
| Vaginal haemorrhage                  | 4                                                  | (2.0)                                              | 0                                                    | (0.0)                                                | 10                                           | (5.2)                                        |                                              0 | (0.0)                                          |                                                     0 | (0.0)                                                 |
| Drug hypersensitivity                | 3                                                  | (1.5)                                              | 6                                                    | (5.4)                                                | 8                                            | (4.1)                                        |                                              3 | (2.6)                                          |                                                     6 | (0.1)                                                 |
| Lymphopenia                          | 3                                                  | (1.5)                                              | 6                                                    | (5.4)                                                | 3                                            | (1.6)                                        |                                              3 | (2.6)                                          |                                                    33 | (0.5)                                                 |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

e Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054,KN055,KN087,KN177,and KN204.

- Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MA Y2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019,KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for Cervical (KN826:03MAY2021)

Source: [ISS: adam-adsl; adae]

## Grade 3-5 AEs

## Table 70. Participants with Grade 3-5 Adverse Events by Decreasing Incidence (Incidence ≥5% in One or More Treatment Groups) (APaT Popu lation)

|                                 | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | PooledSafetyDatasetfor Pembrolizumab + Chemotherapy   | PooledSafetyDatasetfor Pembrolizumab + Chemotherapy   | CervicalSafetyDataset for Pembrolizumab Monotherapyd   | CervicalSafetyDataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|---------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|-------------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                 | n                                    | (%)                                  |                                | (%)                            | n                                                     | (%)                                                   | n                                                      | (%)                                                    | n                                                    | (%)                                                  |
| Participants in population      | 307                                  |                                      | 309                            |                                | 2,033                                                 |                                                       | 122                                                    |                                                        | 6,185                                                |                                                      |
| with one or more adverse events | 251                                  | (81.8)                               | 232                            | (75.1)                         | 1,583                                                 | (77.9)                                                | 65                                                     | (53.3)                                                 | 2,984                                                | (48.2)                                               |
| with no adverse events          | 56                                   | (18.2)                               | 77                             | (24.9)                         | 450                                                   | (22.1)                                                | 57                                                     | (46.7)                                                 | 3,201                                                | (51.8)                                               |
| Anaemia                         | 93                                   | (30.3)                               | 83                             | (26.9)                         | 374                                                   | (18.4)                                                | 17                                                     | (13.9)                                                 | 247                                                  | (4.0)                                                |
| Neutrophil count decreased      | 40                                   | (13.0)                               | 26                             | (8.4)                          | 254                                                   | (12.5)                                                | 0                                                      | (0.0)                                                  | 9                                                    | (0.1)                                                |
| Neutropenia                     | 38                                   | (12.4)                               | 30                             | (9.7)                          | 413                                                   | (20.3)                                                |                                                        | (0.8)                                                  | 19                                                   | (0.3)                                                |
| Hypertension                    | 29                                   | (9.4)                                | 33                             | (10.7)                         | 54                                                    | (2.7)                                                 | 0                                                      | (0.0)                                                  | 113                                                  | (1.8)                                                |
| Urinary tract infection         | 27                                   | (8.8)                                | 25                             | (8.1)                          | 19                                                    | (0.9)                                                 | 5                                                      | (4.1)                                                  | 74                                                   | (1.2)                                                |
| Thrombocytopenia                | 23                                   | (7.5)                                | 14                             | (4.5)                          | 157                                                   | (7.7)                                                 | 0                                                      | (0.0)                                                  | 21                                                   | (0.3)                                                |
| Febrile neutropenia             | 22                                   | (7.2)                                | 14                             | (4.5)                          | 93                                                    | (4.6)                                                 | 0                                                      | (0.0)                                                  | 10                                                   | (0.2)                                                |
| Platelet count decreased        | 21                                   | (6.8)                                | 14                             | (4.5)                          | 71                                                    | (3.5)                                                 | 0                                                      | (0.0)                                                  | 8                                                    | (0.1)                                                |
| Whiteblood cellcount decreased  | 21                                   | (6.8)                                | 13                             | (4.2)                          | 136                                                   | (6.7)                                                 | 0                                                      | (0.0)                                                  | 4                                                    | (0.1)                                                |
| Fatigue                         | I1                                   | (3.6)                                | 14                             | (4.5)                          | 117                                                   | (5.8)                                                 | 3                                                      | (2.5)                                                  | 150                                                  | (2.4)                                                |

<div style=\"page-break-after: always\"></div>

|           | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapyf   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab MonotherapyReference Safety Datasete   |
|-----------|--------------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|
|           | I1 (%)                               | (%)                            | n (%)                                                    | (%)                                                      | n (%)                                                |
| Pneumonia | 2 (0.7)                              | 9 (2.9)                        | 138 (6.8)                                                | 0 (0.0)                                                  | 255 (4.1)                                            |

Source: [ISS: adam-adsl; adae]

<!-- image -->

## Table 71. Participants with Grade 3-5 Drug-related Adverse Events by Decreasing Incidence (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

|                                  | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|----------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                  | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Participants in population       | 307                                  |                                      | 309                            |                                | 2,033                                                    |                                                          | 122                                                      |                                                          | 6,185                                                |                                                      |
| with one or more adverse events  | 210                                  | (68.4)                               | 198                            | (64.1)                         | 1,285                                                    | (63.2)                                                   | 17                                                       | (13.9)                                                   | 975                                                  | (15.8)                                               |
| with no adverse events           | 97                                   | (31.6)                               | 111                            | (35.9)                         | 748                                                      | (36.8)                                                   | 105                                                      | (86.1)                                                   | 5,210                                                | (84.2)                                               |
| Anaemia                          | 76                                   | (24.8)                               | 65                             | (21.0)                         | 307                                                      | (15.1)                                                   |                                                          | (0.8)                                                    | 32                                                   | (0.5)                                                |
| Neutrophil count decreased       | 40                                   | (13.0)                               | 26                             | (8.4)                          | 242                                                      | (11.9)                                                   | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Neutropenia                      | 37                                   | (12.1)                               | 29                             | (9.4)                          | 403                                                      | (19.8)                                                   |                                                          | (0.8)                                                    | 12                                                   | (0.2)                                                |
| Febrile neutropenia              | 21                                   | (6.8)                                | 13                             | (4.2)                          | 85                                                       | (4.2)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Platelet count decreased         | 21                                   | (6.8)                                | 14                             | (4.5)                          | 68                                                       | (3.3)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Thrombocytopenia                 | 21                                   | (6.8)                                | 12                             | (3.9)                          | 143                                                      | (7.0)                                                    | 0                                                        | (0.0)                                                    | 9                                                    | (0.1)                                                |
| White blood cell count decreased | 21                                   | (6.8)                                | 12                             | (3.9)                          | 130                                                      | (6.4)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |

|              | KN826 Pembrolizimab + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|--------------|--------------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
|              | n (%)                                | (%)                            | n (%)                                                    | n (%)                                                    | n (%)                                                 |
| Hypertension | 20 (6.5)                             | 23 (7.4)                       | 10 (0.5)                                                 | 0 (0.0)                                                  | 11 (0.2)                                              |

Every participant is counted a single time for each applicable row and column.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

A specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Grades are based on NCI CTCAE version 4.0.

d Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024,

KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018,KN087:21MAR2019,KN204:16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for Esophageal(KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

Source:[ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Table 72. Participants with Grade 3-5 Adverse Events by Decreasing Incidence by Bevacizumab Use (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

|                                  |   KN826 Pembrolizumab + Chemotherapy w/Bevacizumab | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   |   KN826 Placebo + Chemotherapy w/Bevacizumab | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|----------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                  |                                                 11 | (%)                                                | 11                                                   | (%)                                                  |                                           11 | (%)                                          | n                                              | (%)                                            |                                                      | (%)                                                  |
| Participants in population       |                                                196 |                                                    |                                                      |                                                      |                                          193 |                                              | 116                                            |                                                | 6,185                                                |                                                      |
| with one or more adverse events  |                                                164 | (83.7)                                             | 87                                                   | (78.4)                                               |                                          144 | (74.6)                                       | 88                                             | (75.9)                                         | 2,984                                                | (48.2)                                               |
| with no adverse events           |                                                 32 | (16.3)                                             | 24                                                   | (21.6)                                               |                                           49 | (25.4)                                       | 28                                             | (24.1)                                         | 3,201                                                | (51.8)                                               |
| Anaemia                          |                                                 52 | (26.5)                                             | 41                                                   | (36.9)                                               |                                           37 | (19.2)                                       | 46                                             | (39.7)                                         | 247                                                  | (4.0)                                                |
| Neutrophil count decreased       |                                                 29 | (14.8)                                             | 11                                                   | (9.9)                                                |                                           20 | (10.4)                                       | 6                                              | (5.2)                                          | 9                                                    | (0.1)                                                |
| Hypertension                     |                                                 26 | (13.3)                                             | 3                                                    | (2.7)                                                |                                           29 | (15.0)                                       | 4                                              | (3.4)                                          | 113                                                  | (1.8)                                                |
| Neutropenia                      |                                                 26 | (13.3)                                             | 12                                                   | (10.8)                                               |                                           17 | (8.8)                                        | 13                                             | (11.2)                                         | 19                                                   | (0.3)                                                |
| Urinary tract infection          |                                                 20 | (10.2)                                             | 7                                                    | (6.3)                                                |                                           16 | (8.3)                                        | 9                                              | (7.8)                                          | 74                                                   | (1.2)                                                |
| Platelet count decreased         |                                                 16 | (8.2)                                              | 5                                                    | (4.5)                                                |                                           13 | (6.7)                                        | 1                                              | (0.9)                                          | 8                                                    | (0.1)                                                |
| Febrile neutropenia              |                                                 15 | (7.7)                                              | 7                                                    | (6.3)                                                |                                           12 | (6.2)                                        | 2                                              | (1.7)                                          | 10                                                   | (0.2)                                                |
| Thrombocytopenia                 |                                                 12 | (6.1)                                              |                                                      | (9.9)                                                |                                            6 | (3.1)                                        | 8                                              | (6.9)                                          | 21                                                   | (0.3)                                                |
| White blood cell count decreased |                                                 12 | (6.1)                                              | 9                                                    | (8.1)                                                |                                           10 | (5.2)                                        | 3                                              | (2.6)                                          | 4                                                    | (0.1)                                                |
| Sepsis                           |                                                 10 | (5.1)                                              | 1                                                    | (0.9)                                                |                                            4 | (2.1)                                        | 0                                              | (0.0)                                          | 47                                                   | (0.8)                                                |
| Acute kidney injury              |                                                  7 | (3.6)                                              | 6                                                    | (5.4)                                                |                                            4 | (2.1)                                        | 5                                              | (4.3)                                          | 56                                                   | (0.9)                                                |
| Fatigue                          |                                                  5 | (2.6)                                              | 6                                                    | (5.4)                                                |                                            7 | (3.6)                                        | 7                                              | (6.0)                                          | 150                                                  | (2.4)                                                |

Every participant is counted a single time for each applicable row and column.

- A specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

- MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCI CTCAE version 4.0.

- e Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024,KN040, KN042, KN045, KN048, KN052, KN054,KN055,KN087,KN177,and KN204.
- Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054: 03APR2020)
- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017,KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN177:19FEB2020)

Database cutoff date for Cervical (KN826: 03MAY2021)

Source: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table 73. Participants with Grade 3-5 Drug-related Adverse Events by Decreasing Incidence by Bevacizumab Use (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

|                                  | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   |   KN826 Placebo + Chemotherapy w/Bevacizumab | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|----------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                  |                                                    | (%)                                                | 1                                                    | (%)                                                  |                                           11 | (%)                                          |                                                | (%)                                            | 11                                                    | (%)                                                   |
| Participants in population       | 196                                                |                                                    |                                                      |                                                      |                                          193 |                                              | 116                                            |                                                | 6,185                                                 |                                                       |
| with one or more adverse events  | 143                                                | (73.0)                                             | 67                                                   | (60.4)                                               |                                          126 | (65.3)                                       | 72                                             | (62.1)                                         | 975                                                   | (15.8)                                                |
| with no adverse events           | 53                                                 | (27.0)                                             | 44                                                   | (39.6)                                               |                                           67 | (34.7)                                       | 44                                             | (37.9)                                         | 5,210                                                 | (84.2)                                                |
| Anaemia                          | 40                                                 | (20.4)                                             | 36                                                   | (32.4)                                               |                                           28 | (14.5)                                       | 37                                             | (31.9)                                         | 32                                                    | (0.5)                                                 |
| Neutrophil count decreased       | 29                                                 | (14.8)                                             | 11                                                   | (9.9)                                                |                                           20 | (10.4)                                       | 6                                              | (5.2)                                          | 5                                                     | (0.1)                                                 |
| Neutropenia                      | 25                                                 | (12.8)                                             | 12                                                   | (10.8)                                               |                                           16 | (8.3)                                        | 13                                             | (11.2)                                         | 12                                                    | (0.2)                                                 |
| Hypertension                     | 20                                                 | (10.2)                                             | 0                                                    | (0.0)                                                |                                           22 | (11.4)                                       | 1                                              | (0.9)                                          | 11                                                    | (0.2)                                                 |
| Platelet count decreased         | 16                                                 | (8.2)                                              | 5                                                    | (4.5)                                                |                                           13 | (6.7)                                        | 1                                              | (0.9)                                          | 2                                                     | (0.0)                                                 |
| Febrile neutropenia              | 14                                                 | (7.1)                                              | 7                                                    | (6.3)                                                |                                           11 | (5.7)                                        | 2                                              | (1.7)                                          | 0                                                     | (0.0)                                                 |
| Thrombocytopenia                 | 12                                                 | (6.1)                                              | 9                                                    | (8.1)                                                |                                            5 | (2.6)                                        | 7                                              | (6.0)                                          | 9                                                     | (0.1)                                                 |
| White blood cell count decreased | 12                                                 | (6.1)                                              | 9                                                    | (8.1)                                                |                                            9 | (4.7)                                        | 3                                              | (2.6)                                          | 1                                                     | (0.0)                                                 |
| Fatigue                          | 3                                                  | (1.5)                                              | 5                                                    | (4.5)                                                |                                            7 | (3.6)                                        | 6                                              | (5.2)                                          | 66                                                    | (1.1)                                                 |

Every participant is counted a single time for each applicable row and column.

- A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. Grades are based on NCI CTCAE version 4.0.

- e Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2,KN013 cohort 3,KN024,KN040, KN042, KN045, KN048, KN052, KN054,KN055,KN087,KN177,and KN204.
- Database cutoff date for Melanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054: 03APR2020)
- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)
- Database cutoff date for HNSCC (KN012 cohort B and B2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort3:28SEP2018,KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for Cervical (KN826: 03MAY2021)

Somrce:[ISS·adam-adsl·adae]

## Serious adverse event/deaths/other significant events

## SAEs

Table 74. Participants with Serious Adverse Events by Decreasing Inc idence (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

|                                 | KN826Pembrolizumab + Chemotherapy   | KN826Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled SafetyDataset for Pembrolizumab+ Chemotherapy   | Pooled SafetyDataset for Pembrolizumab+ Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab MonotherapyReference Safety Dataset   | Pembrolizumab MonotherapyReference Safety Dataset   |
|---------------------------------|-------------------------------------|-------------------------------------|--------------------------------|--------------------------------|--------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                 |                                     | (%)                                 |                                | (%)                            | I                                                      | (%)                                                    | I1                                                       | (%)                                                      |                                                     | (%)                                                 |
| Participants in population      | 307                                 |                                     | 309                            |                                | 2,033                                                  |                                                        | 122                                                      |                                                          | 6,185                                               |                                                     |
| with one or more adverse events | 153                                 | (49.8)                              | 131                            | (42.4)                         | 962                                                    | (47.3)                                                 | 52                                                       | (42.6)                                                   | 2.371                                               | (38.3)                                              |
| with no adverse events          | 154                                 | (50.2)                              | 178                            | (57.6)                         | 1,071                                                  | (52.7)                                                 | 70                                                       | (57.4)                                                   | 3,814                                               | (61.7)                                              |
| Febrile neutropenia             | 21                                  | (6.8)                               | 13                             | (4.2)                          | 78                                                     | (3.8)                                                  | 0                                                        | (0.0)                                                    | 7                                                   | (0.1)                                               |
| Urinary tract infection         | 16                                  | (5.2)                               | 18                             | (5.8)                          | 10                                                     | (0.5)                                                  | 4                                                        | (3.3)                                                    | 59                                                  | (1.0)                                               |
| Anaemia                         | 14                                  | (4.6)                               | 12                             | (3.9)                          | 52                                                     | (2.6)                                                  | 7                                                        | (5.7)                                                    | 61                                                  | (1.0)                                               |

<div style=\"page-break-after: always\"></div>

|           | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-----------|--------------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|
|           | (%)                                  | n (%)                          | n (%)                                                    | (%)                                                      | n (%)                                                |
| Pneumonia | (0.3)                                | 7 (2.3)                        | 137 (6.7)                                                | (0.8)                                                    | 257 (4.2)                                            |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\",\"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Includes allparticipants whoreceived at least one dose ofpembrolizumabinKN001Part B1,B2,B3,D,C,F1,F2,F3,KN002(original phase),KN006,KN010,KN012 cohort B and B2,KN013cohort 3,KN024, KN040,KN042,KN045, KN048, KN052, KN054, KN055, KN087,KN177, andKN204.

d Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015,KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016,KN040: 15MAY2017, KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021,KN028 cohort B4: 20FEB2017,KN158 cohort E: 27JUN2019)

Source: [ISS: adam-adsl; adae]

## Table 75. Participants with Serious Adverse Events by Decreasing Incidence by Bevacizumab Use (Incidence ≥5% in One or More Treatment Groups) (APaT Population)

|                                 | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   |   KN826 Placebo + Chemotherapy w/o Bevacizumab | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|---------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                 | 11                                                 | (%)                                                |                                                      | (%)                                                  | 11                                           | (%)                                          |                                             11 | (%)                                            | 11                                                   | (%)                                                  |
| Participants in population      | 196                                                |                                                    | 111                                                  |                                                      | 193                                          |                                              |                                            116 |                                                | 6,185                                                |                                                      |
| with one or more adverse events | 99                                                 | (50.5)                                             | 54                                                   | (48.6)                                               | 87                                           | (45.1)                                       |                                             44 | (37.9)                                         | 2.371                                                | (38.3)                                               |
| with no adverse events          | 97                                                 | (49.5)                                             | 57                                                   | (51.4)                                               | 106                                          | (54.9)                                       |                                             72 | (62.1)                                         | 3.814                                                | (61.7)                                               |
| Febrile neutropenia             | 14                                                 | (7.1)                                              | 7                                                    | (6.3)                                                |                                              | (5.7)                                        |                                              2 | (1.7)                                          | 7                                                    | (0.1)                                                |
| Urinary tract infection         | 12                                                 | (6.1)                                              | 4                                                    | (3.6)                                                | 12                                           | (6.2)                                        |                                              6 | (5.2)                                          | 59                                                   | (1.0)                                                |
| Anaemia                         |                                                    | (5.6)                                              | 3                                                    | (2.7)                                                | 5                                            | (2.6)                                        |                                              7 | (6.0)                                          | 61                                                   | (1.0)                                                |
| Acute kidney injury             | 4                                                  | (2.0)                                              | 6                                                    | (5.4)                                                | 3                                            | (1.6)                                        |                                              2 | (1.7)                                          | 55                                                   | (0.9)                                                |

Every participant is counted a single time for each applicable row and column.

- A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days oflast dose are included. MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

- e Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040,KN042, KN045, KN048, KN052, KN054,KN055,KN087,KN177,and KN204.
- Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054: 03APR2020)
- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)
- Database cutoff date for HNSCC (KN012 cohort B and B2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff dateforBladder (KN045:26OCT2017,KN052:26SEP2018)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for Cervical (KN826: 03MA Y2021)

Source:[ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Deaths

Table  76.  Participants  with  Adverse  Events  Resulting  in  Death  by  Decreasing  Incidence (Incidence ≥0% in One or More Treatment Groups) (APaT Population)

|                                 | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled SafetyDataset for Pembrolizumab + Chemotherapy   | Pooled SafetyDataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|---------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                 | n                                    | (%)                                  | n                              | (%)                            | n                                                       | (%)                                                     | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Participants in population      | 307                                  |                                      | 309                            |                                | 2,033                                                   |                                                         | 122                                                      |                                                          | 6,185                                                |                                                      |
| with one or more adverse events | 14                                   | (4.6)                                | 14                             | (4.5)                          | 139                                                     | (6.8)                                                   | 4                                                        | (3.3)                                                    | 321                                                  | (5.2)                                                |
| with no adverse events          | 293                                  | (95.4)                               | 295                            | (95.5)                         | 1,894                                                   | (93.2)                                                  | 118                                                      | (96.7)                                                   | 5,864                                                | (94.8)                                               |
| Death                           | 2                                    | (0.7)                                | 3                              | (1.0)                          | 15                                                      | (0.7)                                                   | 3                                                        | (2.5)                                                    | 44                                                   | (0.7)                                                |
| Sepsis                          | 2                                    | (0.7)                                | 1                              | (0.3)                          | 6                                                       | (0.3)                                                   | 0                                                        | (0.0)                                                    | 9                                                    | (0.1)                                                |
| Shock haemorrhagic              | 2                                    | (0.7)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Acute myocardial infarction     |                                      | (0.3)                                | 0                              | (0.0)                          | 2                                                       | (0.1)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Cardiac arrest                  |                                      | (0.3)                                | 0                              | (0.0)                          | 9                                                       | (0.4)                                                   | 0                                                        | (0.0)                                                    | 9                                                    | (0.1)                                                |
| Cerebrovascular accident        |                                      | (0.3)                                | 0                              | (0.0)                          |                                                         | (0.0)                                                   | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Encephalitis autoimmune         |                                      | (0.3)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Femur fracture                  |                                      | (0.3)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Intestinal perforation          |                                      | (0.3)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Pelvic infection                |                                      | (0.3)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Uterine haemorrhage             |                                      | (0.3)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Abdominal sepsis                | 0                                    | (0.0)                                | 1                              | (0.3)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Accidental death                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Acute coronary syndrome         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Acute graft versus host disease | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Acute kidney injury             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 4                                                       | (0.2)                                                   | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Acute respiratory failure       | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                         | (0.0)                                                   | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Adenocarcinoma gastric          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Alcohol poisoning               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Anaemia                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

d  Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

f  Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

<div style=\"page-break-after: always\"></div>

Table 77. Participants with Adverse Events Resulting in Death by Decreasing Incidence by Bevacizumab Use (Incidence ≥0% in One or More Treatment Groups) (APaT Population)

|                                              | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|----------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                              | 11                                                 | (%)                                                | 1n (%)                                               | 1n (%)                                               | 11 (%)                                       | 11 (%)                                       | (%)                                            | (%)                                            | 11 (%)                                               | 11 (%)                                               |
| Participants in population                   | 196                                                |                                                    |                                                      |                                                      | 193                                          |                                              | 116                                            |                                                | 6,185                                                |                                                      |
| withoneormoreadverseevents                   | 10                                                 | (5.1)                                              | 4                                                    | (3.6)                                                |                                              | (5.7)                                        | 3                                              | (2.6)                                          | 321                                                  | (5.2)                                                |
| with no adverse events                       | 186                                                | (94.9)                                             | 107                                                  | (96.4)                                               | 182                                          | (94.3)                                       | 113                                            | (97.4)                                         | 5,864                                                | (94.8)                                               |
| Death                                        | 乙                                                  | (1.0)                                              | 0                                                    | (0.0)                                                | 3                                            | (1.6)                                        | 0                                              | (0.0)                                          | 44                                                   | (0.7)                                                |
| Sepsis                                       | 2                                                  | (1.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          | 9                                                    | (0.1)                                                |
| Shock haemorrhagic                           | 2                                                  | (1.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                    | (0.0)                                                |
| Acute myocardial infarction                  | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                    | (0.0)                                                |
| Cardiac arrest                               | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 9                                                    | (0.1)                                                |
| Intestinal perforation                       |                                                    | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                    | (0.0)                                                |
| Pelvic infection                             | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                    | (0.0)                                                |
| Abdominal sepsis                             | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Accidental death                             | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Acute coronary syndrome                      | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Acutegraftversushostdisease                  | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                    | (0.0)                                                |
| Acute kidney injury                          | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 3                                                    | (0.0)                                                |
| Acute respiratory failure                    | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 5                                                    | (0.1)                                                |
| Adenocarcinoma gastric                       | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 一                                                    | (0.0)                                                |
| Alcohol poisoning                            | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Anaemia                                      | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Anaphylactic shock                           | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Arterial injury                              | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Aspiration                                   | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 3                                                    | (0.0)                                                |
| Atypical pneumonia                           | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                    | (0.0)                                                |
| Autoinflammatory disease                     | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Brain oedema                                 | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                    | (0.0)                                                |
| COVID-19 pneumonia                           | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          | 0                                                    | (0.0)                                                |
| Cachexia                                     | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 3                                                    | (0.0)                                                |
| Cardiac complication associated with device  | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                    | (0.0)                                                |
| Cardiac failure                              | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 2                                                    | (0.0)                                                |
| Cardiac failure acute                        | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            |                                              | 0 0                                            | (0.0)                                          | 乙                                                    | (0.0) (0.0)                                          |
| Cardiac failure congestive Cardiac tamponade | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0) (0.0)                                  |                                                | (0.0)                                          | 2                                                    | (0.0)                                                |
| Cardio-respiratory arrest                    | 0 0                                                | (0.0) (0.0)                                        | 0 0                                                  | (0.0) (0.0)                                          | 0 0                                          | (0.0) (0.0)                                  | 0 0                                            | (0.0) (0.0)                                    | 1 4                                                  | (0.1)                                                |
| Cardiopulmonary failure                      | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 一                                                    | (0.0)                                                |
| Cellulitis                                   | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Cerebral haemorrhage                         | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                    | (0.0)                                                |
|                                              | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          |                                                      | (0.0)                                                |
| Cerebral ischaemia                           |                                                    |                                                    |                                                      |                                                      |                                              |                                              |                                                |                                                |                                                      |                                                      |

Every participant is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)

<div style=\"page-break-after: always\"></div>

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for Cervical (KN826: 03MAY2021)

## Adverse Events of Special Interest (AEOSIs)

Table 78. Adverse Event Summary for AEOSI (APaT Population)

|                                                                   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                   | n                                    | (%)                                  | n                              | (%)                            | n                                                       | (%)                                                     | n                                                       | (%)                                                     | n                                                    | (%)                                                  |
| Participants in population                                        | 307                                  |                                      | 309                            |                                | 2,033                                                   |                                                         | 122                                                     |                                                         | 6,185                                                |                                                      |
| with one or more adverse events                                   | 126                                  | (41.0)                               | 82                             | (26.5)                         | 585                                                     | (28.8)                                                  | 29                                                      | (23.8)                                                  | 1,579                                                | (25.5)                                               |
| with no adverse event                                             | 181                                  | (59.0)                               | 227                            | (73.5)                         | 1,448                                                   | (71.2)                                                  | 93                                                      | (76.2)                                                  | 4,606                                                | (74.5)                                               |
| with drug-related adverse events                                  | 115                                  | (37.5)                               | 70                             | (22.7)                         | 514                                                     | (25.3)                                                  | 26                                                      | (21.3)                                                  | 1,368                                                | (22.1)                                               |
| with toxicity grade 3-5 adverse events                            | 41                                   | (13.4)                               | 16                             | (5.2)                          | 169                                                     | (8.3)                                                   | 7                                                       | (5.7)                                                   | 406                                                  | (6.6)                                                |
| with toxicity grade 3-5 drug-related adverse events               | 36                                   | (11.7)                               | 13                             | (4.2)                          | 151                                                     | (7.4)                                                   | 7                                                       | (5.7)                                                   | 351                                                  | (5.7)                                                |
| with serious adverse events                                       | 26                                   | (8.5)                                | 12                             | (3.9)                          | 143                                                     | (7.0)                                                   | 5                                                       | (4.1)                                                   | 406                                                  | (6.6)                                                |
| with serious drug-related adverse events                          | 22                                   | (7.2)                                | 9                              | (2.9)                          | 129                                                     | (6.3)                                                   | 5                                                       | (4.1)                                                   | 359                                                  | (5.8)                                                |
| who died                                                          | 1                                    | (0.3)                                | 0                              | (0.0)                          | 6                                                       | (0.3)                                                   | 0                                                       | (0.0)                                                   | 11                                                   | (0.2)                                                |
| who died due to a drug-related adverse event                      | 1                                    | (0.3)                                | 0                              | (0.0)                          | 6                                                       | (0.3)                                                   | 0                                                       | (0.0)                                                   | 11                                                   | (0.2)                                                |
| discontinued any drug due to an adverse event                     | 27                                   | (8.8)                                | II                             | (3.6)                          | 116                                                     | (5.7)                                                   | 4                                                       | (3.3)                                                   | 256                                                  | (4.1)                                                |
| discontinued pembrolizumab or placebo                             | 17                                   | (5.5)                                | 2                              | (0.6)                          | 98                                                      | (4.8)                                                   | 4                                                       | (3.3)                                                   | 256                                                  | (4.1)                                                |
| discontinued all drugs                                            | 3                                    | (1.0)                                | 0                              | (0.0)                          | 17                                                      | (0.8)                                                   | 4                                                       | (3.3)                                                   | 256                                                  | (4.1)                                                |
| discontinued any drug due to a drug-related adverse event         | 26                                   | (8.5)                                |                                | (3.6)                          | 113                                                     | (5.6)                                                   | 4                                                       | (3.3)                                                   | 252                                                  | (4.1)                                                |
| discontinued pembrolizumab or placebo                             | 16                                   | (5.2)                                | 2                              | (0.6)                          | 95                                                      | (4.7)                                                   | 4                                                       | (3.3)                                                   | 252                                                  | (4.1)                                                |
| discontinued all drugs                                            | 3                                    | (1.0)                                | 0                              | (0.0)                          | 17                                                      | (0.8)                                                   | 4                                                       | (3.3)                                                   | 252                                                  | (4.1)                                                |
| discontinued any drug due to a serious adverse event              | 11                                   | (3.6)                                | 3                              | (1.0)                          | 85                                                      | (4.2)                                                   | 3                                                       | (2.5)                                                   | 172                                                  | (2.8)                                                |
| discontinued pembrolizumab or placebo                             | 11                                   | (3.6)                                | 1                              | (0.3)                          | 78                                                      | (3.8)                                                   | 3                                                       | (2.5)                                                   | 172                                                  | (2.8)                                                |
| discontinued all drugs                                            | 3                                    | (1.0)                                | 0                              | (0.0)                          | 14                                                      | (0.7)                                                   | 3                                                       | (2.5)                                                   | 172                                                  | (2.8)                                                |
| discontinued any drug due to a serious drug-related adverse event | 11                                   | (3.6)                                | 3                              | (1.0)                          | 82                                                      | (4.0)                                                   | 3                                                       | (2.5)                                                   | 170                                                  | (2.7)                                                |
| discontinued pembrolizumab or placebo                             | 11                                   | (3.6)                                |                                | (0.3)                          | 75                                                      | (3.7)                                                   | 3                                                       | (2.5)                                                   | 170                                                  | (2.7)                                                |

|                        | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|------------------------|--------------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
|                        | n (%)                                | n (%)                          | n (%)                                                    | n (%)                                                    | n (%)                                                 |
| discontinued all drugs | 3 (1.0)                              | 0 (0.0)                        | 14 (0.7)                                                 | 3 (2.5)                                                  | 170 (2.7)                                             |

* Determined by the investigator to be related to the drug.

Grades are based on NCICTCAE version 4.0.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

d Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3,KN024, KN040, KN042,KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015,KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016,KN040: 15MAY2017, KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date forTNBC (KN355: 11DEC2019)

Database cutoff date for Cervical(KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

Source: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table 79. Exposure-Adjusted Adverse Event of Special Interest Summary (Including Multiple Occurrences of Events) (APaT Population)

|                                                               | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)        | Event Count and Rate (Events/100 person-years)         | Event Count and Rate (Events/100 person-years)     |
|---------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------|
|                                                               | KN826 Pembrolizumab + Chemotherapy               | KN826 Placebo + Chemotherapy                     | PooledSafety Dataset for Pembrolizumab + Chemotherapy | Cervical Safety Dataset for Pembrolizumab Monotherapyd | Pembrolizumab Monotherapy Reference Safety Dataset |
| Number of subjects exposed                                    | 307                                              | 309                                              | 2033                                                  | 122                                                    | 6185                                               |
| Total exposure in person-years                                | 322.11                                           | 265.35                                           | 1688.88                                               | 66.15                                                  | 4336.02                                            |
| Total events (rate)                                           |                                                  |                                                  |                                                       |                                                        |                                                    |
| adverse events                                                | 223 (69.23)                                      | 108 (40.70)                                      | 852 (50.45)                                           | 41 (61.98)                                             | 2271 (52.38)                                       |
| drug-relatede adverse events                                  | 195 (60.54)                                      | 88 (33.16)                                       | 727 (43.05)                                           | 38 (57.45)                                             | 1951 (45.00)                                       |
| toxicity grade 3-5 adverse events                             | 51 (15.83)                                       | 17 (6.41)                                        | 198 (11.72)                                           | 8 (12.09)                                              | 483 (11.14)                                        |
| toxicity grade 3-5 drug-related adverse events                | 46 (14.28)                                       | 14 (5.28)                                        | 179 (10.60)                                           | 8 (12.09)                                              | 418 (9.64)                                         |
| serious adverse events                                        | 31 (9.62)                                        | 12 (4.52)                                        | 167 (9.89)                                            | 6 (9.07)                                               | 479 (11.05)                                        |
| serious drug-related adverse events                           | 27 (8.38)                                        | 9 (3.39)                                         | 151 (8.94)                                            | 6 (9.07)                                               | 426 (9.82)                                         |
| adverse events leading to death                               | 1 (0.31)                                         | 0 (0.00)                                         | 6 (0.36)                                              | 0 (0.00)                                               | 11 (0.25)                                          |
| drug-related adverse events leading to death                  | 1 (0.31)                                         | 0 (0.00)                                         | 6 (0.36)                                              | 0 (0.00)                                               | 11 (0.25)                                          |
| adverse events resulting in drug discontinuation              | 29 (9.00)                                        | 12 (4.52)                                        | 118 (6.99)                                            | 4 (6.05)                                               | 262 (6.04)                                         |
| drug-related adverse events resulting in drug discontinuation | 27 (8.38)                                        | 12 (4.52)                                        | 115 (6.81)                                            | 4 (6.05)                                               | 258 (5.95)                                         |
| serious adverse events resulting in drug discontinuation      | 12 (3.73)                                        | 3 (1.13)                                         | 85 (5.03)                                             | 3 (4.54)                                               | 177 (4.08)                                         |

|                                                                       | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)        | Event Count and Rate (Events/100 person-years)         | Event Count and Rate (Events/100 person-years)      |
|-----------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|
|                                                                       | KN826 Pembrolizumab + Chemotherapy               | KN826 Placebo + Chemotherapy                     | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy | Cervical Safety Dataset for Pembrolizumab Monotherapyd | Pembrolizumab Monotherapy Reference Safety Datasete |
| serious drug-related adverse events resulting in drug discontinuation | 12 (3.73)                                        | 3 (1.13)                                         | 82 (4.86)                                             | 3 (4.54)                                               | 175 (4.04)                                          |

Event rate per100person-years of exposure=event count *100/person-years of exposure.

Determined by the investigator to be related to the drug.

b Drug exposure is defined as the time from the first dose date to the earlier of the last dose date + 30 or the database cut-off date.

Non-serious adverse events up to 30 days oflast dose and serious adverse events up to 90 days of last dose are included. Grades are based on NCI CTCAE version 4.0.

d Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2,B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3,KN024,KN040,KN042,KN045,KN048,KN052,KN054,KN055,KN087,KN177, and KN204.

f Includes allsubjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:03APR2020)

Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024: 10JUL2017,KN042: 04SEP2018,KN021: 19AUG2019,KN189: 20MAY2019, KN407: 09MAY2019) Databasecutoff dateforHNSCC(KN012cohortBandB2:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoff date for Bladder(KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff dateforTNBC (KN355:11DEC2019)

Database cutoff date for Cervical(KN826:03MAY2021,KN028 cohort B4: 20FEB2017,KN158 cohort E: 27JUN2019)

Source:[ISS: adam-adsl; adae]

## Table 80. Adverse Event Summary for AEOSI by Bevacizumab Use (APaT Population)

|                                                                   | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                   | n                                                   | (%)                                                 |                                                      | (%)                                                  | n                                             | (%)                                           | n                                              | (%)                                            | n                                                    | (%)                                                  |
| Participants in population                                        | 196                                                 |                                                     | 111                                                  |                                                      | 193                                           |                                               | 116                                            |                                                | 6,185                                                |                                                      |
| with one or more adverse events                                   | 85                                                  | (43.4)                                              | 41                                                   | (36.9)                                               | 59                                            | (30.6)                                        | 23                                             | (19.8)                                         | 1,579                                                | (25.5)                                               |
| with no adverse event                                             | 1I1                                                 | (56.6)                                              | 70                                                   | (63.1)                                               | 134                                           | (69.4)                                        | 93                                             | (80.2)                                         | 4,606                                                | (74.5)                                               |
| with drug-related adverse events                                  | 78                                                  | (39.8)                                              | 37                                                   | (33.3)                                               | 50                                            | (25.9)                                        | 20                                             | (17.2)                                         | 1,368                                                | (22.1)                                               |
| with toxicity grade 3-5 adverse events                            | 30                                                  | (15.3)                                              | II                                                   | (9.9)                                                |                                               | (5.7)                                         | 5                                              | (4.3)                                          | 406                                                  | (6.6)                                                |
| with toxicity grade 3-5 drug-related adverse events               | 27                                                  | (13.8)                                              | 9                                                    | (8.1)                                                | 10                                            | (5.2)                                         | 3                                              | (2.6)                                          | 351                                                  | (5.7)                                                |
| with serious adverse events                                       | 19                                                  | (9.7)                                               | 7                                                    | (6.3)                                                | 9                                             | (4.7)                                         | 3                                              | (2.6)                                          | 406                                                  | (6.6)                                                |
| with serious drug-related adverse events                          | 16                                                  | (8.2)                                               | 6                                                    | (5.4)                                                | 7                                             | (3.6)                                         | 2                                              | (1.7)                                          | 359                                                  | (5.8)                                                |
| who died                                                          | 0                                                   | (0.0)                                               |                                                      | (0.9)                                                | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 11                                                   | (0.2)                                                |
| who died due to a drug-related adverse event                      | 0                                                   | (0.0)                                               |                                                      | (0.9)                                                | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 11                                                   | (0.2)                                                |
| discontinued any drug due to an adverse event                     | 20                                                  | (10.2)                                              |                                                      | (6.3)                                                | 9                                             | (4.7)                                         | 2                                              | (1.7)                                          | 256                                                  | (4.1)                                                |
| discontinued pembrolizumab or placebo                             | 12                                                  | (6.1)                                               | 5                                                    | (4.5)                                                |                                               | (0.5)                                         | I                                              | (0.9)                                          | 256                                                  | (4.1)                                                |
| discontinued all drugs                                            | 2                                                   | (1.0)                                               |                                                      | (0.9)                                                | 0                                             | (0.0)                                         |                                                | (0.0)                                          | 256                                                  | (4.1)                                                |
| discontinued any drug due to a drug-related adverse event         | 20                                                  | (10.2)                                              | 6                                                    | (5.4)                                                | 9                                             | (4.7)                                         | 2                                              | (1.7)                                          | 252                                                  | (4.1)                                                |
| discontinued pembrolizumab or placebo                             | 12                                                  | (6.1)                                               | 4                                                    | (3.6)                                                |                                               | (0.5)                                         |                                                | (0.9)                                          | 252                                                  | (4.1)                                                |
| discontinued all drugs                                            | 2                                                   | (1.0)                                               |                                                      | (0.9)                                                | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 252                                                  | (4.1)                                                |
| discontinued any drug due to a serious adverse event              | 9                                                   | (4.6)                                               | 2                                                    | (1.8)                                                | 3                                             | (1.6)                                         | 0                                              | (0.0)                                          | 172                                                  | (2.8)                                                |
| discontinued pembrolizumab or placebo                             | 9                                                   | (4.6)                                               | 2                                                    | (1.8)                                                | 1                                             | (0.5)                                         | 0                                              | (0.0)                                          | 172                                                  | (2.8)                                                |
| discontinued all drugs                                            | 2                                                   | (1.0)                                               |                                                      | (0.9)                                                | 0                                             | (0.0)                                         | 0                                              | (0.0)                                          | 172                                                  | (2.8)                                                |
| discontinued any drug due to a serious drug-related adverse event | 9                                                   | (4.6)                                               | 2                                                    | (1.8)                                                | 3                                             | (1.6)                                         | 0                                              | (0.0)                                          | 170                                                  | (2.7)                                                |
| discontinued pembrolizumab or placebo                             | 9                                                   | (4.6)                                               | 2                                                    | (1.8)                                                |                                               | (0.5)                                         | 0                                              | (0.0)                                          | 170                                                  | (2.7)                                                |

<div style=\"page-break-after: always\"></div>

| KN826 Pembrolizumab + Chemotherapy w/ Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/ Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-----------------------------------------------------|------------------------------------------------------|-----------------------------------------------|------------------------------------------------|------------------------------------------------------|
| n (%) 2 (1.0)                                       | n (%) (0.9)                                          | n (%) 0 (0.0)                                 | (%) 0 (0.0)                                    | n (%) 170 (2.7)                                      |

<!-- image -->

Source:[ISS: adam-adsl; adae]

Table  81.  Exposure-Adjusted  Adverse  Event  of  Special  Interest  by  AEOSI  Category  and Preferred Term (Including Multiple Occurrences of Events) (APaT Population)

|                                        | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)         | Event Count and Rate (Events/100 person-years)         | Event Count and Rate (Events/100 person-years)      |
|----------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|
|                                        | KN826 Pembrolizumab + Chemotherapy               | KN826 Placebo + Chemotherapy                     | Pooled Safety Dataset for Pembrolizumab + Chemotherapy | Cervical Safety Dataset for Pembrolizumab Monotherapyd | Pembrolizumab Monotherapy Reference Safety Datasete |
| Number of subjects exposed             | 307                                              | 309                                              | 2033                                                   | 122                                                    | 6185                                                |
| Total exposureb in person- years       | 322.11                                           | 265.35                                           | 1688.88                                                | 66.15                                                  | 4336.02                                             |
| Total events (rate)                    | 223 (69.23)                                      | 108 (40.70)                                      | 852 (50.45)                                            | 41 (61.98)                                             | 2271 (52.38)                                        |
| AEOSI Category and Preferred Term      | AEOSI Category and Preferred Term                | AEOSI Category and Preferred Term                | AEOSI Category and Preferred Term                      | AEOSI Category and Preferred Term                      | AEOSI Category and Preferred Term                   |
| AdrenalInsufficiency                   | 4 (1.2)                                          | 0 (0.0)                                          | 16 (0.9)                                               | 1 (1.5)                                                | 54 (1.2)                                            |
| Adrenal insufficiency                  | 4 (1.2)                                          | 0 (0.0)                                          | 15 (0.9)                                               | 0 (0.0)                                                | 48 (1.1)                                            |
| Addison's disease                      | 0 (0.0)                                          | 0 (0.0)                                          | 1 (0.1)                                                | 0 (0.0)                                                | 2 (0.0)                                             |
| Adrenocortical insufficiency acute     | 0 (0.0)                                          | 0 (0.0)                                          | 0 (0.0)                                                | 0 (0.0)                                                | 2 (0.0)                                             |
| Primary adrenal insufficiency          | 0 (0.0)                                          | 0 (0.0)                                          | 0 (0.0)                                                | 1 (1.5)                                                | 0 (0.0)                                             |
| Secondary adrenocortical insufficiency | 0 (0.0)                                          | 0 (0.0)                                          | 0 (0.0)                                                | 0 (0.0)                                                | 2 (0.0)                                             |
| Cholangitis Sclerosing                 | 1 (0.3)                                          | 0 (0.0)                                          | 1 (0.1)                                                | 0 (0.0)                                                | 0 (0.0)                                             |
| Immune-mediated cholangitis            | 1 (0.3)                                          | 0 (0.0)                                          | 0 (0.0)                                                | 0 (0.0)                                                | 0 (0.0)                                             |
| Cholangitis sclerosing                 | 0 (0.0)                                          | 0 (0.0)                                          | 1 (0.1)                                                | 0 (0.0)                                                | 0 (0.0)                                             |
| Colitis                                | 21 (6.5)                                         | 5 (1.9)                                          | 60 (3.0)                                               | 4 (6.0)                                                | 170 (3.9)                                           |
| Colitis                                | 14 (4.3)                                         | 3 (1.1)                                          | 49 (2.9)                                               | 4 (6.0)                                                | 140 (3.2)                                           |

<div style=\"page-break-after: always\"></div>

|                               | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)   | Event Count and Rate (Events/100 person-years)          | Event Count and Rate (Events/100 person-years)         | Event Count and Rate (Events/100 person-years)      |
|-------------------------------|--------------------------------------------------|--------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|
|                               | KN826 Pembrolizumab + Chemotherapy               | KN826 Placebo + Chemotherapy                     | Pooled Safety Dataset for Pembrolizumab + Chemotherapy' | Cervical Safety Dataset for Pembrolizumab Monotherapyd | Pembrolizumab Monotherapy Reference Safety Datasete |
| Colitis                       | 21 (6.5)                                         | 5 (1.9)                                          | 60 (3.0)                                                | 4 (6.0)                                                | 170 (3.9)                                           |
| Enterocolitis                 | 5 (1.6)                                          | 1 (0.4)                                          | 7 (0.4)                                                 | 0 (0.0)                                                | 8 (0.2)                                             |
| Immune-mediated enterocolitis | 2 (0.6)                                          | 1 (0.4)                                          | 0 (0.0)                                                 | 0 (0.0)                                                | 11 (0.3)                                            |
| Autoimmune colitis            | 0 (0.0)                                          | 0 (0.0)                                          | 3 (0.2)                                                 | 0 (0.0)                                                | 5 (0.1)                                             |
| Colitis microscopic           | 0 (0.0)                                          | 0 (0.0)                                          | 1 (0.1)                                                 | 0 (0.0)                                                | 6 (0.1)                                             |
| Encephalitis                  | 1 (0.3)                                          | 0 (0.0)                                          | 2 (0.1)                                                 | 0 (0.0)                                                | 4 (0.1)                                             |
| Encephalitis autoimmune       | 1 (0.3)                                          | 0 (0.0)                                          | 0 (0.0)                                                 | 0 (0.0)                                                | 1 (0.0)                                             |
| Encephalitis                  | 0 (0.0)                                          | 0 (0.0)                                          | 2 (0.1)                                                 | 0 (0.0)                                                | 3 (0.1)                                             |
| Guillain-Barre Syndrome       | 0 (0.0)                                          | 0 (0.0)                                          | 2 (0.1)                                                 | 1 (1.5)                                                | 4 (0.1)                                             |
| Axonal neuropathy             | 0 (0.0)                                          | 0 (0.0)                                          | 0 (0.0)                                                 | 0 (0.0)                                                | 1 (0.0)                                             |
| Demyelinating polyneuropathy  | 0 (0.0)                                          | 0 (0.0)                                          | 1 (0.1)                                                 | 0 (0.0)                                                | 1 (0.0)                                             |
| Guillain-Barre syndrome       | 0 (0.0)                                          | 0 (0.0)                                          | 1 (0.1)                                                 | 1 (1.5)                                                | 2 (0.0)                                             |
| Hepatitis                     | 5 (1.0)                                          | 1 (0.4)                                          | 28 (1.7)                                                | 2 (3.0)                                                | 77 (1.8)                                            |
| Immune-mediated hepatitis     | 3 (0.9)                                          | 0 (0.0)                                          | 3 (0.2)                                                 | 0 (0.0)                                                | 2 (0.0)                                             |
| Autoimmune hepatitis          | 1 (0.3)                                          | 0 (0.0)                                          | 13 (0.8)                                                | 0 (0.0)                                                | 31 (0.7)                                            |
| Hepatitis                     | 1 (0.3)                                          | 0 (0.0)                                          | 12 (0.7)                                                | 2 (3.0)                                                | 35 (0.8)                                            |
| Drug-induced liver injury     | 0 (0.0)                                          | 1 (0.4)                                          | 0 (0.0)                                                 | 0 (0.0)                                                | 8 (0.2)                                             |
| Hepatitis acute               | 0 (0.0)                                          | (0:0) 0                                          | 0 (0.0)                                                 | 0 (0.0)                                                | 1 (0.0)                                             |

|                                | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a        | Event Count and Rate (Events/100 person-years)a       | Event Count and Rate (Events/100 person-years)a     |
|--------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------|
|                                | KN826 Pembrolizumab + Chemotherapy                | KN826 Placebo + Chemotherapy                      | Pooled Safety Dataset for Pembrolizumab + Chemotherapy | Cervical Safety Dataset for Pembrolizumab Monotherapy | Pembrolizumab Monotherapy Reference Safety Datasete |
| Hyperthyroidism                | 23 (7.1)                                          | 10 (3.8)                                          | 114 (6.8)                                              | 10 (15.1)                                             | 282 (6.5)                                           |
| Hyperthyroidism                | 22 (6.8)                                          | 10 (3.8)                                          | 113 (6.7)                                              | 10 (15.1)                                             | 282 (6.5)                                           |
| Basedow's disease              | 1 (0.3)                                           | 0 (0.0)                                           | 1 (0.1)                                                | 0 (0.0)                                               | 0 (0.0)                                             |
| Hypophysitis                   | 1 (0.3)                                           | 1 (0.4)                                           | 13 (0.8)                                               | 0 (0.0)                                               | 45 (1.0)                                            |
| Hypophysitis                   | 1 (0.3)                                           | 1 (0.4)                                           | 7 (0.4)                                                | 0 (0.0)                                               | 26 (0.6)                                            |
| Hypopituitarism                | 0 (0.0)                                           | 0 (0.0)                                           | 6 (0.4)                                                | 0 (0.0)                                               | 18 (0.4)                                            |
| Lymphocytic hypophysitis       | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                               | 1 (0.0)                                             |
| Hypothyroidism                 | 62 (19.2)                                         | 32 (12.1)                                         | 292 (17.3)                                             | 12 (18.1)                                             | 774 (17.9)                                          |
| Hypothyroidism                 | 60 (18.6)                                         | 32 (12.1)                                         | 292 (17.3)                                             | 12 (18.1)                                             | 772 (17.8)                                          |
| Immune-mediated hypothyroidism | 2 (0.6)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                               | 0 (0.0)                                             |
| Myxoedema                      | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                               | 1 (0.0)                                             |
| Primary hypothyroidism         | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                               | 1 (0.0)                                             |
| InfusionReactions              | 61 (18.9)                                         | 55 (20.7)                                         | 87 (5.2)                                               | 7 (10.6)                                              | 182 (4.2)                                           |
| Infusion related reaction      | 26 (8.1)                                          | 18 (6.8)                                          | 42 (2.5)                                               | 6(9.1)                                                | 73 (1.7)                                            |
| Hypersensitivity               | 22 (6.8)                                          | 18 (6.8)                                          | 26 (1.5)                                               | 1 (1.5)                                               | 58 (1.3)                                            |
| Drug hypersensitivity          | 9 (2.8)                                           | 18 (6.8)                                          | 13 (0.8)                                               | 0 (0.0)                                               | 21 (0.5)                                            |
| Anaphylactic reaction          | 3 (0.9)                                           | 1 (0.4)                                           | 5 (0.3)                                                | 0 (0.0)                                               | 10 (0.2)                                            |
| Cytokine release syndrome      | 1 (0.3)                                           | 0 (0.0)                                           | 1 (0.1)                                                | 0 (0.0)                                               | 19 (0.4)                                            |
| Anaphylactoid reaction         | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                               | 1 (0.0)                                             |
| MyasthenicSyndrome             | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                               | 5 (0.1)                                             |

<div style=\"page-break-after: always\"></div>

|                              | Event Count and Rate (Events/100 person-years)\"   | Event Count and Rate (Events/100 person-years)\"   | Event Count and Rate (Events/100 person-years)\"        | Event Count and Rate (Events/100 person-years)\"        | Event Count and Rate (Events/100 person-years)\"     |
|------------------------------|---------------------------------------------------|---------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|
|                              | KN826 Pembrolizumab + Chemotherapy                | KN826 Placebo + Chemotherapy                      | Pooled Safety Dataset for Pembrolizumab + Chemotherapy | Cervical Safety Dataset for Pembrolizumab Monotherapyd | Pembrolizumab Monotherapy Reference Safety Datasete |
| MyasthenicSyndrome           | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 5 (0.1)                                             |
| Myasthenia gravis            | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 3 (0.1)                                             |
| Myasthenic syndrome          | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 2 (0.0)                                             |
| Myelitis                     | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 2 (0.0)                                             |
| Myelitis                     | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 1 (0.0)                                             |
| Myelitis transverse          | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 1 (0.0)                                             |
| Myocarditis                  | 1 (0.3)                                           | 0 (0.0)                                           | 3 (0.2)                                                | 0 (0.0)                                                | 8 (0.2)                                             |
| Myocarditis                  | 1 (0.3)                                           | 0 (0.0)                                           | 2 (0.1)                                                | 0 (0.0)                                                | 8 (0.2)                                             |
| Autoimmune myocarditis       | 0 (0.0)                                           | 0 (0.0)                                           | 1 (0.1)                                                | 0 (0.0)                                                | 0 (0.0)                                             |
| Myositis                     | 2 (0.0)                                           | 0 (0.0)                                           | 7 (0.4)                                                | 1 (1.5)                                                | 24 (0.6)                                            |
| Autoimmune myositis          | 1 (0.3)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 0 (0.0)                                             |
| Myositis                     | 1 (0.3)                                           | 0 (0.0)                                           | 2 (0.1)                                                | 1 (1.5)                                                | 15 (0.3)                                            |
| Dermatomyositis              | 0 (0.0)                                           | 0 (0.0)                                           | 1 (0.1)                                                | 0 (0.0)                                                | 0 (0.0)                                             |
| Myopathy                     | 0 (0.0)                                           | 0 (0.0)                                           | 4 (0.2)                                                | 0 (0.0)                                                | 5 (0.1)                                             |
| Necrotising myositis         | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 1 (0.0)                                             |
| Rhabdomyolysis               | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 3 (0.1)                                             |
| Nephritis                    | 1 (0.3)                                           | 0 (0.0)                                           | 18 (1.1)                                               | 0 (0.0)                                                | 26 (0.6)                                            |
| Tubulointerstitial nephritis | 1 (0.3)                                           | 0 (0.0)                                           | 5 (0.3)                                                | 0 (0.0)                                                | 12 (0.3)                                            |
| Acute kidney injury          | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 2 (0.0)                                             |
| Autoimmune nephritis         | 0 (0.0)                                           | 0 (0.0)                                           | 1 (0.1)                                                | 0 (0.0)                                                | 3 (0.1)                                             |
| Glomerulonephritis           | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                | 0 (0.0)                                                | 1 (0.0)                                             |

|                               | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a   | Event Count and Rate (Events/100 person-years)a         | Event Count and Rate (Events/100 person-years)a        | Event Count and Rate (Events/100 person-years)a     |
|-------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|
|                               | KN826 Pembrolizumab + Chemotherapy                | KN826 Placebo + Chemotherapy                      | Pooled Safety Dataset for Pembrolizumab + Chemotherapy' | Cervical Safety Dataset for Pembrolizumab Monotherapyd | Pembrolizumab Monotherapy Reference Safety Datasete |
| Nephritis                     | 1 (0.3)                                           | 0 (0.0)                                           | 18 (1.1)                                                | 0 (0.0)                                                | 26 (0.6)                                            |
| Glomerulonephritis membranous | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                | 1 (0.0)                                             |
| Nephritis                     | 0 (0.0)                                           | 0 (0.0)                                           | 12 (0.7)                                                | 0 (0.0)                                                | 4 (0.1)                                             |
| Nephrotic syndrome            | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                | 1 (0.0)                                             |
| Renal failure                 | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                | 2 (0.0)                                             |
| Pancreatitis                  | 3 (0.9)                                           | 1 (0.4)                                           | 7 (0.4)                                                 | 0 (0.0)                                                | 24 (0.6)                                            |
| Pancreatitis                  | 2 (0.6)                                           | 0 (0.0)                                           | 5 (0.3)                                                 | 0 (0.0)                                                | 19 (0.4)                                            |
| Pancreatitis acute            | 1 (0.3)                                           | 1 (0.4)                                           | 2 (0.1)                                                 | 0 (0.0)                                                | 4 (0.1)                                             |
| Autoimmune pancreatitis       | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                | 1 (0.0)                                             |
| Pneumonitis                   | (6D)9                                             | 1 (0.4)                                           | 116 (6.9)                                               | 0 (0.0)                                                | 344 (7.9)                                           |
| Pneumonitis                   | 5 (1.6)                                           | 1 (0.4)                                           | 106 (6.3)                                               | 0 (0.0)                                                | 310 (7.1)                                           |
| Immune-mediated lung disease  | 1 (0.3)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                | 0 (0.0)                                             |
| Interstitial lung disease     | 0 (0.0)                                           | 0 (0.0)                                           | 9 (0.5)                                                 | 0 (0.0)                                                | 30 (0.7)                                            |
| Organising pneumonia          | 0 (0.0)                                           | 0 (0.0)                                           | 1 (0.1)                                                 | 0 (0.0)                                                | 4 (0.1)                                             |
| Sarcoidosis                   | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                | 12 (0.3)                                            |
| Sarcoidosis                   | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                | 12 (0.3)                                            |
| SevereSkinReactions           | 16 (5.0)                                          | 1 (0.4)                                           | 46 (2.7)                                                | 2 (3.0)                                                | 112 (2.6)                                           |
| Rash maculo-papular           | 7 (2.2)                                           | 0 (0.0)                                           | 15 (0.9)                                                | 1 (1.5)                                                | 17 (0.4)                                            |
| Rash                          | 3 (0.9)                                           | 1 (0.4)                                           | 22 (1.3)                                                | 1 (1.5)                                                | 33 (0.8)                                            |
| Dermatitis bullous            | 2 (0.6)                                           | 0 (0.0)                                           | 2 (0.1)                                                 | 0 (0.0)                                                | 9 (0.2)                                             |
| Pruritus                      | 2 (0.6)                                           | 0 (0.0)                                           | 2 (0.1)                                                 | 0 (0.0)                                                | 12 (0.3)                                            |

a  Event rate per 100 person-years of exposure=event count *100/person-years of exposure.

<div style=\"page-break-after: always\"></div>

- b  Drug exposure is defined as the time from the first dose date to the earlier of the last dose date + 30 or the database cut-off date. Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.
- d  Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.
- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.
- f  Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.
- Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)
- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)
- Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)
- Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)
- Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)
- Database cutoff date for Esophageal (KN590: 02JUL2020)
- Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

- Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

## Laboratory findings

The most frequently reported ( ≥ 50%) laboratory abnormalities were similar in the pembrolizumab + chemotherapy ± bevacizumab group and the placebo + chemotherapy ± bevacizumab group, and the majority were CTCAE Grade 1 to 2 toxicity.

The most frequently reported laboratory abnormalities in the pembrolizumab + chemotherapy ± bevacizumab group were generally similar to the pembrolizumab monotherapy RSD, though the frequency of these abnormalities was higher in the pembrolizumab + chemotherapy ± bevacizumab group. The increased incidence of these abnormalities reflects myelosuppression (decreased white blood cell, red blood cell, and platelet counts) associated with the chemotherapy components of the combination treatment.

No clinically meaningful differences in Grade 3 to 4 laboratory anomalies (incidence ≥ 0%) were observed between the pembrolizumab + chemotherapy ± bevacizumab and placebo + chemotherapy ± bevacizumab groups.

The most frequently reported Grade 3 to 4 laboratory abnormalities in the pembrolizumab + chemotherapy ± bevacizumab group were consistent with myelosuppression (decreased white blood cell, red blood cell, and platelet counts), a known risk of the administered chemotherapy. As such, the frequencies of these abnormalities in the pembrolizumab + chemotherapy ± bevacizumab group were higher compared with the pembrolizumab monotherapy RSD.

In KEYNOTE-826, there was no trend in laboratory abnormalities suggesting any safety concerns for use of bevacizumab with pembrolizumab + chemotherapy. Although some laboratory abnormalities (notably liver function abnormalities and neutropenia) occurred at a higher incidence in participants who received bevacizumab compared with those who did not receive bevacizumab, these abnormalities were generally consistent with the known safety profile of bevacizumab, and showed a similar trend in the pembrolizumab + chemotherapy ± bevacizumab and the placebo + chemotherapy ± bevacizumab groups.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Age

## Table 82 . Adverse Event Summary by age Category (&lt;65, ≥65 Years) (APaT Population)

|                                                            | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapyf   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy ReferenceSafetyDataset   | Pembrolizumab Monotherapy ReferenceSafetyDataset   | Pembrolizumab Monotherapy ReferenceSafetyDataset   | Pembrolizumab Monotherapy ReferenceSafetyDataset   | Pembrolizumab Monotherapy ReferenceSafetyDataset   |
|------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                                            | <65                                  | <65                                  | >65                                  | >65                                  | <65                            | <65                            | >=65                           | >=65                                                     | <65                                                      | <65                                                      | >=65                                                     | >=65                                                    | <65                                                     | <65                                                     | >65 <65                                            | >65 <65                                            |                                                    |                                                    | >=65                                               |
|                                                            | n                                    | (%)                                  | n                                    | (%)                                  | n                              | (%)                            | n                              | (%)                                                      | n                                                        | (%)                                                      | n                                                        | (%)                                                     | n                                                       | (%) n                                                   | (%)                                                | n                                                  | (%)                                                | n                                                  | (%)                                                |
| Participants in population                                 | 259                                  |                                      | 48                                   |                                      | 257                            |                                | 52                             |                                                          | 1,218                                                    |                                                          | 815                                                      |                                                         | 114 111                                                 | 8                                                       |                                                    | 3,587                                              |                                                    | 2,598                                              |                                                    |
| with one or more adverse events                            | 257                                  | (99.2)                               | 48                                   | (100.0                               | 256                            | (99.6)                         | 51                             | (98.1)                                                   | 1,207                                                    | (99.1)                                                   | 808                                                      | (99.1)                                                  | (97.4)                                                  | 8                                                       | (100.0                                             | 3,469                                              | (96.7)                                             | 2,520                                              | (97.0)                                             |
| with no adverse event                                      | 2                                    | (0.8)                                | 0                                    | (0.0)                                | 1                              | (0.4)                          | 1                              | (1.9)                                                    | 11                                                       | (0.9)                                                    | 7                                                        | (0.9)                                                   | 3 (2.6)                                                 | 0                                                       | (0.0)                                              | 118                                                | (3.3)                                              | 78                                                 | (3.0)                                              |
| with drug-relatedf adverse events                          | 250                                  | (96.5)                               | 48                                   | (100.0                               | 249                            | (96.9)                         | 51                             | (98.1)                                                   | 1,165                                                    | (95.6)                                                   | 783                                                      | (96.1)                                                  | 76 (66.7)                                               | 6                                                       | (75.0)                                             | 2,521                                              | (70.3)                                             | 1,845                                              | (71.0)                                             |
| with toxicity grade 3-5 adverse events                     | 209                                  | (80.7)                               | 42                                   | (87.5)                               | 190                            | (73.9)                         | 42                             | (80.8)                                                   | 940                                                      | (77.2)                                                   | 643                                                      | (78.9)                                                  | 64 (56.1)                                               | 1                                                       | (12.5)                                             | 1,596                                              | (44.5)                                             | 1,388                                              | (53.4)                                             |
| with toxicity grade 3-5 drug-related adverse events        | 169                                  | (65.3)                               | 41                                   | (85.4)                               | 165                            | (64.2)                         | 33                             | (63.5)                                                   | 760                                                      | (62.4)                                                   | 525                                                      | (64.4)                                                  | 17 (14.9)                                               | 0                                                       | (0.0)                                              | 495                                                | (13.8)                                             | 480                                                | (18.5)                                             |
| with serious adverse events                                | 127                                  | (49.0)                               | 26                                   | (54.2)                               | 112                            | (43.6)                         | 19                             | (36.5)                                                   | 512                                                      | (42.0)                                                   | 450                                                      | (55.2)                                                  | 51 (44.7) 12                                            | 1 0                                                     | (12.5)                                             | 1,236                                              | (34.5)                                             | 1,135                                              | (43.7)                                             |
| with serious drug-related adverse events                   | 75                                   | (29.0)                               | 18                                   | (37.5)                               | 57                             | (22.2)                         | 14                             | (26.9)                                                   | 289                                                      | (23.7)                                                   | 261                                                      | (32.0)                                                  |                                                         | (10.5)                                                  | (0.0)                                              | 371                                                | (10.3)                                             | 330                                                | (12.7)                                             |
| who died                                                   | 9                                    | (3.5)                                | 5                                    | (10.4)                               | 12                             | (4.7)                          | 2                              | (3.8)                                                    | 58                                                       | (4.8)                                                    | 81                                                       | (9.9)                                                   | 4                                                       | (3.5) 0                                                 | (0.0)                                              | 148                                                | (4.1)                                              | 173                                                | (6.7)                                              |
| who died due to a drug-related adverse event               | 1                                    | (0.4)                                | 1                                    | (2.1)                                | 4                              | (1.0)                          | 0                              | (0.0)                                                    | 17                                                       | (1.4)                                                    | 26                                                       | (3.2)                                                   | 0                                                       | (0.0) 0                                                 | (0.0)                                              | 21                                                 | (0.6)                                              | 18                                                 | (0.7)                                              |
| discontinued any drug due to an adverse event              | 95                                   | (36.7)                               | 20                                   | (41.7)                               | 68                             | (26.5)                         | 14                             | (26.9)                                                   | 275                                                      | (22.6)                                                   | 276                                                      | (33.9)                                                  | 11                                                      | (9.6) 0                                                 | (0.0)                                              | 423                                                | (11.8)                                             | 409                                                | (15.7)                                             |
| discontinued pembrolizumab or placebo                      | 38                                   | (14.7)                               | 8                                    | (16.7)                               | 23                             | (8.9)                          | 2                              | (3.8)                                                    | 162                                                      | (13.3)                                                   | 183                                                      | (22.5)                                                  | 11                                                      | (9.6) 0                                                 | (0.0)                                              | 423                                                | (11.8)                                             | 409                                                | (15.7)                                             |
| discontinued all drugs                                     | 13                                   | (5.0)                                | 5                                    | (10.4)                               | 13                             | (5.1)                          | 2                              | (3.8)                                                    | 58                                                       | (4.8)                                                    | 67                                                       | (8.2)                                                   | 11 (9.6)                                                | 0                                                       | (0.0)                                              | 423                                                | (11.8)                                             | 409                                                | (15.7)                                             |
| discontinued any drug due to a drug- related adverse event | 82                                   | (31.7)                               | 14                                   | (29.2)                               | 57                             | (22.2)                         | 12                             | (23.1)                                                   | 228                                                      | (18.7)                                                   | 206                                                      | (25.3)                                                  | 6 (5.3)                                                 | 0                                                       | (0.0)                                              | 228                                                | (6.4)                                              | 216                                                | (8.3)                                              |
| discontinued pembrolizumab or placebo                      | 27                                   | (10.4)                               | 4                                    | (8.3)                                | 11                             | (4.3)                          | 1                              | (1.9)                                                    | 116                                                      | (9.5)                                                    | 118                                                      | (14.5)                                                  | 6 (5.3)                                                 | 0                                                       | (0.0)                                              | 228                                                | (6.4)                                              | 216                                                | (8.3)                                              |
| discontinued all drugs                                     | 6                                    | (2.3)                                | 4                                    | (8.3)                                | 5                              | (1.9)                          | 1                              | (1.9)                                                    | 39                                                       | (3.2)                                                    | 37                                                       | (4.5)                                                   | 6 (5.3)                                                 | 0                                                       | (0.0)                                              | 228                                                | (6.4)                                              |                                                    | (8.3)                                              |
| discontinued any drug due to a serious                     |                                      |                                      | 8                                    |                                      | 27                             | (10.5)                         | 5                              | (9.6)                                                    |                                                          |                                                          | 173                                                      |                                                         | 9                                                       |                                                         | (0.0)                                              | 301                                                |                                                    | 216                                                |                                                    |
| adverse event                                              | 43                                   | (16.0)                               |                                      | (16.7)                               |                                |                                |                                |                                                          | 154                                                      | (12.6)                                                   |                                                          | (21.2)                                                  | (7.9)                                                   |                                                         | 0                                                  |                                                    | (8.4)                                              | 297                                                | (11.4)                                             |

|                                                                   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                   | <65                                  | <65                                  | >=65                                 | <65                            | <65                            | >=65                           | <65                                                      | <65                                                      | >=65                                                     | >=65                                                     | <65                                                      | <65                                                      | >=65                                                     | >=65                                                 | <65                                                  | <65                                                  | >=65                                                 |
|                                                                   | n                                    | (%)                                  | n (%)                                | n                              | (%)                            | n (%)                          | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n (%)                                                    | n                                                    | (%)                                                  | n                                                    | (%)                                                  |
| discontinued pembrolizumab or placebo                             | 27                                   | (10.4)                               | 6 (12.5)                             | 14                             | (5.4)                          | 2 (3.8)                        | 120                                                      | (9.9)                                                    | 148                                                      | (18.2)                                                   | 9                                                        | (7.9)                                                    | 0 (0.0)                                                  | 301                                                  | (8.4)                                                | 297                                                  | (11.4)                                               |
| discontinued all drugs                                            | 13                                   | (5.0)                                | 4 (8.3)                              | 9                              | (3.5)                          | 2 (3.8)                        | 50                                                       | (4.1)                                                    | 60                                                       | (7.4)                                                    | 9                                                        | (7.9)                                                    | 0 (0.0)                                                  | 301                                                  | (8.4)                                                | 297                                                  | (11.4)                                               |
| discontinued any drug due to a serious drug-related adverse event | 33                                   | (12.7)                               | 6 (12.5)                             | 19                             | (7.4)                          | 4 (7.7)                        | 112                                                      | (9.2)                                                    | 108                                                      | (13.3)                                                   | 4                                                        | (3.5)                                                    | 0 (0.0)                                                  | 135                                                  | (3.8)                                                | 130                                                  | (5.0)                                                |
| discontinued pembrolizumab or placebo                             | 18                                   | (6.9)                                | 4 (8.3)                              | 7                              | (2.7)                          | 1 (1.9)                        | 79                                                       | (6.5)                                                    | 88                                                       | (10.8)                                                   | 4                                                        | (3.5)                                                    | 0 (0.0)                                                  | 135                                                  | (3.8)                                                | 130                                                  | (5.0)                                                |

|                        | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo+Chemotherapy   | KN826 Placebo+Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy ReferenceSafety Dataset   | Pembrolizumab Monotherapy ReferenceSafety Dataset   | Pembrolizumab Monotherapy ReferenceSafety Dataset   |
|------------------------|--------------------------------------|--------------------------------------|------------------------------|------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                        | <65                                  | >65                                  | <65                          | >=65                         |                                                          | <65                                                      | >=65                                                     | <65                                                     | >=65                                                    | <65                                                 | >=65                                                |                                                     |
|                        | n (%)                                | n (%)                                | n                            | (%) n                        | (%) n                                                    | (%)                                                      | n (%)                                                    | n (%)                                                   |                                                         | n (%)                                               | (%) n                                               | (%)                                                 |
| discontinued all drugs | 6 (2.3)                              | 4 (8.3)                              | 3                            | (1.2) 1                      | (1.9) 31                                                 | (2.5)                                                    | 32 (3.9)                                                 | 4                                                       | (3.5)                                                   | 0 (0.0)                                             | n 135 (3.8) 130                                     | (5.0)                                               |

* Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\",\"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCICTCAE version 4.0.

dIncludes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2,B3, D, C,F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3,KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014,KN002: 28FEB2015,KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016,KN040: 15MAY2017,KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177: 19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

Source:[ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table 83. Adverse Event summary by age Category (&gt;65, 65-74, 7584, ≥85 Y ears) (APaT Population)

|                                                                    | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826Placebo +Chemotherapy   | KN826Placebo +Chemotherapy   | KN826Placebo +Chemotherapy   | KN826Placebo +Chemotherapy   | KN826Placebo +Chemotherapy   | KN826Placebo +Chemotherapy   | KN826Placebo +Chemotherapy   | KN826Placebo +Chemotherapy   |
|--------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                    | <65                                  | <65                                  | 65-74                                | 65-74                                | 75-84                                | 75-84                                | >=85                                 | >=85                                 | <65                          | <65                          | 65-74                        | 65-74                        | 75-84                        | 75-84                        | >=85                         | >=85                         |
|                                                                    | n                                    | (%)                                  | n                                    | (%)                                  | n                                    | (%)                                  | n                                    | (%)                                  | n                            | (%)                          | n                            | (%)                          | n                            | (%)                          | n                            | (%)                          |
| Participants in population                                         | 259                                  |                                      | 38                                   |                                      | 10                                   |                                      | 0                                    |                                      | 257                          |                              | 42                           |                              | 10                           |                              | 0                            |                              |
| with one or more adverse events                                    | 257                                  | (99.2)                               | 38                                   | (100.0)                              | 10                                   | (100.0)                              | 0                                    | (0.0)                                | 256                          | (99.6)                       | 41                           | (97.6)                       | 10                           | (100.0)                      | 0                            | (0.0)                        |
| with no adverse event                                              | 2                                    | (0.8)                                | 0                                    | (0.0)                                | 0                                    | (0.0)                                | 0                                    | (0.0)                                | 1                            | (0.4)                        | 1                            | (2.4)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| with drug-related adverse events                                   | 250                                  | (96.5)                               | 38                                   | (100.0)                              | 10                                   | (100.0)                              | 0                                    | (0.0)                                | 249                          | (96.9)                       | 41                           | (97.6)                       | 10                           | (100.0)                      | 0                            | (0.0)                        |
| with toxicity grade 3-5 adverse events                             | 209                                  | (80.7)                               | 34                                   | (89.5)                               | 8                                    | (80.0)                               | 0                                    | (0.0)                                | 190                          | (73.9)                       | 34                           | (81.0)                       | 8                            | (80.0)                       | 0                            | (0.0)                        |
| with toxicity grade 3-5 drug-related adverse events                | 169                                  | (65.3)                               | 33                                   | (86.8)                               | 8                                    | (80.0)                               | 0                                    | (0.0)                                | 165                          | (64.2)                       | 25                           | (59.5)                       | 8                            | (80.0)                       | 0                            | (0.0)                        |
| with serious adverse events                                        | 127                                  | (49.0)                               | 21                                   | (55.3)                               | 5                                    | (50.0)                               | 0                                    | (0.0)                                | 112                          | (43.6)                       | 17                           | (40.5)                       | 2                            | (20.0)                       | 0                            | (0.0)                        |
| with serious drug-related adverse events                           | 75                                   | (29.0)                               | 13                                   | (34.2)                               | 5                                    | (50.0)                               | 0                                    | (0.0)                                | 57                           | (22.2)                       | 12                           | (28.6)                       | 2                            | (20.0)                       | 0                            | (0.0)                        |
| who died                                                           | 9                                    | (3.5)                                | 3                                    | (7.9)                                | 2                                    | (20.0)                               | 0                                    | (0.0)                                | 12                           | (4.7)                        | 2                            | (4.8)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| who died due to a drug-related adverse event                       | 1                                    | (0.4)                                | 1                                    | (2.6)                                | 0                                    | (0.0)                                | 0                                    | (0.0)                                | 4                            | (1.6)                        | 0                            | (0.0)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| discontinued any drug due to an adverse event                      | 95                                   | (36.7)                               | 16                                   | (42.1)                               | 4                                    | (40.0)                               | 0                                    | (0.0)                                | 68                           | (26.5)                       | 12                           | (28.6)                       | 2                            | (20.0)                       | 0                            | (0.0)                        |
| discontinued pembrolizumab or placebo                              | 38                                   | (14.7)                               | 6                                    | (15.8)                               | 2                                    | (20.0)                               | 0                                    | (0.0)                                | 23                           | (8.9)                        | 2                            | (4.8)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| discontinued all drugs                                             | 13                                   | (5.0)                                | 4                                    | (10.5)                               | I                                    | (10.0)                               | 0                                    | (0.0)                                | 13                           | (5.1)                        | 2                            | (4.8)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| discontinued any drug due to a drug-related adverse event          | 82                                   | (31.7)                               | 12                                   | (31.6)                               | 2                                    | (20.0)                               | 0                                    | (0.0)                                | 57                           | (22.2)                       | 10                           | (23.8)                       | 2                            | (20.0)                       | 0                            | (0.0)                        |
| discontinued pembrolizumab or placebo                              | 27                                   | (10.4)                               | 4                                    | (10.5)                               | 0                                    | (0.0)                                | 0                                    | (0.0)                                | 11                           | (4.3)                        | 1                            | (2.4)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| discontinued all drugs                                             | 6                                    | (2.3)                                | 4                                    | (10.5)                               | 0                                    | (0.0)                                | 0                                    | (0.0)                                | 5                            | (1.9)                        | 1                            | (2.4)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| discontinued any drug due to a serious adverse event               | 43                                   | (16.6)                               | 6                                    | (15.8)                               | 2                                    | (20.0)                               | 0                                    | (0.0)                                | 27                           | (10.5)                       | 5                            | (11.9)                       | 0                            | (0.0)                        | 0                            | (0.0)                        |
| discontinued pembrolizumab or placebo                              | 27                                   | (10.4)                               | 5                                    | (13.2)                               |                                      | (10.0)                               | 0                                    | (0.0)                                | 14                           | (5.4)                        | 2                            | (4.8)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| discontinued all drugs                                             | 13                                   | (5.0)                                | 4                                    | (10.5)                               | 0                                    | (0.0)                                | 0                                    | (0.0)                                | 9                            | (3.5)                        | 2                            | (4.8)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| discontinued any drug due to a serious drug- related adverse event | 33                                   | (12.7)                               | 5                                    | (13.2)                               |                                      | (10.0)                               | 0                                    | (0.0)                                | 19                           | (7.4)                        | 4                            | (9.5)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |
| discontinued pembrolizumab or placebo                              | 18                                   | (6.9)                                | 4                                    | (10.5)                               | 0                                    | (0.0)                                | 0                                    | (0.0)                                | 7                            | (2.7)                        |                              | (2.4)                        | 0                            | (0.0)                        | 0                            | (0.0)                        |

|                                                                    | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   |
|--------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                                    | <65                                                      | <65                                                      | 65-74                                                    | 65-74                                                    | 75-84                                                    | 75-84                                                    | >=85                                                     | >=85                                                     | <65                                                      | <65                                                      | 65-74                                                    | 65-74                                                    | 75-84                                                    | >=85                                                     |
|                                                                    | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n (%)                                                    |                                                          | (%)                                                      | n (%)                                                    |
| Participants in population                                         | 1,218                                                    |                                                          | 653                                                      |                                                          | 157                                                      |                                                          | 5                                                        |                                                          | 114                                                      |                                                          | 7                                                        |                                                          | 1                                                        | 0                                                        |
| with one or more adverse events                                    | 1,207                                                    | (99.1)                                                   | 647                                                      | (99.1)                                                   | 156                                                      | (99.4)                                                   | 5                                                        | (100.0)                                                  | 111                                                      | (97.4)                                                   | 7 (100.0)                                                | 1                                                        | (100.0)                                                  | 0 (0.0)                                                  |
| with no adverse event                                              | 11                                                       | (0.9)                                                    | 6                                                        | (0.9)                                                    | 1                                                        | (0.6)                                                    | 0                                                        | (0.0)                                                    | 3                                                        | (2.6)                                                    | 0 (0.0)                                                  |                                                          | 0 (0.0)                                                  | 0 (0.0)                                                  |
| with drug-related adverse events                                   | 1,165                                                    | (95.6)                                                   | 629                                                      | (96.3)                                                   | 150                                                      | (95.5)                                                   | 4                                                        | (80.0)                                                   | 76                                                       | (66.7)                                                   | 5 (71.4)                                                 |                                                          | 1 (100.0)                                                | 0 (0.0)                                                  |
| with toxicity grade 3-5 adverse events                             | 940                                                      | (77.2)                                                   | 506                                                      | (77.5)                                                   | 132                                                      | (84.1)                                                   | 5                                                        | (100.0)                                                  | t9                                                       | (56.1)                                                   | 1                                                        | (14.3)                                                   | 0 (0.0)                                                  | 0 (0.0)                                                  |
| with toxicity grade 3-5 drug-related adverse events                | 760                                                      | (62.4)                                                   | 422                                                      | (64.6)                                                   | 99                                                       | (63.1)                                                   | 4                                                        | (80.0)                                                   | 17                                                       | (14.9)                                                   | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  | 0 (0.0)                                                  |
| with serious adverse events                                        | 512                                                      | (42.0)                                                   | 353                                                      | (54.1)                                                   | 93                                                       | (59.2)                                                   | 4                                                        | (80.0)                                                   | 51                                                       | (44.7)                                                   |                                                          | (14.3)                                                   | 0 (0.0)                                                  | 0 (0.0)                                                  |
| with serious drug-related adverse events                           | 289                                                      | (23.7)                                                   | 205                                                      | (31.4)                                                   | 53                                                       | (33.8)                                                   | 3                                                        | (60.0)                                                   | 12                                                       | (10.5)                                                   | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  | 0 (0.0)                                                  |
| who died                                                           | 58                                                       | (4.8)                                                    | 49                                                       | (7.5)                                                    | 28                                                       | (17.8)                                                   | 4                                                        | (80.0)                                                   | 4                                                        | (3.5)                                                    | 0 (0.0)                                                  |                                                          | 0 (0.0)                                                  | 0 (0.0)                                                  |
| who died due to a drug-related adverse event                       | 17                                                       | (1.4)                                                    | 15                                                       | (2.3)                                                    | 8                                                        | (5.1)                                                    | 3                                                        | (60.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  | 0 (0.0)                                                  |
| discontinued any drug due to an adverse event                      | 275                                                      | (22.6)                                                   | 209                                                      | (32.0)                                                   | 63                                                       | (40.1)                                                   | 4                                                        | (80.0)                                                   | 11                                                       | (9.6)                                                    | 0 (0.0)                                                  |                                                          | 0 (0.0)                                                  | 0 (0.0)                                                  |
| discontinued pembrolizumab or placebo                              | 162                                                      | (13.3)                                                   | 131                                                      | (20.1)                                                   | 48                                                       | (30.6)                                                   | 4                                                        | (80.0)                                                   | I1                                                       | (9.6)                                                    | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  | 0 (0.0)                                                  |
| discontinued all drugs                                             | 58                                                       | (4.8)                                                    | 42                                                       | (6.4)                                                    | 21                                                       | (13.4)                                                   | 4                                                        | (80.0)                                                   | I1                                                       | (9.6)                                                    | 0 (0.0)                                                  | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  |
| discontinued any drug due to a drug-related adverse event          | 228                                                      | (18.7)                                                   | 161                                                      | (24.7)                                                   | 42                                                       | (26.8)                                                   | 3                                                        | (60.0)                                                   | 6                                                        | (5.3)                                                    | 0 (0.0)                                                  | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  |
| discontinued pembrolizumab or placebo                              | 116                                                      | (9.5)                                                    | 88                                                       | (13.5)                                                   | 27                                                       | (17.2)                                                   | 3                                                        | (60.0)                                                   | 6                                                        | (5.3)                                                    | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  |
| discontinued all drugs                                             | 39                                                       | (3.2)                                                    | 24                                                       | (3.7)                                                    | 10                                                       | (6.4)                                                    | 3                                                        | (60.0)                                                   | 6                                                        | (5.3)                                                    | 0 0                                                      | (0.0) 0                                                  | (0.0)                                                    | 0 (0.0)                                                  |
| discontinued any drug due to a serious adverse event               | 154                                                      | (12.6)                                                   | 122                                                      | (18.7)                                                   | 47                                                       | (29.9)                                                   | 4                                                        | (80.0)                                                   | 9                                                        | (7.9)                                                    | 0 (0.0)                                                  | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  |
| discontinued pembrolizumab or placebo                              | 120                                                      | (9.9)                                                    | 101                                                      | (15.5)                                                   | 43                                                       | (27.4)                                                   | 4                                                        | (80.0)                                                   | 9                                                        | (7.9)                                                    | 0 (0.0)                                                  | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  |
| discontinued all drugs                                             | 50                                                       | (4.1)                                                    | 37                                                       | (5.7)                                                    | 19                                                       | (12.1)                                                   | 4                                                        | (80.0)                                                   | 9                                                        | (7.9)                                                    | 0 (0.0)                                                  |                                                          | 0 (0.0)                                                  | 0 (0.0)                                                  |
| discontinued any drug due to a serious drug- related adverse event | 112                                                      | (9.2)                                                    | 78                                                       | (11.9)                                                   | 27                                                       | (17.2)                                                   | 3                                                        | (60.0)                                                   | 4                                                        | (3.5)                                                    | 0 (0.0)                                                  | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  |
| discontinued pembrolizumab or placebo                              | 79                                                       | (6.5)                                                    | 62                                                       | (9.5)                                                    | 23                                                       | (14.6)                                                   | 3                                                        | (60.0)                                                   | 4                                                        | (3.5)                                                    | 0 (0.0)                                                  | 0                                                        | (0.0)                                                    | 0 (0.0)                                                  |

|                                                                   | PembrolizumabMonotherapyReferenceSafetyDataser   | PembrolizumabMonotherapyReferenceSafetyDataser   | PembrolizumabMonotherapyReferenceSafetyDataser   | PembrolizumabMonotherapyReferenceSafetyDataser   | PembrolizumabMonotherapyReferenceSafetyDataser   | PembrolizumabMonotherapyReferenceSafetyDataser   | PembrolizumabMonotherapyReferenceSafetyDataser   | PembrolizumabMonotherapyReferenceSafetyDataser   |
|-------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                                                                   | <65                                              | <65                                              | 65-74                                            | 65-74                                            | 75-84                                            | 75-84                                            | >=85                                             | >=85                                             |
|                                                                   | n                                                | (%)                                              | n                                                | (%)                                              | n                                                | (%)                                              | n                                                | (%)                                              |
| Participants in population                                        | 3,587                                            |                                                  | 1,797                                            |                                                  | 69                                               |                                                  | 107                                              |                                                  |
| with one or more adverse events                                   | 3,469                                            | (96.7)                                           | 1,737                                            | (96.7)                                           | 677                                              | (97.6)                                           | 106                                              | (99.1)                                           |
| with no adverse event                                             | 118                                              | (3.3)                                            | 60                                               | (3.3)                                            | 17                                               | (2.4)                                            | 1                                                | (0.9)                                            |
| with drug-related adverse events                                  | 2,521                                            | (70.3)                                           | 1,272                                            | (70.8)                                           | 491                                              | (70.7)                                           | 82                                               | (76.0)                                           |
| with toxicity grade 3-5 adverse events                            | 1,596                                            | (44.5)                                           | 928                                              | (51.6)                                           | 392                                              | (56.5)                                           | 68                                               | (63.0)                                           |
| with toxicity grade 3-5 drug-related adverse events               | 495                                              | (13.8)                                           | 321                                              | (17.9)                                           | 135                                              | (19.5)                                           | 24                                               | (22.4)                                           |
| with serious adverse events                                       | 1,236                                            | (34.5)                                           | 749                                              | (41.7)                                           | 329                                              | (47.4)                                           | 57                                               | (53.3)                                           |
| with serious drug-related adverse events                          | 371                                              | (10.3)                                           | 223                                              | (12.4)                                           | 06                                               | (13.0)                                           | 17                                               | (15.9)                                           |
| who died                                                          | 148                                              | (4.1)                                            | 106                                              | (5.9)                                            | 55                                               | (7.9)                                            | 12                                               | (11.2)                                           |
| who died due to a drug-related adverse event                      | 21                                               | (0.6)                                            | 12                                               | (0.7)                                            | 5                                                | (0.7)                                            |                                                  | (0.9)                                            |
| discontinued any drug due to an adverse event                     | 423                                              | (11.8)                                           | 255                                              | (14.2)                                           | 138                                              | (661)                                            | 16                                               | (15.0)                                           |
| discontinued pembrolizumab or placebo                             | 423                                              | (11.8)                                           | 255                                              | (14.2)                                           | 138                                              | (661)                                            | 16                                               | (15.0)                                           |
| discontinued all drugs                                            | 423                                              | (11.8)                                           | 255                                              | (14.2)                                           | 138                                              | (661)                                            | 16                                               | (15.0)                                           |
| discontinued any drug due to a drug-related adverse event         | 228                                              | (6.4)                                            | 142                                              | (7.9)                                            | 67                                               | (9.7)                                            | 7                                                | (6.5)                                            |
| discontinued pembrolizumab or placebo                             | 228                                              | (6.4)                                            | 142                                              | (7.9)                                            | 67                                               | (9.7)                                            | 7                                                | (6.5)                                            |
| discontinued all drugs                                            | 228                                              | (6.4)                                            | 142                                              | (7.9)                                            | 67                                               | (9.7)                                            | 7                                                | (6.5)                                            |
| discontinued any drug due to a serious adverse event              | 301                                              | (8.4)                                            | 181                                              | (10.1)                                           | 103                                              | (14.8)                                           | 13                                               | (12.1)                                           |
| discontinued pembrolizumab or placebo                             | 301                                              | (8.4)                                            | 181                                              | (10.1)                                           | 103                                              | (14.8)                                           | 13                                               | (12.1)                                           |
| discontinued all drugs                                            | 301                                              | (8.4)                                            | 181                                              | (10.1)                                           | 103                                              | (14.8)                                           | 13                                               | (12.1)                                           |
| discontinued any drug due to a serious drug-related adverse event | 135                                              | (3.8)                                            | 86                                               | (4.8)                                            | 40                                               | (5.8)                                            | 4                                                | (3.7)                                            |
| discontinued pembrolizumab or placebo                             | 135                                              | (3.8)                                            | 86                                               | (4.8)                                            | 40                                               | (5.8)                                            | 4                                                | (3.7)                                            |

|                        | KN826 Pembrolizumab+Chemotherapy   | KN826 Pembrolizumab+Chemotherapy   | KN826 Pembrolizumab+Chemotherapy   | KN826 Pembrolizumab+Chemotherapy   | KN826 Pembrolizumab+Chemotherapy   | KN826Placebo+Chemotherapy   | KN826Placebo+Chemotherapy   | KN826Placebo+Chemotherapy   | KN826Placebo+Chemotherapy   | KN826Placebo+Chemotherapy   | KN826Placebo+Chemotherapy   |
|------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                        | <65                                | 65-74                              |                                    | 75-84                              | >=85                               |                             | <65                         | 65-74                       | 75-84                       | >=85                        |                             |
|                        | n (%)                              | n                                  | (%)                                | n (%)                              | n (%)                              | n                           | (%)                         | n (%)                       | (%)                         | n (%)                       |                             |
| discontinued all drugs | 6 (2.3)                            | 4                                  | (10.5)                             | 0 (0.0)                            | 0 (0.0)                            | 3                           | (1.2)                       | (2.4)                       | (0.0)                       | 0 (0.0)                     |                             |

<div style=\"page-break-after: always\"></div>

|                        | Pooled Safety Dataset forPembrolizumab + Chemotherapy   | Pooled Safety Dataset forPembrolizumab + Chemotherapy   | Pooled Safety Dataset forPembrolizumab + Chemotherapy   | Pooled Safety Dataset forPembrolizumab + Chemotherapy   | Pooled Safety Dataset forPembrolizumab + Chemotherapy   | Pooled Safety Dataset forPembrolizumab + Chemotherapy   | Cervical SafetyDataset forPembrolizumabMonotherapyd   | Cervical SafetyDataset forPembrolizumabMonotherapyd   | Cervical SafetyDataset forPembrolizumabMonotherapyd   | Cervical SafetyDataset forPembrolizumabMonotherapyd   | Cervical SafetyDataset forPembrolizumabMonotherapyd   | Cervical SafetyDataset forPembrolizumabMonotherapyd   |
|------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                        | <65                                                     |                                                         | 65-74                                                   | 75-84                                                   |                                                         | >=85                                                    |                                                       | <65                                                   | 65-74                                                 |                                                       | 75-84                                                 | >=85                                                  |
|                        | n                                                       | (%)                                                     | n (%)                                                   | n                                                       | (%)                                                     | n (%)                                                   | n                                                     | (%)                                                   | n (%)                                                 | n                                                     | (%)                                                   | n (%)                                                 |
| discontinued all drugs | 31                                                      | (2.5)                                                   | 20 (3.1)                                                | 9                                                       | (5.7)                                                   | 3 (60.0)                                                | 4                                                     | (3.5)                                                 | 0 (0.0)                                               | 0                                                     | (0.0)                                                 | 0 (0.0)                                               |

|                        | PembrolizumabMonotherapyReferenceSafetyDataset   | PembrolizumabMonotherapyReferenceSafetyDataset   | PembrolizumabMonotherapyReferenceSafetyDataset   | PembrolizumabMonotherapyReferenceSafetyDataset   |
|------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                        | <65                                              | 65-74                                            | 75-84                                            | >=85                                             |
|                        | n (%)                                            | n (%)                                            | n (%)                                            | n (%)                                            |
| discontinued all drugs | 135 (3.8)                                        | 86 (4.8)                                         | 40 (5.8)                                         | 4 (3.7)                                          |

Source: [ISS: adam-adsl; adae]

<!-- image -->

## Table 84. Adverse Event Summary by age Category by Bevacizumab Use (&lt;65, ≥65 Years) (APaT Population)

|                                                                                            | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo+ Chemotherapy w/Bevacizumab   | KN826 Placebo+ Chemotherapy w/Bevacizumab   | KN826 Placebo+ Chemotherapy w/Bevacizumab   | KN826 Placebo+ Chemotherapy w/Bevacizumab   | KN826Placebo + Chemotherapy w/oBevacizumab   | KN826Placebo + Chemotherapy w/oBevacizumab   | KN826Placebo + Chemotherapy w/oBevacizumab   | KN826Placebo + Chemotherapy w/oBevacizumab   | Pembrolizumab Monotherapy Reference Safety Dataset°   | Pembrolizumab Monotherapy Reference Safety Dataset°   | Pembrolizumab Monotherapy Reference Safety Dataset°   | Pembrolizumab Monotherapy Reference Safety Dataset°   |
|--------------------------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                                                            | <65                                                | <65                                                | >65                                                | >65                                                | <65                                                  | <65                                                  | >=65                                                 | >=65                                        | <65                                         | <65                                         | >=65                                        | >=65                                         | <65                                          | <65                                          | >65                                          | >65                                                   | <65                                                   | <65                                                   | >=65                                                  |
|                                                                                            | n (%)                                              | n (%)                                              | n (%)                                              | n (%)                                              | n (%)                                                | n (%)                                                | n (%)                                                | n (%)                                       | n (%)                                       | n (%)                                       | n (%)                                       | n (%)                                        | n                                            | n                                            | (%) n (%)                                    | n                                                     | (%) n                                                 | (%) n                                                 | (%)                                                   |
| Participants in population with one or more adverse events                                 | 170 170                                            | (100.0                                             | 26 26                                              | (100.0                                             | 89 87                                                | (97.8)                                               | 22 22                                                | (100.0                                      | 165 165                                     | (100.0 ）                                    | 28 28                                       | (100.0 ）                                     | 92 91                                        | 24 (98.9) 23                                 | (95.8)                                       | 3,587 3,469                                           | (96.7)                                                | 2,598 2,520                                           | (97.0)                                                |
| with no adverse event with drug-related adverse events                                     | 0 165                                              | (0.0) (97.1)                                       | 0 26                                               | (0.0) (100.0                                       | 2 85                                                 | (2.2) (95.5)                                         | 0 22                                                 | (0.0) (100.0                                | 0 162                                       | (0.0) (98.2)                                | 0 28                                        | (0.0) (100.0                                 | 1 (1.1) 87 (94.6)                            | 1 23                                         | (4.2) (95.8)                                 | 118 2,521                                             | (3.3) (70.3)                                          | 78 1,845                                              | (3.0) (71.0)                                          |
| with toxicity grade 3-5 adverse events with toxicity grade 3-5 drug-related adverse events | 140 119                                            | (82.4)                                             | 24 24                                              | (92.3) (92.3)                                      | 69                                                   | (77.5)                                               | 18 17                                                | (81.8)                                      | 120                                         | (72.7)                                      | 24 20                                       | ） (85.7) (71.4)                              | (76.1) (64.1)                                | 18 13                                        | (75.0)                                       | 1,596                                                 | (44.5) (13.8)                                         | 1,388 480                                             | (53.4) (18.5)                                         |
|                                                                                            |                                                    | (70.0)                                             |                                                    |                                                    | 50                                                   | (56.2)                                               |                                                      | (77.3)                                      | 106                                         | (64.2)                                      |                                             |                                              | 70 59                                        |                                              | (54.2)                                       | 495                                                   |                                                       |                                                       |                                                       |
| with serious adverse events with serious drug-related adverse events                       | 85 56                                              | (50.0) (32.9)                                      | 14 9                                               | (53.8) (34.6)                                      | 42 19                                                | (47.2) (21.3)                                        | 12 9                                                 | (54.5) (40.9)                               | 74 38                                       | (44.8) (23.0)                               | 13 10                                       | (46.4) (35.7)                                | 38 (41.3) 19 (20.7)                          | 6 4                                          | (25.0) (16.7)                                | 1,236 371                                             | (34.5) (10.3)                                         | 1,135 330                                             | (43.7) (12.7)                                         |
| who died                                                                                   | 7                                                  | (4.1)                                              | 3                                                  | (11.5)                                             | 2                                                    | (2.2)                                                | 2 1                                                  | (9.1)                                       | 10                                          | (6.1)                                       | 1                                           | (3.6)                                        | 2 (2.2)                                      | 1 0                                          | (4.2) (0.0)                                  | 148                                                   | (4.1)                                                 | 173                                                   | (6.7)                                                 |
| who died due to a drug-related adverse event                                               | 1                                                  | (0.6)                                              | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                                      | (4.5)                                       | 3                                           | (1.8)                                       | 0                                           | (0.0)                                        | (1.1)                                        |                                              |                                              | 21                                                    | (0.6)                                                 | 18                                                    | (0.7)                                                 |
|                                                                                            | 75                                                 | (44.1)                                             | 13                                                 | (50.0)                                             | 20                                                   | (22.5)                                               | 7                                                    | (31.8)                                      | 50                                          | (30.3)                                      |                                             | (39.3)                                       | 18 (19.6)                                    | 3                                            | (12.5)                                       | 423                                                   | (11.8)                                                | 409                                                   |                                                       |
| discontinued any drug due to an adverse event                                              | 30                                                 | (17.6)                                             |                                                    | (19.2)                                             | 8                                                    |                                                      | 3                                                    | (13.6)                                      | 12                                          |                                             | 11                                          |                                              | 11 (12.0)                                    | 2                                            | (8.3)                                        | 423                                                   |                                                       | 409                                                   | (15.7) (15.7)                                         |
| discontinued pembrolizumab or placebo discontinued all drugs                               | 10                                                 |                                                    | 5                                                  | (15.4)                                             |                                                      | (9.0)                                                |                                                      |                                             | 7                                           | (7.3)                                       | 0                                           | (0.0)                                        | 6                                            |                                              | (8.3)                                        | 423                                                   | (11.8)                                                | 409                                                   | (15.7)                                                |
| discontinued any drug due to a drug- related adverse event                                 |                                                    | (5.9)                                              | 4                                                  |                                                    | 3                                                    | (3.4)                                                | 1                                                    | (4.5)                                       |                                             | (4.2)                                       | 0                                           | (0.0)                                        | (6.5) 12                                     | 2                                            |                                              |                                                       | (11.8)                                                |                                                       |                                                       |
|                                                                                            | 65                                                 | (38.2)                                             | 9                                                  | (34.6)                                             | 17                                                   | (19.1)                                               | 5                                                    | (22.7)                                      | 45                                          | (27.3)                                      | 10                                          | (35.7)                                       | (13.0)                                       | 2                                            | (8.3)                                        | 228                                                   | (6.4)                                                 | 216                                                   | (8.3)                                                 |
| discontinued pembrolizumab or placebo                                                      | 22                                                 | (12.9)                                             | 3                                                  | (11.5)                                             | 5                                                    | (5.0)                                                | 1                                                    | (4.5)                                       | 6                                           | (3.6)                                       | 0                                           | (0.0)                                        | 5 (5.4)                                      |                                              | (4.2)                                        | 228                                                   | (6.4)                                                 | 216                                                   | (8.3)                                                 |
| discontinued all drugs                                                                     | 5                                                  | (2.9)                                              | 3                                                  | (11.5)                                             | 1                                                    | (1.1)                                                |                                                      | (4.5)                                       | 2                                           | (1.2)                                       | 0                                           | (0.0)                                        | 3 (3.3)                                      |                                              | (4.2)                                        | 228                                                   | (6.4)                                                 | 216                                                   | (8.3)                                                 |
| adverse event                                                                              | 35                                                 | (20.6)                                             | 6                                                  | (23.1)                                             | 8                                                    | (9.0)                                                | 2                                                    | (9.1)                                       | 23                                          | (13.9)                                      | 3                                           |                                              | 4 (4.3)                                      | 2                                            | (8.3)                                        | 301                                                   | (8.4)                                                 | 297                                                   | (11.4)                                                |
| discontinued any drug due to a serious                                                     |                                                    |                                                    |                                                    |                                                    |                                                      |                                                      |                                                      |                                             |                                             |                                             |                                             | (10.7)                                       |                                              |                                              |                                              |                                                       |                                                       |                                                       |                                                       |

|                                                                  | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo+ Chemotherapy w/Bevacizumab   | KN826 Placebo+ Chemotherapy w/Bevacizumab   | KN826 Placebo +Chemotherapy w/oBevacizumab   | KN826 Placebo +Chemotherapy w/oBevacizumab   | KN826 Placebo +Chemotherapy w/oBevacizumab   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                  | <65                                                | <65                                                | >65                                                | <65                                                  | >=65                                                 |                                             | <65                                         | >=65                                         | <65                                          | >65                                          | >65                                                  | <65                                                  | <65                                                  | >=65                                                 |
|                                                                  | n                                                  | (%)                                                | n (%)                                              | n (%)                                                | n                                                    | (%) n                                       | (%)                                         | n (%)                                        | n (%)                                        | n (%)                                        | n                                                    | (%)                                                  | n                                                    | (%)                                                  |
| discontinued pembrolizumab or placebo                            | 23                                                 | (13.5)                                             | 4 (15.4)                                           | 4 (4.5)                                              | 2 (9.1)                                              | 11                                          | (6.7)                                       | 0 (0.0)                                      | 3 (3.3)                                      | 2 (8.3)                                      | 301                                                  | (8.4)                                                | 297                                                  | (11.4)                                               |
| discontinued all drugs                                           | 10                                                 | (5.9)                                              | 3 (11.5)                                           | 3 (3.4)                                              | 1 (4.5)                                              | 6                                           | (3.6)                                       | 0 (0.0)                                      | 3 (3.3)                                      | 2 (8.3)                                      | 301                                                  | (8.4)                                                | 297                                                  | (11.4)                                               |
| discontinued any drug dueto a serious drug-related adverse event | 27                                                 | (15.9)                                             | 4 (15.4)                                           | 6 (6.7)                                              | 2                                                    | (9.1) 17                                    | (10.3)                                      | 3 (10.7)                                     | 2 (2.2)                                      | 1 (4.2)                                      | 135                                                  | (3.8)                                                | 130                                                  | (5.0)                                                |
| discontinued pembrolizumab or placebo                            | 16                                                 | (9.4)                                              | 3 (11.5)                                           | 2 (2.2)                                              | (4.5)                                                | 6                                           | (3.6)                                       | 0 (0.0)                                      | 1 (1.1)                                      | 1 (4.2)                                      | 135                                                  | (3.8)                                                | 130                                                  | (5.0)                                                |
| discontinued all drugs                                           | 5                                                  | (2.9)                                              | 3 (11.5)                                           | 1 (1.1)                                              |                                                      | (4.5) 2                                     | (1.2)                                       | 0 (0.0)                                      | 1 (1.1)                                      | (4.2)                                        | 135                                                  | (3.8)                                                | 130                                                  | (5.0)                                                |

Source: [ISS: adam-adsl; adae]

<!-- image -->

Upon request, exposure-adjusted AE summaries in participants by age (age &lt;65 years and ≥ 65 years were provided. The AE profile in the pembrolizumab + chemotherapy + bevacizumab group was

<div style=\"page-break-after: always\"></div>

generally similar between participants who were &lt;65 years and ≥ 65 years. The small sample size for the ≥ 65 years age subgroup in KEYNOTE-826 should be considered when comparing the AE data by age.

Table  85.  Exposure-Adjusted  Adverse  Event  Summary  by  Bevacizumab  Use  (Including Multiple Occurrences of Events) (Participants Age &lt;65 Years) (APaT Population)

|                                                                       | Event Coumt and Rate (Events/100 person-years)t   | Event Coumt and Rate (Events/100 person-years)t   | Event Coumt and Rate (Events/100 person-years)t   | Event Coumt and Rate (Events/100 person-years)t   | Event Coumt and Rate (Events/100 person-years)t   | Event Coumt and Rate (Events/100 person-years)t   | Event Coumt and Rate (Events/100 person-years)t   | Event Coumt and Rate (Events/100 person-years)t   |
|-----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                                       | Pembrolizumab + Chemotherapy w/ Bevacizumab       | Pembrolizumab + Chemotherapy w/ Bevacizumab       | Pembrolizumab + Chemotherapy w/o Bevacizuma       | Pembrolizumab + Chemotherapy w/o Bevacizuma       | Placebo + Chemotherapy w/ Bevacizumab             | Placebo + Chemotherapy w/ Bevacizumab             | Placebo + Chemotherapy w/o Bevacizumab            | Placebo + Chemotherapy w/o Bevacizumab            |
| Number of Participants exposed                                        | 170                                               | 170                                               | 89                                                | 89                                                | 165                                               | 165                                               | 92                                                | 92                                                |
| Total exposure in person- years                                       | 202.97                                            | 202.97                                            | 73.67                                             | 73.67                                             | 159.16                                            | 159.16                                            | 56.94                                             | 56.94                                             |
| Total events (rate)                                                   | Total events (rate)                               | Total events (rate)                               | Total events (rate)                               | Total events (rate)                               | Total events (rate)                               | Total events (rate)                               | Total events (rate)                               | Total events (rate)                               |
| adverse events                                                        |                                                   | 3,939 (1940.67)                                   | 1,436                                             | (1949.18)                                         |                                                   | 3,275 (2057.66)                                   |                                                   | 1,388 (2437.86)                                   |
| drug-related adverse events                                           |                                                   | 2,286 (1126.27)                                   | 829                                               | (1125.26)                                         |                                                   | 1,841 (1156.69)                                   | 765                                               | (1343.63)                                         |
| toxicity grade 3-5 adverse events                                     | 570                                               | (280.83)                                          | 253                                               | (343.41)                                          | 478                                               | (300.32)                                          | 249                                               | (437.34)                                          |
| toxicity grade 3-5 drug- related adverse events                       | 371                                               | (182.79)                                          | 151                                               | (204.96)                                          | 290                                               | (182.21)                                          | 133                                               | (233.60)                                          |
| serious adverse events                                                | 200                                               | (98.54)                                           | 8                                                 | (115.38)                                          | 145                                               | (91.10)                                           | 75                                                | (131.73)                                          |
| serious drug-related adverse events                                   | 96                                                | (47.30)                                           |                                                   | (40.72)                                           | 60                                                | (37.70)                                           | 24                                                | (42.15)                                           |
| adverse events leading to death                                       | 7                                                 | (3.45)                                            | 2                                                 | (2.71)                                            | 10                                                | (6.28)                                            | 2                                                 | (3.51)                                            |
| drug-related adverse events leading to death                          | 1                                                 | (0.49)                                            | 0                                                 | (0.00)                                            | 3                                                 | (1.88)                                            | 1                                                 | (1.76)                                            |
| adverse events resulting in drug discontinuation                      | 99                                                | (48.78)                                           | 22                                                | (29.86)                                           | 66                                                | (41.47)                                           | 22                                                | (38.64)                                           |
| drug-related adverse events resulting in drug discontinuation         | 85                                                | (41.88)                                           | 18                                                | (24.43)                                           | 58                                                | (36.44)                                           | 15                                                | (26.35)                                           |
| serious adverse events resulting in drug discontinuation              | 40                                                | (19.71)                                           | 8                                                 | (10.86)                                           | 28                                                | (17.59)                                           | 4                                                 | (7.03)                                            |
| serious drug-related adverse events resulting in drug discontimuation | 30                                                | (14.78)                                           | 6                                                 | (8.14)                                            | 22                                                | (13.82)                                           | 2                                                 | (3.51)                                            |

Event rate per 100 person-years of exposure = event count *100/person-years of exposure.

+ Drug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date + 30 or the database cutoff date.

Determined by the investigator to be related to the drug.

MedDRA V24.0 preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Database Cutoff Date: 03MA Y2021

<div style=\"page-break-after: always\"></div>

Table  86.  Exposure-Adjusted  Adverse  Event  Summary  by  Bevacizumab  Use  (Including Multiple Occurrences of Events) (Participants Age ≥65 Years) (APaT Population)

|                                                                       | Event Count and Rate (Events/100 person-years)f   | Event Count and Rate (Events/100 person-years)f   | Event Count and Rate (Events/100 person-years)f   | Event Count and Rate (Events/100 person-years)f   | Event Count and Rate (Events/100 person-years)f   | Event Count and Rate (Events/100 person-years)f   | Event Count and Rate (Events/100 person-years)f   |
|-----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                                       | Pembrolizumab + Chemotherapy w/ Bevacizumab       | Pembrolizumab + Chemotherapy w/ Bevacizumab       | Pembrolizumab + Chemotherapy w/o Bevacizuma       | Pembrolizumab + Chemotherapy w/o Bevacizuma       | Placebo + Chemotherapy w/ Bevacizumab             | Placebo + Chemotherapy w/ Bevacizumab             | Placebo + Chemotherapy w/o Bevacizumab            |
| Number of Participants exposed Total exposure in person-years         | 26 27.75                                          | 26 27.75                                          | 22 17.72                                          | 22 17.72                                          | 28 32.50                                          | 28 32.50                                          | 24 16.75                                          |
| Total events (rate)                                                   |                                                   |                                                   |                                                   |                                                   |                                                   |                                                   |                                                   |
| adverse events                                                        | 471                                               | (1697.37)                                         | 414                                               | (2336.00)                                         | 587                                               | (1805.90)                                         | 378 (2256.26)                                     |
| drug-related adverse events                                           | 290                                               | (1045.09)                                         | 256                                               | (1444.48)                                         | 324                                               | (996.78)                                          | 222 (1325.11)                                     |
| toxicity grade 3-5 adverse events                                     | 100                                               | (360.37)                                          | 86                                                | (485.26)                                          | 82                                                | (252.27)                                          | 42 (250.70)                                       |
| toxicity grade 3-5 drug-related adverse events                        | 73                                                | (263.07)                                          | 65                                                | (366.76)                                          | 52                                                | (159.98)                                          | 30 (179.07)                                       |
| serious adverse events                                                | 27                                                | (97.30)                                           | 28                                                | (157.99)                                          | 35                                                | (107.68)                                          | 11 (65.66)                                        |
| serious drug-related adverse events                                   | 10                                                | (36.04)                                           | 15                                                | (84.64)                                           | 16                                                | (49.22)                                           | 6 (35.81)                                         |
| adverse events leading to death                                       | 3                                                 | (10.81)                                           | 2                                                 | (11.29)                                           | 1                                                 | (3.08)                                            | 1 (5.97)                                          |
| drug-related adverse events                                           | 0                                                 | (0.00)                                            | 1                                                 | (5.64)                                            | 0                                                 | (0.00)                                            | 0 (0.00)                                          |
| leading to death adverse events resulting in drug discontinuation     | 19                                                | (68.47)                                           | 11                                                | (62.07)                                           | 13                                                | (39.99)                                           | 3 (17.91)                                         |
| drug-related adverse events resulting in drug discontinuation         | 11                                                | (39.64)                                           | 8                                                 | (45.14)                                           | 12                                                | (36.92)                                           | 2 (11.94)                                         |
| serious adverse events resulting in drug discontinuation              | 7                                                 | (25.23)                                           | 3                                                 | (16.93)                                           | +                                                 | (12.31)                                           | 2 (11.94)                                         |
| serious drug-related adverse events resulting in drug discontimuation | +                                                 | (14.41)                                           | 2                                                 | (11.29)                                           | +                                                 | (12.31)                                           | 1 (5.97)                                          |

Event rate per 100 person-years of exposure = event count *100/person-years of exposure.

+ Drug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date + 30 or the database cutoff date.

Determined by the investigator to be related to the drug.

progression\" not related to the drug are excluded.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Database Cutoff Date: 03MAY2021

<div style=\"page-break-after: always\"></div>

## Sex

## Table 87. Adverse Event Summary by Sex (Male, Female) (APaT Population)

|                                                            | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                            | M                                    | M                                    | F                                    | F                                    | M                              | M                              | M                              | F                              | F                                                        | M                                                        | M                                                        | F                                                        | F                                                        | M F                                                      | M F                                                      | M                                                    | M                                                    | F                                                    | F                                                    |
|                                                            | (%)                                  | (%)                                  | n (%)                                | n (%)                                | n (%)                          | n (%)                          | n                              | n                              | (%) (%)                                                  | (%) (%)                                                  | (%)                                                      | (%)                                                      | n (%)                                                    | n (%)                                                    | n (%)                                                    | n (%)                                                | (%) n                                                | (%) n                                                | (%)                                                  |
| Participants in population                                 | 0                                    |                                      | 307                                  |                                      | 0                              |                                | 309                            |                                | 1,041                                                    |                                                          | 992                                                      |                                                          | 0 0                                                      | 122                                                      |                                                          | 4,039                                                |                                                      | 2,146                                                |                                                      |
| with one or more adverse events                            | 0                                    | (0.0)                                | 305                                  | (99.3)                               | 0                              | (0.0)                          | 307                            | (99.4)                         | 1,034                                                    | (99.3)                                                   | 981                                                      | (98.9)                                                   | (0.0)                                                    | 119                                                      | (97.5)                                                   | 3,908                                                | (96.8)                                               | 2,081                                                | (97.0)                                               |
| with no adverse event                                      | 0                                    | (0.0)                                | 2                                    | (0.7)                                | 0                              | (0.0)                          | 2                              | (0.0)                          | 7                                                        | (0.7)                                                    | I1                                                       | (1.1)                                                    | 0 (0.0)                                                  | 3                                                        | (2.5)                                                    | 131                                                  | (3.2)                                                | 65                                                   | (3.0)                                                |
| with drug-relatedf adverse events                          | 0                                    | (0.0)                                | 298                                  | (97.1)                               | 0                              | (0.0)                          | 300                            | (97.1)                         | 995                                                      | (95.6)                                                   | 953                                                      | (96.1)                                                   | 0 (0.0)                                                  | 82                                                       | (67.2)                                                   | 2.826                                                | (70.0)                                               | 1,540                                                | (71.8)                                               |
| with toxicity grade 3-5 adverse events                     | 0                                    | (0.0)                                | 251                                  | (81.8)                               | 0                              | (0.0)                          | 232                            | (75.1)                         | 813                                                      | (78.1)                                                   | 770                                                      | (77.6)                                                   | 0 (0.0)                                                  | 65                                                       | (53.3)                                                   | 1,965                                                | (48.7)                                               | 1,019                                                | (47.5)                                               |
| with toxicity grade 3-5 drug-related adverse events        | 0                                    | (0.0)                                | 210                                  | (68.4)                               | 0                              | (0.0)                          | 198                            | (64.1)                         | 640                                                      | (61.5)                                                   | 645                                                      | (65.0)                                                   | 0 (0.0)                                                  | 17                                                       | (13.9)                                                   | 662                                                  | (16.4)                                               | 313                                                  | (14.6)                                               |
| with serious adverse events                                | 0                                    | (0.0)                                | 153                                  | (49.8)                               | 0                              | (0.0)                          | 131                            | (42.4)                         | 562                                                      | (54.0)                                                   | 400                                                      | (40.3)                                                   | 0 (0.0)                                                  | 52                                                       | (42.0)                                                   | 1,580                                                | (39.1)                                               | 791                                                  | (36.9)                                               |
| with serious drug-related adverse events                   | 0                                    | (0.0)                                | 93                                   | (30.3)                               | 0                              | (0.0)                          | 71                             | (23.0)                         | 320                                                      | (30.7)                                                   | 230                                                      | (23.2)                                                   | 0 (0.0)                                                  | 12                                                       | (9.8)                                                    | 473                                                  | (11.7)                                               | 228                                                  | (10.6)                                               |
| who died                                                   | 0                                    | (0.0)                                | 14                                   | (4.6)                                | 0                              | (0.0)                          | 14                             | (4.5)                          | 98                                                       | (9.4)                                                    | 41                                                       | (4.1)                                                    | 0 (0.0)                                                  | 4                                                        | (3.3)                                                    | 224                                                  | (5.5)                                                | 97                                                   | (4.5)                                                |
| who died due to a drug-related adverse event               | 0                                    | (0.0)                                | 2                                    | (0.7)                                | 0                              | (0.0)                          | 4                              | (1.3)                          | 32                                                       | (3.1)                                                    |                                                          | (1.1)                                                    | 0 (0.0)                                                  | 0                                                        | (0.0)                                                    | 24                                                   | (0.6)                                                | 15                                                   | (0.7)                                                |
| discontinued any drug due to an adverse event              | 0                                    | (0.0)                                | 115                                  | (37.5)                               | 0                              | (0.0)                          | 82                             | (26.5)                         | 307                                                      | (29.5)                                                   | 244                                                      | (24.6)                                                   | 0 (0.0)                                                  | 11                                                       | (9.0)                                                    | 544                                                  | (13.5)                                               | 288                                                  | (13.4)                                               |
| discontinued pembrolizumab or placebo                      | 0                                    | (0.0)                                | 46                                   | (15.0)                               | 0                              | (0.0)                          | 25                             | (8.1)                          | 198                                                      | (19.0)                                                   | 147                                                      | (14.8)                                                   | 0 (0.0)                                                  | 11                                                       | (9.0)                                                    | 544                                                  | (13.5)                                               | 288                                                  | (13.4)                                               |
| discontinued all drugs                                     | 0                                    | (0.0)                                | 18                                   | (5.9)                                | 0                              | (0.0)                          | 15                             | (4.9)                          | 76                                                       | (7.3)                                                    | 49                                                       | (4.9)                                                    | 0 (0.0)                                                  | 11                                                       | (9.0)                                                    | 544                                                  | (13.5)                                               | 288                                                  | (13.4)                                               |
| discontinued any drug due to a drug- related adverse event | 0                                    | (0.0)                                | 96                                   | (31.3)                               | 0                              | (0.0)                          | 69                             | (22.3)                         | 230                                                      | (22.1)                                                   | 204                                                      | (20.6)                                                   | 0 (0.0)                                                  | 6                                                        | (4.9)                                                    | 292                                                  | (7.2)                                                | 152                                                  | (7.1)                                                |
| discontinued pembrolizumab or placebo                      | 0                                    | (0.0)                                | 31                                   | (10.1)                               | 0                              | (0.0)                          | 12                             | (3.9)                          | 121                                                      | (11.6)                                                   | 113                                                      | (11.4)                                                   | 0 (0.0)                                                  | 6                                                        | (4.9)                                                    | 292                                                  | (7.2)                                                | 152                                                  | (7.1)                                                |
| discontinued all drugs                                     | 0                                    | (0.0)                                | 10                                   | (3.3)                                | 0                              | (0.0)                          | 6                              | (1.9)                          | 44                                                       | (4.2)                                                    | 32                                                       | (3.2)                                                    | 0 (0.0)                                                  | 6                                                        | (4.9)                                                    | 292                                                  | (7.2)                                                | 152                                                  | (7.1)                                                |
| discontinued any drug due to a serious adverse event       |                                      |                                      |                                      |                                      | 0                              |                                |                                |                                |                                                          |                                                          |                                                          |                                                          | 0                                                        |                                                          | (7.4)                                                    | 397                                                  |                                                      |                                                      |                                                      |
|                                                            | 0                                    | (0.0)                                | 51                                   | (16.6)                               |                                | (0.0)                          | 32                             | (10.4)                         | 199                                                      | (19.1)                                                   | 128                                                      | (12.9)                                                   | (0.0)                                                    |                                                          | 9                                                        |                                                      | (9.8)                                                | 201                                                  | (9.4)                                                |

|                                                                   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo +Chemotherapy   | KN826 Placebo +Chemotherapy   | KN826 Placebo +Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-------------------------------|-------------------------------|-------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                   | M                                    | M                                    | F                                    | F                                    | M                             | M                             | F                             | F                                                        | M                                                        | M                                                        | F                                                        | F                                                        | M                                                        | M                                                        | F M                                                  | F M                                                  |                                                      |                                                      | F                                                    |
|                                                                   | n                                    | (%)                                  | n                                    | (%)                                  | n                             | (%)                           | n                             | (%)                                                      | n                                                        | (%)                                                      |                                                          | (%)                                                      | n                                                        | (%)                                                      | n (%)                                                | n                                                    | (%)                                                  | n                                                    | (%)                                                  |
| discontinued pembrolizumab or placebo                             | 0                                    | (0.0)                                | 33                                   | (10.7)                               | 0 (0.0)                       |                               | 16                            | (5.2) 157                                                | (15.1)                                                   |                                                          | III                                                      | (11.2)                                                   | 0 (0.0)                                                  | 9                                                        | (7.4)                                                | 397                                                  | (9.8)                                                | 201                                                  | (9.4)                                                |
| discontinued all drugs                                            | 0                                    | (0.0)                                | 17                                   | (5.5)                                | 0                             | (0.0)                         | 11                            | (3.0 71                                                  | (6.8)                                                    |                                                          | 39                                                       | (3.9)                                                    | 0 (0.0)                                                  | 9                                                        | (7.4)                                                | 397                                                  | (9.8)                                                | 201                                                  | (9.4)                                                |
| discontinued any drug due to a serious drug-related adverse event | 0                                    | (0.0)                                | 39                                   | (12.7)                               | 0                             | (0.0)                         | 23                            | (7.4) 125                                                |                                                          | (12.0)                                                   | 95                                                       | (9.6)                                                    | 0 (0.0)                                                  | 4                                                        | (3.3)                                                | 177                                                  | (4.4)                                                | 88                                                   | (4.1)                                                |
| discontinued pembrolizumab or placebo                             | 0                                    | (0.0)                                | 22                                   | (7.2)                                | 0                             | (0.0)                         | 8 (2.0)                       | 87                                                       | (8.4)                                                    |                                                          | 80                                                       | (8.1)                                                    | 0 (0.0)                                                  | 4                                                        | (3.3)                                                | 177                                                  | (4.4)                                                | 88                                                   | (4.1)                                                |

|                        | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo +Chemotherapy   | KN826 Placebo +Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-------------------------------|-------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                        | M                                    |                                      | F                                    | M                             |                               | M                                                        |                                                          | F                                                        | M                                                        | F                                                        | M                                                    | F                                                    |
|                        | n                                    | (%)                                  | n (%)                                | I1 (%)                        | n (%)                         | n                                                        | (%)                                                      | n (%)                                                    | n (%)                                                    | n (%)                                                    | n (%)                                                | (%)                                                  |
| discontinued all drugs | 0                                    | (0.0)                                | 10 (3.3)                             | 0 (0.0)                       | 4 (1.3)                       | 40                                                       | (3.8)                                                    | 23 (2.3)                                                 | 0 (0.0)                                                  | 4 (3.3)                                                  | 177 (4.4)                                            | 88 (4.1)                                             |

* Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\",\"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Grades are based on NCICTCAE version 4.0.

Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase),KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, d Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015,KN006: 03MAR2015, KN054: 03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019,KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016,KN040: 15MAY2017, KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018,KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff date for CRC (KN177:19FEB2020)

Database cutoff date for TNBC (KN355:11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

Source: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## ECOG

## Table 88. Adverse Event Summary by ECOG (APaT Population)

|                                                            | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   |                             |                     |                     | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|-----------------------------|---------------------|---------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                            | [0] Normal Activity                  | [0] Normal Activity                  | [1] Symptoms, but ambulatory         | [1] Symptoms, but ambulatory         | [0] Normal Activity            | [0] Normal Activity            | [1]Symptoms, but ambulatory    | [1]Symptoms, but ambulatory | [0] Normal Activity | [0] Normal Activity | [1] Symptoms, but ambulatory                              | [1] Symptoms, but ambulatory                              | [0] Normal Activity                                       | [0] Normal Activity                                      | [1]Symptoms, [0] Normal but ambulatory Activity          | [1]Symptoms, [0] Normal but ambulatory Activity          |                                                      |                                                      | [1] Symptoms, but ambulatory                         |
|                                                            | n (%)                                | n (%)                                | n (%)                                | n (%)                                | n (%)                          | n (%)                          | n (%)                          | n (%)                       | n (%)               | n (%)               | n (%)                                                     | n (%)                                                     | n (%)                                                     | n (%)                                                    | n (%) n                                                  | n (%) n                                                  | (%) n                                                | (%) n                                                | (%)                                                  |
| Participants in population                                 | 178                                  | 178                                  | 127                                  | 127                                  | 170                            | 170                            | 139                            | 139                         | 913                 | 913                 | 1,116                                                     | 1,116                                                     | 40                                                        | 40                                                       | 82 2,942                                                 | 82 2,942                                                 | 3,069                                                | 3,069                                                |                                                      |
| with one or more adverse events                            | 177                                  | (99.4)                               | 126                                  | (99.2)                               | 168                            | (98.8)                         | 139                            | (100.0                      | 908                 | (99.5)              | 1,103                                                     | (98.8)                                                    | 39                                                        | (97.5)                                                   | 80 (97.0)                                                | 2,852                                                    | (96.9)                                               | 2,970                                                | (96.8)                                               |
| with no adverse event                                      | 1                                    | (0.6)                                | 1                                    | (0.8)                                | 2                              | (1.2)                          | 0                              | (0.0)                       | 5                   | (0.5)               | 13                                                        | (1.2)                                                     | 1 (2.5)                                                   | 2                                                        | (2.4)                                                    | 90                                                       | (3.1)                                                | 99                                                   | (3.2)                                                |
| with drug-related adverse events                           | 175                                  | (98.3)                               | 121                                  | (95.3)                               | 164                            | (96.5)                         | 136                            | (97.8)                      | 883                 | (96.7)              | 1,061                                                     | (95.1)                                                    | 33                                                        | (82.5) 49                                                | (59.8)                                                   | 2,223                                                    | (75.6)                                               | 2,048                                                | (66.7)                                               |
| with toxicity grade 3-5 adverse events                     | 151                                  | (84.8)                               | 98                                   | (77.2)                               | 123                            | (72.4)                         | 109                            | (78.4)                      | 689                 | (75.5)              | 890                                                       | (79.7)                                                    | 18                                                        | (45.0) 47                                                | (57.3)                                                   | 1,196                                                    | (40.7)                                               | 1,680                                                | (54.7)                                               |
| with toxicity grade 3-5 drug-related adverse events        | 129                                  | (72.5)                               | 80                                   | (63.0)                               | 109                            | (64.1)                         | 89                             | (64.0)                      | 583                 | (63.9)              | 699                                                       | (62.6)                                                    | 8                                                         | (20.0) 9                                                 | (0'11)                                                   | 446                                                      | (15.2)                                               | 499                                                  | (16.3)                                               |
| with serious adverse events                                | 91                                   | (51.1)                               | 60                                   | (47.2)                               | 62                             | (36.5)                         | 69                             | (49.6)                      | 368                 | (40.3)              | 590                                                       | (52.9)                                                    | 12                                                        | (30.0) 40 9                                              | (48.8)                                                   | 930                                                      | (31.0)                                               | 1,347                                                | (43.9)                                               |
| with serious drug-related adverse events                   | 59                                   | (33.1)                               | 32                                   | (25.2)                               | 36                             | (21.2)                         | 35                             | (25.2)                      | 205                 | (22.5)              | 344                                                       | (30.8)                                                    | 3                                                         | (7.5)                                                    | (0'11)                                                   | 336                                                      | (11.4)                                               | 348                                                  | (11.3)                                               |
| who died                                                   | 5                                    | (2.8)                                | 8                                    | (6.3)                                | 3                              | (1.8)                          | 11                             | (7.9)                       | 40                  | (4.4)               | 99                                                        | (8.9)                                                     | 0                                                         | (0.0) 4 0                                                | (4.9)                                                    | 83                                                       | (2.8)                                                | 222                                                  | (7.2)                                                |
| who died due to a drug-related adverse event               | 1                                    | (0.6)                                | 1                                    | (0.8)                                | 1                              | (0.0)                          | 3                              | (2.2)                       | 18                  | (2.0)               | 25                                                        | (2.2)                                                     | 0                                                         | (0.0)                                                    | (0.0)                                                    | 13                                                       | (0.4)                                                | 26                                                   | (0.8)                                                |
| discontinued any drug due to an adverse event              | 72                                   | (40.4)                               | 43                                   | (33.9)                               | 41                             | (24.1)                         | 41                             | (29.5)                      | 238                 | (26.1)              | 312                                                       | (28.0)                                                    | 3                                                         | (7.5) 8                                                  | (9.8)                                                    | 333                                                      | (11.3)                                               | 470                                                  | (15.3)                                               |
| discontinued pembrolizumab or placebo                      | 31                                   | (17.4)                               | 15                                   | (11.8)                               | 14                             | (8.2)                          | 11                             | (7.9)                       | 134                 | (14.7)              | 210                                                       | (18.8)                                                    | 3                                                         | (7.5) 8                                                  | (9.8)                                                    | 333                                                      | (11.3)                                               | 470                                                  | (15.3)                                               |
| discontinued all drugs                                     | 8                                    | (4.5)                                | 10                                   | (7.9)                                | 7                              | (4.1)                          | 8                              | (5.8)                       | 36                  | (3.9)               | 89                                                        | (8.0)                                                     | 3                                                         | 8                                                        | (9.8)                                                    | 333                                                      | (11.3)                                               | 470                                                  | (15.3)                                               |
| discontinued any drug due to a drug- related adverse event | 65                                   | (36.5)                               | 31                                   | (24.4)                               | 36                             | (21.2)                         | 33                             | (23.7)                      | 204                 | (22.3)              | 230                                                       | (20.6)                                                    | (7.5) 2 (5.0)                                             | 4                                                        | (4.9)                                                    | 217                                                      | (7.4)                                                | 214                                                  | (7.0)                                                |
| discontinued pembrolizumab or placebo                      | 25                                   | (14.0)                               | 6                                    | (4.7)                                | 9                              | (5.3)                          | 3                              | (2.2)                       | 103                 | (11.3)              | 131                                                       | (11.7)                                                    | 2 (5.0)                                                   | 4                                                        | (4.9)                                                    | 217                                                      | (7.4)                                                | 214                                                  |                                                      |
|                                                            |                                      | (3.9)                                | 3                                    | (2.4)                                |                                |                                | 3                              | (2.2)                       | 27                  |                     |                                                           |                                                           | 2                                                         |                                                          | 4                                                        |                                                          |                                                      |                                                      | (7.0)                                                |
| discontinued all drugs                                     | 7                                    |                                      |                                      |                                      | 3                              | (1.8)                          |                                |                             |                     | (3.0)               | 49                                                        | (4.4)                                                     | (5.0)                                                     |                                                          | (4.9)                                                    | 217                                                      | (7.4)                                                | 214                                                  | (7.0)                                                |

|                                                                   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826Placebo+Chemotherapy   | KN826Placebo+Chemotherapy   | KN826Placebo+Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                                   | [0] Normal Activity                  | [0] Normal Activity                  | [1]Symptoms, but ambulatory          | [1]Symptoms, but ambulatory          | [0] Nomal Activity          | [0] Nomal Activity          | [1]Symptoms, but ambulatory | [1]Symptoms, but ambulatory                               | [0] Nomal Activity                                        | [1] Symptoms, but ambulatory                              | [1] Symptoms, but ambulatory                             | [0] Normal Activity                                      | [0] Normal Activity                                      | [1] Symptoms, [0] Normal but ambulatory Activity     | [1] Symptoms, [0] Normal but ambulatory Activity     | but ambulatory                                       | but ambulatory                                       | [1] Symptoms,                                        |
|                                                                   |                                      | (%)                                  | n                                    | (%)                                  | n                           | (%)                         | n                           | (%)                                                       | n                                                         | n                                                         | (%)                                                      | n (%)                                                    | n                                                        | (%)                                                  | n                                                    | (%)                                                  | n                                                    | (%)                                                  |
| discontinued any drug due to a serious adverse event              | 32                                   | (18.0)                               | 19                                   | (15.0)                               | 18                          | (10.6)                      | 14                          | (10.1) 125                                                | (%) (13.7)                                                | 201                                                       | (18.0)                                                   | 2 (5.0)                                                  | 7                                                        | (8.5)                                                | 214                                                  | (7.3)                                                | 363                                                  | (11.8)                                               |
| discontinued pembrolizumab or placebo                             | 19                                   | (10.7)                               | 14                                   | (11.0)                               | 9                           | (5.3)                       | 7                           | (5.0) 100                                                 | (11.0)                                                    | 167                                                       | (15.0)                                                   | 2 (5.0)                                                  | 7                                                        | (8.5)                                                | 214                                                  | (7.3)                                                | 363                                                  | (11.8)                                               |
| discontinued all drugs                                            | 8                                    | (4.5)                                | 9                                    | (7.1)                                | 5                           | (2.9)                       | 6                           | (4.3) 29                                                  | (3.2)                                                     | 81                                                        | (7.3)                                                    | 2 (5.0)                                                  | 7                                                        | (8.5)                                                | 214                                                  | (7.3)                                                | 363                                                  | (11.8)                                               |
| discontinued any drug due to a serious drug-related adverse event | 28                                   | (15.7)                               | 11                                   | (8.7)                                | 14                          | (8.2)                       | 9                           | (6.5) 95                                                  | (10.4)                                                    | 125                                                       | (11.2)                                                   | 1 (2.5)                                                  | 3                                                        | (3.7)                                                | 118                                                  | (4.0)                                                | 140                                                  | (4.0)                                                |
| discontinued pembrolizumab or placebo                             | 16                                   | (9.0)                                | 6                                    | (4.7)                                | 6                           | (3.5)                       | 2                           | (1.4) 73                                                  | (8.0)                                                     | 94                                                        | (8.4)                                                    | 1 (2.5)                                                  | 3                                                        | (3.7)                                                | 118                                                  | (4.0)                                                | 140                                                  | (4.0)                                                |

|                        | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo +Chemotherapy   | KN826 Placebo +Chemotherapy   | KN826 Placebo +Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Pooled Safety Dataset for Pembrolizumab + Chemotherapyf   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-------------------------------|-------------------------------|-------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                        | [0] Normal Activity                  | [0] Normal Activity                  | [1] Symptoms, but ambulatory         | [0] Normal Activity           | [0] Normal Activity           | [1] Symptoms, but ambulatory  |                                                           |                                                           | [0] Normal Activity                                       | [1] Symptoms, but ambulatory                              |                                                          |                                                          | [0] Normal Activity                                      | [1] Symptoms, [0] Normal but ambulatory Activity     | [1] Symptoms, [0] Normal but ambulatory Activity     | [1] Symptoms, but ambulatory                         | [1] Symptoms, but ambulatory                         |
|                        | n                                    | (%)                                  | n                                    | (%)                           | n (%)                         | n                             | (%)                                                       |                                                           | (%)                                                       | n (%)                                                     |                                                          |                                                          | (%) n                                                    | (%) n                                                | (%)                                                  | n                                                    | (%)                                                  |
| discontinued all drugs | 7                                    | (3.9)                                | 3                                    | (2.4)                         | 2 (1.2)                       | 2                             | (1.4)                                                     | 21                                                        | (2.3)                                                     | 42                                                        | (3.8)                                                    | (2.5)                                                    | 3                                                        | (3.7) 118                                            | (4.0)                                                | 140                                                  | (4.0)                                                |

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

a Determined by the investigator to be related to the drug.

Grades are based on NCICTCAE version 4.0.

Includes allparticipants who received at least one dose of pembrolizumab in KN001 Part B1,B2,B3,D,C,F1,F2,F3,KN002 (original phase),KN006,KN010,KN012 cohort B and B2,KN013 cohort 3,KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

dIncludes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E.

Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014, KN002: 28FEB2015,KN006: 03MAR2015,KN054: 03APR2020)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for Esophageal (KN590:02JUL2020)

Database cutoff date for CRC (KN177:19FEB2020)

Database cutoff date for TNBC (KN355: 11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021,KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

Source:[ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Region

## Table 89. Adverse Event summary by Region (EU, ex-EU) (APaT Population)

|                                                             | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826Placebo+Chemotherapy   | KN826Placebo+Chemotherapy   | KN826Placebo+Chemotherapy   |             |           |           | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset*   | Pembrolizumab Monotherapy Reference Safety Dataset*   | Pembrolizumab Monotherapy Reference Safety Dataset*   |
|-------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|-------------|-----------|-----------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                             | EU                                   | EU                                   | Ex-EU                                | Ex-EU                                | EU                          | EU                          | Ex-EU                       | Ex-EU       | EU        | EU        | Ex-EU                                                    | Ex-EU                                                    | EU                                                       | EU                                                       | Ex-EU                                                    | Ex-EU                                                    | EU                                                    | EU                                                    | Ex-EU                                                 |
|                                                             | n (%)                                | n (%)                                | n (%)                                | n (%)                                | n                           | n                           | (%) n                       | (%) n       | (%) n (%) | (%) n (%) | n (%)                                                    | n (%)                                                    | n                                                        | n                                                        | (%) n (%)                                                | n                                                        | (%) n                                                 | (%) n                                                 | (%)                                                   |
| Participants in population                                  | 103                                  |                                      | 204                                  |                                      | 108                         |                             | 201                         |             | 690       |           | 1,343                                                    |                                                          | 61 60                                                    | 61                                                       |                                                          | 2,217                                                    |                                                       | 3,968                                                 |                                                       |
| with one or more adverse events                             | 101                                  | (98.1)                               | 204                                  | (100.0                               | 107                         | (99.1)                      | 200                         | (99.5)      | 681       | (98.7)    | 1,334                                                    | (99.3)                                                   | (98.4)                                                   | 59                                                       | (96.7)                                                   | 2,135                                                    | (96.3)                                                | 3,854                                                 | (97.1)                                                |
| with no adverse event                                       | 2                                    | (1.9)                                | 0                                    | (0.0)                                | 1                           | (0.9)                       | 1                           | (0.5)       | 9         | (1.3)     | 9                                                        | (0.7)                                                    | 1 (1.6)                                                  | 2                                                        | (3.3)                                                    | 82                                                       | (3.7)                                                 | 114                                                   | (2.9)                                                 |
| with drug-relatedf adverse events                           | 101                                  | (98.1)                               | 197                                  | (96.0)                               | 105                         | (97.2)                      | 195                         | (97.0)      | 647       | (93.8)    | 1,301                                                    | (96.9)                                                   | 44 (72.1)                                                | 38                                                       | (62.3)                                                   | 1,526                                                    | (68.8)                                                | 2,840                                                 | (71.6)                                                |
| with toxicity grade 3-5 adverse events                      | 79                                   | (76.7)                               | 172                                  | (84.3)                               | 74                          | (68.5)                      | 158                         | (78.6)      | 515       | (74.6)    | 1,068                                                    | (79.5)                                                   | 35 (57.4)                                                | 30                                                       | (49.2)                                                   | 1,022                                                    | (46.1)                                                | 1,962                                                 | (49.4)                                                |
| with toxicity grade 3-5 drug-related adverse events         | 67                                   | (65.0)                               | 143                                  | (70.1)                               | 63                          | (58.3)                      | 135                         | (67.2)      | 395       | (57.2)    | 890                                                      | (66.3)                                                   | 10 (16.4)                                                | 7                                                        | (11.5)                                                   | 341                                                      | (15.4)                                                | 634                                                   | (091)                                                 |
| with serious adverse events                                 | 50                                   | (48.5)                               | 103                                  | (50.5)                               | 36                          | (33.3)                      | 95                          | (47.3)      | 348       | (50.4)    | 614                                                      | (45.7)                                                   | 32 (52.5)                                                | 20                                                       | (32.8)                                                   | 846                                                      | (38.2)                                                | 1,525                                                 | (38.4)                                                |
| with serious drug-related adverse events                    | 27                                   | (26.2)                               | 66                                   | (32.4)                               | 22                          | (20.4)                      | 49                          | (24.4)      | 192       | (27.8)    | 358                                                      | (26.7)                                                   | 9 (14.8)                                                 | 3                                                        | (4.9)                                                    | 260                                                      | (11.7)                                                | 441                                                   | (11.1)                                                |
| who died                                                    | 3                                    | (2.9)                                | 11                                   | (5.4)                                | 6                           | (5.0)                       | 8                           | (4.0)       | 49        | (7.1)     | 90                                                       | (6.7)                                                    | 2 (3.3)                                                  | 2                                                        | (3.3)                                                    | 113                                                      | (5.1)                                                 | 208                                                   | (5.2)                                                 |
| who died due to a drug-related adverse event                | 1                                    | (1.0)                                | 1                                    | (0.5)                                | 3                           | (2.8)                       | 1                           | (0.5)       | 9         | (1.3)     | 34                                                       | (2.5)                                                    | 0 (0.0)                                                  | 0                                                        | (0.0)                                                    | 11                                                       | (0.5)                                                 | 28                                                    | (0.7)                                                 |
| discontinued any drug due to an adverse event               | 37                                   | (35.9)                               | 78                                   | (38.2)                               | 25                          | (23.1)                      | 57                          | (28.4)      | 225       | (32.6)    | 326                                                      | (24.3)                                                   | 6 (9.8)                                                  | 5                                                        | (8.2)                                                    | 287                                                      | (12.9)                                                | 545                                                   | (13.7)                                                |
| discontinued pembrolizumab or placebo                       | 14                                   | (13.6)                               | 32                                   | (15.7)                               | 9                           | (8.3)                       | 16                          | (8.0)       | 138       | (20.0)    | 207                                                      | (15.4)                                                   | 6 (9.8)                                                  | 5                                                        | (8.2)                                                    | 287                                                      | (12.9)                                                | 545                                                   | (13.7)                                                |
| discontinued all drugs discontinued any drug due to a drug- | 6 32                                 | (5.8) (31.1)                         | 12 64                                | (5.9) (31.4)                         | 6 22                        | (5.0)                       | 9                           | (4.5)       | 46        | (6.7)     | 79 259                                                   | (5.9)                                                    | 6 (9.8) 4                                                | 5                                                        | (8.2)                                                    | 287 166                                                  | (12.9)                                                | 545                                                   | (13.7) (7.0)                                          |
| related adverse event discontinued pembrolizumab or         |                                      | (8.7)                                | 22                                   |                                      | 5                           | (20.4)                      | 47                          | (23.4)      | 175       | (25.4)    |                                                          | (19.3)                                                   | (6.6)                                                    | 2                                                        | (3.3)                                                    |                                                          | (7.5)                                                 | 278                                                   | (7.0)                                                 |
| placebo                                                     | 9                                    |                                      |                                      | (10.8)                               |                             | (4.0)                       | 7                           | (3.5)       | 87        | (12.6)    | 147                                                      | (10.9)                                                   | 4 (6.6)                                                  | 2                                                        | (3.3)                                                    | 166                                                      | (7.5)                                                 | 278                                                   |                                                       |
| discontinued any drug due to a serious adverse event        | 16                                   | (15.5)                               | 5                                    | (2.5)                                | 4                           | (3.7)                       | 17                          |             | 133       | (3.5)     | 52                                                       | (3.9)                                                    | 4 (6.6)                                                  | 4                                                        |                                                          | 205                                                      |                                                       | 393                                                   | (9.9)                                                 |
| discontinued all drugs                                      | 5                                    | (4.9)                                | 35                                   | (17.2)                               | 15                          | (13.9)                      | 2                           | (1.0) (8.5) | 24        | (19.3)    | 194                                                      | (14.4)                                                   | 5 (8.2)                                                  | 2                                                        | (3.3) (6.6)                                              | 166                                                      | (7.5) (9.2)                                           | 278                                                   | (7.0)                                                 |

|                                                                   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Cervical SafetyDataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy ReferenceSafetyDataset   | Pembrolizumab Monotherapy ReferenceSafetyDataset   | Pembrolizumab Monotherapy ReferenceSafetyDataset   | Pembrolizumab Monotherapy ReferenceSafetyDataset   |
|-------------------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                                                   | EU                                   | EU                                   | Ex-EU                                | Ex-EU                                | EU                             | EU                             | Ex-EU                          | EU                                                       | EU                                                       | Ex-EU                                                    | Ex-EU                                                    | EU                                                      | Ex-EU                                                   | Ex-EU                                                   | EU                                                 | EU                                                 | Ex-EU                                              | Ex-EU                                              |
|                                                                   | n                                    | (%)                                  | n                                    | (%)                                  |                                | (%)                            | n (%)                          | n                                                        | (%)                                                      | n                                                        | (%)                                                      | n                                                       | (%)                                                     | n (%)                                                   | n                                                  | (%)                                                | n                                                  | (%)                                                |
| discontinued pembrolizumab or placebo                             | I1                                   | (10.7)                               | 22                                   | (10.8)                               | 8                              | (7.4)                          | 8 (4.0)                        | 107                                                      | (15.5)                                                   | 161                                                      | (12.0)                                                   | 5                                                       | (8.2)                                                   | 4 (6.6)                                                 | 205                                                | (9.2)                                              | 393                                                | (9.9)                                              |
| discontinued all drugs                                            | 6                                    | (5.8)                                |                                      | (5.4)                                | 6                              | (5.0)                          | 5 (2.5)                        | 43                                                       | (6.2)                                                    | 67                                                       | (5.0)                                                    | 5                                                       | (8.2)                                                   | 4 (6.6)                                                 | 205                                                | (9.2)                                              | 393                                                | (9.9)                                              |
| discontinued any drug due to a serious drug-related adverse event | 13                                   | (12.0)                               | 26                                   | (12.7)                               | 12                             | (11.1)                         | 11 (5.5)                       | 85                                                       | (12.3)                                                   | 135                                                      | (10.1)                                                   | 3                                                       | (4.9)                                                   | 1 (1.6)                                                 | 98                                                 | (4.4)                                              | 167                                                | (4.2)                                              |
| discontinued pembrolizumab or placebo                             | 7                                    | (6.8)                                | 15                                   | (7.4)                                | 5                              | (4.0)                          | 3 (1.5)                        | 59                                                       | (8.6)                                                    | 108                                                      | (8.0)                                                    | 3                                                       | (4.9)                                                   | 1 (1.6)                                                 | 98                                                 | (4.4)                                              | 167                                                | (4.2)                                              |

|                        | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo +Chemotherapy   | KN826 Placebo +Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------|--------------------------------------|--------------------------------------|-------------------------------|-------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                        | EU                                   | Ex-EU                                | EU                            | Ex-EU                         | EU                                                      | Ex-EU                                                   | EU                                                       | Ex-EU                                                    | EU                                                   | Ex-EU                                                |
|                        | n (%)                                | n (%)                                | n (%)                         | n (%)                         | n (%)                                                   | n (%)                                                   | n (%)                                                    | n (%)                                                    | n (%)                                                | n (%)                                                |
| discontinued all drugs | 5 (4.9)                              | 5 (2.5)                              | 4 (3.7)                       | 0 (0.0)                       | 21 (3.0)                                                | 42 (3.1)                                                | 3 (4.9)                                                  | 1 (1.6)                                                  | 98 (4.4)                                             | 167 (4.2)                                            |

* Determined by the investigator to be related to the drug.

MedDRA preferred terms \"Neoplasm Progression\",\"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Grades are based on NCICTCAE version 4.0.

dIncludes all participants who received at least one dose of pembrolizumab inKN028 cohort B4 andKN158 cohort E.

KN040,KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006: 03MAR2015,KN054:03APR2020)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016,KN040: 15MAY2017, KN048: 25FEB2019,KN055: 22APR2016)

Database cutoff date for Bladder (KN045: 26OCT2017,KN052: 26SEP2018)

Database cutoff date for CRC (KN177:19FEB2020)

Database cutoff date for Esophageal (KN590: 02JUL2020)

Database cutoff datefor TNBC (KN355:11DEC2019)

Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E: 27JUN2019)

Source: [ISS: adam-adsl; adae]

## Safety related to drug-drug interactions and other interactions

Please refer to the Discussion on clinical pharmacology.

## Immunogenicity

No new immunogenicity data are available.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

## Table 90. Participants With Adverse Events Resulting in Discontinuation of Any Treatment by System Organ Class and Preferred Term (Incidence &gt;0% in One or More Treatment Groups) (APaT Population)

|                                        | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+ Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|----------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                        | n                                    | (%)                                  | n                              | (%)                            | n                                                       | (%)                                                     | n                                                        | (%)                                                      | n                                                    | (%)                                                  |
| Participants in population             | 307                                  |                                      | 309                            |                                | 2,033                                                   |                                                         | 122                                                      |                                                          | 6,185                                                |                                                      |
| with one or more adverse events        | 115                                  | (37.5)                               | 82                             | (26.5)                         | 551                                                     | (27.1)                                                  | 11                                                       | (9.0)                                                    | 832                                                  | (13.5)                                               |
| with no adverse events                 | 192                                  | (62.5)                               | 227                            | (73.5)                         | 1,482                                                   | (72.9)                                                  | I11                                                      | (91.0)                                                   | 5,353                                                | (86.5)                                               |
| Blood and lymphatic system disorders   | 12                                   | (3.9)                                | 10                             | (3.2)                          | 60                                                      | (3.0)                                                   | 0                                                        | (0.0)                                                    | 12                                                   | (0.2)                                                |
| Anaemia                                | 7                                    | (2.3)                                | 4                              | (1.3)                          |                                                         | (0.5)                                                   | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Autoimmune haemolytic anaemia          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Disseminated intravascular coagulation | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Febrile neutropenia                    | 1                                    | (0.3)                                | 1                              | (0.3)                          | 14                                                      | (0.7)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Haemolytic anaemia                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Immune thrombocytopenia                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Leukopenia                             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                       | (0.1)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Neutropenia                            | 3                                    | (1.0)                                | 3                              | (1.0)                          | 24                                                      | (1.2)                                                   | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Pancytopenia                           | 1                                    | (0.3)                                | 0                              | (0.0)                          | 3                                                       | (0.1)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Thrombocytopenia                       | 2                                    | (0.7)                                | 2                              | (0.6)                          | 9                                                       | (0.4)                                                   | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Thrombotic microangiopathy             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Cardiae disorders                      | 4                                    | (1.3)                                | 1                              | (0.3)                          | 30                                                      | (1.5)                                                   | 0                                                        | (0.0)                                                    | 36                                                   | (0.6)                                                |
| Acute coronary syndrome                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Acute myocardial infarction            | 1                                    | (0.3)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Angina unstable                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Arrhythmia                             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                       | (0.1)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Arteriospasm coronary                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Atrial fibrillation                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                       | (0.0)                                                   | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |

|                             | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-----------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                             | n                                    | (%)                                  | n                              | (%)                            |                                                          | (%)                                                      |                                                          | (%)                                                      |                                                      | (%)                                                  |
| Ear and labyrinth disorders | 1                                    | (0.3)                                | 1                              | (0.3)                          | 11                                                       | (0.5)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Deafness                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Hypoacusis                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 3                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Ototoxicity                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Tinnitus                    | 1                                    | (0.3)                                |                                | (0.3)                          | 6                                                        | (0.3)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Endocrine disorders         | 1                                    | (0.3)                                | 0                              | (0.0)                          | 4                                                        | (0.2)                                                    | 0                                                        | (0.0)                                                    | 18                                                   | (0.3)                                                |
|                             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Adrenal insufficiency       | 1                                    | (0.3)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Hyperthyroidism             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Hypophysitis                | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 5                                                    | (0.1)                                                |
| Hypopituitarism             | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 4                                                    | (0.1)                                                |
| Hypothyroidism              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Eye disorders               | 1                                    | (0.3)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Cystoid macular oedema      | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Iridocyclitis               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Lacrimation increased       | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Optic neuropathy            |                                      | (0.3)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Uveitis                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Gastrointestinal disorders  | 23                                   | (7.5)                                | 10                             | (3.2)                          | 56                                                       | (2.8)                                                    | 5                                                        | (4.1)                                                    | 88                                                   | (1.4)                                                |
| Abdominal distension        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Abdominal pain              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |

<div style=\"page-break-after: always\"></div>

|                                                      | KN826 Pembrolizumab + Chemotherapy   | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|------------------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                      | n                                    | (%)                                  | n                              | (%)                            | n                                                        | (%)                                                      |                                                          | (%)                                                      | n                                                    | (%)                                                  |
| General disorders and administration site conditions | 8                                    | (2.0)                                | 7                              | (2.3)                          | 49                                                       | (2.4)                                                    | 0                                                        | (0.0)                                                    | 87                                                   | (1.4)                                                |
| Localised oedema                                     | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Malaise                                              | 1                                    | (0.3)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Mucosalinflammation                                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 8                                                        | (0.4)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Multiple organ dysfunction syndrome                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 2                                                        | (0.1)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Oedema                                               | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 3                                                    | (0.0)                                                |
| Oedema peripheral                                    | 0                                    | (0.0)                                | 0                              | (0.0)                          | 4                                                        | (0.2)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Pain                                                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 7                                                    | (0.1)                                                |
| Performance status decreased                         | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Physical deconditioning                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Prosthetic cardiac valve thrombosis                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Pyrexia                                              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Sudden cardiac death                                 | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Sudden death                                         | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Swelling face                                        | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 2                                                    | (0.0)                                                |
| Systemic inflammatory response syndrome              | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 1                                                    | (0.0)                                                |
| Hepatobiliary disorders                              | 4                                    | (1.3)                                | 0                              | (0.0)                          | 26                                                       | (1.3)                                                    | 3                                                        | (2.5)                                                    | 34                                                   | (0.5)                                                |
| Autoimmune hepatitis                                 | 1                                    | (0.3)                                | 0                              | (0.0)                          | 11                                                       | (0.5)                                                    | 0                                                        | (0.0)                                                    | 12                                                   | (0.2)                                                |
| Biliary obstruction                                  | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Cholangitis                                          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |
| Cholangitis sclerosing                               | 0                                    | (0.0)                                | 0                              | (0.0)                          |                                                          | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Cholestasis                                          | 0                                    | (0.0)                                | 0                              | (0.0)                          | 1                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    | 0                                                    | (0.0)                                                |
| Drug-induced liver injury                            | 0                                    | (0.0)                                | 0                              | (0.0)                          | 0                                                        | (0.0)                                                    | 0                                                        | (0.0)                                                    |                                                      | (0.0)                                                |

|                             | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab + Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-----------------------------|--------------------------------------|--------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                             | n (%)                                | n (%)                          | n (%)                                                    | n (%)                                                    | n                                                    | (%)                                                  |
| Hepatobiliary disorders     | 4 (1.3)                              | 0 (0.0)                        | 26 (1.3)                                                 | 3 (2.5)                                                  | 34                                                   | (0.5)                                                |
| Hepatic failure             | 0 (0.0)                              | 0 (0.0)                        | 2 (0.1)                                                  | 0 (0.0)                                                  | 3                                                    | (0.0)                                                |
| Hepatic function abnormal   | 0 (0.0)                              | 0 (0.0)                        | 3 (0.1)                                                  | 0 (0.0)                                                  | 2                                                    | (0.0)                                                |
| Hepatitis                   | 0 (0.0)                              | 0 (0.0)                        | 6 (0.3)                                                  | 2 (1.6)                                                  | 9                                                    | (0.1)                                                |
| Hepatitis toxic             | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                                                  | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Hepatotoxicity              | 1 (0.3)                              | 0 (0.0)                        | 0 (0.0)                                                  | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Hyperbilirubinaemia         | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                                                  | 1 (0.8)                                                  | 1                                                    | (0.0)                                                |
| Immune-mediated hepatitis   | 2 (0.7)                              | 0 (0.0)                        | 2 (0.1)                                                  | 0 (0.0)                                                  | 2                                                    | (0.0)                                                |
| Liver disorder              | 0 (0.0)                              | 0 (0.0)                        | 1 (0.0)                                                  | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Liver injury                | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                                                  | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Immune system disorders     | 8 (2.0)                              | 8 (2.0)                        | 7 (0.3)                                                  | 0 (0.0)                                                  | 9                                                    | (0.1)                                                |
| Anaphylactic reaction       | I (0.3)                              | 0 (0.0)                        | (0.0)                                                    | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Anaphylactic shock          | 0 (0.0)                              | 1 (0.3)                        | 0 (0.0)                                                  | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Anaphylactoid reaction      | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                                                  | 0 (0.0)                                                  |                                                      | (0.0)                                                |
| Autoimmune disorder         | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                                                  | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Autoinflammatory disease    | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                                                  | 0 (0.0)                                                  |                                                      | (0.0)                                                |
| Cytokine release syndrome   | (0.3)                                | 0 (0.0)                        | 0 (0.0)                                                  | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Drug hypersensitivity       | 2 (0.7)                              | 3 (1.0)                        | 2 (0.1)                                                  | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Hypersensitivity            | 4 (1.3)                              | 4 (1.3)                        | 4 (0.2)                                                  | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Sarcoidosis                 | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                                                  | 0 (0.0)                                                  | 3                                                    | (0.0)                                                |
| Serum sickness              | 0 (0.0)                              | 0 (0.0)                        | 0 (0.0)                                                  | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Infections and infestations | 7 (2.3)                              | 3 (1.0)                        | 63 (3.1)                                                 | 1 (0.8)                                                  | 85                                                   | (1.4)                                                |

|                                               | KN826 Pembrolizumab + Chemotherapy   | KN826 Placebo + Chemotherapy   | Pooled Safety Dataset for Pembrolizumab+   | Chemotherapy   | Cervical Safety Dataset for Pembrolizumab Monotherapyd   | Pembrolizumab Monotherapy Reference Safety Dataset   | Pembrolizumab Monotherapy Reference Safety Dataset   |
|-----------------------------------------------|--------------------------------------|--------------------------------|--------------------------------------------|----------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                               | n (%)                                | n                              | (%)                                        | (%)            | (%)                                                      | n                                                    | (%)                                                  |
| Infections and infestations                   | 7 (2.3)                              | 3                              | (1.0)                                      | 63 (3.1)       | 1 (0.8)                                                  | 85                                                   | (1.4)                                                |
| Thrombophlebitis septic                       | 0 (0.0)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Tracheitis                                    | 0 (0.0)                              | 0 (0.0)                        | 0                                          | (0.0)          | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Tuberculosis                                  | 0 (0.0)                              | 0 (0.0)                        | 1                                          | (0.0)          | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Urinary tract infection                       | 0 (0.0)                              | 0 (0.0)                        | 0                                          | (0.0)          | 0 (0.0)                                                  | 3                                                    | (0.0)                                                |
| Urosepsis                                     | 0 (0.0)                              | 0                              | (0.0) 1                                    | (0.0)          | 0 (0.0)                                                  | 5                                                    | (0.1)                                                |
| Injury,poisoning and procedural complications | 5 (1.6)                              | 3                              | (1.0)                                      | 10 (0.5)       | 0 (0.0)                                                  | 12                                                   | (0.2)                                                |
| Alcohol poisoning                             | 0 (0.0)                              | 0                              | (0.0)                                      | 1 (0.0)        | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Arterial injury                               | 0 (0.0)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  |                                                      | (0.0)                                                |
| Facial bones fracture                         | 0 (0.0)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  |                                                      | (0.0)                                                |
| Fall                                          | 0 (0.0)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  |                                                      | (0.0)                                                |
| Femur fracture                                | 1 (0.3)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Infusion related reaction                     | 3 (1.0)                              | 3                              | (1.0) 7                                    | (0.3)          | 0 (0.0)                                                  | 3                                                    | (0.0)                                                |
| Pneumonitis chemical                          | 0 (0.0)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  |                                                      | (0.0)                                                |
| Post procedural haemorrhage                   | 0 (0.0)                              | 0                              | (0.0)                                      | (0.0)          | 0 (0.0)                                                  |                                                      | (0.0)                                                |
| Radiation pneumonitis                         | 0 (0.0)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  |                                                      | (0.0)                                                |
| Radiation proctitis                           | 1 (0.3)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Spinal fracture                               | 0 (0.0)                              | 0                              | (0.0)                                      | (0.0)          | 0 (0.0)                                                  | 0                                                    | (0.0)                                                |
| Traumatic intracranial haemorrhage            | 0 (0.0)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Wound decomposition                           | 0 (0.0)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Wound haemorrhage                             | 0 (0.0)                              | 0                              | (0.0)                                      | 0 (0.0)        | 0 (0.0)                                                  | 1                                                    | (0.0)                                                |
| Investigations                                | 11 (3.0)                             | 5                              | (1.6)                                      | 69 (3.4)       | 0 (0.0)                                                  | 49                                                   | (0.8)                                                |

Every participant is counted a single time for each applicable row and column.

- A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
- Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

<div style=\"page-break-after: always\"></div>

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded. d  Includes all participants who received at least one dose of pembrolizumab in KN028 cohort B4 and KN158 cohort E. e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204. f  Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021 cohort A/C/G, KN048, KN189, KN355, KN407, and KN590. Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020) Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018, KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019) Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016) Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020) Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018) Database cutoff date for Esophageal (KN590: 02JUL2020) Database cutoff date for CRC (KN177: 19FEB2020) Database cutoff date for TNBC (KN355: 11DEC2019) Database cutoff date for Cervical (KN826: 03MAY2021, KN028 cohort B4: 20FEB2017, KN158 cohort E:

- 27JUN2019)

<div style=\"page-break-after: always\"></div>

Table 91. Participants With Adverse Events Resulting in Discontinuation of Any Treatment by System Organ Class and Preferred Term by Bevacizumab Use (Incidence &gt;0% in One or More Treatment Groups) (APaT Population)

|                                        | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   |   KN826 Placebo + Chemotherapy w/Bevacizumab | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|----------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                        | n                                                  | (%)                                                | n                                                    | (%)                                                  |                                           11 | (%)                                          |                                                | (%)                                            | n                                                     | (%)                                                   |
| Participants in population             | 196                                                |                                                    | III                                                  |                                                      |                                          193 |                                              | 116                                            |                                                | 6,185                                                 |                                                       |
| with one or more adverse events        | 88                                                 | (44.9)                                             | 27                                                   | (24.3)                                               |                                           61 | (31.6)                                       | 21                                             | (18.1)                                         | 832                                                   | (13.5)                                                |
| with no adverse events                 | 108                                                | (55.1)                                             | 84                                                   | (75.7)                                               |                                          132 | (68.4)                                       | 95                                             | (81.9)                                         | 5,353                                                 | (86.5)                                                |
| Blood andlymphatic system disorders    | 8                                                  | (4.1)                                              | 4                                                    | (3.6)                                                |                                            8 | (4.1)                                        | 2                                              | (1.7)                                          | 12                                                    | (0.2)                                                 |
| Anaemia                                | 6                                                  | (3.1)                                              | 1                                                    | (0.9)                                                |                                            3 | (1.6)                                        | 1                                              | (0.9)                                          | 3                                                     | (0.0)                                                 |
| Autoimmunehaemolytic anaemia           | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Disseminated intravascular coagulation | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Febrile neutropenia                    | 0                                                  | (0.0)                                              | 1                                                    | (0.9)                                                |                                            1 | (0.5)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Haemolytic anaemia                     | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Immune thrombocytopenia                | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Neutropenia                            |                                                    | (1.0)                                              | 1                                                    | (0.9)                                                |                                            2 | (1.0)                                        | 1                                              | (0.9)                                          | 1                                                     | (0.0)                                                 |
| Pancytopenia                           | 0                                                  | (0.0)                                              | 1                                                    | (0.9)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Thrombocytopenia                       | 乙                                                  | (1.0)                                              | 0                                                    | (0.0)                                                |                                            2 | (1.0)                                        | 0                                              | (0.0)                                          | 3                                                     | (0.0)                                                 |
| Cardiac disorders                      | 4                                                  | (2.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 1                                              | (0.9)                                          | 36                                                    | (0.0)                                                 |
| Acute coronary syndrome                | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Acute myocardial infarction            | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Atrial fibrillation                    | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 3                                                     | (0.0)                                                 |
| Atrioventricular block complete        | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Autoimmune pericarditis                | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Cardiac arrest                         | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 7                                                     | (0.1)                                                 |
| Cardiac failure                        | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| Cardiac failure acute                  | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 一                                                     | (0.0)                                                 |
| Cardiac failure congestive             | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Cardiac ventricular disorder           | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| Cardio-respiratory arrest              | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 4                                                     | (0.1)                                                 |
| Ischaemic cardiomyopathy               | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| Left ventricular failure               | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| Myocardial infarction                  | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 1                                              | (0.9)                                          | 6                                                     | (0.1)                                                 |
| Myocardial necrosis                    | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Myocarditis                            | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 4                                                     | (0.1)                                                 |
| Pericardial effusion                   | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Stress cardiomyopathy                  | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                |                                            0 | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |

<div style=\"page-break-after: always\"></div>

|                            | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|----------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                            | n                                                  | (%)                                                | n                                                    | (%)                                                  | n                                            | (%)                                          | n                                              | (%)                                            | n                                                     | (%)                                                   |
| Ear andlabyrinth disorders | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Tinnitus                   |                                                    | (0.5)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Endocrine disorders        | 0                                                  | (0.0)                                              | 1                                                    | (0.9)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 18                                                    | (0.3)                                                 |
| Addison's disease          | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Adrenal insufficiency      | 0                                                  | (0.0)                                              | 1                                                    | (0.9)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 4                                                     | (0.1)                                                 |
| Hyperthyroidism            | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 3                                                     | (0.0)                                                 |
| Hypophysitis               | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 5                                                     | (0.1)                                                 |
| Hypopituitarism            | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 4                                                     | (0.1)                                                 |
| Hypothyroidism             | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Eye disorders              | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 3                                                     | (0.0)                                                 |
| Iridocyclitis              | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Optic neuropathy           |                                                    | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Uveitis                    | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Gastrointestinal disorders | 17                                                 | (8.7)                                              | 6                                                    | (5.4)                                                | 9                                            | (4.7)                                        | 1                                              | (0.9)                                          | 88                                                    | (1.4)                                                 |
| Abdominal distension       | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Abdominal pain             | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Abdominal pain upper       | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Anal fistula               | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Anal haemorrhage           | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Aptyalism                  | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Ascites                    | 0                                                  | (0.0)                                              | 1                                                    | (0.9)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 乙                                                     | (0.0)                                                 |
| Autoimmune colitis         | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Autoimmunepancreatitis     | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Chronic gastritis          | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Colitis                    | 1                                                  | (0.5)                                              | 2                                                    | (1.8)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 29                                                    | (0.5)                                                 |
| Colitis microscopic        | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Diarrhoea                  | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 13                                                    | (0.2)                                                 |
| Duodenal obstruction       | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Duodenal perforation       | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Enteritis                  | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Enterocolitis              | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 7                                                     | (0.0)                                                 |
| Enterocutaneous fistula    | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Enterovesical fistula      | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Gastric disorder           | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Gastric haemorrhage        | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |

<div style=\"page-break-after: always\"></div>

|                                                    | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   |   KN826 Placebo + Chemotherapy w/o Bevacizumab | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                    | 1n                                                 | (%)                                                | n                                                    | (%)                                                  | 1                                            | (%)                                          |                                             11 | (%)                                            | 1n                                                    | (%)                                                   |
| General disorders and administrationsiteconditions | 7                                                  | (3.6)                                              | 1                                                    | (0.9)                                                | 5                                            | (2.6)                                        |                                              2 | (1.7)                                          | 87                                                    | (1.4)                                                 |
| General physical health deterioration              |                                                    | (0.5)                                              | 0                                                    | (0.0)                                                |                                              | (0.5)                                        |                                              0 | (0.0)                                          | 10                                                    | (0.2)                                                 |
| Generalised oedema                                 | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 4                                                     | (0.1)                                                 |
| Infusion site reaction                             | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Localised oedema                                   | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Malaise                                            | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 乙                                                     | (0.0)                                                 |
| Mucosal inflammation                               | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Multiple organ dysfunction syndrome                | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Oedema                                             | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 3                                                     | (0.0)                                                 |
| Pain                                               | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 7                                                     | (0.1)                                                 |
| Performance status decreased                       | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Prosthetic cardiac valve thrombosis                | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Pyrexia                                            | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          |                                                       | (0.0)                                                 |
| Sudden death                                       | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          |                                                       | (0.0)                                                 |
| Swelling face                                      | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 乙                                                     | (0.0)                                                 |
| Systemic inflammatory response syndrome            | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Hepatobiliarydisorders                             | 4                                                  | (2.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 34                                                    | (0.5)                                                 |
| Autoimmune hepatitis                               | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 12                                                    | (0.2)                                                 |
| Biliary obstruction                                | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Cholangitis                                        | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 一                                                     | (0.0)                                                 |
| Drug-induced liver injury                          | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Hepatic failure                                    | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 3                                                     | (0.0)                                                 |
| Hepatic function abnormal                          | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Hepatitis                                          | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 9                                                     | (0.1)                                                 |
| Hepatitis toxic                                    | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Hepatotoxicity                                     | 1                                                  | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Hyperbilirubinaemia                                | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Immune-mediated hepatitis                          | 2                                                  | (1.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          |                                                       | (0.0)                                                 |
| Liver injury                                       | 0                                                  | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Immune system disorders                            | 6                                                  | (3.1)                                              | 2                                                    | (1.8)                                                | 7                                            | (3.6)                                        |                                              1 | (0.9)                                          | 9                                                     | (0.1)                                                 |
| Anaphylactic reaction                              |                                                    | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |

<div style=\"page-break-after: always\"></div>

|                                                | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o   | KN826 Pembrolizumab + Chemotherapy w/o   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------|------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                | 11                                                 | (%)                                                | n                                        | (%)                                      | n                                            | (%)                                          | n                                              | (%)                                            | n                                                     | (%)                                                   |
| Infections and infestations                    | 5                                                  | (2.0)                                              | 2                                        | (1.8)                                    | 3                                            | (1.0)                                        | 0                                              | (0.0)                                          | 85                                                    | (1.4)                                                 |
| Septic shock                                   | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 8                                                     | (0.1)                                                 |
| Soft tissue infection                          | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Staphylococcal bacteraemia                     | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Thrombophlebitis septic                        | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 一                                                     | (0.0)                                                 |
| Tracheitis                                     | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Urinary tract infection                        | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 3                                                     | (0.0)                                                 |
| Urosepsis                                      | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 5                                                     | (0.1)                                                 |
| Injury, poisoning and procedural complications | 4                                                  | (2.0)                                              | 1                                        | (0.9)                                    | 2                                            | (1.0)                                        | 1                                              | (0.9)                                          | 12                                                    | (0.2)                                                 |
| Arterial injury                                | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Facial bones fracture                          | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| Fall                                           | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| Femur fracture                                 | 0                                                  | (0.0)                                              | 1                                        | (0.9)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Infusion related reaction                      | 3                                                  | (1.5)                                              | 0                                        | (0.0)                                    | 2                                            | (1.0)                                        | 1                                              | (0.9)                                          | 3                                                     | (0.0)                                                 |
| Pneumonitis chemical                           | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Post procedural haemorrhage                    | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 一                                                     | (0.0)                                                 |
| Radiation pneumonitis                          | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 一                                                     | (0.0)                                                 |
| Radiation proctitis                            | 1                                                  | (0.5)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Traumatic intracranial                         | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| haemorrhage Wound decomposition                | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| Wound haemorrhage                              | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Investigations                                 | 8                                                  | (4.1)                                              | 3                                        | (2.7)                                    | 3                                            | (1.6)                                        | 2                                              | (1.7)                                          | 49                                                    | (0.8)                                                 |
| Alanine aminotransferase imcreased             | 2                                                  | (1.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 2                                              | (1.7)                                          | 21                                                    | (0.3)                                                 |
| Amylase increased                              |                                                    | (0.5)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Aspartate aminotransferase increased           | 2                                                  | (1.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 1                                              | (0.9)                                          | 20                                                    | (0.3)                                                 |
| Blood alkaline phosphatase increased           | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 2                                                     | (0.0)                                                 |
| Blood bilirubin increased                      | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 5                                                     | (0.1)                                                 |
| Blood creatine phosphokinase increased         | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Blood creatinine increased                     | 0                                                  | (0.0)                                              | 2                                        | (1.8)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Blood uric acid increased                      | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 一                                                     | (0.0)                                                 |
| Nervous system disorders                       | 10                                                 | (5.1)                                              | 5                                        | (4.5)                                    | 14                                           | (7.3)                                        | 6                                              | (5.2)                                          | 52                                                    | (0.8)                                                 |
| Ataxia                                         | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Autoimmune neuropathy                          | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          | (0.0)                                                 |                                                       |
| Axonal neuropathy                              | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| Brain oedema                                   | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                       |                                                       |
| Cerebral ischaemia                             | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 1                                            | (0.5)                                        | 0                                              | (0.0)                                          | (0.0)                                                 | (0.0)                                                 |
| Cerebrovascular accident                       | 0                                                  | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.1)                                                 |
|                                                | 0                                                  |                                                    |                                          |                                          |                                              |                                              |                                                |                                                |                                                       | (0.0)                                                 |
| Cognitive disorder                             |                                                    | (0.0)                                              | 0                                        | (0.0)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0)                                          |                                                       | (0.0)                                                 |
| Coma                                           | 0 0                                                | (0.0)                                              | 0                                        | (0.0)                                    | 0 0                                          | (0.0)                                        | 0                                              | (0.0) (0.0)                                    |                                                       | (0.0)                                                 |
| Dementia                                       | 0                                                  | (0.0)                                              | 0                                        | (0.0) (0.0)                              | 0                                            | (0.0)                                        | 0 0                                            | (0.0)                                          | (0.0)                                                 |                                                       |
| Demyelinating polyneuropathy Embolic stroke    | 0                                                  | (0.0) (0.0)                                        | 0 0                                      | (0.0)                                    | 0                                            | (0.0) (0.0)                                  | 0                                              | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Encephalitis autoimmune                        | 0                                                  | (0.0)                                              | 1                                        | (0.9)                                    | 0                                            | (0.0)                                        | 0                                              | (0.0) (0.0)                                    | 1                                                     | (0.0)                                                 |
| Encephalopathy Epilepsy                        | 0 0                                                | (0.0) (0.0)                                        | 0 0                                      | (0.0) (0.0)                              | 0 0                                          | (0.0) (0.0)                                  | 0 0                                            | (0.0)                                          | 乙 (0.0) 2                                             | (0.0)                                                 |

<div style=\"page-break-after: always\"></div>

|                                                |   KN826 Pembrolizumab + Chemotherapy w/Bevacizumab | KN826 Pembrolizumab + Chemotherapy w/Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Pembrolizumab + Chemotherapy w/o Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   | KN826 Placebo + Chemotherapy w/Bevacizumab   |   KN826 Placebo + Chemotherapy w/o Bevacizumab | KN826 Placebo + Chemotherapy w/o Bevacizumab   | Pembrolizumab Monotherapy Reference Safety Datasete   | Pembrolizumab Monotherapy Reference Safety Datasete   |
|------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                |                                                  1 | (%)                                                | n                                                    | (%)                                                  | 1                                            | (%)                                          |                                              1 | (%)                                            | 1                                                     | (%)                                                   |
| Renal andurinarydisorders                      |                                                 12 | (6.1)                                              | 0                                                    | (0.0)                                                | 9                                            | (4.7)                                        |                                              3 | (2.6)                                          | 28                                                    | (0.5)                                                 |
| Acute kidney injury                            |                                                  5 | (2.6)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        |                                              2 | (1.7)                                          | 8                                                     | (0.1)                                                 |
| Autoimmune nephritis                           |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Azotaemia                                      |                                                  7 | (1.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Bladder diverticulum                           |                                                  1 | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Chronic kidney disease                         |                                                  1 | (0.5)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              1 | (0.9)                                          | 0                                                     | (0.0)                                                 |
| Glomerulonephritis membranous                  |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Haematuria                                     |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 3                                            | (1.6)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Hydronephrosis                                 |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          |                                                       | (0.0)                                                 |
| Nephritis                                      |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Nephropathy                                    |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          |                                                       | (0.0)                                                 |
| Nephrotic syndrome                             |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Postrenal failure                              |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Proteinuria                                    |                                                  5 | (2.6)                                              | 0                                                    | (0.0)                                                | 2                                            | (1.0)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Renal failure                                  |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        |                                              0 | (0.0)                                          | 6                                                     | (0.1)                                                 |
| Renal impairment                               |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Tubulointerstitial nephritis                   |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 4                                                     | (0.1)                                                 |
| Urinary tract obstruction                      |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Urogenital fistula                             |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 2                                            | (1.0)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Reproductive system and breast disorders       |                                                  7 | (3.0)                                              | 3                                                    | (2.7)                                                | 12                                           | (6.2)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Female genital tract fistula                   |                                                  4 | (2.0)                                              | 2                                                    | (1.8)                                                | 7                                            | (3.6)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Uterine haemorrhage                            |                                                  0 | (0.0)                                              | 1                                                    | (0.9)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Vaginal fistula                                |                                                  2 | (1.0)                                              | 0                                                    | (0.0)                                                | 2                                            | (1.0)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Vaginal haemorrhage                            |                                                  1 | (0.5)                                              | 0                                                    | (0.0)                                                | 3                                            | (1.6)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Vulval ulceration                              |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 1                                            | (0.5)                                        |                                              0 | (0.0)                                          | 0                                                     | (0.0)                                                 |
| Respiratory,thoracic and mediastinal disorders |                                                  3 | (1.5)                                              | 0                                                    | (0.0)                                                |                                              | (0.5)                                        |                                              2 | (1.7)                                          | 201                                                   | (3.2)                                                 |
| Acute respiratory failure                      |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 4                                                     | (0.1)                                                 |
| Aspiration                                     |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Bronchostenosis                                |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Chronic obstructive pulmonary disease          |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 4                                                     | (0.1)                                                 |
| Cough                                          |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Diffuse alveolar damage                        |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 1                                                     | (0.0)                                                 |
| Dyspnoea                                       |                                                  0 | (0.0)                                              | 0                                                    | (0.0)                                                | 0                                            | (0.0)                                        |                                              0 | (0.0)                                          | 16                                                    | (0.3)                                                 |

Every participant is counted a single time for each applicable row and column.

- A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

- e  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 cohort B and B2, KN013 cohort 3, KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.
- Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 03APR2020)
- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)
- Database cutoff date for HNSCC (KN012 cohort B and B2: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013 cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020) Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018) Database cutoff date for CRC (KN177: 19FEB2020) Database cutoff date for Cervical (KN826: 03MAY2021)

<div style=\"page-break-after: always\"></div>

## Post marketing experience

The safety profile of pembrolizumab was summarized in the Periodic Safety Update Report covering the period 04-SEP-2019 through 03-SEP-2020, specifically Appendix 20.3 (Numbers of Adverse Reactions and Events by Preferred Term from Postauthorization Sources).

## 2.5.1. Discussion on clinical safety

The  safety  profile  of  pembrolizumab  (KEYTRUDA®,  MK-3475)  in  combination  with  chemotherapy with/without bevacizumab for the treatment of cervical tumours in adults is derived from the pivotal study KEYNOTE-826. In order to contextualise the study results with respect to the overall toxicity of pembrolizumab given as add-on to chemotherapeutic agents, the trial was analysed in comparison with a pooled safety dataset for pembrolizumab+chemotherapy  including  all indications for which pembrolizumab drug combinations are currently approved in the EU (n=2033). Moreover, to better characterise the contribution of pembrolizumab to the adverse events associated with the backbone therapy,  the  MAH  also  presented  data  by  bevacizumab  use.  Supportive  data  were  also  submitted attaining the use of pembrolizumab as monotherapy in the intended indication, which derive from the Phase  I  and  II  studies  KN028  (cohort  B4)  and  KN158  (cohort  E)  (n=122);  these  populations  were separately analysed from the large pembrolizumab monotherapy reference safety database (RSD=6185) that was also presented as comparative group.

With a cut-off date of 03 May 2021, KEYNOTE-826 includes a total of 616 participants allocated with a 1:1 randomisation scheme to the active and control arm. The majority of the study population received bevacizumab (196 patients, 63.8% in the pembrolizumab+chemotherapy group; 193 patients, 62.4% in  the  placebo+chemotherapy  group).  Overall,  exposure  in  the  placebo  group  was  shorter  than  in pembrolizumab: 54.6% and 28.5% of total patients in the group of pembrolizumab+chemotherapy with and without  bevacizumab  had  &gt;12-month  exposure  vs  40.9%  and  14.7%  in  the  group  of placebo+chemotherapy with and without bevacizumab, respectively. Of note, the use of bevacizumab was associated with a longer exposure to treatment in both arms (13.91 months in median vs 6.31 in the counterpart in the pembrolizumab arm and 9.69 vs 5.39 months in median in the placebo), likely due to a more favourable disease progression conferred by this treatment.

However, unlike the placebo arm, the pembrolizumab group showed a worse baseline performance score in patients not receiving bevacizumab (53.2% with ECOG 1 vs 34.7% with ECOG score 1 in the group with bevacizumab), which also could have concurred to the observed shorter length of treatment in this subgroup. Assignment of patients to bevacizumab was an investigator decision driven by the clinical conditions at baseline and the expected patient drug tolerability. It is therefore recognised that a poorer performance status in patients not receiving bevacizumab compared to those assigned to bevacizumab likely  reflects  the  typology of patients generally excluded from treatment. The comparative datasets including pembrolizumab monotherapy in both participants with cervical tumour and RSD showed a more limited exposure length than study KEYNOTE-826 (&gt;12-month exposure was in the 14.8% and 23.1% of the dataset, respectively); similarly, the pooled pembrolizumab+chemotherapy database provided data for a 12-month exposure in 27.1% of the recruited population.

<div style=\"page-break-after: always\"></div>

According with disease epidemiology and clinical features, cervical tumour patients were younger (above 80% were aged &lt;65-years compared to 59.9% and 58%) and with better ECOG score (above 50% with ECOG score 1 compared to 44.9% and 47.6%) than the pooled pembrolizumab+chemotherapy dataset and RSD.

The analysis of overall adverse events revealed an unfavourable outcome for the experimental therapy compared to placebo as demonstrated by increased frequency in grade 3-5 AEs (81.8% vs 75.1%), drug-related SAEs (30.3% vs 23%) and drug discontinuations (37.5%vs 26.5%) compared to control. Of note, fatalities were similar between groups (4.6% vs 4.5%). The rate of AE across all the different categories  was  overall  consistent  with  the  pooled  dataset  of  pembrolizumab+chemotherapy.  As expected,  the  drug  combination  tested  in  KEYNOTE-826  appeared  worse  than  pembrolizumab monotherapy relatively to either the specific indication (cervical monotherapy) or the totality of treated patients across all different clinical settings (RSD); the only exception was for the rate of fatalities that was higher in the RSD, likely due to the older age and different tumour-specific clinical course of the RSD  database.  Exposure  adjusted  results  confirmed  a  potentiating  effect  of  pembrolizumab  on chemotherapy-related AEs for what concerns the incidence of grade 3-5 drug-related AEs, drug-related SAEs and drug discontinuations due to AEs, all of them occurring with a similar incidence compared to the  historical  data  on  combined  therapies  as  defined  by  the  pooled  pembrolizumab+chemotherapy dataset. The contribution of the individual component of the drug combination administrated in study KEYNOTE-826 varied, with the addition of bevacizumab worsening the safety profile of placebo+chemotherapy, which was further compromised by the addition of pembrolizumab particularly for the category of drug discontinuations. Overall, pembrolizumab+chemotherapy without bevacizumab appeared similarly tolerated than placebo+chemotherapy with bevacizumab.

The pattern of AEs was consistent with the known safety profiles of pembrolizumab, chemotherapy and bevacizumab. Specifically, alopecia, anaemia, nausea, diarrhea, fatigue, and system nervous disorders were among the most common (&gt;20% of incidence) side effects across all chemotherapy subgroups regardless  of  the  use  of  bevacizumab  or  pembrolizumab;  in  patients  receiving  bevacizumab, hypertension,  rash,  ALT  increase  and  epistaxis  occurred  more  frequently  than  in  the  absence  of bevacizumab; pembrolizumab was associated with a higher rate of endocrine disturbances. Compared to the control arm, treatment with pembrolizumab enhanced the incidence of blood and lymphatic system disorders (72.3% vs 67.7%), endocrine disturbances (25.7% vs 12.65%), hepatobiliary disorders (6.2% vs 4.9%) that were also reflected in the higher incidence of laboratory investigation abnormalities mainly related to myelosuppression and liver dysfunction. The majority of these AEs were judged drug-related by Investigators. The rate of all these AEs was more frequent than previously reported in the pooled dataset of pembrolizumab+chemotherapy, likely because of the longer exposure of study KEYNOTE-826. However,  the  exposure-adjusted  analysis  by  bevacizumab  showed  that  pembrolizumab  mainly contributed to the endocrine disturbances, while no impact of immunotherapy was apparent for the events in the other SOC categories.

In terms of severity, pembrolizumab mainly increased Grade 3-5 AEs (81.8% vs 75.1%) within the SOC  category  of  blood  and  lymphatic  system  disorders  (i.e.  anaemia,  neutrophil  count  decrease, trombocytopenia, febrile neutropenia) that are typically associated with the use of chemotherapeutic agents, while toxicity classically related to bevacizumab (i.e. hypertension) was not worsen. Among fatal AEs,  however,  the  group  treated  with  pembrolizumab+chemotherapy+bevacizumab  more  frequently presented events of cardiac and hemorragic nature in addition to sepsis, relatively to placebo.

As regards SAEs (50.5% vs 48.6%), events included febrile neutropenia (6.8% vs 4.2%), and anaemia (4.6% vs 3.9%) among those that were impaired by pembrolizumab treatment.

As expected, the incidence of AEOSIs was more frequent in the pembrolizumab group compared to placebo (69.23% vs 40.70%). The pattern of events was typical of pembrolizumab monotherapy as

<div style=\"page-break-after: always\"></div>

colitis (6.5% vs 1.9%), hepatitis (1.6% vs 0.4%), hyperthyroidism (7.1% vs 3.8%), hypothyroidism (19.2% vs 12.1%), severe skin reactions (5% vs 0.4%), and pneumonitis (1.9% vs 0.4%) were among the most frequently reported events. There was one death related to AEOSIs in the experimental arm (0.3%).

The rate of AEOSIs (41% vs 26.5%), grade 3-5 AEOSIs (13.4% vs 5.2%), drug-related grade 3-5 AEOSIs (11.7% vs 4.2%) and any study drug dose discontinuation due to AESOIs (8.8% vs 3.6%) was above the previously reported experience of the pooled pembrolizumab+chemotherapy dataset. These data were confirmed by the exposure-adjusted analysis showing added toxicities for each drug component, with  the  combination  of  pembrolizumab+chemotherapy+bevacizumab  displaying  the  worst  safety profile, although the only AEOSI-related death occurred in the group of pembrolizumab-treated patients not receiving bevacizumab.

The data show added toxicities for each drug component and the different comparisons might be also impacted  by  different  baseline  characteristics  (with  generally  younger  and  fitter  patients  in  the  EC indication  compared to the pooled pembro+chemo dataset and with also generally more favourable baseline  characteristics  for  the  patients  attributed  to  bevacizumab  compared  to  those  without bevacizumab).

The  rate  of drug  discontinuations was  higher  in  the  pembrolizumab  group  compared  to  control, particularly in association with bevacizumab. The same trend was observable in the control arm.

<div style=\"page-break-after: always\"></div>

## Analysis by subgroups

Age : unlike the placebo arm, tolerability within the pembrolizumab treated patient group in combination with  chemotherapy  with/without  bevacizumab  worsened  by  age,  as  demonstrated  by  an  increased incidence of events across all categories in patients aged &gt;65 years compared to the &lt;65-years of age counterpart. However, the requested exposure-adjusted analysis did not reveal significant differences between the two categories. The limited numerosity of the sample size for ages &gt;75 years (n=10/arm) hampers definitive conclusion in this patient subgroup that, however, has been historically characterised by the worse pembrolizumab toxicity when administrated as add-on to chemotherapy.

Sex : considering that the totality of recruited patients were women, a sex-dependent analysis of toxicity is of scarce value.

ECOG score : Participants with a higher (1 vs 0) ECOG PS at baseline reported higher frequencies of fatalities  in  both  treatment arms; pembrolizumab slightly augmented the toxicity of therapy in both ECOG score categories.

Race : Race does not seem to influence the toxicity profile of either regimens since similar rate of events is observable in white and non-white across all AEs categories; pembrolizumab worsened the toxicity of chemotherapy regardless of race.

Region : ex-EU showed a higher incidence of AEs than EU across all categories. No specific causes related to different patient management or study conduct between the two geographic areas could be identified.

## 2.5.2. Conclusions on clinical safety

Pembrolizumab as add-on to chemotherapy with/without bevacizumab impaired the overall toxicity of the backbone therapy with an increased frequency of adverse events than previously reported in other indications for which pembrolizumab+chemotherapy was licenced. The safety profile of the experimental treatment used in study KEYNOTE-826 reflected the established toxicity of the individual components of the  drug  combination.  No  new  safety  signals  emerged.  AEOSI  were  more  frequent  than  previously registered  in  other  chemotherapy/pembrolizumab  associations,  mainly  with  the  concomitant  use  of bevacizumab. As expected, an age-dependent reduction in tolerability was observed.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 35 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 35 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

## Table SVIII.1:  Summary of Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related adverse reactions (including immune related pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies)                                                                                                                                                                                      |
| Important potential risks    | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information          | None                                                                                                                                                                                                                                                                                                              |

## Pharmacovigilance plan

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance studies that are required for pembrolizumab.

## Risk minimisation measures

Table V.3.1: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                               | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                          | Pharmacovigilance Activities                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks: Immune-Related Adverse Reactions                                                                 | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                                                                                                                                                        | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                          |
| Immune-related adverse reactions (including immune- related pneumonitis, colitis, hepatitis, nephritis and endocrinopathies) | Routine risk minimisation measures: The risk of the immune-related adverse reactions (including immune-related pneumonitis colitis, hepatitis, nephritis, and endocrinopathies) associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Routine pharmacovigilance activities Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire for spontaneous postmarketing reports of all adverse events |
|                                                                                                                              | Additional risk minimisation measures: Patient educational materials                                                                                                                                                                                                                                                                                | Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types                                                                     |

<div style=\"page-break-after: always\"></div>

Table V.3.1: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                                                | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance Activities                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                      | Important Potential Risks                                                                                                                                                              |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: Safety monitoring in the ongoing HL trial (KN204).                                                        |
| GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                          | Routine risk minimisation measures: GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted                                                                   | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.8, and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

there are only minor changes in the leaflet section 1, currently no changes of the package leaflet are foreseen impacting the safe use of the medicinal product, moreover, no changes are foreseen in the design, layout and format of the package leaflet.

## 2.7.2. Additional monitoring

Pursuant to Article 23(3) of Regulation No (EU) 726/2004, Keytruda (pembrolizumab) has been removed from the additional monitoring list with the renewal procedure five years after the Union reference date.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Persistent, recurrent or metastatic cervical cancer not amenable to curative treatment, first line.

The adopted indication is 'KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥ 1'.

## 3.1.2. Available therapies and unmet medical need

Cisplatin-based doublets with topotecan or paclitaxel have demonstrated superiority to cisplatin monotherapy as first line treatment of advanced/metastatic cancer, with cisplatin plus paclitaxel the preferred regimen based on the balance between efficacy and toxicity profile (ESMO GL; Monk BJ, 2009). The combination of paclitaxel and carboplatin could be considered an alternative for patients that are not candidates for cisplatin. The addition of bevacizumab to chemotherapy significantly prolonged overall survival as compared chemotherapy alone, at the expenses of higher toxicity (Tewari KS, 2014). The triplet combination bevacizumab-cisplatin-paclitaxel is considered the preferred firstline regimen in metastatic or recurrent cervical cancer (ESMO, NCCN).

## 3.1.3. Main clinical studies

KEYNOTE-826: a phase 3 randomized, double-blind, placebo-controlled trial of pembrolizumab plus chemotherapy (cisplatin or carboplatin plus paclitaxel) with or without bevacizumab vs placebo plus chemotherapy with or without bevacizumab for the 1L treatment of persistent, recurrent, or metastatic cervical cancer. Results of interim analysis 1 support the extension of indication application.

## 3.2. Favourable effects

- Statistically significant and clinically relevant improvement in OS in all the populations analysed (all-comers, CPS ≥ 1, CPS ≥ 10: in CPS ≥ 1 OS HR 0.64, median OS NR (19.8, NR) vs 16.3 (14.5, 19.4) (gain in median OS of 8 months in the all-comers population), KM curves separated at month 3 and remain in favour of pembrolizumab combination.
- Statistically significant improvement in PFS by investigator for the addition of pembrolizumab to chemotherapy +/- bevacizumab in all the populations analysed (all-comers, CPS ≥ 1, CPS ≥ 10): in CPS ≥ 1 PFS HR 0.62, gain in median PFS of 2 months.
- Supportive ORR and DOR trends: 18% increase in ORR, median DOR 18 vs 10.4 months in the CPS ≥ 1 population.

## 3.3. Uncertainties and limitations about favourable effects

- Acknowledging the small number of subjects (34 vs 34), apparent lack of benefit in CPS&lt;1 population: OS HR 1, PFS HR 0.94, ORR difference -6.4%, DOR 10.7 vs 8.5. This lack of benefit of

<div style=\"page-break-after: always\"></div>

pembrolizumab in PD-L1 CPS&lt;1 is supported by biological plausibility and external data (KEYNOTE-158). As a result, the MAH restricted t he indication to CPS≥1 population.

## 3.4. Unfavourable effects

- increased frequency in grade 3-5 AEs (81.8% vs 75.1%), drug-related SAEs (30.3% vs 23%) and drug discontinuations (37.5% vs 26.5%) in the group of pembrolizumab+chemotherapy with/without bevacizumab compared to the control arm
- alopecia, anaemia, nausea, diarrhea, fatigue, and neuropathies were among the most common (&gt;20% of incidence) side effects across all chemotherapy subgroups regardless of the use of bevacizumab or pembrolizumab
- in patients receiving bevacizumab, hypertension, rash, ALT increase and hepixtasis occurred more frequently than in the absence of bevacizumab in both treatment arms
- Compared to the control arm, treatment with pembrolizumab enhanced the incidence of blood and lymphatic system disorders (72.3% vs 67.7%), endocrine disturbances (25.7% vs 12.65%), hepatobiliary disorders (6.2% vs 4.9%)
- Pembrolizumab mainly increased Grade 3-5 AEs (81.8% vs 75.1%) within the SOC category of blood and lymphatic system disorders (i.e. anaemia, neutrophil count decrease, trombocytopenia, febrile neutropenia)
- As regards SAEs (50.5% vs 48.6%), events included febrile neutropenia (6.8% vs 4.2%), and anaemia (4.6% vs 3.9%) among those impaired by pembrolizumab treatment
- the incidence of AEOSIs was more frequent in the pembrolizumab group compared to placebo (69.23% vs 40.70%). The pattern of events is typical of pembrolizumab monotherapy as colitis (6.5% vs 1.9%), hepatitis (1.6% vs 0.4%), hyperthyroidism (7.1% vs 3.8%), hypothyroidism (19.2% vs 12.1%), severe skin reactions (5% vs 0.4%), and pneumonitis (1.9% vs 0.4%) were among the most frequently reported events.
- The rate of AEOSIs (41% vs 26.5%), grade 3-5 AEs (13.4% vs 5.2%), drug-related grade 3-5 AEs (11.7% vs 4.2%) and any study drug dose discontinuation due to AESOIs (8.8% vs 3.6%) was above the previously reported experience of the pooled pembrolizumab+chemotherapy dataset. These data were confirmed by the exposure-adjusted analysis and with the combination of pembrolizumab+chemotherapy+bevacizumab displaying the worst safety profile.

## 3.5. Uncertainties and limitations about unfavourable effects

None.

## 3.6. Effects Table

Table 92. Effects Table for Keytruda in persistent, recurrent, or metastatic cervical cancer in adults (study KEYNOTE-826, data cut-off: 03 May 2021)

| Effect                                         | Short description                              | Unit                                           | Treatment Pembro + chemo +/- beva              | Control Placebo + chemo +/- beva               | Uncertainties / Strength of evidence              | Refe renc es                                   |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|---------------------------------------------------|------------------------------------------------|
| Favourable Effects in PD-L1 CPS ≥ 1 population | Favourable Effects in PD-L1 CPS ≥ 1 population | Favourable Effects in PD-L1 CPS ≥ 1 population | Favourable Effects in PD-L1 CPS ≥ 1 population | Favourable Effects in PD-L1 CPS ≥ 1 population | Favourable Effects in PD-L1 CPS ≥ 1 population    | Favourable Effects in PD-L1 CPS ≥ 1 population |
| PFS (by inv                                    | Time from randomization to first documented    | months (95% CI)                                | CPS ≥ 1: 10.4 (9.7, 12.3)                      | CPS ≥ 1: 8.2 (6.3, 8.5)                        | Statistically significant and clinically relevant | CSR KN- 826                                    |

<div style=\"page-break-after: always\"></div>

| Effect                             | Short description                                                                                                    | Unit                               | Treatment Pembro + chemo +/- beva   | Control Placebo + chemo +/- beva   | Uncertainties / Strength of evidence                                                                                                                                                        | Refe renc es                       |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------|------------------------------------|-------------------------------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| per RECIS T 1.1)                   | disease progression per RECIST 1.1 based on investigator or death due to any cause, whichever occurs first           |                                    | CPS≥1: 0.62 (0.50,                  | 0.77), p<0.0001                    | survival advantage in all populations analysed (all- comers, CPS ≥ 1, CPS ≥ 10)/ supportive ORR and DOR/due to the lack of benefit in CPS<1 population indication was restricted to CPS ≥ 1 |                                    |
| OS                                 | Time from randomization to death due to any cause                                                                    | months (95% CI)                    | CPS ≥ 1: NR (19.8, NR)              | CPS ≥ 1: 16.3 (14.5, 19.4)         |                                                                                                                                                                                             |                                    |
| CPS≥1: 0.64 (0.50, 0.81), p<0.0001 | CPS≥1: 0.64 (0.50, 0.81), p<0.0001                                                                                   | CPS≥1: 0.64 (0.50, 0.81), p<0.0001 | CPS≥1: 0.64 (0.50, 0.81), p<0.0001  | CPS≥1: 0.64 (0.50, 0.81), p<0.0001 | CPS≥1: 0.64 (0.50, 0.81), p<0.0001                                                                                                                                                          | CPS≥1: 0.64 (0.50, 0.81), p<0.0001 |
| ORR                                | Confirmed CR or PR (by inv per RECIST 1.1)                                                                           | % (95% CI)                         | CPS ≥ 1: 68.1 (62.2, 73.6)          | CPS ≥ 1: 50.2 (44.1, 56.2)         |                                                                                                                                                                                             |                                    |
| DOR                                | Time from first response to PD or death due to any cause, whichever occurs first, in subjects who achieve a PR or CR | months (range)                     | CPS ≥ 1: 18 (1.3+, 24.2+)           | CPS ≥ 1: 10.4 (1.5+, 22+)          |                                                                                                                                                                                             |                                    |
| PFS by BICR                        | Time from randomization to first documented disease progression per RECIST 1.1 based on BICR or                      | months (95% CI)                    | CPS ≥ 1: 12.8 (10.4, 20.6)          | CPS ≥ 1: 8.3 (7.7, 9.2)            | PFS by BICR consistent with PFS by investigator                                                                                                                                             |                                    |
| PFS by BICR                        | death due to any cause, whichever occurs first                                                                       |                                    | CPS≥1: 0.60 (0.48, 0.75)            | CPS≥1: 0.60 (0.48, 0.75)           |                                                                                                                                                                                             |                                    |
| Unfavourable Effects               | Unfavourable Effects                                                                                                 | Unfavourable Effects               | Unfavourable Effects                | Unfavourable Effects               | Unfavourable Effects                                                                                                                                                                        | Unfavourable Effects               |
| AE summ ary                        | AE                                                                                                                   | %                                  | 99.3                                | 99.4                               | Pembrolizumab increased the toxicity of the SoC. AEOSI were higher compared to other pembrolizumab+che motherapy combination, mostly in the presence of bevacizumab.                        | CSR KN- 826                        |
|                                    | drug related AE                                                                                                      | %                                  | 97.1                                | 97.1                               |                                                                                                                                                                                             |                                    |
|                                    | G3-5 AE                                                                                                              | %                                  | 81.8                                | 75.1                               |                                                                                                                                                                                             |                                    |
|                                    | drug related G3- 5 AE                                                                                                | %                                  | 68.4                                | 64.1                               |                                                                                                                                                                                             |                                    |
|                                    | SAE                                                                                                                  | %                                  | 49.8                                | 42.4                               |                                                                                                                                                                                             |                                    |
|                                    | drug related                                                                                                         | %                                  | 30.3                                | 23                                 |                                                                                                                                                                                             |                                    |
|                                    | SAE death due to AE                                                                                                  | %                                  | 3.9                                 | 4.9                                |                                                                                                                                                                                             |                                    |
|                                    | death due to                                                                                                         | %                                  | 0.7                                 | 1.3                                |                                                                                                                                                                                             |                                    |
|                                    | drug related AE discontinuation due to AE                                                                            | %                                  | 37.5                                | 26.5                               |                                                                                                                                                                                             |                                    |
|                                    | discontinuation due to drug related AE                                                                               | %                                  | 31.3                                | 22.3                               |                                                                                                                                                                                             |                                    |
| AEOS                               | hypothyroidism                                                                                                       | %                                  | 12.4                                | 2.1                                |                                                                                                                                                                                             |                                    |
| I                                  | Hyperthyroidism                                                                                                      | %                                  | 7.1                                 | 3.8                                |                                                                                                                                                                                             |                                    |
|                                    | colitis                                                                                                              | %                                  | 6.5                                 | 1.9                                |                                                                                                                                                                                             |                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Effect   | Short description     | Unit   |   Treatment Pembro + chemo +/- beva |   Control Placebo + chemo +/- beva | Uncertainties Strength of evidence   | Refe renc es   |
|----------|-----------------------|--------|-------------------------------------|------------------------------------|--------------------------------------|----------------|
|          | Severe skin reactions | %      |                                 5   |                                0.4 |                                      |                |
|          | Pneumonitis           | %      |                                 1.9 |                                0.4 |                                      |                |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Pembrolizumab as add-on to chemotherapy with/without bevacizumab in the pivotal study KEYNOTE826 demonstrated statistically significant and clinically meaningful improvement in OS at the interim analysis, supported by statistically significant PFS and positive ORR and DOR trends as compared to placebo+chemotherapy with/without bevacizumab. Such results were observed consistently in all the populations analysed (allcomers, CPS≥1 and CPS≥10). However, the results in the all -comers population are driven by PD-L1 positive disease, as apparent lack of benefit is observed in patients with PD-L1 negative tumours (CPS&lt;1). Acknowledging that this represent only a small subgroup not included in the multiplicity strategy, biological plausibility is supported by the results of pembrolizumab monotherapy in 2L cervical cancer. The MAH has restricted the indication t o CPS≥1 population. Although results were from interim analysis, the median follow up, number of events and subjects who had discontinued treatment are considered sufficient to conclude on the B/R in the sought indication in view of the overall data provided. All the populations analysed for efficacy impaired the overall toxicity of the backbone therapy with an increased frequency of adverse events than previously reported in other indications for which pembrolizumab+chemotherapy was licenced. The safety profile of the experimental treatment used in study KEYNOTE-826 reflected the established toxicity of the individual components of the drug combination. No new safety signals emerged. AEOSI were more frequent than previously reported in other chemotherapy/pembrolizumab associations, mainly observed with the concomitant use of bevacizumab. As expected, an age-dependent reduction in tolerability was observed.

## 3.7.2. Balance of benefits and risks

Relevant benefit is observed from the experimental therapy as compared to standard treatment for first line treatment of persistent, recurrent or metastatic cervical cancer. However, the CPS&lt;1 population did not appear to benefit from the addition of pembrolizumab to standard treatment. Despite the add-on toxicity, the benefit outweighs the risks in the PD-L1 CPS ≥ 1 population.

## 3.7.3. Additional considerations on the benefit-risk balance

According to data utilization provided by the MAH, the use of platinum doublet in 1L +/- bevacizumab is the standard of care globally, and platinum-paclitaxel doublet is the most used chemotherapy doublet worldwide. The use of topotecan in 1L (which can be associated with paclitaxel and bevacizumab in 1L cervical cancer as per bevacizumab label) appears limited and this drug tends to be used as monotherapy in 2L or 3L.

Based on prior experience for pembrolizumab in combination with chemotherapy, it has been observed that safety of combination regimens usually reflects the established toxicity of the individual components of the combined drug. As a result, physicians experienced in the use of anticancer drugs might be expected to be able to manage side effect of a combination with anti-PD(L)1.

<div style=\"page-break-after: always\"></div>

On the other hand, uncertainties might be raised due to the lack of safety data for the combination with any topotecan-based regimens, along with difficulties to conclude on the possibility to extrapolate from irinotecan to topotecan. However, any combination with topotecan-based treatment might be expected to be limited in clinical practice, as discussed above.

With regard to efficacy aspects, it seems unlikely that the added benefit of pembrolizumab would change if added to one or another regimen considered active in a certain disease/setting.

To conclude, the B/R can be considered positive for general use 'in combination with chemotherapy' as in the sought indication.

## 3.8. Conclusions

The overall B/R of Keytruda in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults in PD-L1 CPS ≥ 1 population is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include a new indication for Keytruda, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults; as a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 35 of the RMP has also been submitted.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, II and IIIB and to the Risk Management Plan are recommended.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

<div style=\"page-break-after: always\"></div>

## Summary

Please refer to Scientific Discussion 'Keytruda-H-C-3820-II-0117'